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Summary 
Huntington’s disease (HD) is a progressive autosomal dominant neurodegenerative disorder 
caused by expansion of a trinucleotide CAG repeat in the Huntingtin gene (HTT) on chromosome 
4. HD symptomatology is characterised by a triad of motor, cognitive, and psychiatric 
disturbances, as well as transcriptional dysregulation.  
The identification of HTT as the single causative gene in HD has led to the development of a 
number of animal models that are designed to recreate the molecular and behavioural 
phenotypes of the human disease; one such model is the HdhQ150 mouse model of HD. 
Investigation into the cognitive capacities of animals heterozygous for the HdhQ150 mutant 
allele (HdhQ150/+) revealed a series of novel cognitive impairments that recapitulate aspects of 
the cognitive phenotype observed in human HD patients; deficits in conditioning task acquisition 
and performance were identified in HdhQ150/+ mice, as were impairments in visuospatial 
attention, and delayed acquisition and cognitive processing of spatial discrimination (SD) 
learning. However, implicit learning capabilities of HdhQ150/+ animals were analogous to those of 
wild-type mice. 
Microarray and reverse transcription quantitative polymerase chain reaction (RT-qPCR) 
investigations into the transcriptional correlates of cognition did not identify significant learning-
dependent gene expression level changes in the striata of HdhQ150/+ or wild-type mice. Similarly, 
these techniques did not report significant striatal gene expression level alterations across 
distinct stages of SD and reversal learning operant task performance in wild-type animals. In 
contrast, RT-qPCR revealed significant differences in the striatal expression levels of Adora2A, 
Arc, Drd2, and Homer1 genes between HdhQ150/+ and wild-type mice at 44-60 weeks of age, 
supporting previous evidence of abnormal expression or signalling of these genes in the HD 
phenotype. 
Overall, this body of work contributes novel evidence that HdhQ150/+ animals present with 
molecular and cognitive phenotypes comparable to those seen in the human form of the 
disease. 
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Chapter 1: General introduction 
1.1 Huntington’s disease 
1.1.1 Clinical phenotypes 
Huntington’s disease (HD) is a progressive neurodegenerative disorder characterised by a triad 
of motor, cognitive and psychiatric disturbances (Duff et al., 2007; Paulsen et al., 2008; Biglan et 
al., 2009; Novak and Tabrizi, 2010; Ross and Tabrizi, 2011; Wexler, 2012; Kim and Fung, 2014; 
Bates et al., 2015). Disease onset most commonly occurs in the fourth or fifth decades of life 
(Andrew et al., 1993; Snell et al., 1993; Purdon et al., 1994; Gusella and MacDonald, 2009; Novak 
and Tabrizi, 2010), however there is a considerable range in the age of onset and disease 
manifestation has been reported in patients from 2 to over 80 years of age (Andrew et al., 1993; 
Duyao et al., 1993; Snell et al., 1993; Wexler, 2012). The HD clinical phenotype progressively 
worsens until death, typically 15-20 years following symptom onset (Wexler and Res, 2004; 
Roos, 2010; Tabrizi et al., 2013). 
 
1.1.1.1 Motor symptoms 
A number of subtle motor symptoms, such as slowed movement and reaction time, reduced 
force when protruding the tongue, and oculomotor deficits, can be detectable prior to clinical 
onset of a motor deficit (Penney et al., 1990; Kirkwood et al., 2000; Tabrizi et al., 2009; Orth et 
al., 2011; Tabrizi et al., 2011; Tabrizi et al., 2012; Tabrizi et al., 2013). Recent studies suggest that 
accuracy in the estimation of motor symptom onset in pre-manifest HD patients can be 
increased by incorporating the Unified Huntington’s Disease Rating Scale (UHDRS) motor and 
cognitive data collected upon observation into predictive models that include the patient’s age 
and CAG repeat length (Liu et al., 2015; Long et al., 2015). The diagnosis of HD is typically made 
after the onset of motor symptom presentation, with examination of choreiform movements 
and fine motor skills, such as finger-tapping rhythm and rate, acting as useful criteria for disease 
diagnosis (Kirkwood et al., 2000; Walker, 2007; Tabrizi et al., 2009; Long et al., 2014). The 
characteristic involuntary choreiform movement that becomes progressively more severe over 
time during the early stages of the disease is one of the most common motor symptoms in HD 
(Young et al., 1986; MacDonald et al., 1993; Mahant et al., 2003; Walker, 2007; Roos, 2010). In 
the early stages of HD, the presence of chorea is often accompanied by incoordination, rigidity, 
oculomotor dysfunction, and reduced control over handwriting, while the middle stage of the 
disease frequently presents with more pronounced chorea, gait abnormalities, motor 
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impersistence, impaired speech, and decreased manual dexterity (Phillips et al., 1994; Reilmann 
et al., 2001; Walker, 2007; Tabrizi et al., 2009; Scahill et al., 2013; Skodda et al., 2014). 
Despite chorea being prevalent and useful for diagnosis, it may not be a suitable indicator for 
severity of disease progression (Young et al., 1986; Mahant et al., 2003) because not all HD 
sufferers develop choreiform movements, or such movements may only arise transiently during 
their illness (Walker, 2007). Bradykinesia and dystonia can also develop in later stages of the 
disease, which act to make the chorea appear less prominent (Berardelli et al., 1999; Squitieri et 
al., 2000). The presence of rigidity and bradykinesia in more advanced stages of the disease 
often requires affected individuals to obtain assistance with self-care, as sufferers are often 
unable to walk, speak and perform everyday tasks. 
 
1.1.1.2 Cognitive symptoms 
Cognitive dysfunction often precedes motor symptom onset in HD (Diamond et al., 1992; Foroud 
et al., 1995; Kirkwood et al., 2000; Paulsen et al., 2001b; Paulsen et al., 2008; Tabrizi et al., 2009; 
Paulsen et al., 2014), with clinically pre-manifest HD patients showing impairments in emotion 
recognition (Gray et al., 1997; Johnson et al., 2007; Stout et al., 2011), working memory (van 
Walsem et al., 2010; Stout et al., 2011), visual discrimination (Lawrence et al., 1998b), and 
implicit learning (Kim et al., 2004; Ghilardi et al., 2008; van Asselen et al., 2012). One report 
found that almost 40% of pre-symptomatic HD participants met the criteria for mild cognitive 
impairment, which is the transitional stage between cognition and dementia (Duff et al., 2010). 
Cognitive processing speed progressively worsens closer to disease onset and is believed to 
result from frontostriatal impairments (Rothlind and Brandt, 1993; Sanchez-Pernaute et al., 
2000; Snowden et al., 2002; Ho et al., 2003; Larsen et al., 2015). 
Cognitive capabilities deteriorate further during the early stages of HD, with pre-clinical and 
early-stage HD populations showing evidence of progressive declines in executive functioning 
(Ho et al., 2003; Stout et al., 2012; Hart et al., 2013; Holl et al., 2013; Tabrizi et al., 2013), working 
memory (Tabrizi et al., 2011; Harrington et al., 2012; Stout et al., 2012), emotion recognition 
(Stout et al., 2012; Tabrizi et al., 2013) and attention (Harrington et al., 2012; Stout et al., 2012). 
Other cognitive domains impaired in HD include spatial learning and memory (Lange et al., 1995; 
Davis et al., 2003; Brandt et al., 2005; Pirogovsky et al., 2015), and cognitive flexibility (Lange et 
al., 1995; Lawrence et al., 1996; Lawrence et al., 1999; Lawrence et al., 2000; Aron et al., 2003; 
Tabrizi et al., 2013).  
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With regards to functional deficits in everyday life, an inability to independently manage 
finances often arises (Beglinger et al., 2010) and HD patients have displayed pathological 
gambling traits (De Marchi et al., 1998), which may be attributable to deficits in risky decision-
making (Stout et al., 2001). Difficulties in multitasking, concentrating, and short term memory 
are also known to occur, as are complications in planning, initiating and organising time, 
thoughts and activities (Novak and Tabrizi, 2010). The ability to safely drive vehicles is also 
diminished in HD, as a result of both motor and cognitive deficits (Devos et al., 2014). Both pre-
manifest and manifest HD patients consistently underestimate the extent of their cognitive 
decline (Ho et al., 2006; Williams et al., 2015), with evidence that this lack of awareness of 
cognitive decline may be associated with heightened disease severity (Cleret de Langavant et 
al., 2013). Estimating the prevalence of dementia in the HD population is difficult because there 
is currently no universally accepted criterion for diagnosing dementia in the disease (Paulsen, 
2011), as most criteria focuses on dementia features in Alzheimer’s disease (Peavy et al., 2010). 
Thus, the dementia diagnosis criteria used does not accurately reflect the unique deficits seen 
in HD. 
 
1.1.1.3 Psychiatric symptoms 
Similar to the cognitive phenotype in HD, psychiatric symptoms commonly manifest in the 
disease and frequently arise prior to motor symptom onset (Duff et al., 2007; Julien et al., 2007; 
Marshall et al., 2007; Tabrizi et al., 2009; Smith et al., 2012; Paulsen et al., 2014). Increased 
anxiety, apathy, depression, irritability, obsessive-compulsiveness, perseveration and suicidal 
ideation have all been observed prior to clinical diagnosis of HD (Duff et al., 2007; Tabrizi et al., 
2009; Epping et al., 2013; Tabrizi et al., 2013; Epping et al., 2016). Unlike the cognitive and motor 
phenotypes of HD, the psychiatric phenotype is not necessarily progressive (Walker, 2007; 
Phillips et al., 2008), however, recent longitudinal studies have reported progressive psychiatric 
disturbances (Tabrizi et al., 2013; Paulsen et al., 2014; Epping et al., 2016) and reduced 
awareness of such symptoms in pre-manifest HD patients (Epping et al., 2016). Depressive 
symptoms in pre-manifest HD sufferers do not increase in severity with proximity to disease 
diagnosis and are not associated with CAG repeat length (Epping et al., 2013). 
HD sufferers are known to have a higher incidence of depression than the general population 
(Marshall et al., 2007; Van Duijn et al., 2008) and approximately 33-69% of the HD population 
suffer from depression (Paulsen et al., 2005b; Van Duijn et al., 2008; Chisholm et al., 2013), 
which has recently been associated with changes in white matter microstructure in the HD brain 
(Gregory et al., 2015b). Apathy is estimated to be experienced by as many as 50-99% of patients 
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(Paulsen et al., 2001a; Thompson et al., 2012) while anxiety and irritability occur in estimates of 
34-61% and 38-83% of patients, respectively (Craufurd et al., 2001; Kulisevsky et al., 2001; 
Paulsen et al., 2001a; Thompson et al., 2012). However, a recent and currently ongoing 
multinational observational study of HD patients in Europe reports a lower incidence of 
depression (12.7%), apathy (28.1%), and irritability (13.9%) than these estimates (van Duijn et 
al., 2014). Similar to depressive symptoms, irritability has been found to be associated with 
white matter microstructural changes in the HD brain, whereas no such relationship was 
identified for the apathy phenotype (Gregory et al., 2015b). The frequency of suicide is higher 
in HD patients than in the general population (Dimaio et al., 1993; Hubers et al., 2011) and the 
risk of HD sufferers committing suicide is estimated to be 4-8 times higher than the suicide rate 
in the general population (Schoenfeld et al., 1984; Farrer, 1986; Dimaio et al., 1993; Bird, 1999). 
The risk of suicidal ideation or attempted suicide appears to be most prominent in the HD 
population either during the early stages of disease manifestation or immediately prior to a 
formal diagnosis of the condition (Schoenfeld et al., 1984; Paulsen et al., 2005a). Suicidal 
ideation in the European HD population has been correlated with shorter estimated disease 
duration, heightened depression, anxiety, and aggression, and a previous suicide attempt 
(Hubers et al., 2013). 
 
1.1.2 Molecular genetics of HD 
The age of onset of HD is correlated with the genetic basis of the condition. HD is inherited in an 
autosomal dominant manner as the result of a polymorphic expansion of a trinucleotide 
cytosine-adenine-guanine (CAG) repeat on the 5’ end of the Huntingtin gene (HTT) localised to 
chromosome 4p16.3 (MacDonald et al., 1993). CAG repeat lengths in the unaffected general 
population largely range from 9-35 repeats while expansions of HD sufferers have been reported 
between 36 and 121 repeats, with a mean repeat length of approximately 46, and age of disease 
onset is inversely correlated with CAG repeat length (Andrew et al., 1993; Duyao et al., 1993; 
Snell et al., 1993). However, CAG repeat length accounts for only approximately 50-70% of the 
variation in age of disease onset (Andrew et al., 1993; Rosenblatt et al., 2001; Novak and Tabrizi, 
2010; Rosenblatt et al., 2012), while the remaining variance is the result of other modifying 
genes and environmental and familial factors (Rosenblatt et al., 2001; Chattopadhyay et al., 
2003; Wexler and Res, 2004; Chattopadhyay et al., 2005; Dhaenens et al., 2009; Taherzadeh-
Fard et al., 2010). 
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1.1.2.1 CAG repeat length and age of onset 
An inverse correlation between CAG repeat length and age of disease onset has consistently 
been identified in the literature (Andrew et al., 1993; Duyao et al., 1993; Snell et al., 1993). 
However, for any CAG repeat length there is a wide range of associated ages of onset (Macmillan 
et al., 1993). For CAG repeat lengths of 40-50, which is the range in which 90% of the HD 
population lie, CAG repeat length accounts for only 40% of the variation in age of onset (Wexler, 
2012). Conversely, age of disease onset has been found to be fully dependent upon the 
expanded CAG repeat length in combination with recently identified disease modifying genetic 
loci, in studies examining over 4,000 HD patients (Lee et al., 2012; Lee et al., 2015b). Specifically, 
genome-wide association analysis identified a locus on chromosome 15 displaying two 
independent effects of single-nucleotide polymorphisms that accelerate or delay disease onset 
by 6.1 and 1.4 years, respectively, and also identified a variant at a chromosome 8 locus that 
hastens onset by 1.6 years (Lee et al., 2015b). However, 73% of the variation in age of onset is 
accounted for by CAG repeat length in cases of juvenile HD, which is associated with much larger 
CAG repeat sizes (Telenius et al., 1993). The HD phenotype is believed to be fully penetrant in 
individuals with 40 or more CAG repeats but individuals with 36-39 repeats show decreased 
penetrance, where they may or may not inherit the disease (Rubinsztein et al., 1994; Rubinsztein 
et al., 1996). The exact mechanisms contributing to the differences in penetrance are unknown, 
however, much of the variance has been found to be heritable, suggesting that genetic modifiers 
may play a role (Dhaenens et al., 2009; Langbehn et al., 2010; Taherzadeh-Fard et al., 2010). 
 
1.1.2.2 Juvenile HD 
The manifestation of HD before 21 years of age is known as juvenile HD (van Dijk, 1985), and has 
been reported in 1-15% of HD case studies, with a meta-analysis estimating that juvenile HD 
patients comprise 4.92% of the HD population (Quarrell et al., 2012). Juvenile HD is associated 
with considerably longer CAG repeat lengths than the adult onset form of the disease, with 
juvenile cases typically presenting with 60 or more repeats (Andresen et al., 2007), although a 
juvenile HD patient has been identified as having a repeat expansion as low as 48 (Ribai et al., 
2007). Similar to adult onset HD, juvenile cases often present with cognitive and psychiatric 
disturbances prior to the emergence of motor abnormalities (Duesterhus et al., 2004). These 
disturbances can include depression, anxiety, isolation, aggression, general changes in conduct 
and personality, and a decline in school performance (Rasmussen et al., 2000; Duesterhus et al., 
2004; Geevasinga et al., 2006). The movement disorder in juvenile cases of HD primarily consists 
of bradykinesia, dystonia and rigidity, and does not usually present with the chorea 
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characteristic of adult onset HD (Rasmussen et al., 2000; Ribai et al., 2007; Douglas et al., 2013). 
There is also an increased incidence of seizures, myoclonus and epilepsy in juvenile HD 
(Rasmussen et al., 2000; Gonzalez-Alegre and Afifi, 2006; Chuo et al., 2012; Douglas et al., 2013), 
and the juvenile condition may also have a more rapid and severe rate of progression than adult 
onset HD (van Dijk, 1985). 
 
1.1.3 Neuropathology 
1.1.3.1 Gross neuropathology 
Post-mortem examination and in vivo imaging techniques of HD brains have produced 
substantial evidence for the presence of widespread neuropathology in the disease (Scahill et 
al., 2013). Cell loss and astrogliosis occur most prominently in the caudate and putamen (Lange 
et al., 1976; Vonsattel et al., 1985; Vonsattel and DiFiglia, 1998), and this degeneration has been 
found to be a function of CAG repeat length and age of death (Furtado et al., 1996; Penney et 
al., 1997). Atrophy is not limited to the striatum and putamen, as extensive degeneration is seen 
in cortical structures (Rosas et al., 2003; Rosas et al., 2005; Rosas et al., 2008), including the 
angular gyrus in the parietal lobe (Macdonald et al., 1997) and the motor cortices (Macdonald 
and Halliday, 2002), and subcortical structures, such as the hypothalamus  (Kremer et al., 1991; 
Politis et al., 2008; Soneson et al., 2010), thalamus (Heinsen et al., 1999), brainstem (Rueb et al., 
2014), globus pallidus, subthalamic nucleus, substantia nigra and hippocampus (Spargo et al., 
1993; Vonsattel and DiFiglia, 1998; Rueb et al., 2014), as well as the cerebellum (Fennema-
Notestine et al., 2004). 
In vivo quantitative measurement of HD neurodegeneration has been made possible through 
the development of imaging techniques that include positron emission topography (PET), 
magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI) and diffusion 
tensor imaging (DTI). Imaging studies have confirmed that a loss of striatal volume and 
subsequent increase in lateral ventricle volume occurs in the brains of HD patients (Aylward et 
al., 1997; Aylward et al., 2004; Tabrizi et al., 2009; Aylward et al., 2011; Tabrizi et al., 2011; 
Tabrizi et al., 2012; Tabrizi et al., 2013), and that this atrophy can begin up to 11 years prior to 
estimated symptom onset in the caudate, and 9 years prior in the putamen (Aylward et al., 2004; 
Paulsen et al., 2004; Kipps et al., 2005; Aylward et al., 2011; Tabrizi et al., 2012). Alongside 
striatal volume loss, there is also evidence of global brain atrophy (Thieben et al., 2002; Henley 
et al., 2009; Squitieri et al., 2009; Tabrizi et al., 2012) and cortical thinning (Rosas et al., 2002; 
Rosas et al., 2005; Nopoulos et al., 2010; Johnson et al., 2015); all of which have been correlated 
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with the clinical HD phenotype (Rosas et al., 2005; Henley et al., 2008; Rosas et al., 2008; Tabrizi 
et al., 2013; Johnson et al., 2015).  
DTI has detected differences in white matter microstructure, in axial and radial diffusivity, for 
example, between pre-manifest HD, early HD and healthy brains (Gregory et al., 2015a; Odish 
et al., 2015), which show significant correlation with depressive and irritability symptoms in the 
disease (Gregory et al., 2015b). Levels of putaminal metabolites that act as neuronal integrity 
markers are also abnormal in pre-manifest and early HD (Sturrock et al., 2015), while elevated 
concentrations of  iron have been identified in the caudate and putamen of early, but not pre-
manifest, HD patients (Dumas et al., 2012). 
 
1.1.3.2 Cellular pathogenesis 
Gamma aminobutyric acid (GABA)-ergic medium spiny neurons (MSNs) form approximately 90-
95% of striatal neurons (Gerfen, 1992a, b) and are the neuron population most vulnerable to 
degeneration in HD, while striatal cholinergic medium aspiny interneurons remain relatively 
spared until later stages of the disease (Ferrante et al., 1985; Ferrante et al., 1987). Two key 
subpopulations of MSNs have been defined based upon their projection targets; striatopallidal 
neurons project to the globus pallidus, and striatonigral neurons project to the substantia nigra. 
Neurodegeneration differentially occurs in distinct subsets of neurons in these MSN 
subpopulations throughout HD. In early HD, striatopallidal neurons that contain enkephalin and 
project to the external segment of the globus pallidus (GPe) present with heightened levels of 
cell death compared to those that contain substance P and project to the internal segment of 
the globus pallidus (GPi) (Reiner et al., 1988). Striatonigral cells containing substance P with 
afferents to the substantia nigra pars compacta (SNc) are more resistant to cell death than those 
that project to the substantia nigra pars reticulata (SNr) (Reiner et al., 1988). Loss of the ‘indirect’ 
striatopallidal innervation in early HD results in disinhibition of the GPe, which then causes 
increased inhibition of the subthalamic nucleus (STN) and subsequently causes less excitatory 
drive to the GPi and SNr, resulting in disinhibition of the thalamus (Figure 1.1). This causes 
increased excitatory innervation from the thalamus to the motor cortex and produces the 
choreic movements that characterise HD. 
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Figure 1.1. The direct and indirect pathways of the basal ganglia in HD (adapted from 
Alexander et al. 1990). Dashed lines represent pathways degenerated in HD. DRD1 = Dopamine 
receptor D1; DRD2 = Dopamine receptor D2; Enk = Enkephalin-containing neurons; Sub P = 
Substance P-containing neurons. 
 
In the early stages of HD, loss of cortical volume develops prominently in posterior cortical 
regions, which include the middle occipital and temporal lobes, as well as the angular and 
supramarginal gyri (Rosas et al., 2002). As the disease progresses, cortical volume loss becomes 
more generalised and extends to more anterior cortical areas, causing the frontal lobes to be 
severely affected (Rosas et al., 2002). The cortical cells most vulnerable to degeneration are the 
pyramidal neurons of the middle to deep cortical layers (layers III, V and VI) (Cudkowicz and 
Kowall, 1990; Hedreen et al., 1991; Macdonald and Halliday, 2002). Cortical cells primarily 
produce brain derived neurotrophic factor (BDNF) and transport it to the striatum in an axonal 
anterograde manner through corticostriatal afferents (Altar et al., 1997). Degeneration of 
Dopamine 
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cortical cells and corticostriatal afferents during HD pathology therefore reduces the amount of 
BDNF available in the striatum and may contribute to the striatal cell death found in the disease 
(Zuccato and Cattaneo, 2007), with evidence that HD results in decreased cortical BDNF 
production (Zuccato et al., 2001) and loss of BDNF transport activity, causing a loss of 
neurotrophic support and neuronal toxicity (Gauthier et al., 2004).  
Loss of cortical interneurons has been associated with symptom heterogeneity in HD; patients 
with severe motor symptoms display significant loss of calbindin interneurons in the primary 
motor cortex, which is not seen in patients with a dominant mood phenotype (Kim et al., 2014). 
Conversely, HD patients with major mood disorder showed significant loss of calbindin, 
calretinin, and parvalbumin interneurons in the anterior cingulate cortex, while the 
aforementioned patients with dominant motor symptoms presented with no interneuron loss 
in this area. This suggests that region-specific degeneration of particular cortical interneurons 
may play a key role in the neural basis of different HD phenotypes. 
Dendritic alterations also occur in HD, with disease progression producing a diphasic pattern of 
dendrite modification (Ferrante et al., 1991). Cases of HD with moderate severity predominantly 
presented with the initial proliferative changes in MSNs, whereby the number and size of 
dendrite spines were increased, which may reflect an early compensatory mechanism designed 
to remodel degenerating contacts (Ferrante et al., 1991). By contrast, patients with severe 
grades of HD pathology primarily presented with degenerative alterations to MSNs, such as 
dendritic swelling and discernible spine loss (Ferrante et al., 1991).  
 
1.1.3.3 Molecular pathogenesis 
Ubiquitin- and Huntingtin protein (HTT)-rich neuronal intranuclear inclusions (NIIs) have been 
identified in HD patients (DiFiglia et al., 1997; Becher et al., 1998; Gutekunst et al., 1999) and 
several mouse models of the disease (Davies et al., 1997; Lin et al., 2001; Bayram-Weston et al., 
2012c, a, b; Bayram-Weston et al., 2012d). In HD patients, NIIs are present in MSNs of the 
striatum but not in neurons of the globus pallidus or cerebellum, while neurons with NIIs have 
been detected in all cortical layers (DiFiglia et al., 1997). NII-containing cortical neurons are more 
commonly found in juvenile HD patients, where they comprise 38-52% of neurons, than in adult 
onset sufferers, where only 3-6% of cortical neurons contain NIIs (DiFiglia et al., 1997). The 
presence of NIIs before the onset of behavioural symptoms and substantial neuronal death 
(Davies et al., 1997; Ordway et al., 1997), in combination with the correlation between NII 
presence and neuropathological severity (Davies et al., 1997; DiFiglia et al., 1997), lead to the 
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proposal that NIIs are causative in HD pathology, with recent evidence suggesting that NIIs may 
act to prevent clearance of mutant HTT (mHTT) and thereby enhance cellular toxicity (Tsvetkov 
et al., 2013). Conversely, an opposing theory is that NIIs may act as a cellular mechanism to 
protect neurons from mHTT-induced cell death (Saudou et al., 1998; Gutekunst et al., 1999; 
Kuemmerle et al., 1999; Arrasate et al., 2004). This has been proposed as a result of evidence 
that exposing mHTT-transfected striatal neurons to conditions that suppress the formation of 
NIIs leads to increased levels of cell death (Saudou et al., 1998), whereas NII formation reduces 
both the level of mHTT within the neuron and the risk of cell death (Arrasate et al., 2004). Further 
support for the theory that protein aggregation formation does not correspond to disease 
severity comes from evidence that NIIs are predominantly observed in the striatal cholinergic 
interneurons spared by degeneration in HD, while few aggregates are detected in the MSNs 
vulnerable to mHTT toxicity (Kuemmerle et al., 1999). Similarly, almost 50% (49.2%) of the mHTT 
toxicity resistant striatal population were found to contain smaller neuropil and cytoplasmic 
inclusions, in comparison to only 4% of the MSN population (Kuemmerle et al., 1999). Dystrophic 
neurites are known to arise in an uneven distribution through cortical layers V and VI in HD 
brains, and are present at a higher incidence in adult onset cases compared to juvenile patients 
(DiFiglia et al., 1997; Sapp et al., 1997). 
 
1.1.4 Epidemiology and inheritance 
Despite occurring worldwide, HD exhibits significant geographical differences in its prevalence, 
similar to the differential prevalence of spinocerebellar ataxias (a group of diseases also caused 
by CAG repeat expansions) identified between Japanese and Caucasian populations (Takano et 
al., 1998). For example, the prevalence of HD in individuals aged 21 or over has been recently 
been estimated at between 4.00 to 12.30 per 100,000 individuals in the United Kingdom 
(Hoppitt et al., 2011; Evans et al., 2013), approximately 2.12 per 100,000 individuals in Finland 
(Sipila et al., 2015), and 13.7 per 100,000 individuals in the general population of Canada (Fisher 
and Hayden, 2014). The general prevalence of HD in Caucasian populations is estimated at 5.70 
per 100,000 individuals, which is much higher than the 0.40 per 100,000 individuals incidence 
rate reported in Asia (Pringsheim et al., 2012), while the incidence of HD in sub-Saharan African 
populations is approximately 3.50 per 100,000 individuals (Lekoubou et al., 2014). The 
differences in prevalence for HD between European and East-Asian populations has been 
suggested to arise as a result of geographical differences in HTT haplotypes that influence CAG-
tract instability (Warby et al., 2009; Warby et al., 2011). A set of 22 single nucleotide 
polymorphisms that constitute a single haplogroup, where inheritance of the haplogroup has a 
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predisposing influence on CAG instability in HTT, has been found to be significantly enriched in 
HD patients of European origin (>95%) but is absent in the East Asian populations of Japan and 
China (Warby et al., 2009). In East-Asian populations, the majority of HD chromosomes are 
associated with  an alternate haplogroup, and both East-Asian and European populations share 
a similar low level of HD on this alternate haplogroup (Warby et al., 2011). This evidence 
suggests that CAG expansion bias may occur in different geographical populations because of 
genetic cis-elements within the haplotype that influence CAG instability in HTT, potentially 
through different mutational mechanisms for the different haplogroups. This hypothesis is 
supported by recent evidence suggesting that a single ancestral chromosome contributes to 55% 
of the European HD population, and that the CAG tract instability in this population may be the 
result of variants produced by de novo mutations, simple recombination, structural alteration, 
gene conversion or double recombination within the ancient haplotype (Lee et al., 2015a). 
Carrying a CAG repeat of greater than 39 repeats within HTT appears to produce complete 
penetrance of the HD phenotype (Walker, 2007). A lower CAG-tract range of 36-39 repeats 
causes the HD phenotype to show reduced penetrance, with a number of individuals carrying 
CAG repeats within this range being reported to live unaffected by HD up to 95 years of age 
(Goldberg et al., 1993; Rubinsztein et al., 1996) whilst others carrying CAG repeats within this 
range display the HD phenotype (Duyao et al., 1993; Kremer et al., 1994; Rubinsztein et al., 
1996). There are also reports of individuals displaying HD phenotypes with CAG repeat lengths 
as low as 31-34 CAGs (Andrich et al., 2008; Groen et al., 2010). In these cases, known 
phenocopies have been dismissed but post-mortem neuropathological examinations have not 
yet been possible as a means of confirming HD diagnoses. Taken together, these cases suggest 
that, within this reduced penetrance repeat size range of 36-39 CAGs, HD penetrance may be 
moderated by additional factors, and consequently that these factors may also influence the 
variation in age of onset observed at all CAG repeat lengths and contribute to the heightened 
disease severity exhibited in the presence of longer repeat lengths. 
The expanded CAG repeat within HTT is known to be unstable (MacDonald et al., 1993), 
particularly during parental transmission, where approximately 80% of inherited alleles display 
alterations in CAG repeat length (Duyao et al., 1993). These alterations in CAG repeat length 
exist in the form of both expansions and contractions of repeat length, and occur in 
transmissions from parents of either sex, although the largest expansions to HTT CAG repeat 
length predominantly arise from paternal transmissions (Derooij et al., 1993; Duyao et al., 1993; 
Zuhlke et al., 1993a; Kremer et al., 1995; Norremolle et al., 1995; Ranen et al., 1995). This 
paternal transmission-derived CAG repeat length expansion is believed to arise during 
spermatogenesis, as the CAG repeat lengths of HD patients display a large degree of mosaicism 
12 
 
between spermatocytes (Macdonald et al., 1993; Zuhlke et al., 1993a; Telenius et al., 1995), and 
because repeat lengths much larger than those found in patient lymphocytes have been 
observed in these cells (Duyao et al., 1993; Macdonald et al., 1993; Wheeler et al., 2007). 
The prevalent CAG expansion event arising during parental transmission of HTT has contributed 
to the occurrence of ‘anticipation’ in HD families whereby offspring inheriting the HD phenotype 
tend to have a lower age of onset in comparison to the affected parent (Ridley et al., 1988). 
Paternal transmission of the HD allele is believed to produce a stronger anticipation effect and 
therefore an earlier age of onset in offspring (Ridley et al., 1988; Roos et al., 1991; Snell et al., 
1993; Ranen et al., 1995). This paternal transmission anticipation effect is highlighted in a cohort 
of HD families where paternally transmitted cases of HD presented an age of onset that is on 
average 9.11 years earlier than in the parent, while maternally transmitted cases displayed a 
mean difference of only 2.75 years (Snell et al., 1993). An investigation in a cohort of juvenile 
HD patients of Italian origin did not replicate this paternal transmission anticipation effect, 
despite reporting larger intergenerational CAG repeat length changes in patients with paternally 
transmitted HD in comparison to counterparts inheriting the maternal mutation (Cannella et al., 
2004). Nonetheless, this supports the suggestion that CAG repeat length is not the sole 
determinant of age of onset in HD. 
The higher risk of CAG repeat length expansion during spermatogenesis compared to oogenesis 
(Zuhlke et al., 1993a) causes both juvenile and sporadic forms of HD to be more highly associated 
with paternally inherited cases of HD, rather than cases arising from maternal transmission of 
the HD allele (Ridley et al., 1988; Derooij et al., 1993; Goldberg et al., 1993; Telenius et al., 1993; 
Ranen et al., 1995; Cannella et al., 2004). As mentioned in section 1.1.1.5, juvenile HD is 
associated with longer CAG repeat lengths than adult onset cases of the disease (MacDonald et 
al., 1993; Andresen et al., 2007), and shows high frequency of paternal inheritance, with 
approximately 70-80% of cases being paternally transmitted (Telenius et al., 1993; Cannella et 
al., 2004); the frequency of paternal inheritance rises to 90% in cases where children display 
disease onset under 10 years of age (Telenius et al., 1993). Sporadic cases of HD, where offspring 
inherit an allele containing a CAG repeat expanded to a fully penetrant length from an 
unaffected parent, are estimated to comprise as many as 10% of HD cases (Almqvist et al., 2001; 
Falush et al., 2001), and have also displayed patterns of paternal inheritance (Derooij et al., 
1993; Goldberg et al., 1993; Zuhlke et al., 1993b); multiple cases of sporadic HD have been 
reported where the unaffected father carries an intermediate allele containing 27-35 CAG 
repeats, or a reduced penetrance allele consisting of 36-39 CAG repeats, that has expanded to 
fully penetrant repeat sizes of 42-46 CAGs in offspring (Derooij et al., 1993; Goldberg et al., 1993; 
Zuhlke et al., 1993b), as a result of meiotic variability in CAG repeat lengths (Zuhlke et al., 1993b). 
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Conversely, the majority of European HD patients share the same haplotype, of which two 
variants are associated with CAG repeat length instability (Warby et al., 2009; Warby et al., 
2011). Thus, these ‘HD-haplotypes’ are more susceptible to CAG repeat length expansion and 
account for many sporadic cases of HD (Myers et al., 1993; Goldberg et al., 1995; Warby et al., 
2011). 
 
1.1.5 Current treatment and therapeutics 
Despite HD being a monogenic disease with a known gene and gene product being identified 
over 20 years ago (MacDonald et al., 1993), there is no known cure for the disease at the time 
of writing. Nevertheless, there are a number of pharmacological agents currently in use that aim 
to alleviate disease symptom severity. Hyperkinetic movements, such as chorea, dystonia and 
myoclonus, are the motor symptoms typically targeted for pharmacological intervention in HD 
(Shannon and Fraint, 2015); the antidopaminergic agent tetrabenazine is currently the only 
approved medication for treating chorea in HD in the United States (Venuto et al., 2012; 
Shannon and Fraint, 2015), whilst European experts prefer the use of the antipsychotics 
olanzapine and risperidone (Burgunder et al., 2011), and these antipsychotics also show 
potential to alleviate the dystonia and Parkinsonism that may arise in patients (Venuto et al., 
2012). Antiparkinsonian medications such as levodopa and amantadine can also be used to treat 
Parkinsonism in HD patients (Frank, 2014). To alleviate myoclonus, a number of anti-epileptic 
drugs can be prescribed, such as valproic acid and clonazepam (Adam and Jankovic, 2008). 
Selective serotonin reuptake inhibitors, serotonin-noradrenaline reuptake inhibitors, and both 
tricyclic and atypical antipsychotics are frequently utilised in the treatment of the psychiatric 
disturbances seen in HD patients, such as depression, anxiety and irritability, despite little 
evidence from clinical trials on the usefulness of these drugs in effectively alleviating these 
symptoms in HD (Venuto et al., 2012; Frank, 2014). Treating the cognitive decline displayed in 
HD is particularly challenging, with no pharmacological intervention currently available (Venuto 
et al., 2012; Frank, 2014; Shannon and Fraint, 2015). 
 
1.2 HTT 
1.2.1 Gene expression, alternative splicing and somatic mosaicism 
HTT is extensively expressed throughout the body, with particular enrichment in the brain and 
testes (Li et al., 1993; Strong et al., 1993). Within the brain, HTT expression is widespread, 
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though it is not enriched within the striatum, the primary site of disease pathology, and displays 
greater enrichment in neurons compared with glial cells (Li et al., 1993; Strong et al., 1993; 
Landwehrmeyer et al., 1995), with the corticostriatal projection pyramidal neurons of cortical 
layers III and V showing strongest HTT neuronal expression (Fusco et al., 1999). Peripheral 
expression of HTT is generally accepted to be ubiquitous, occurring in tissues such as testis, lung, 
spleen, liver, heart and kidney (Li et al., 1993; Strong et al., 1993). 
In the human transcriptome, the majority of multi-exon genes are alternatively spliced (Pan et 
al., 2008), which is the process by which deoxyribonucleic acid (DNA) encoding a single gene can 
generate multiple messenger ribonucleic acid (mRNA) transcripts, and thus functionally 
different proteins, through the inclusion or exclusion of specific exons (Kim et al., 2008a). HTT 
contains 67 exons known to produce two major mRNA transcripts dependent upon differential 
polyadenylation sites on the 3’ end of the HTT mRNA; a 10.3 kb transcript that is predominantly 
expressed throughout peripheral tissues, and a 13.7 kb transcript with an extended untranslated 
region at the 3’ end of the mRNA sequence, which is predominantly expressed in the brain (Lin 
et al., 1993). Recently, a series of novel alternatively spliced HTT mRNA variants have been 
identified in the brains of post-mortem HD patients (Sathasivam et al., 2013; Hughes et al., 2014; 
Labadorf and Myers, 2015; Mort et al., 2015) and mouse models of the disease (Sathasivam et 
al., 2013; Hughes et al., 2014), as well as in human embryonic stem cells (Ruzo et al., 2015). It is 
postulated that these HTT mRNA splice variants may give rise to distinct isoforms of the HTT 
protein; thus it is possible that alternative splicing of HTT plays an integral role in HD pathology. 
In line with this theory, Sathasivam et al. (2013) discovered the presence of a short 
polyadenylated HTT mRNA transcript, which is created by CAG repeat length-dependent 
aberrant splicing of exon 1 HTT, in the brains of all HD mouse models expressing mHtt or mHTT, 
as well as in fibroblast cell lines derived from HD patients and post-mortem HD brains, that is 
translated into an exon 1 HTT protein believed to be pathogenic in HD. 
The presence of an expanded CAG repeat has also been found to alter the expression of HTT in 
lymphoblast cultures taken from heterozygote juvenile HD patients, whereby the expression of 
the mutant HD allele is relatively reduced in comparison to the healthy allele (Gutekunst et al., 
1995; Persichetti et al., 1996). The length of the pathological CAG repeat is believed to affect the 
degree of reduced expression in these studies, and a similar observation has been made in 
expanded CAG repeat-transfected striatal rat cultures (Miller et al., 2010). However, it is not 
known whether this reduction in mutant HTT allele expression is the result of a CAG repeat 
length-dependent reduction in transcription, alteration of the subsequent HTT protein 
processing, or aberrant splicing of HTT, as identified by Sathasivam et al. (2013). 
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Somatic mosaicism has been identified in human HD tissues as well as in models of the disease, 
with evidence of somatic expansion of the CAG repeat in HTT in blood, brain, kidneys, liver, heart 
and stomach tissue (Telenius et al., 1994; Mangiarini et al., 1997; Wheeler et al., 1999; Ishiguro 
et al., 2001; Mollersen et al., 2010), where initially larger CAG repeats have a greater propensity 
for expansion than smaller CAG repeats (Wheeler et al., 1999; Cannella et al., 2009). Neural 
tissue displays greater CAG repeat length instability than peripheral tissues (Telenius et al., 1994; 
Mangiarini et al., 1997), occurring to a greater extent in neurons than glia (Shelbourne et al., 
2007), and is most marked in the neural regions showing greatest neurodegeneration in HD, the 
striatum and cortex, while being observed to a lesser extent in the cerebellum, where 
neuropathology is less extensive (Telenius et al., 1994; Mangiarini et al., 1997; Ishiguro et al., 
2001; Kennedy et al., 2003; Mollersen et al., 2010). Human pre-symptomatic HD carriers have 
been shown to exhibit greatest CAG repeat length instability in the striatum, where CAG repeat 
expansions have been detected that exceed 300 and 1000 CAG repeats (Kennedy et al., 2003; 
Shelbourne et al., 2007). By contrast, the cortex displays higher CAG repeat instability than the 
striatum in late stage HD brains (Shelbourne et al., 2007). These observations support the 
proposal that somatic CAG repeat expansion instability may be a mechanism for the progressive 
and cell-selective neurodegeneration that occurs in HD. 
 
1.2.2 Protein structure, localisation and function 
HTT is a protein containing 3,144 amino acids with a molecular weight of approximately 348 kDa 
(MacDonald et al., 1993), and this high molecular weight has so far prevented the elucidation of 
its structure by mass spectrometry and crystallography studies. One feature of HTT that has 
undergone substantial investigation is the polyglutamine tract (encoded by the CAG repeat) 
containing N-terminus. The first 17 amino acids of HTT’s N-terminus have been shown to contain 
a nuclear export signal (Zheng et al., 2013) and form an α-helical structure (Atwal et al., 2007; 
Kim et al., 2009; Dlugosz and Trylska, 2011; Michalek et al., 2013) that modulates HTT 
localisation, aggregation and toxicity (Atwal et al., 2007; Rockabrand et al., 2007; Maiuri et al., 
2013; Arndt et al., 2015). The structure of this α-helix can be altered by pathogenic CAG repeat 
expansion (Legleiter et al., 2010; Dlugosz and Trylska, 2011; Peters-Libeu et al., 2012; 
Vachharajani et al., 2012), mutations to amino acids 1-17 (Atwal et al., 2007), and by post-
translational modifications such as phosphorylation events (Aiken et al., 2009; Atwal et al., 
2011).  
The polyglutamine tract begins at the 18th amino acid of the N-terminus of  HTT (MacDonald et 
al., 1993) and forms a polar zipper structure, which is a complex that promotes transcription 
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factor binding, thus suggesting that HTT may play a role in regulation of transcription (Perutz et 
al., 1994). Expansion of the polyglutamine tract within the N-terminus is believed to contribute 
to mHTT aggregate formation and cellular toxicity by reducing the stability of the HTT protein, 
promoting N-terminal fragment aggregation, and impairing degradation of such fragments (Li 
and Li, 1998; Mende-Mueller et al., 2001; Landles et al., 2010; Juenemann et al., 2011; 
Vachharajani et al., 2012). HTT destabilisation can occur as a result of disruption of the α-helical 
structure of HTT amino acids 1-17; the α-helical structure of the non-pathogenic HTT N-terminus 
is stabilised by interactions between amino acids 1-17 and the polyproline rich COOH-terminal 
that follows the polyglutamine tract (Dlugosz and Trylska, 2011). The expanded polyglutamine 
tract in mHTT prevents these stabilising interactions, which causes ‘loosening’ of the α-helix and 
allows the N-terminus to form more aberrant associations and structures (Li et al., 2007; Dlugosz 
and Trylska, 2011). This mechanism of pathogenicity has been challenged, however, by evidence 
that CAG repeat length has no effect on murine HTT interactions in the absence of mHTT 
aggregation, and that it is the presence of aggregates that causes aberrant spatial distribution 
and solubility of HTT protein partners (Davranche et al., 2011). 
The proline-rich C-terminus of HTT, found downstream of the polyglutamine tract, contains a 
nuclear export signal (Xia et al., 2003) and is structurally dynamic; being capable of existing in 
both a polyproline II helical and random coil formation (Isas et al., 2015). Downstream of the 
CAG repeat sequence, HTT also contains multiple huntingtin, elongation factor 3, protein 
phosphatase 2A, and TOR 1 (HEAT) repeat sequences, which are repeatedly occurring binding 
regions consisting of sequences of ~40 amino acids that promote protein-protein interactions 
(Andrade and Bork, 1995). This suggests that HTT may bind to a variety of proteins to perform 
its physiological function. The number of HEAT repeats found in HTT is disputed, with one 
laboratory identifying the presence of 16 HEAT repeats, arranged into four clusters, along the 
length of HTT (Tartari et al., 2008), while another has reported the presence of up to 36 HEAT 
repeats (Takano and Gusella, 2002). Also present in HTT are a number of caspase and calpain 
proteolytic cleavage sites that lead to the generation of a variety of fragments following HTT 
protein cleavage (Wellington et al., 1998; Gafni et al., 2004; Hermel et al., 2004), and the 
presence of a pathogenic CAG repeat length in HTT can lead to aberrant processing of the mHTT 
protein and cause cell toxicity (Martindale et al., 1998; Wellington et al., 2002; Juenemann et 
al., 2011; Ratovitski et al., 2011; El-Daher et al., 2015). 
Within the cell, HTT subcellular localisation may be regulated by kinase signalling activity 
(Bowles et al., 2015) and the protein is associated with a variety of subcellular compartments 
and organelles that include dendrites, nerve terminals, axons and cell bodies, as well as the 
nucleus, mitochondria, microtubules, endoplasmic reticulum, Golgi complex and vesicles 
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(DiFiglia et al., 1995; Sharp et al., 1995; Trottier et al., 1995; Velier et al., 1998; Hilditch-Maguire 
et al., 2000; Hoffner et al., 2002; Kegel et al., 2002). This diversity in subcellular localisation 
hinders efforts to define its molecular function. 
While the exact functions of HTT have yet to be elucidated, it is known to play a number of 
diverse molecular roles. The HTT protein is known to be integral to embryonic development 
because total absence of murine Htt results in embryonic lethality of knock-out mice before day 
8.5 (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995). A role in cerebral spinal fluid 
homeostasis regulation has also been discovered through evidence that conditional inactivation 
of Htt in the midbrain and hindbrain of mice produces congenital hydrocephalus (Dietrich et al., 
2009). There is also a large body of evidence implicating HTT in modulating transcriptional 
regulation (Cha et al., 1999; Kegel et al., 2002; Hodges et al., 2006; Kuhn et al., 2007; Benn et al., 
2008b; Kim et al., 2008b; Futter et al., 2009), with the protein capable of up-regulating BDNF 
transcription (Zuccato et al., 2001) by indirectly interacting with repressor element-1 silencing 
transcription factor/neuron restrictive silencer factor (REST/NRSF) to repress the silencing 
activity of the neuron restrictive silencing element (Zuccato et al., 2003; Shimojo, 2008), while 
pathogenic CAG repeat lengths have been shown to disrupt this silencing activity (Zuccato et al., 
2007; Ravache et al., 2010; Soldati et al., 2013) as well as cAMP-responsive element binding 
protein (CREB)-dependent gene transcription (Shimohata et al., 2000; Steffan et al., 2000). 
Recently HTT has been found to act as a scaffold protein for selective macroautophagy, thus 
identifying a role for the protein in protection against cellular stress (Rui et al., 2015). Alongside 
these roles, HTT is also associated with protein and vesicular trafficking (Velier et al., 1998; 
Hilditch-Maguire et al., 2000; Gauthier et al., 2004; Strehlow et al., 2007), iron homeostasis 
(Hilditch-Maguire et al., 2000), neuronal synaptic activity (Xu et al., 2013), and regulation of 
mammary stem cell division and differentiation (Elias et al., 2014). 
 
1.3 Genetic mouse models of HD 
The identification of HTT as the single causative gene in HD has led to the development of a 
number of animal models of HD that are designed to recreate the molecular and behavioural 
phenotypes of the human disease. Genetic manipulation in mice has allowed the effects of Htt 
CAG repeat length, protein fragment size and expression levels to be explored in physiological 
models of HD. This has enabled characterisation of HD pathology at the cellular, molecular and 
behavioural levels across the animals’ lifespan, generating further understanding of the 
pathological effects of mHTT. Mouse and rat models of HD also allow the assessment of 
potential therapeutics in vivo and are therefore a crucial aspect of the future of HD research, as 
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any treatments for the disease are unlikely to reach clinical trials without in vivo evidence of 
their efficacy. 
Many mouse models of HD are currently available and the model to be utilised is dependent on 
the requirements and objectives of the study, as different models exhibit differences in 
molecular and behavioural phenotypes, lifespan, and rates of disease progression. Mouse 
models are generally grouped depending on their genetic manipulation; transgenic models are 
created by insertion of either truncated or full length HTT indiscriminately into the genome, 
while ‘knock-in’ models are generated by insertion of a pathological length CAG repeat 
expansion into the mouse genome at the appropriate location on the Htt gene, which is 
expressed under the control of the endogenous mouse promoter. Inducible mouse models of 
HD have also been created, where a truncated HTT exon 1, or a chimeric HTT/Htt exon 1, is 
inserted into the mouse genome under the control of a tetracycline-regulated system, allowing 
inducible expression of mHTT in the presence or absence of doxycycline. Further details 
regarding the most commonly used mouse models of HD can be found in Table 1.1. 
 
Background 
strain 
Transgene Promoter 
CAG 
repeat 
length 
Lifespan Reference 
N-terminal transgenic models 
R6/1 
CBA x 
C57BL/6 
Exon 1 human 
HTT 
Human 
HTT 
116 32-40 weeks 
(Mangiarini et 
al., 1996) 
R6/2 
CBA x 
C57BL/6 
Exon 1 human 
HTT 
Human 
HTT 
150 10-13 weeks 
(Mangiarini et 
al., 1996) 
N171-82Q 
C3H/HEJ x 
C57BL/6 
First 171 
amino acids 
human HTT 
Mouse 
prion 
promoter 
82 16-22 weeks 
(Schilling et al., 
1999; Schilling 
et al., 2004) 
Full-length transgenic models 
YAC72 FVB/N Human HTT 
Human 
HTT 
72 Normal 
(Hodgson et al., 
1999) 
YAC128 FVB/N Human HTT 
Human 
HTT 
120 Normal 
(Slow et al., 
2003) 
BACHD FVB/N Human HTT 
Human 
HTT 
97 Normal 
(Gray et al., 
2008) 
Knock-in models 
HdhQ72-
80 
129Sv x 
C57BL/6 
Expanded CAG 
inserted in 
endogenous 
mouse Htt 
Mouse 
Htt 
72, 80 Normal 
(Shelbourne et 
al., 1999) 
HdhQ92 
CD1 x 
129SvEv 
Endogenous 
mouse Htt 
with chimeric 
human/mouse 
exon 1 
Mouse 
Htt 
90 Normal 
(Wheeler et al., 
1999) 
HdhQ94 C57BL/6 
Endogenous 
mouse Htt 
with chimeric 
human/mouse 
exon 1 
Mouse 
Htt 
94 Normal 
(Levine et al., 
1999; Menalled 
et al., 2002) 
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HdhQ111 
CD1 x 
129SvEv 
Endogenous 
mouse Htt 
with chimeric 
human/mouse 
exon 1 
Mouse 
Htt 
109 Normal 
(Wheeler et al., 
1999; Wheeler 
et al., 2002) 
HdhQ140 C57BL/6 
Endogenous 
mouse Htt 
with chimeric 
human/mouse 
exon 1 
Mouse 
Htt 
140 Normal 
(Menalled et 
al., 2003) 
HdhQ150 
129/Ola x 
C57BL/J6 
Expanded CAG 
inserted in 
endogenous 
mouse Htt 
Mouse 
Htt 
150 Normal 
(Lin et al., 
2001) 
HdhQ200 C57BL/6J 
Expanded CAG 
inserted in 
endogenous 
mouse Htt 
Mouse 
Htt 
200 
Euthanised at 
80 weeks 
(Heng et al., 
2010) 
zQ175 C57BL/6J 
Expanded CAG 
inserted in 
endogenous 
mouse Htt 
Mouse 
Htt 
175 
Homozygotes: 
90 weeks 
Heterozygotes: 
Normal 
(Menalled et 
al., 2012) 
Inducible models 
HD94 
CBA x 
C57BL/6 
Chimeric 
human/mouse 
exon 1 HTT 
TetO + 
tTA 
94 Normal 
(Yamamoto et 
al., 2000) 
Inducible-
148Q 
C57BL/6 
First 171 
amino acids 
human HTT 
PrP + tTA 148 28-40 weeks 
(Tanaka et al., 
2006) 
Table 1.1. Key features and lifespans of commonly used mouse models of HD. Abbreviations: 
TetO = TetO operator; tTa = tetracycline-regulated transactivator; Prp = prion promoter. 
 
1.3.1 Behavioural phenotypes 
Each mouse model of HD has its own unique assortment of behavioural phenotypic 
characteristics (summarised in Table 1.2). The R6/1, R6/2, and N171-82Q mouse models, known 
as the N-terminal transgenic models, develop motor irregularities at an earlier age than full 
length transgenic and pathological length knock-in models, while also presenting with greatly 
diminished life spans (Table 1.1). YAC72, YAC128 and BACHD animals are full-length transgenic 
models of HD, meaning they contain a full length human HTT transgene, and develop similar 
behavioural phenotypes as the N-terminal transgenic models, but with delayed onset (Table 
1.2). Despite expressing CAG repeats that are much longer than those found in transgenic mouse 
models of HD, knock-in models tend to display less severe phenotypes than their transgenic 
counterparts, with delayed onset of motor symptoms and lifespans equivalent to wild-type mice 
(Table 1.1 and Table 1.2).  
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 Motor phenotypes Cognitive phenotypes Psychiatric phenotypes References 
N-terminal transgenic models 
R6/1 
Hyperactivity [4w]; hypoactivity & nest-
building impairments [6w]; balance 
beam deficits [8w]; irregular gait, 
choreiform movements, tremor [15w]; 
rotarod deficits [18w] 
Nest-building impairments [6w]; 
procedural learning and spatial 
memory deficits [8w]; visual & reversal 
learning deficits [15w]; ↓ novel object 
exploration [22w]  
↓ startle response & prepulse 
inhibition [8w]; ↓ fear response [12w]; 
↑ clasping [14w]; ↓ anxiety [24w] 
(Mangiarini et al., 1996; Naver 
et al., 2003; Bolivar et al., 
2004; Hodges et al., 2008; 
Brooks et al., 2012e; Rattray 
et al., 2013) 
R6/2 
Hyperactivity [3w]; hypoactivity [4.5w]; 
↓ balance beam, rotarod & swimming 
abilities [5w]; ↓ grip strength [7w]; ↓ 
rearing [8w]; irregular gait, choreiform 
movements, tremor [9w]; ↑ weight 
loss [13w] 
Spatial memory deficits [3.5w]; 
contextual memory deficits [5w]; 
working memory deficits [6w]; reversal 
learning deficits [6.5w]; visual 
discrimination & response inhibition 
deficits [9w]  
↑ clasping [9w]; ↓ anxiety, startle 
reactivity & prepulse inhibition [8w] 
(Mangiarini et al., 1996; File 
et al., 1998; Carter et al., 
1999; Bolivar et al., 2003; 
Hickey et al., 2005; Oakeshott 
et al., 2013; Li et al., 2015) 
N171-82Q 
Tremor, abnormal gait, hypokinesis, 
uncoordination, ↑ weight loss [10w]; 
rotarod deficits [13w]; hypoactivity 
[21w] 
Spatial learning & memory deficits 
[12.5w] 
↑ clasping [10w]; ↑ anxiety [12w] 
(Schilling et al., 1999; Schilling 
et al., 2001; Schilling et al., 
2004; Potter et al., 2010; 
Swarnkar et al., 2015) 
Full-length transgenic models 
YAC72 
Abnormal gait, choreoathetoid 
movements, disorientation & balance 
beam deficits [39w]; ↑ weight loss 
[52w]; hypoactivity & rotarod deficits 
[69.5w] 
n.r. ↑ clasping [39w] 
(Hodgson et al., 1999; Seo et 
al., 2008) 
YAC128 
↑ weight gain [8w]; hyperactivity 
[13w]; rotarod deficits [17-26w]; 
balance beam deficits [34.5w]; 
hypoactivity [52w] 
Motor & reversal learning deficits 
[8.5w]; spatial learning deficits [26w]; 
motor learning deficits [34.5w] 
↓ startle response & prepulse 
inhibition [52w] 
(Slow et al., 2003; Van 
Raamsdonk et al., 2005b; Van 
Raamsdonk et al., 2006; 
Brooks et al., 2012c) 
BACHD 
Rotarod deficits [4w]; ↑ weight gain 
[8-26w]; hyperactivity [13w]; gait 
abnormalities [39w]; hypoactivity 
[52w] 
Reversal learning & set-shifting deficits 
[39w]; impaired nest-building [40w]; 
novel stimuli discrimination deficits 
[87w] 
↑ grooming [20w]; ↑ anxiety & fear 
response [39w]; depressive-like 
phenotype in forced swimming test 
[52w] 
(Gray et al., 2008; Menalled et 
al., 2009; Abada et al., 2013; 
Farrar et al., 2014; Wang et 
al., 2014; Estrada-Sanchez et 
al., 2015) 
Knock-in models 
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HdhQ72-80 Rotarod deficits [17w] n.r. ↑ aggression [13w] 
(Shelbourne et al., 1999; 
Kennedy et al., 2003) 
HdhQ92 
↓ grip strength [17w]; ↑ weight loss 
[74w]; hypoactivity [104w]; rotarod 
deficits [117w] 
Rule learning deficits [22w]; attention, 
visuomotor & spatial learning deficits 
[52w]; ↓ motivation [65w] 
↓ startle response & prepulse 
inhibition [17w] 
(Trueman et al., 2009; Brooks 
et al., 2012a; Trueman et al., 
2012a; Trueman et al., 2012b) 
HdhQ94 
↑ rearing [8w]; hyperactivity [8w]; 
hypoactivity [17w] 
n.r. n.r. (Menalled et al., 2002) 
HdhQ111 
Hyperactivity [4w]; ↑ weight loss 
[28w]; abnormal gait [104w] 
Long-term spatial & recognition 
memory deficits [34.5w] 
Sex-dependent anxio-depressive 
phenotype [13w] 
(Wheeler et al., 2002; 
Menalled et al., 2009; Giralt 
et al., 2012; Orvoen et al., 
2012) 
HdhQ140 
↑ rearing and hyperactivity [4w]; 
hypoactivity, ↓ running speed, 
climbing & rotarod ability [17w]; 
abnormal gait [52w]; tremor [87w] 
Motor learning deficits [26w] ↑ anxiety & fear response [17-26w] 
(Menalled et al., 2003; Dorner 
et al., 2007; Hickey et al., 
2008) 
HdhQ150 
↓ grip strength [6w]; ↑ weight loss 
[70w]; rotarod deficits [78w]; balance 
beam deficits [100w]; abnormal gait 
[100w]  
Spatial memory deficit [17w]; reversal 
learning deficit [26w]; extra-
dimensional set-shifting deficit [104w] 
↓ startle reactivity [26w]; ↓ 
aggression, anxiety & irritability [65w]; 
↑ clasping [70w]; absent fear response 
[95w]; ↓ exploratory activity [100w]  
(Lin et al., 2001; Brooks et al., 
2006; Heng et al., 2007; 
Woodman et al., 2007; Brooks 
et al., 2012b) 
HdhQ200 
↑ weight loss & balance beam deficits 
[20w]; abnormal gait [60w]; 
hypoactivity, ↓ grooming & grip 
strength [80w] 
n.r. n.r. (Heng et al., 2010) 
zQ175 
↓ grip strength [4w]; ↑ weight loss 
[6w]; hypoactivity & ↑ rearing [8w]; 
rotarod deficits [30w]; ↓ climbing 
[32w] 
Visual discrimination, novel stimuli & 
reversal learning deficits [26w]; ↓ 
response inhibition [26w]; working 
memory deficits [39w]; procedural 
learning deficits [43.5w] 
↓ motivation [32-33w] 
(Heikkinen et al., 2012; 
Menalled et al., 2012; 
Oakeshott et al., 2013; Farrar 
et al., 2014; Menalled et al., 
2014; Curtin et al., 2016) 
Inducible models 
HD94 
Rotarod deficit [12w]; tremor & ↓ 
grooming [20w]; hypoactivity [36w] 
n.r. ↑ clasping [4w] 
(Yamamoto et al., 2000; 
Martin-Aparicio et al., 2001) 
Inducible-
148Q 
Abnormal gait, tremor, incoordination, 
rotarod deficits & ↑ weight loss [26w] 
n.r. n.r. (Tanaka et al., 2006) 
Table 1.2. Behavioural phenotypes of the most widely used mouse models of HD. w = weeks of age; n.r. = not reported; ↑ = increase in; ↓ = decrease in. 
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1.3.1.1 The HdhQ150 knock-in mouse model of HD 
The HdhQ150 mouse model of HD was generated by replacing the native non-pathogenic CAG 
sequence of exon 1 of the endogenous mouse Htt locus with a pathogenic repeat length of 150 
CAG residues (Lin et al., 2001). The original study on the HdhQ150 mouse model of HD identified 
a number of motor and psychiatric phenotypes, consisting of abnormalities in general activity, 
‘clasping’, gait variability, and rotarod performance (Lin et al., 2001), which have since been 
expanded upon by further longitudinal studies (Heng et al., 2007; Woodman et al., 2007; Brooks 
et al., 2012b). Lin and colleagues (2001) also discovered that HdhQ150/Q150 mice have a lower body 
mass than wild-type animals at 25-30 weeks of age. This recapitulates the weight loss that is 
seen in human HD patients (Sanberg et al., 1981; Farrer and Yu, 1985; Stoy and McKay, 2000; 
Djousse et al., 2002; Robbins et al., 2006; van der Burg et al., 2009) and has since been found to 
represent a progressive decline in HdhQ150/Q150 animal bodyweight from 9-14 months of age (M) 
until end-stage disease at approximately 22-23M (Heng et al., 2007; Woodman et al., 2007; 
Brooks et al., 2012b). 
With regards to motor impairments, animals heterozygous and homozygous for the mutant 
HdhQ150 allele (HdhQ150/+ and HdhQ150/Q150, respectively) present with gait disturbances in 
comparison to wild-type animals, with this phenotype occurring from 40 weeks of age in 
heterozygote animals and from 25 weeks of age in homozygotes (Lin et al., 2001), which suggests 
that gait variability onset is affected by gene dosage in HdhQ150 mice. However, Heng and 
colleagues (2007) only identified significant abnormalities in gait, in measures that included 
stride lengths and base lengths, in HdhQ150/+ and HdhQ150/Q150 mice, in comparison to wild-type 
animals, at 100 weeks of age. This would suggest that the gait abnormalities present in the 
HdhQ150 mouse model have a late-onset but are not affected by gene dosage. Despite 
identifying different onsets of gait abnormalities in HdhQ150/+ and HdhQ150/Q150 animals, the two 
studies both identify a gait impairment in the HdhQ150 mouse model of HD; it is possible that 
the differences observed in the two studies is a result of the differing proportions of background 
strains in the mouse lines used in each study. The ability to remain on a rotating rod, another 
measure of motor capacity, has revealed a late-onset age-related decline in the motor ability of 
HdhQ150/Q150 mice (Lin et al., 2001; Heng et al., 2007; Woodman et al., 2007; Brooks et al., 2012b). 
Rotarod performance and learning deficits have been identified in homozygous animals from as 
early as 40 weeks of age (Lin et al., 2001; Heng et al., 2007), although the majority of reports 
identify these motor ability impairments at 18-23M (Heng et al., 2007; Woodman et al., 2007; 
Brooks et al., 2012b). Conversely, HdhQ150/+ mice have not displayed motor performance deficits 
in the rotarod when examined up to 100 weeks of age (Lin et al., 2001; Heng et al., 2007), 
suggesting that there is a gene dosage-dependent rotarod performance impairment in the 
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HdhQ150 mouse model of HD. At 100 weeks of age, HdhQ150/+ and HdhQ150/Q150 animals both 
display impairments in motor function, in relation to limb coordination and balance as assessed 
using a balance beam, as shown by a greater length of time being required by both genotypes 
to traverse the balance beam, when compared to wild-type counterparts (Heng et al., 2007). 
Motor learning capacities were also examined in this task, through analysis of the times taken 
to traverse the beam in the first 3 trials, and were found to be impaired in 100 week old 
homozygotes but preserved in age-matched heterozygote animals, which is indicative of a late-
onset gene dosage-dependent impairment in motor learning. The manner in which HdhQ150 
animals traversed the balance beam also differed to wild-type animals, with HdhQ150/Q150 mice 
displaying a “hindlimb drag” motion (where the abdomen is pressed against the beam, the 
hindlimbs are laterally wrapped around the beam, and the forelimbs are used to drag the mouse 
along the beam) from 40 weeks of age. Both homozygote and heterozygote animals displayed 
significantly greater use of this method than wild-type animals from 100 weeks of age, which 
provides further support for a late-onset motor impairment in the HdhQ150 mouse model of 
HD. To test whether the motor impairments identified were related to loss of muscle power, 
Heng et al. (2007) performed the hanging wire test, and found that there was no significant 
difference in the latency to fall between wild-type animals and heterozygote or homozygote 
HdhQ150 mice up to 100 weeks of age. This would suggest that there is no loss of muscle power 
in aged HdhQ150 mice and provides further support the evidence for a late-onset motor 
impairment in this mouse model. However, HdhQ150/Q150 mice have been reported elsewhere to 
display significant deficits in grip strength from as early as 1.5M (Woodman et al., 2007) and 
10M (Brooks et al., 2012b), which would suggest that weakness in grip strength is a motor 
phenotype in mice homozygous for the HdhQ150 mutant allele. 
Lin and colleagues (2001) reported two psychiatric phenotypes in their original study of the 
HdhQ150 mouse model of HD. The first was a deficit in exploratory activity, where HdhQ150/+ 
animals display greater levels of inactivity than their wild-type counterparts from 40 weeks of 
age, while HdhQ150/Q150 mice show this inactivity phenotype prior to 40 weeks of age, which 
suggests there may be a gene dosage effect in this behavioural abnormality. However, 
subsequent longitudinal analyses past the 52-week time point studied by Lin et al. (2001) have 
revealed that HdhQ150/Q150 mice exhibit deficits in exploratory activity only from 100 weeks of age 
(Heng et al., 2007), which are not evident at 18M (Woodman et al., 2007), and that heterozygote 
animals display activity levels comparable to wild-type counterparts until 100 weeks of age 
(Heng et al., 2007). The discrepancy in activity level findings between the original HdhQ150 study 
and subsequent longitudinal studies is likely to be the result of the different parameters and 
methodologies used to study activity levels; Lin and colleagues (2001) measured inactivity in the 
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first 30 s of a trial, whereas automated activity cages quantifying the number of beam breaks 
made by animals during a 60 or 120 min session were used to assess activity by Woodman and 
colleagues (2007) and Heng et al. (2007). The second psychiatric phenotype identified by Lin and 
colleagues (2001) was an increase in ‘clasping’ when HdhQ150 mice were suspended from the 
tail. Increased clasping arose in both HdhQ150/+ and HdhQ150/Q150 animals, when compared to wild-
type littermates, and the onset of this neurological irregularity seems to display an apparent 
gene dosage effect, as HdhQ150/+ and HdhQ150/Q150 mice exhibited this deficit from 40 and 25 weeks 
of age, respectively (Lin et al., 2001). Clasping behaviour has also been identified in HdhQ150/Q150 
animals as early as 20 weeks of age and was found to occur frequently from 70 weeks of age 
(Heng et al., 2007). Further evidence for the presence of a psychiatric phenotype in the HdhQ150 
mouse model of HD comes from reports that HdhQ150/Q150 animals display reduced startle 
reactivity from 6M (Brooks et al., 2012b), reduced aggression, anxiety and irritability from 15M, 
and an absent fear response at 22M (Woodman et al., 2007). 
Cognitive deficits have also been identified in the HdhQ150 mouse model of HD, with evidence 
of HdhQ150/Q150 mice requiring greater lengths of time to find the platform in the Morris water 
maze task from as early as 4M (Brooks et al., 2012b), which is suggestive of a spatial memory 
impairment that recapitulates aspects of the visuospatial memory deficiencies identified in 
human HD patients (Lange et al., 1995; Lawrence et al., 2000; Brandt et al., 2005; Majerova et 
al., 2012; Pirogovsky et al., 2015). HdhQ150/Q150 animals also presented with prolonged latencies 
in finding the reverse platform position in the Morris water maze task from 6M (Brooks et al., 
2012b), which may be indicative of a reversal learning (RL) deficit similar to those seen in HD 
patients (Lange et al., 1995; Lawrence et al., 1999). A deficit in extra-dimensional set-shifting 
has also been demonstrated in homozygous HdhQ150 animals at 24M (Brooks et al., 2006), 
which is comparable to the extra-dimensional set-shifting cognitive deficit observed in the 
human disease (Lawrence et al., 1996). 
In summary, a number of motor, psychiatric and cognitive phenotypes that can be argued to be 
analogous to those seen in human HD patients have been identified in the HdhQ150 mouse 
model of HD (Table 1.2). Motor phenotypes demonstrated include an abnormal gait, deficits in 
rotarod and balance beam performance, and a weakness in grip strength, while psychiatric 
disturbances include deficits in exploratory and startle activity, as well as reductions in 
aggression, anxiety and irritability, but increased clasping behaviour (Lin et al., 2001; Heng et al., 
2007; Woodman et al., 2007; Brooks et al., 2012b). Cognitive assessment of the HdhQ150 mouse 
model of HD has not been as extensive as the motor and psychiatric evaluations, however there 
is evidence of disturbances in spatial memory and extra-dimensional set-shifting in HdhQ150/Q150 
mice (Brooks et al., 2006; Brooks et al., 2012b). 
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1.3.2 Neuropathology 
The neuropathological profile of each mouse model of HD is unique, however there are some 
common characteristics (summarised in Table 1.3). In N-terminal transgenic mice, the onset of 
neuropathological features occurs at a similar time to the manifestation of behavioural 
symptoms (Table 1.2 and Table 1.3). Neuropathology in full-length transgenic animal models, on 
the other hand, tends to arise at a later time point than behavioural phenotypes (Table 1.2 and 
Table 1.3). Similar to their behavioural phenotypes, the neuropathology in knock-in mouse 
models of HD is generally milder than that of their transgenic counterparts, and also occurs later 
in the mouse life time (Table 1.2 and Table 1.3). 
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 Neuronal cell loss & degeneration Inclusions & aggregates References 
N-terminal transgenic models 
R6/1 
↓ brain volume [8w]; ↓ striatal, cortical & hippocampal 
volume [17w] 
Widespread HTT nuclear and extranuclear inclusion 
distribution [8w] 
(Davies et al., 1997; Bayram-
Weston et al., 2012a; Rattray et 
al., 2013) 
R6/2 
Cortical atrophy [3w]; ↓ brain weight [4w]; striatal, 
hippocampal & thalamic atrophy [5w]; ↓ brain volume 
[8.5w]; ↓ striatal volume & cell count [13w]; ↑ GFAP 
immunostaining [13w] 
Cortical HTT NIIs [3.5w]; striatal HTT NIIs [4.5w]; cortical & 
striatal ubiquitin NIIs [5-6w]; widespread inclusion 
distribution [8w] 
(Mangiarini et al., 1996; Davies 
et al., 1997; Naver et al., 2003; 
Stack et al., 2005; Aggarwal et 
al., 2012) 
N171-82Q 
Striatal, cortical, hippocampal, amygdalar atrophy [10w]; 
↑ GFAP immunostaining [13w]; striatal atrophy [17w]; ↑ 
striatal & cortical neuron apoptosis [20w] 
Widespread distribution of HTT & ubiquitin NIIs, & neuritic 
aggregates [12-18w] 
(Schilling et al., 1999; Yu et al., 
2003; Gardian et al., 2005; 
Cheng et al., 2011; Aggarwal et 
al., 2012) 
Full-length transgenic models 
YAC72 Evidence of striatal degeneration [52w] 
Nuclear translocation of N-terminal HTT fragments of 
striatal & cortical neurons [52w] 
(Hodgson et al., 1999) 
YAC128 
↓ brain weight & striatal & cortical volumes [39w]; ↓ 
striatal cell count & size [52w]; ↑ cortical GFAP 
immunostaining [65w] 
Nuclear translocation of N-terminal HTT fragments of 
striatal, cortical, hippocampal & cerebellar neurons [13w]; 
widespread NII distribution [65w] 
(Slow et al., 2003; Van 
Raamsdonk et al., 2005a; 
Bayram-Weston et al., 2012b) 
BACHD 
Brain atrophy, ↓ striatal & cortical volume & presence of 
dark degenerating striatal & cortical neurons [52w] 
Striatal & cortical mHTT aggregate accumulation [52w] 
(Gray et al., 2008; Wang et al., 
2014) 
Knock-in models 
HdhQ72-80 10-15% ↓ brain weight [13w] 
Striatal neuropil aggregate accumulation [52w]; striatal 
nuclear mHTT aggregate accumulation [91-117w] 
(Shelbourne et al., 1999; Li et 
al., 2000; Li et al., 2001) 
HdhQ92 ↓ striatal volume & cell count [65-104w] 
Striatal nuclear staining of HTT [11w]; striatal nuclear 
translocation of HTT [22w]; widespread NII distribution 
[43.5w]; striatal mHTT aggregate formation [52-65w] 
(Wheeler et al., 2000; Bayram-
Weston et al., 2012c) 
HdhQ94 ↓ striatal volume & striatal neuron density [78w] 
Striatal nuclear staining & microaggregate distribution [17-
26w]; mHTT NIIs [78w] 
(Menalled et al., 2002) 
HdhQ111 ↑ GFAP immunostaining [104w] 
Striatal nuclear staining of HTT [6w]; striatal nuclear 
translocation of HTT [22w]; striatal HTT aggregate 
formation [43.5w]; striatal NII formation [43.5-52w]; 
striatal neuropil aggregate formation [74w] 
(Wheeler et al., 2000; Wheeler 
et al., 2002) 
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HdhQ140 
Progressive ↓ MSN cell number [52w]; ↑ cortical GFAP 
immunostaining [52w]; ↓ brain weight, striatal volume & 
striatal cell count [87-113w]; ↑ striatal GFAP 
immunostaining [104w] 
Progressive HTT nuclear inclusion distribution [4-26w]; 
progressive neuropil aggregate distribution [8-26w] 
(Menalled et al., 2003; Hickey 
et al., 2008) 
HdhQ150 
↑ GFAP immunostaining [52-61w]; HdhQ150/Q150 striatal cell 
& volume loss [26-100w]; HdhQ150/+ striatal cell loss [100w] 
Striatal HTT NIIs [21-26w]; striatal ubiquitin NIIs [45w]; 
widespread distribution of NIIs and neuropil aggregates 
[52-70w] 
(Lin et al., 2001; Yu et al., 2003; 
Tallaksen-Greene et al., 2005; 
Heng et al., 2007; Woodman et 
al., 2007; Bayram-Weston et al., 
2012d) 
HdhQ200 
↑ autophagy markers in the brain [9w]; ↓ Purkinje cell 
count [50w] 
Striatal & cortical cytoplasmic HTT aggregate distribution 
[9w]; striatal & cortical HTT NII distribution [20w] 
(Heng et al., 2010; Dougherty et 
al., 2013) 
zQ175 
↓ brain, striatal & cortical volumes [13w]; ↓ striatal 
neuron number [19.5w]; impaired myelination of striatal 
neurons [52w] 
Striatal diffuse nuclear staining [13w]; progressive striatal 
HTT NII distribution [17w]; progressive cortical HTT NII 
distribution & diffuse nuclear staining [35w] 
(Heikkinen et al., 2012; Carty et 
al., 2015; Ma et al., 2015) 
Inducible models 
HD94 
↓ brain & striatal volume [18w]; ↑ striatal GFAP 
immunostaining [18w]; striatal cell loss [74w] 
Striatal HTT & ubiquitin intranuclear staining & cytoplasmic 
aggregates [12w] 
(Yamamoto et al., 2000; Martin-
Aparicio et al., 2001; Diaz-
Hernandez et al., 2005) 
Inducible-
148Q 
Mild brain atrophy, ventricular enlargement & ↑ striatal & 
cortical GFAP immunostaining [43.5w] 
Striatal, cortical, hippocampal & cerebellar HTT NIIs 
[43.5w]; Striatal & cortical cytoplasmic aggregates [43.5w] 
(Tanaka et al., 2006) 
Table 1.3. Neuropathological phenotypes of the most widely used mouse models of HD. GFAP = glial fibrillary acid protein; n.r. = not reported; w = weeks of age; 
↑ = increase in; ↓ = decrease in. 
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1.3.2.1 The HdhQ150 knock-in mouse model of HD 
Neuroanatomical analyses of post-mortem HdhQ150 mice have revealed a number of 
neuropathologies consistent with those found in human HD cases (Table 1.3). As discussed in 
Chapter 1.1.2.1, loss of striatal volume and neuron number are pathological traits in HD (Lange 
et al., 1976; Vonsattel et al., 1985; Aylward et al., 1997; Vonsattel and DiFiglia, 1998; Aylward et 
al., 2004; Tabrizi et al., 2009; Tabrizi et al., 2011; Tabrizi et al., 2012; Tabrizi et al., 2013), and are 
recreated in HdhQ150 animals; evidence of striatal volume loss in HdhQ150/Q150 mice from 6M has 
been described (Bayram-Weston et al., 2012d), while this phenotype has been reported to have 
an onset later than 70 weeks of age in another study (Heng et al., 2007). Heterozygous HdhQ150 
animals, on the other hand, do not display striatal volume loss up to 100 weeks of age but 
present with an approximate 60% decrease in striatal neuron number at this age (Heng et al., 
2007). These alterations in striatal neuron number were found to occur after 70 weeks of age, 
which strengthens the findings of Lin and colleagues (2001) whereby HdhQ150/+ animals 
presented with healthy striatal volumes and neuronal numbers at 52 weeks of age. An increase 
in striatal glial fibrillary acidic protein (GFAP), a marker for reactive gliosis and thus nervous 
system damage, has also identified in HdhQ150/+ animals at 52-61 weeks of age (Lin et al., 2001; 
Yu et al., 2003). This suggests that striatal neuronal dysfunction may occur as early as 52-61 
weeks of age in heterozygote animals but may not result in cell loss until after 70 weeks of age, 
as reported by Heng and colleagues (2007). The concurrent loss of striatal neuron number and 
volume in HdhQ150/Q150 mice at 100 weeks of age (Heng et al., 2007) suggests that this genotype 
undergoes extensive striatal neurodegeneration. While striatal volume loss was not observed in 
HdhQ150/+ animals at this time point, a large reduction in striatal neuron number was apparent, 
which indicates that heterozygote HdhQ150 mice experience striatal neurodegeneration that is 
less extensive than their homozygote counterparts.  
The presence of NIIs is also recapitulated in HdhQ150 mice, with HTT immunoreactive NIIs being 
identified in the striatum of homozygote mutants as early as 21 and 26 weeks of age (Woodman 
et al., 2007; Bayram-Weston et al., 2012d). By contrast, these NIIs have been observed in 
HdhQ150/+ mice from 40-42 weeks of age, while ubiquitin immunoreactive NIIs are detected in 
approximately 10% of striatal neurons by 45 weeks of age (Tallaksen-Greene et al., 2005). These 
HTT- and ubiquitin-containing NIIs become more widespread as time progresses (Tallaksen-
Greene et al., 2005; Woodman et al., 2007; Bayram-Weston et al., 2012d), being observed 
throughout the dorsal striatum, nucleus accumbens and the rostral part of the piriform cortex 
at 52 weeks of age in HdhQ150/+ mice, and are also present with less frequency in layers III and IV 
of the somatosensory cortex, the pyramidal cell layer of the hippocampus, and the neurons of 
the deep nuclei and granular cell layer of the cerebellar cortex (Lin et al., 2001). At approximately 
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65 weeks of age, HTT immunoreactive NIIs are present throughout the brain in HdhQ150/Q150 mice 
(Bayram-Weston et al., 2012d) and appear in approximately 40% and 65% of striatal neurons in 
HdhQ150/+ and HdhQ150/Q150 animals, respectively, by 70 weeks of age, while ubiquitin 
immunoreactive NIIs are found throughout the striatum by 72 weeks of age (Tallaksen-Greene 
et al., 2005). At very late stages in life (107 weeks of age), as many as 90% of striatal neurons 
and 85% of layer IV primary somatosensory cortical neurons contain NIIs in heterozygous 
HdhQ150 animals (Tallaksen-Greene et al., 2005). Tallaksen-Green et al. (2005) report that HTT 
immunoreactive NIIs are more frequently identified than ubiquitin immunoreactive inclusions 
in the HdhQ150 mouse model of HD, and recently this same finding has also been reported in 
HdhQ150/Q150 animals (Bayram-Weston et al., 2015), and the higher frequency of NIIs identified in 
homozygote HdhQ150 mutant animals, when compared to heterozygote littermates, is 
indicative of a gene dosage effect existing in this neuropathological feature. At 22M, HdhQ150/Q150 
mice also present with polyglutamine aggregate pathology, in the form of nuclear inclusions, in 
a wide range of peripheral tissues that include heart, liver and skeletal tissue (Moffitt et al., 
2009). It is not known whether this peripheral pathology is a pathological feature of the human 
disease, as peripheral organs are not typically collected from post-mortem HD patients and 
therefore are not available for analysis. Despite this, HTT inclusions have been identified in 
human HD myotubules (Ciammola et al., 2006) but not in myoblasts, fibroblasts, or lymphoblasts 
(Sawa et al., 1999; Sathasivam et al., 2001; Ciammola et al., 2006), which does not elucidate 
whether peripheral polyglutamine aggregate pathology is a feature of the human condition. 
As well as displaying neuronal loss and the presence of NIIs, HdhQ150 animals also show 
diminished levels of striatal dopamine D1 and D2 receptor (DRD1 and DRD2, respectively) binding 
sites from 70 weeks of age, which further decline at 100 weeks (Heng et al., 2007). These age-
dependent decreases in striatal receptor binding sites were found to be more pronounced in 
HdhQ150/Q150 mice than in their HdhQ150/+ counterparts, suggesting a gene dosage effect is present 
in the apparent deficit in dopamine transmission and signalling. This conclusion is also supported 
by evidence that homozygote animals exhibited a significant reduction in striatal dopamine 
transporter binding sites at 100 weeks of age, while no such deficit was present in heterozygote 
mice. 
To summarise, the HdhQ150 mouse model of HD exhibits a number of neuropathological 
features comparable to those seen in the human disease (Table 1.3). These phenotypes have 
been found to be age-dependent and include a reduction in striatal cell number and dopamine 
receptor binding sites, the formation of HTT and ubiquitin immunoreactive NIIs throughout the 
brain, and an increase in reactive gliosis (Lin et al., 2001; Tallaksen-Greene et al., 2005; Heng et 
al., 2007; Woodman et al., 2007; Bayram-Weston et al., 2012d; Bayram-Weston et al., 2015). 
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The severity of neuropathology seems to be gene dosage dependent in HdhQ150 animals, with 
evidence of homozygote mutant mice presenting with earlier and more severe phenotypes than 
their heterozygote counterparts (Tallaksen-Greene et al., 2005; Heng et al., 2007). 
 
1.5 Gene expression in HD 
There are a number of potential mechanisms of HD pathogenesis, which include vulnerability of 
striatal MSNs to mitochondrial dysfunction (Squitieri et al., 2006; Orr et al., 2008; Kim et al., 
2010; Shirendeb et al., 2011; Shirendeb et al., 2012; Damiano et al., 2013), excitotoxicity (Leavitt 
et al., 2006; Fernandes et al., 2007; Heng et al., 2009; Botelho et al., 2014), and the possible 
toxicity of mHTT NIIs and aggregates (Davies et al., 1997; DiFiglia et al., 1997; Ordway et al., 
1997; Legleiter et al., 2010; Tsvetkov et al., 2013). Aberrant transcriptional regulation has also 
been identified as an integral process in the manifestation of HD (Cha, 2000; Luthi-Carter and 
Cha, 2003; Cha, 2007; Bowles et al., 2012; Seredenina and Luthi-Carter, 2012; Kumar et al., 2014; 
Valor, 2015), and is detectable in pre-symptomatic patients (Dunah et al., 2002; Borovecki et al., 
2005; Mastrokolias et al., 2015) and mouse models of the disease (Cha et al., 1998; Carnemolla 
et al., 2009; Becanovic et al., 2010). 
The striatal transcriptional profiles of multiple mouse models of HD have been found to 
recapitulate many features of the transcriptional dysregulation observed in the caudate of post-
mortem human HD patients, despite variation in CAG length, and HTT gene dosage and 
expression context between each model (Hodges et al., 2006; Kuhn et al., 2007). Striatal 
transcriptional profiles of human HD patients can only be determined for the end-stage of the 
disease because sample collection is only possible from post-mortem caudate. However, the use 
of cell and mouse models of the disease allows longitudinal characterisation of transcriptional 
dysregulation in HD, and the assessment of potentially disease-modifying factors, because of 
the similarity of gene expression level changes detected in human HD caudate and such models. 
The genes exhibiting reproducible changes in expression between HD populations and models 
are associated with a number of biological pathways that include neurotransmitter, 
neurotrophin and G-protein receptor signalling, as well as energy and lipid metabolism, 
transcription and chromatin remodelling (Luthi-Carter et al., 2000; Hodges et al., 2006; Kuhn et 
al., 2007; Seredenina and Luthi-Carter, 2012). 
Decreased gene expression levels are consistently observed in models of HD, particularly in early 
stages of the disease (Luthi-Carter et al., 2000; Sipione et al., 2002; Kuhn et al., 2007), and is 
generally associated with genes involved in neurotransmitter receptor functions, synaptic 
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transmission, signalling pathways, neuropeptides, and calcium binding and homeostasis, while 
upregulated genes are largely associated with genes related to stress markers, ribonucleic acid 
(RNA) metabolism, and protein folding (Valor, 2015). One mechanism by which these 
transcriptional discrepancies are believe to arise is through loss of REST/NRSF mediated gene 
expression regulation (Zuccato et al., 2007; Buckley et al., 2010; Soldati et al., 2013). The pattern 
of transcriptional alterations in response to mHTT is likely to be complex and may not be stable 
over time, with evidence that striatal gene expression level profiles are altered following 
aggregate formation in a cell model of the disease (van Roon-Mom et al., 2008) and across the 
lifespan of HD mouse models (Kuhn et al., 2007; Giles et al., 2012; Bayram-Weston et al., 2015). 
It is important to note, however, that the dysregulation of gene expression observed is unlikely 
to be entirely caused by direct mHTT interference with transcriptional machinery because 
autocompensatory mechanisms designed to counter mHTT toxicity are likely to be present in 
the transcriptional profiles of HD and HD models, and the regulation of these genes may not 
necessarily be modulated by mHTT (Seredenina and Luthi-Carter, 2012). An example of an 
autocompensatory mechanism of transcriptional dysregulation in HD comes from evidence that 
the forkhead class O transcription factor forkhead box O3 (FOXO3a), which is activated by 
decreased survival signalling and/or increased cellular stress, regulates its own transcription by 
binding to the conserved response element in the Foxo3a promoter, and that levels of FOXO3a 
are elevated in HD (Kannike et al., 2014). 
 
1.6 Cognition 
Cognition has been defined as the mental action or process of acquiring knowledge and 
understanding through thought, experience, and the senses, and is a highly complex 
phenomenon that has received extensive research into its neural and molecular foundations. 
 
1.6.1 Neural networks underpinning cognition 
The use of neuroimaging techniques that provide high spatial resolution, such as PET, MRI and 
fMRI, has allowed the identification of neural networks involved in different aspects of 
cognition, with these complex networks comprising a number of distinct structures and regions. 
Cognitive ability, or intelligence, has previously been defined as “… a very general capacity that, 
among other things, involves the ability to reason, plan, solve problems, think abstractly, 
comprehend complex ideas, learn quickly, and learn from experience” (Gottfredson, 1997), 
which highlights the multitude of processes that encompass cognition. The parietofrontal 
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integration theory of intelligence emphasises the differing roles of distinct neural structures and 
pathways in the varied aspects of cognition. In this theory, the extrastriate cortex and fusiform 
gyrus are believed to be involved in intelligent behaviour because of their contribution to 
recognition, imagery, and elaboration of visual input (Brancucci, 2012). The parietal cortex and 
angular gyrus then process information captured through these pathways and potentially 
produce structural symbolism, abstraction, and elaboration, before frontal cortical areas 
interact with these parietal areas and establish a working memory network that compares 
different potential task responses (Brancucci, 2012). Finally, the anterior cingulate cortex 
intervenes, once a task response is selected, and supports response engagement and the 
inhibition of alternative responses (Brancucci, 2012). A review of all the neural pathways 
associated with cognition will not be undertaken here, instead the overlapping neural structures 
and pathways pertinent to both cognition and HD, as well as the experiments of this thesis, will 
be discussed. 
The striatum forms part of a number of functional subcortico-thalamo-cortical loops, where it 
receives afferent projections from the dorsolateral prefrontal cortex (PFC), lateral orbitofrontal 
cortex, supplementary motor area, frontal eye fields and anterior cingulate areas of the cortex, 
amongst others, while projecting efferent neurons to a number of regions within the pallidum 
and substantia nigra, which then project to different areas of the thalamus, which closes the 
loops by projecting to the aforementioned cortical regions (Alexander et al., 1986; DeLong and 
Wichmann, 2007; Leh et al., 2007). Specific frontostriatal interconnections have also been 
identified between the striatum and the primary and premotor areas as well as the inferior and 
middle temporal gyrus, and striato-cerebellar interconnections are also present (Leh et al., 
2007). With such diverse and extensive neural connectivity, it is unsurprising that the striatum 
is utilised in a variety of cognitive processes. One such cognitive function is RL, which has been 
found to produce co-activation of the striatum and frontal cortex in human fMRI studies (Cools 
et al., 2002; Kringelbach and Rolls, 2003; Hampton and O'Doherty, 2007; Ghahremani et al., 
2010; Ruge and Wolfensteller, 2016) and is impaired in individuals with lesions to either region 
(Hornak et al., 2004; Bellebaum et al., 2008). Taken together, this evidence suggests that the 
frontostriatal circuitry governs RL, and thus cognitive flexibility, and this suggestion is supported 
by numerous lesion studies in rodents and non-human primates (Roberts et al., 1990; Roberts 
et al., 1992; Featherstone and McDonald, 2005; Kim and Ragozzino, 2005; Ragozzino, 2007; 
Brigman and Rothblat, 2008; Clarke et al., 2008; McDonald et al., 2008b; Castane et al., 2010).  
Similar to the frontostriatal involvement in RL, this neural circuit has also been linked with set-
shifting, which is an aspect of cognitive flexibility defined as the ability to change attention from 
one response set to another according to the changing goals of a task. Significant increases in 
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activity in the PFC and striatum have been identified in individuals performing the Wisconsin 
Card Sorting Task during inhibition of previously acquired stimulus-response rules and 
acquisition of new stimulus-response associations (Monchi et al., 2001; Lie et al., 2006). These 
studies suggest that the frontostriatal neural network is activated, and necessary for, the 
switching from one rule to another following an incorrect pairing in the Wisconsin Card Sorting 
Task. This is supported by evidence that striatal dopamine is released during the planning and 
execution of a set-shift (Monchi et al., 2006) and that using transcranial magnetic stimulation to 
deliver continual theta burst impulses at the left dorsolateral PFC interferes with striatal 
dopamine release and impairs set-shifting performance (Ko et al., 2008). Further examination of 
the role of frontostriatal connectivity in set-shifting has revealed that striatal activity is required 
until a rule is used continuously for several trials (Provost et al., 2012), suggesting that the 
striatum is necessary for the acquisition of a new rule in set-shifting. A similar role for the 
striatum has also been reported in a variety of learning paradigms, with PET and fMRI studies 
providing evidence for the involvement of a cortical-striatal-hippocampal network during rule 
learning (Poldrack et al., 1999; Toni and Passingham, 1999; Seger and Cincotta, 2005; Seger and 
Cincotta, 2006). 
Working memory is another aspect of cognition that is believed to utilise the frontostriatal 
circuitry, with evidence that functional connectivity between the PFC and the striatum is 
increased during the performance of working memory tasks (Hampson et al., 2006) and that 
striatal dopamine signalling capacities are associated with working memory ability (Cools et al., 
2008; Landau et al., 2009; Liang et al., 2016). Striatal lesions in rodents have also been found to 
significantly impair spatial working memory performance (Mair et al., 2002), which suggests that 
the striatum may also form part of a neural network responsible for aspects of spatial memory, 
a form of memory that is known to be dependent upon hippocampal activity (Morris, 1981; Silva 
et al., 1992b; Moser et al., 1995; Tsien et al., 1996; Maguire et al., 1997; Maguire et al., 2000; 
Burgess et al., 2002; Ekstrom et al., 2003). Reports of a cortical-striatal-hippocampal network 
necessary for novel exploratory goal-directed navigation (Floresco et al., 1997) and disrupted 
spatial learning in striatum lesioned mice (Pooters et al., 2016) act to support evidence for a 
striatal role in spatial memory. 
In summary, there is substantial evidence for the necessity of neural networks in many forms of 
cognition, with the striatum forming part of frontostriatal and cortical-striatal-hippocampal 
networks associated with cognitive flexibility, in the form of rule learning, set-shifting and RL, as 
well as working and spatial memory. There are also a wealth of studies implicating the striatum 
in cognitive processes that include motivation (Kimura et al., 2003; Aarts et al., 2011; Ena et al., 
2011; Shohamy, 2011), habit formation (Yin et al., 2004; Yin and Knowlton, 2006; Tang et al., 
34 
 
2007; Grahn et al., 2008; Tricomi et al., 2009) and implicit learning (Rauch et al., 1997; Schendan 
et al., 2003; Aizenstein et al., 2004; Destrebecqz et al., 2005; Reiss et al., 2005; Bennett et al., 
2011; Gheysen et al., 2011), which have not been discussed in this body of work thus far. 
Similarly, a range of neural structures have been associated with multiple aspects of cognition, 
with evidence that the hippocampus is integral to spatial memory, as previously highlighted, as 
well as memory formation (Scoville and Milner, 1957; Zolamorgan et al., 1986; Squire and 
Zolamorgan, 1991; Squire, 1992; Bliss and Collingridge, 1993; Gould et al., 1999; Shors et al., 
2001) while the amygdala is known to be involved in emotion and fear memory (Davis, 1992; 
Phillips and Ledoux, 1992; Adolphs et al., 1994; LeDoux, 2000; Davis and Whalen, 2001; Phan et 
al., 2002). Thus, cognition is a diverse and complex phenomenon that requires interactions 
between multiple brain structures that utilise a number of connective pathways and neural 
networks. Furthermore, the neural structure most extensively degenerated in HD, the striatum, 
is associated with various aspects of cognitive function and ability. 
 
1.6.1.1 Neural networks underpinning instrumental learning in rodents 
As discussed in Chapter 1.6.1, a number of neural networks within the brain form the 
foundations required for different aspects of learning and memory in humans. Similar 
interactions between distinct neural structures and regions are necessary to a number of 
behavioural tasks utilised in rodent studies of cognition, some of which will be discussed here. 
The continuous reinforcement (CRF) schedule for food reinforcement consists of rodents having 
to lever-press or “nose-poke” (np) only once in response to a stimulus in order to receive a 
reward, and is an important reinforcement condition in which, when food is the reward, there 
is primary positive reinforcement involving a natural reinforcer. The striatum has been found to 
be the key neural structure associated with CRF performance in rodents, with evidence that 
lever pressing on a CRF schedule is accompanied by increases in rat nucleus accumbens 
dopamine release, and that these increases in nucleus accumbens dopamine release are highly 
correlated with the number of responses performed (McCullough et al., 1993). This evidence 
suggests that a major function of dopaminergic transmission in the nucleus accumbens, and thus 
the striatum, may be to facilitate the instigation, or acquisition, of some forms of instrumental 
behaviour. This suggestion is also supported by evidence that increases in nucleus accumbens 
dopamine release occur during instrumental lever pressing for a food reward but not during 
increased levels of free food consumption (Salamone et al., 1994). Further support for the role 
of striatal involvement in instrumental learning comes from evidence that depleting dopamine 
levels in the nucleus accumbens via 6-hydroxydopamine injection produces a change in 
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instrumental behaviour (Cousins et al., 1993). Specifically, healthy rats would readily lever-press 
to receive a preferred food reward rather than consume a readily-available, but less preferred, 
food (lab chow), whereas nucleus accumbens dopamine depleted rats would display a significant 
decrease in lever pressing and instead increase their consumption of lab chow. The regional 
specificity of this behavioural effect of dopaminergic depletion within the nucleus accumbens 
on lever pressing was later found be a result of depletion within the nucleus accumbens core, 
as rats receiving 6-hydroxydopamine injection into the nucleus accumbens core showed the 
aforementioned behavioural phenotype while those with dopamine depletion in the nucleus 
accumbens shell displayed no such phenotype (Sokolowski and Salamone, 1998). Similarly, 
injection of the dopamine receptor antagonist haloperidol into the rat striatum has also been 
found to produce a dose-dependent decrease in the number of responses made in an 
instrumental learning task (Salamone et al., 1993). Dissociable roles of distinct subregions within 
the striatum during instrumental learning were also identified by Cousins and colleagues (1993), 
similar to those identified by Sokolowski and Salamone (1998), where dopamine depletion 
within the medial striatum had no effect on lever pressing or lab chow consumption. Conversely, 
ventrolateral striatal dopamine depletion decreased lever pressing but also tended to reduce 
the consumption of lab chow, with these rats also showing profound deficits in home-cage 
feeding to the extent that they required wet mash or tube feeding to maintain body weight. 
These studies identify the rodent striatum, and more specifically the core of the nucleus 
accumbens, as being integral to instrumental learning of food-rewarded behavioural operant 
tasks such as the CRF task, while there is a wealth of evidence that implicates the striatum and 
nucleus accumbens with also playing a key role in the acquisition of drug-seeking behaviour (Ito 
et al., 2002; Ito et al., 2004; Crespo et al., 2006; Neumaier et al., 2009; Murray et al., 2012). 
The five-choice serial reaction time task (5-CSRTT) is a behavioural task used to assess 
visuospatial attentional and impulsivity processes in rodents (Harrison et al., 1997; Robbins, 
2002; Christakou et al., 2004; Fletcher et al., 2007; Sanchez-Roige et al., 2012; Jupp et al., 2013). 
Lesion studies have found the 5-CSRTT to be dependent upon multiple neural structures, with 
deficits in the task identified following lesioning or inactivation of the cortex (Muir et al., 1996), 
striatum (Rogers et al., 2001), subthalamic nucleus (Baunez and Robbins, 1999), dorsal globus 
pallidus (Robbins et al., 1989), and pedunculopine nucleus (Inglis et al., 2001), but not the 
hippocampus (Kirkby and Higgins, 1998). A critical dependence of the 5-CSRTT on corticostriatal 
circuitry is suggested by evidence that performance in the task is impaired following quinolinic 
acid lesions to the medial striatum, medial PFC, peri- and post-genual anterior cingulate cortex, 
and parietal cortex (Muir et al., 1996; Rogers et al., 2001). Similar 5-CSRTT performance deficits 
have been identified by pharmacological antagonism of monoaminergic systems within the 
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striatum or PFC (Fletcher et al., 2007; Pezze et al., 2007; Agnoli and Carli, 2012; Agnoli et al., 
2013), which builds on evidence that alterations in these corticostriatal monoaminergic systems 
underlie poor choice accuracy and impulsivity in rats (Puumala and Sirvio, 1998; Jupp et al., 
2013). Dissociable roles of distinct regions of the striatum and cortex in instrumental learning of 
the 5-CSRTT have also been discovered. For example, lesioning the medial striatum of rats 
causes significant deficits on response accuracy, lengthened response latencies, and increases 
in both premature and perseverative responding, while lateral striatal lesions produce a 
profound inability to perform the 5-CSRTT, with very few trials being performed by lesioned 
animals despite an absence of motor or motivational deficits (Rogers et al., 2001). Thus, this 
study suggests that the medial and lateral striatum are implicated in, or responsible for, different 
aspects of continuous visuospatial attentional task performance. Similarly, increasing the 
attentional load in the 5-CSRTT, by shortening stimulus presentation and presenting white noise 
immediately prior to the visual target, has been found to produce significantly lengthened 
response latencies in medial PFC lesioned and antero-dorsal lesioned animals (Muir et al., 1996). 
This suggests that these animals traded speed for accuracy in the task, and thus that the medial 
PFC and antero-dorsal cortex may play roles in assisting impulsivity. The idea that accuracy and 
impulsivity in the 5-CSRTT can be functionally dissociated is further supported by reports from 
the same study whereby rats with anterior cingulate cortex lesions displayed significant 
increases in impulsive responding, suggesting that the anterior cingulate cortex may play a role 
in suppressing impulsivity, which is different to the potential role identified for the medial PFC 
and antero-dorsal cortex. The evidence described here highlights how the neural processes of 
attention and impulsivity in rodents, as examined by the 5-CSRTT, require a number of structures 
within the brain, and that there is a clear necessity of functional corticostriatal circuitry signalling 
for these cognitive domains. 
The serial implicit learning task (SILT) is a “9-hole” operant box based task developed to allow 
investigation into rodent visuospatial attentional domains and implicit learning, consisting of a 
predictable light sequence being embedded amongst other unpredictable light sequences (see 
Chapter 3.2.4.4 for full description of SILT methodology). Implicit learning is demonstrated in 
the task by animals responding with greater accuracy and/or speed to the predictable sequence 
than to unpredictable sequences. Neuroimaging studies in humans have identified a striatal and 
cortical basis of implicit learning (Rauch et al., 1997; Honda et al., 1998; Schendan et al., 2003; 
Aizenstein et al., 2004; Bennett et al., 2011), while there is also evidence of wider neural 
pathway involvement in this form of cognition (Schendan et al., 2003; Gheysen et al., 2010; 
Schendan et al., 2013). Based upon these findings, implicit learning in the SILT in rodents was 
hypothesised to have a corticostriatal basis, however, quinolinic acid lesions to the striatum or 
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to the premotor or supplementary motor areas of the cortex do not produce implicit learning 
deficits in the SILT, despite generating general deficits in performance of the task (Trueman et 
al., 2005; Brooks et al., 2007; Jay and Dunnett, 2007; Brooks and Dunnett, 2009). These studies 
suggest that implicit learning in rodents, as examined in the SILT, differs from implicit learning 
in humans because it appears to be independent of the corticostriatal circuitry. The neural basis 
for the utilisation of predictable information in the SILT has, at this moment in time, not yet been 
elucidated. 
The neural structure integral to spatial learning and memory, as briefly discussed in Chapter 
1.6.1, is the hippocampus, with a vast number of studies reporting deficits in spatial learning and 
memory tasks such as the Morris water maze, T-maze, Y-maze, and contextual fear conditioning 
following hippocampal lesions or disruption of hippocampal transcriptional regulation in 
rodents (Grant et al., 1992; McHugh et al., 1996; Tsien et al., 1996; Guzowski and McGaugh, 
1997; Frankland et al., 1998; Guzowski et al., 2000; Pittenger et al., 2002; Saxe et al., 2006; 
Dupret et al., 2008; Sekeres et al., 2010). It is not only the hippocampus that plays a role in 
spatial learning and memory, however, as there is evidence that lesions of the rat dorsomedial 
or dorsolateral striatum are capable of disrupting spatial discrimination (SD) acquisition 
(McDonald et al., 2006; McDonald et al., 2008a), while combined lesions of cortices areas are 
capable of impairing contextual discrimination (Burwell et al., 2004). Thus, it seems that the 
neural basis of SD may involve the recruitment of a cortical-striatal-hippocampal pathway, as 
briefly discussed in Chapter 1.6.1. 
Cognitive flexibility requires the ability to learn new rules and to be able to utilise these in place 
of previously learnt rules when the situation requires it. Reversal learning (RL), therefore, is an 
integral aspect of cognitive flexibility and has received investigation into its neural basis in 
humans, non-human primates, and rodents. Strong evidence of corticostriatal involvement in 
RL has been reported from such studies, with lesions to the PFC producing deficits in this form 
of cognition in non-human primates (Roberts et al., 1990; Roberts et al., 1992) and rodents (Kim 
and Ragozzino, 2005; Ragozzino, 2007; Brigman and Rothblat, 2008), while lesioning the 
dorsomedial striatum has also caused RL deficits in non-human primates (Clarke et al., 2008) 
and rats (Ragozzino, 2007; McDonald et al., 2008b; Castane et al., 2010). A large volume of 
molecular data also supports the presence of rodent RL being dependent upon corticostriatal 
circuitry. For example, selective striatal inactivation of adenosine A2A receptors (A2ARs) is 
capable of enhancing RL capabilities (Wei et al., 2011), while dopamine receptor D2 (Drd2) 
expression levels in the PFC have been found to inversely correlate with RL ability (Laughlin et 
al., 2011), and inactivation of Drd2, or antagonism of its protein (DRD2), in the striatum impairs 
RL ability (Kruzich et al., 2006; Desteno and Schmauss, 2009). In vivo electrophysiological 
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recordings have also identified corticostriatal circuits in the mouse that govern RL in an operant 
visual discrimination task, where the dorsal striatum is increasingly activated with the original 
choice learning, whereas prefrontal regions show increased activation during reversal of the 
learned choice (Brigman et al., 2013). Brigman and colleagues (2013) also found that 
corticostriatal or striatal deletion of the Grin2b gene, which encodes the N-Methyl-D-aspartate 
(NMDA)-type receptor subunit GluN2B, or dorsal striatum-restricted antagonism of GluN2B, 
impaired original choice learning, while cortical Grin2b deletion or orbitofrontal cortex GluN2B 
antagonism both impaired RL capabilities. Taken together, these studies identify the 
corticostriatal circuitry as the key neural pathway responsible for RL in non-human primates and 
rodents. 
 
1.6.2 The role of gene expression changes in cognition 
Investigations into the molecular mechanisms of cognition have demonstrated the importance 
of multiple signalling cascades in learning and memory storage that are dependent upon 
regulation of gene expression. Gene knockout studies in rodents have been particularly useful 
in evaluating the behavioural outcome resulting from altered transcription of genes of interest. 
CREB is one of a number of genes that has been found to be associated with memory, through 
such gene knockout studies. Development of a Creb knockout mouse, which lacks two isoforms 
of the CREB protein (Hummler et al., 1994), generated evidence that the CREB-cAMP response 
elements (CRE) signalling pathway is required for hippocampus-dependent long-term memory; 
Creb knockout mice exhibit deficits in contextual fear conditioning, cued fear conditioning, 
spatial memory and the social transmission of food preferences when tested 24 hours, but not 
30 minutes, after training (Bourtchuladze et al., 1994). CREB-CRE signalling is induced by long-
term potentiation in the hippocampus (Impey et al., 1996) and during contextual learning (Impey 
et al., 1998), which strengthens the suggestion that this signalling cascade plays a role in learning 
and memory. CREB is also known to be necessary for both amygdala- (Josselyn et al., 2004) and 
striatum-dependent forms of memory (Pittenger et al., 2006; Brightwell et al., 2008), suggesting 
that the CREB-CRE signalling pathway has diverse learning and memory functionality. CREB 
binding protein (CBP), a transcriptional co-activator of CREB (Kwok et al., 1994), has also been 
heavily implicated in learning and memory, with evidence that reduced Cbp transcription and 
CBP function results in a variety of learning and memory deficits (Alarcon et al., 2004; Wood et 
al., 2005) as well as transcriptional dysregulation of CREB target genes (Wood et al., 2006; 
Barrett et al., 2011). Taken together, these studies reveal that regulation of gene expression in 
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the CREB-CRE signalling cascade is integral for various aspects of learning and memory, and that 
disruption of this signalling pathway can be detrimental to cognition. 
As previously mentioned, the transcription of a number of genes have been associated with 
cognitive processes, which strengthens the theory that gene expression is an important 
mediator of cognition. Another example is BDNF signalling, which has been linked to learning 
and memory due to evidence that hippocampal BDNF mRNA expression is induced during spatial 
learning (Hall et al., 2000; Mizuno et al., 2000) while animals with disrupted BDNF signalling 
display impairments in spatial learning (Linnarsson et al., 1997; Mizuno et al., 2000) and memory 
consolidation (Lee et al., 2004). An effect of impaired BDNF signalling on cognition has also been 
reported in humans, where individuals with a mutation in BDNF that causes decreased BDNF 
secretion present with abnormal hippocampal activation and episodic memory deficits (Egan et 
al., 2003). The extracellular-signal regulated kinase (ERK)/mitogen-activated protein kinase 
(MAPK) signalling cascade provides further evidence for the importance of gene expression in 
cognition. ERK is activated in the hippocampus during associative learning and is necessary for 
contextual fear conditioning and spatial learning (Atkins et al., 1998), whilst dysregulation of the 
ras/ERK pathway is associated with learning and memory deficits similar to those observed in 
neurofibromatosis type 1 (Silva et al., 1997; Costa et al., 2002), a disorder characterised by the 
presence of cognitive deficits (North, 2000; Hyman et al., 2005; Champion et al., 2014). Learning 
and memory abnormalities have also been identified as a result of transcriptional dysregulation 
of genes that encode protein kinase A (Abel et al., 1997), DRD2 (Desteno and Schmauss, 2009; 
Jocham et al., 2009), methyl-CpG-binding protein 2 (Collins et al., 2004; Na et al., 2012), ephrin-
A2 (Arnall et al., 2010), neuronal nitric oxide synthase (Kelley et al., 2009), metabotropic 
glutamate receptor 1 (Aiba et al., 1994a; Aiba et al., 1994b), neurabin (Wu et al., 2008), and 
transcription factor 4 (Sweatt, 2013), as well as numerous other proteins. 
To summarise, transcriptional regulation of a variety of genes has been shown to be 
instrumental in multiple cognitive processes. Thus, cognition is dependent upon healthy 
regulation of gene expression, and transcriptional disruption has been found to result in diverse 
learning and memory deficits. 
 
1.6.2.1 Altered cognition and gene expression levels in HD patients 
As noted in Chapter 1.5, neural transcriptional profiles of human HD patients are most 
frequently determined for the end-stage of the disease because sample collection is only 
possible from post-mortem tissue, which makes correlating human HD cognitive deficits (see 
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Chapter 1.1.1.2) with gene expression abnormalities very difficult. That being said, there is 
evidence that post-mortem neural tissue from HD patients exhibits abnormal expression levels 
of a number of genes known to be involved in cognitive processes while vast transcriptional 
differences have also been identified in areas of the brain associated with cognition (Hodges et 
al., 2006). For example, a reduction in cortical BDNF mRNA and protein levels has been found in 
post-mortem HD patients (Zuccato et al., 2001; Zuccato et al., 2008), and blood serum BDNF 
levels are also reduced in living HD sufferers (Ciammola et al., 2007). Reductions in striatal 
expression of CREB signalling genes have also been identified in post-mortem HD brains (Cui et 
al., 2006; Chaturvedi et al., 2012; Jeong et al., 2012), as have similar reductions in mRNA 
expression levels of cannabinoid receptor 1 (Hodges et al., 2006), DRD1 (Augood et al., 1997; 
Hodges et al., 2006), and DRD2 (Augood et al., 1997). Although transcriptional dysregulation of 
these genes in human HD patients has not been directly attributed to the deficits in cognition 
seen in the disease, it is speculated that such changes in gene expression and gene expression 
levels may result in said cognitive deficits because of the roles that transcription can play in 
learning and memory, and thus cognition (see Chapter 1.6.2). 
 
1.6.2.2 Altered cognition and gene expression levels in mouse models of HD 
The various mouse models of HD present with an array of cognitive phenotypes (Table 1.2), 
some of which have been found to correlate with transcriptional abnormalities. An example of 
such a correlation is shown where R6/1 mice display decreased exploration activity in a novel 
object recognition task, and this behavioural phenotype was found to correlate with altered 
expression of genes associated with cell signalling and ion channels (Hodges et al., 2008). The 
severity of cognitive deficits in R6/1 mice has also been found to be modulated by BDNF 
signalling, with cognitive impairment occurring earlier in the lifespan of BDNF diminished R6/1 
animals than in unaltered R6/1 mutant mice (Giralt et al., 2009). Giralt and colleagues (2009) 
also discovered that downstream BDNF signalling was impaired in the hippocampus of R6/1 
animals and BDNF diminished R6/1 counterparts, suggesting that dysregulation of this BDNF 
cascade is involved in the learning impairment seen in R6/1 mice. BDNF signalling has been 
further implicated in cognitive dysfunction in HD mouse models from evidence that delivery of 
BDNF is capable of ameliorating long-term memory deficits in HdhQ140 mice (Simmons et al., 
2009). 
In the R6/2 mouse model, a combination drug therapy has been found to improve spatial 
navigation and RL deficits while also reversing a number of gene expression irregularities, which 
suggests that the drug-induced improvement in cognitive function may be mediated by the 
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changes to the transcriptional profile (Morton et al., 2005). Long-term spatial and recognition 
memory impairments have been associated with reduced hippocampal expression of CBP and 
decreased levels of histone H3 acetylation in heterozygous HdhQ111 mice (Giralt et al., 2012). 
Interestingly, there was also a significant reduction in the expression levels of CREB/CBP target 
genes that are related to memory, such as activity-regulated cytoskeleton-associated protein 
(Arc) and c-fos, and these transcriptional abnormalities were rescued by administration of a 
histone acetylase inhibitor, as were the recognition memory impairments. This study suggests 
that cognitive dysfunction in HdhQ111 mice may be caused by disruption to CBP mediated 
transcriptional and epigenetic regulation.  
Recent evidence suggests that overexpression of the adenosine A2A receptor (Adora2A) gene 
may contribute to learning and memory impairments seen in HD mouse models, as knockout of 
the Adora2A gene in R6/2 mice was found to prevent working memory deficits in the 8-arm 
radial maze task from 6 weeks of age (Li et al., 2015). Conversely, cognitive deficits in the R6/2 
and zQ175 mouse models of HD have shown no improvement following depletion of the tissue 
transglutaminase 2 gene, which is otherwise over-expressed in HD patients and mouse models, 
suggesting that the abnormal transcriptional regulation of this gene in HD is not responsible for 
the cognitive deficits observed (Menalled et al., 2014).  
The studies discussed here provide evidence for a link between transcriptional dysregulation 
and cognitive impairment in a number of mouse models of HD, however further investigation is 
required to elucidate the molecular and behavioural interactions that exist across the diverse 
array of cognitive phenotypes found in each mouse model of the disease. 
 
1.6.2.3 Altered cognition and transcription in the HdhQ150 mouse model of HD 
Of the cognitive impairments identified in HdhQ150 animals (Table 1.2 and Chapter 1.3.1.1), 
only one has been associated with transcriptional changes in signalling pathways; decreased 
ability in a RL aspect of the Morris water maze in HdhQ150/Q150 mice was correlated with reduced 
expression of sets of histone genes related to chromatin regulation, including nucleosome 
assembly (Giles et al., 2012). Thus, it is likely that these chromatin-related changes impact 
learning and memory in HdhQ150 mice, contributing to the RL deficits observed. The initial 
spatial learning impairment reported in the Morris water maze task significantly correlated with 
abnormal expression levels in 90 genes, however the behavioural/gene expression level 
interaction failed to reach significance in subsequent pathway analyses. While there are multiple 
studies providing evidence that transcriptional changes can correlate with cognitive ability in 
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human HD patients and various mouse models of the disease (see Chapters 1.6.2.1 and 1.6.2.2), 
relatively little is known about such interactions in the HdhQ150 mouse model of HD, and 
further investigation into the transcriptional basis of cognition in this mouse model is required. 
 
1.7 Aims of this work 
The aims of the experimental work in this thesis were to assess cognitive capabilities in the 
heterozygous HdhQ150 mouse model of HD, to investigate gene expression level changes with 
respect to learning, and to investigate whether any potential behavioural dysfunction was 
correlated with an abnormal transcriptional profile within the striatum. HdhQ150/+ mice were 
chosen for examination because they provide a comparable representation of the genetic profile 
of HD patients, as the majority of sufferers are heterozygous for the mutant allele (Alonso et al., 
2002), although the repeat length found in this mouse model is much greater than that found in 
human cases of the disease. Transcriptional changes were investigated in the striatum because 
this neural structure is the primary site of pathology in HD (Lange et al., 1976; Vonsattel et al., 
1985; Vonsattel and DiFiglia, 1998), displays the greatest number and magnitude of differentially 
expressed mRNAs within the HD brain (Hodges et al., 2006), and is associated with various forms 
of cognition (see section 1.6.1). 
The specific aims of this thesis were to: 
 Assess implicit learning capabilities and striatal transcriptional profiles of HdhQ150/+ mice 
using the serial implicit learning task (SILT), and whether the degree of learning 
undertaken or the age of mice contribute to striatal gene expression levels (Chapter 3). 
 Examine the striatal transcriptional profile of wild-type animals across distinct stages of 
an operant-based spatial discrimination (SD) and RL task as a means of identifying 
learning dependent gene expression level changes within the striatum (Chapter 4). 
 Assess SD performance and striatal transcription levels of the target genes identified in 
Chapter 4, in HdhQ150/+ mice (Chapter 5). 
 
 
 
 
 
43 
 
Chapter 2: Methods 
2.1 Animals 
2.1.1 HdhQ150 line 
HdhQ150 mice were bred in-house on the original 129/Ola x C57BL6/J background (Lin et al., 
2001). HdhQ150 mice contain an expanded CAG tract of 150 repeats within the endogenous 
mouse Htt exon 1 sequence. This line was initially generated using a two-step gene targeting 
strategy utilising embryonic stem cells where the endogenous mouse Htt exon 1 sequence was 
replaced with an hypoxanthine guanine phosphoribosyltransferase (Hprt) minigene and the Hprt 
minigene then exchanged with a CAG-expanded mouse Htt exon 1 sequence (Lin et al., 2001). 
This method of construct generation results in the Htt exon 1 sequence 3’ to the CAG tract 
encoding a mouse polyglutamine expanse, and an entirely mouse Htt locus, which is unlike the 
knock-in mice generated by Wheeler and MacDonald (Wheeler et al., 1999) or Zeitlin (Levine et 
al., 1999; Menalled et al., 2003) that encode a human exon 1 sequence within the mouse Htt 
locus. Timed mating was performed by pairing heterozygote HdhQ150 male and female animals 
at 4pm, and leaving overnight until 9am the next morning, when they were then separated and 
presence or absence of a vaginal plug was observed. Female HdhQ150/+ and Hdh+/+ mice were 
used in experimental chapter 3; male Hdh+/+ mice were used in experimental chapter 4; and 
male HdhQ150/+ and Hdh+/+ mice were used in experimental chapter 5. The CAG repeat length of 
HdhQ150/+ mice tested across all experiments ranged between 117 and 164 repeats, with a mean 
of 140 CAG repeats (± 1.66). 
 
2.1.2 Animal husbandry 
Mice were housed in cages in cohorts not greater than five animals per cage in non-barrier 
conditions as per Home Office regulations. Environmental temperature was maintained at 21°C 
± 1°C on a 12-h light/dark cycle with standard food (Harlan, Oxfordshire) and water freely 
accessible, except where described in experimental chapters. All animals were handled for a 
minimum of 1 week prior to behavioural training. 
For water restriction, water accessibility was gradually decreased to 3 hours per day over a five-
day period, with body weight monitored daily during this period. During testing, water access 
remained at 3 hours a day and was provided at a regular time after each task session. Body 
weight was recorded at weekly intervals during testing, ensuring that animals did not fall below 
85% of their normal adult body weight. 
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2.1.3 Genotyping 
Tail biopsy from 3 week old animals was shipped on dry ice to Laragen Inc. (California, USA) for 
genotyping by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) using 
probe-based Taqman® assays (Life Technologies Corporation, California, USA). 
 
2.1.4 Dissections 
Animals were culled by the Schedule 1 method of cervical dislocation, as per Home Office 
regulations, followed by post-mortem decapitation and brain removal from the skull. 
Hemispheres were separated by a cut in the sagittal plane down the longitudinal fissure and 
through the corpus callosum. Unless otherwise stated, the following structures were then 
isolated from both hemispheres: striatum, prefrontal cortex, cerebellum, hippocampus and 
motor cortex. To expose the striatum, a coronal cut was made at the posterior of the lateral 
ventricle and the striatum then removed from the anterior brain segment. The anterior brain 
segment was then turned dorsal side upwards and prefrontal cortex tissue isolated. Motor 
cortex tissue was isolated from the superior surface of the posterior brain segment. The 
hippocampus was exposed by removing the overlaying motor cortex and surrounding tissue. 
The cerebellum was taken from the posterior of the brain. Each structure was snap frozen in 
liquid nitrogen and stored at -80°C for later analysis.  
 
2.2 Behavioural training 
2.2.1 Apparatus 
2.2.1.1 Rotarod 
Two accelerating mouse rotarods (model numbers: 7650 and 47600; Ugo Basile, Italy) were used 
to assess motor ability and co-ordination. Both apparatus consisted of a rotating rod 30 mm in 
diameter, with five separated chambers of 57 mm in width and rod elevation of 160. The Rota-
Rod 7650 (Fig. 2.1A) was used in the initial habituation session (see Chapter 5.2.3.1) while Rota-
Rod 47600 (Fig. 2.1B) was used in the subsequent test sessions (see Chapter 5.2.3.1). Rota-Rod 
7650 rotation acceleration ranged from 3 to 20 rpm over the course of a 300 s session, while 
Rota-Rod 47600 rotation acceleration ranged from 4 to 44 rpm over the course of a 300 s 
session.  
See Chapter 5 for experimental details. 
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Figure 2.1. Mouse rotarod apparatus. Both Rota-Rod 7650 (A) and 47600 (B) consisted of a 
rotating rod 30 mm in diameter, with five separated chambers of 57 mm in width and rod 
elevation of 160 mm. 
 
2.2.1.2 Operant chambers 
Testing was performed in sixteen ‘9-hole’ operant chambers (Fig. 2.2; Campden Instruments, 
Loughborough, UK) used in parallel. Chambers were based on a design first used in rats (Carli et 
al., 1983) and adapted for use in mice (Humby et al., 1999). Each chamber was constructed of 
stainless steel walls, perforated steel floor and a clear Perspex roof, and measured 140 mm x 
130 mm x 125 mm in size. On the front inner wall of each chamber was a horizontal array of 9 
holes (11 mm diameter, 2 mm apart from one another and 15 mm above floor level) along the 
curved front wall of the chamber, each of which housed a 2.5 Watt bulb stimulus light and a 
photocell beam to detect np responses. For the continuous reinforcement (CRF) task, aperture 
5 (from the left side) was used, while the 5-choice serial reaction time task (5-CSRTT) and SILT 
both utilised apertures 1, 3, 5, 7 and 9. Three holes were used in the SD and RL experiments 
(numbers 3, 5 and 7 from left to right). Apertures 2, 4, 6 and 8 were capped and inaccessible 
throughout testing. A reward magazine was located at the rear of the chamber opposite the 
aperture array. For rewarding correct responses, 5 µl of Yazoo strawberry milk (Campina UK, 
Horsham, UK) was delivered by peristaltic pump and 0.8 mm polyethylene tubing to a small 
spout located in the base of the reward magazine. The entry of the mouse’s head into the 
magazine when collecting the reward and the removal of the mouse’s head from the magazine 
after delivery collection was detected by an infrared beam. The magazine was fitted with a light 
57 mm 
30 mm 
160 mm 
57 mm 
30 mm 
160 mm 
A. B. 
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to signal reward delivery. Two additional “house” lights, one situated on each of the side walls, 
were used to signal performance errors. Chambers also contained loudspeakers, although they 
were not utilised in behavioural testing. Each chamber was housed in a sound attenuation 
chamber that was fitted with a fan to keep a low constant noise and provide ventilation. The 
chambers were operated under online control by a PC computer and control unit programmed 
in the BNC Control language (Campden Instruments, Cambridge, UK). 
See Chapter 3, 4 and 5 for experimental details. 
 
 
 
 
 
 
 
Figure 2.2. ‘9-hole’ operant chamber apparatus. 1: response array (9 apertures of 10 mm in 
diameter, spanned by vertical infra-red beams and each containing a small light); 2: food 
magazine (containing reward light and food well); 3: polyethylene tubing; 4: peristaltic pump; 5: 
reinforcer bottle containing Yazoo strawberry milk (Campina UK, Horsham, UK); 6: house light; 
and 7: loudspeakers. 
 
2.3 Molecular methodology 
2.3.1 Phenol/chloroform RNA extraction 
For total RNA extraction, RNA was prepared from striatal tissue using TRIzol (Life Technologies 
Corporation, Carlsbad, California, USA) and RNeasy MinElute Cleanup Kit (Qiagen, Manchester, 
UK) according to manufacturers’ protocols, with minor modifications. Briefly, dissected striata 
were flash frozen within Lysing Matrix D tubes (MP Biomedicals, Santa Ana, California, USA) in 
liquid nitrogen and stored at -80°C. On ice, 1 mL of TRIzol (Life Technologies Corporation, 
Carlsbad, California, USA) was added to dissected striata prior to 3 pulses of 3 s homogenisation 
at speed 4.5 in a FastPrep FP210 homogeniser (MP Biomedicals, Santa Ana, California, USA), 
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with 1 min on ice between pulses. 500 µL of TRIzol Reagent (Life Technologies Corporation, 
Carlsbad, California, USA) was then added to the homogenate and the homogenate transferred 
to a 10 mL polypropylene tube before 5 min incubation at room temperature. 300 µL of 1-
Bromo-3-chloropropane (Sigma-Aldrich Company Ltd, Dorset, UK) was added to samples, 
followed by vortexing for 15 s and 5 min incubation at room temperature.  
Samples were centrifuged at 11,000 rpm for 15 min at 4°C in an Avanti J-E Centrifuge (Beckman 
Coulter (UK) Ltd, High Wycombe, UK) and approximately 600 µL of the upper aqueous phase 
transferred to a 2 mL eppendorf tube. 750 µL of 2-Propanol (Sigma-Aldrich Company Ltd, Dorset, 
UK) was added to the upper aqueous phase and the samples mixed by inversion before being 
left to precipitate at room temperature for 10 min. To pellet the RNA, samples were centrifuged 
at 11,000 rpm for 10 min at 4°C in Biofuge Fresco Heraeus centrifuge (Thermo Fisher Scientific 
Inc., Massachusetts, USA) and the supernatant removed. Pellets were washed in 1.5 mL of 75% 
ethanol (Sigma-Aldrich Company Ltd, Dorset, UK), made with nuclease-free water (Life 
Technologies Corporation, Carlsbad, California, USA), and samples centrifuged at 9,500 rpm for 
5 min at 4°C. The supernatant was removed, pellets washed again in 1.5 mL of 75% ethanol and 
samples centrifuged at 9,500 rpm for 5 min at 4°C. Supernatant was then removed, samples 
centrifuged at 9,500 rpm for 15 s at 4°C to drain the remaining ethanol, remaining ethanol 
removed and RNA pellets dried in a 45°C oven for 5 min. Pellets were resuspended in 100 µL 
nuclease-free H2O (Life Technologies Corporation, Carlsbad, California, USA), vortexed for 15 s, 
heated at 65°C for 5 min on an Eppendorf Thermomixer Comfort heating block (Eppendorf UK 
Ltd, Stevenage, UK), and vortexed again for 15 s. 
For RNA purification, 350 µL of RLT buffer (Qiagen, Manchester, UK) was added to samples and 
mixed by inversion, before centrifuging at 9,500 rpm for 15 s at 22°C. Next, 250 µL of 100% 
ethanol (Sigma-Aldrich Company Ltd, Dorset, UK) was added to the diluted RNA and mixed 
thoroughly by pipetting. The samples (approximately 700 µL) were immediately applied onto a 
Mini-elute column placed in a 2 mL collection tube (Qiagen, Manchester, UK) and centrifuged at 
10,000 rpm for 15 s at 22°C. Flow-through and collection tubes were discarded, Mini-elute 
columns placed into new 2 mL collection tubes, and 500 µL of Buffer RPE (Qiagen, Manchester, 
UK) added to the columns before centrifuging samples at 10,000 rpm for 15 s at 22°C. Flow-
through and collection tubes were discarded, Mini-elute columns placed into new 2 mL 
collection tubes (Qiagen, Manchester, UK), and 500 µL of 80% ethanol (Sigma-Aldrich Company 
Ltd, Dorset, UK), made with nuclease-free water (Life Technologies Corporation, Carlsbad, 
California, USA), was added onto the Mini-elute columns (Qiagen, Manchester, UK). Samples 
were centrifuged at 10,000 rpm for 2 min at 22°C, flow-through and collection tubes discarded, 
Mini-elute columns placed into new 2 mL collection tubes (Qiagen, Manchester, UK), and 
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samples centrifuged at 13,000 rpm for 5 min at 22°C. The samples were rotated 180° in the 
centrifuge and centrifuged at 13,000 rpm for 1 min at 22°C. Mini-elute columns were transferred 
to 1.5 mL collection tubes (Qiagen, Manchester, UK) and 14 µL of nuclease-free water (Qiagen, 
Manchester, UK) pipetted onto the centre of the RNeasy silica-gel membrane. After 5 min, 
samples were centrifuged at 13,000 rpm for 1 min at 22°C. Tubes were rotated 180°C and 
centrifuged for 1 min at 13,000 rpm at 22°C.  
To degrade any possible DNA contaminants, RNA samples were treated with TURBO DNA-free™ 
Kit (Life Technologies Corporation, Carlsbad, California, USA) according to manufacturer’s 
instructions. Briefly, a typical reaction was a 50 µL volume consisting of nuclease-free water, 1x 
TURBO DNase buffer, 1 µL of TURBO DNase for up to 10 µg of RNA. The reaction mixture was 
incubated at 37°C for 30 min before 1x DNase Inactivation reagent was added to the reaction 
and thoroughly mixed. The mixture was then incubated at room temperature for 2 min before 
centrifugation at 10,000 rpm for 90 s. RNA was transferred into a fresh tube and stored at -80°C. 
 
2.3.1.2 Quantification of the RNA sample 
Quantity and quality of RNA was assessed by measurements of ultraviolet (UV) light absorption 
on a NanoVue Plus spectrophotometer (GE Healthcare Life Sciences, Buckinghamshire, UK). RNA 
absorbs UV light maximally at 260 nm, thus the ratio of absorbance at 260 nm and 280 nm 
(protein) was used to assess the RNA purity of a given RNA preparation. Pure RNA has an 
A260/A280 ratio of 2.1. For nucleic acid quantification, the Beer-Lambert equation is 
manipulated to give: 
 
 
Where c is the nucleic acid concentration in ng/µL, A is the absorbance in AU (for the arbitrary 
absorbance unites), e is the wavelength-dependent extinction coefficient in ng-cm/µL and b is 
the path length in cm. For nucleic acids, data are normalised to a 1 cm path length. The generally 
accepted extinction coefficient for RNA is 40. Use of the spectrophotometer enabled highly 
accurate analysis of particularly small sample volumes. Surface tension was used to hold a 
column of liquid sample in place while a measurement was made. 2 µL of the RNA sample was 
pipetted directly onto a measurement pedestal, and a measurement column was then drawn 
between the ends of two fibres in order to establish a measurement path. The measurement 
was carried out and presented on the display of the spectrophotometer. 
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Quality of RNA to be utilised in a microarray was further assessed by Dr. Joanne Morgan or 
Megan Musson of Cardiff University’s Central Biotechnology Services (CBS; Cardiff, UK) using the 
Agilent 2100 Bioanalyzer (Agilent Technologies UK Ltd, Berkshire, UK). This system uses 
electrophoretic separation on microfabricated chips to separate and detect RNA samples via 
laser induced fluorescence detection (Schroeder et al., 2006). An electropherogram and gel-like 
image is then generated alongside details including sample concentration and ribosomal ratio, 
allowing detailed visual assessment of the quality of an RNA sample. A software algorithm 
generates the RNA Integrity Number (RIN) for each sample, an indication of the quality of 
eukaryotic total RNA that takes into account the entire electropherogram and removes 
individual interpretation in RNA quality control. The RIN value ranges from 1 to 10, with 1 being 
the most degraded profile and 10 being the most intact. RIN values of samples are provided in 
the relevant experimental chapters. 
 
2.3.2 Quantitative reverse-transcription polymerase chain reaction 
2.3.2.1 RNA to cDNA conversion 
500 ng RNA from each sample underwent reverse transcription (RT) using a High Capacity RNA 
to cDNA™ kit (Life Technologies Corporation, California, USA) according to manufacturer’s 
instructions. This concentration of RNA was determined by carrying out an RT reaction efficiency 
curve, which was achieved by performing the RT reaction with 250 ng, 500 ng and 1 µg RNA 
followed by quantitative polymerase chain reaction (qPCR) using an example primer pair. If the 
RT reaction is efficient, the cycle threshold (Ct) values will decrease with increased RNA load. 
Briefly, 500 ng of RNA was loaded into each reaction, and made up to a total volume of 9 µL with 
nuclease-free H2O. This was added to 10 µL of 2X RT Buffer Mix and 1 µL of 20X RT Enzyme Mix, 
generating a 1X master mix used for the RT reaction (Table 2.1). Two negative controls were 
included; one in which the RT Enzyme Mix was substituted for nuclease-free H2O and the other 
where RNA was substituted for nuclease-free H2O. The master mix was briefly centrifuged at 
10,000xg before incubation at 37°C for 60 minutes, and the reaction stopped by sample 
incubation at 95°C for 5 minutes. RT reactions were performed using a Bio-Rad S1000™ thermal 
cycler (Bio-Rad Laboratories, Inc., California, USA). Complementary DNA (cDNA) was diluted 1:50 
in nuclease-free H2O for use in PCR and stored at -20°C. 
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Reagent Component Volume/Reaction (µL) 
2X RT Buffer Mix 10.0 
20X RT Enzyme Mix 1.0 
RNA Up to 9.0 
Nuclease-free H2O Up to 9.0 
Table 2.1. 1X master mix for RNA reverse transcription. 
 
2.3.2.2 qPCR protocol 
Similar to the RT reaction efficiency described in Chapter 2.3.2.1, efficiency of TaqMan® assays 
were determined by loading a serial dilution of cDNA into the RT-qPCR reaction. If the reaction 
is efficient, there will be a linear relationship between the concentration of cDNA loaded into 
the reaction and the resulting Ct value. The R2 and slope of this relationship were then identified 
from the Sequence Detection Systems (SDS) Version 2.3 programme (copyright 2005, Applied 
Biosystems), and the PCR efficiency can be determined from these (Efficiency: ((10ˆ(-1/slope)) -
1) x 100). For illustrative purposes, Figure 2.3 displays the efficiency data for the TaqMan® assay 
investigating Dopamine receptor D2 (Drd2) expression levels. 
 
 
 
 
 
 
 
Figure 2.3. The RT-qPCR efficiency curve for the Drd2 TaqMan® assay. The R2 value is provided 
in the chart area, while the slope was determined to be -3.34 by the Sequence Detection Systems 
(SDS) Version 2.3 programme (copyright 2005, Applied Biosystems) and efficiency calculated to 
be 99.43%. 
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For each experiment, amplification of all genes of interest and two housekeeping genes was 
performed in triplicate in the same qPCR run. All preparations were performed on ice.  40 ng of 
cDNA template was used for each reaction and made up to a total volume of 9 µL with nuclease-
free H2O. This was added to 10 µL of TaqMan® Universal Master Mix II, with Uracil-N-Glycosylase 
(UNG; Life Technologies Corporation, California, USA) and 1 µL of the relevant TaqMan® gene 
expression assay (Life Technologies Corporation, California, USA) per well, generating a 1X 
master mix used for the qPCR (Table 2.2).  
 
Reagent Component Volume/Reaction (µL) 
2X TaqMan® Universal Master Mix II, with 
UNG 
10.0 
20X TaqMan® gene expression assay 1.0 
RNA 4.0 
Nuclease-free H2O 5.0 
Table 2.2. 1X qPCR master mix. 
 
To ensure there was no contamination of samples in the 2-step process (cDNA synthesis and the 
qPCR protocol itself), each plate also included an RT-control (where no RT reaction was 
performed), a water RT control (where the RT reaction was performed, but with water replacing 
the RNA template), and a non-template control (where cDNA was replaced with nuclease-free 
H2O). 
Reactions were loaded into MicroAmp® Fast Optical 96 well plates (Life Technologies 
Corporation, California, USA) and sealed with MicroAmp® Optical Adhesive Film (Life 
Technologies Corporation, Carlsbad, California, USA) before brief centrifugation at 4,600xg using 
a Sorvall™ Legend™ RT centrifuge (Thermo Fisher Scientific, Massachusetts, USA). Plates were 
loaded into the StepOnePlus™ Real-Time PCR System (Life Technologies Corporation, California, 
USA) and cycling conditions were as shown in Table 2.3. 
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 Stage 1 Stage 2 
  
UNG 
Activation 
Polymerase 
Activation 
PCR (40 Cycles) 
Denature Annealing/Extension 
Temperature 50°C 95°C 95°C 60°C 
Time 02:00 10:00 00:15 01:00 
Table 2.3. qPCR cycling conditions. 
 
Control and analysis of RT-qPCR protocols were performed by StepOne™ Software Version 2.2.2 
(Life Technologies Corporation, California, USA). 
 
2.3.2.3 Data analysis using the 2-ΔΔCt method 
The 2-ΔΔCt method was used to calculate relative changes in gene expression levels determined 
from each RT-qPCR experiment. Derivation of the 2-ΔΔCt equation, including assumptions, 
experimental design and validation tests have been previously described by (Livak and 
Schmittgen, 2001). In order to normalise the qPCR data for the amount of RNA that is added to 
a reaction, housekeeping genes are commonly used as an internal control. In this thesis, Beta-
actin (Actb) and Ubiquitin C (Ubc) were selected as the reference genes because they showed 
no significant differences in expression in comparisons between groups, or genotypes, in the 
microarray performed in Chapter 3 (data not shown) and have both been reported to show 
stable levels of expression within the striatum of a mouse model of HD (Benn et al., 2008a). The 
change in expression levels of the target gene was normalised to the mean of the mean Ct values 
of Actb and Ubc for each individual sample. In order to minimise sampling errors, each sample 
was run in triplicate. The Ct values (defined by the number of cycles required for the fluorescence 
to cross the threshold, i.e. exceeding the background level) obtained from the StepOne™ 
Software Version 2.2.2 (Life Technologies Corporation, California, USA) were imported into 
Microsoft Excel, which enabled descriptive analysis of the data, and conversion to 2-ΔΔCt for 
subsequent analysis (see (VanGuilder et al., 2008). The Ct values for the control genes (Actb and 
Ubc) mRNAs and the target gene mRNAs were averaged across the triplicates for each sample, 
prior to performance of the ΔCt calculation. The ΔCt value was calculated by subtracting the 
average Ct values of the control genes (consisting of the mean of the average Ct value of both 
Actb and Ubc) from the average Ct values of the target genes. Next, the subtraction of the ΔCt 
values of the control gene samples from the ΔCt values of the target gene samples yielded the 
ΔΔCt values. The negative values of this subtraction, the - ΔΔCt values, were then used as an 
exponent of 2, and represent in “corrected” number of cycles to threshold (Livak and 
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Schmittgen, 2001), but the exponent conversion is based on the fact that the reaction doubles 
the amount of product per cycle. These values were then combined with the values of relative 
change in the expression of the target gene between the comparison groups and presented as 
a graph. 
 
2.3.2.4 Statistical analysis of the RT-qPCR data 
The final stage of the RT-qPCR analysis was to determine the Ct value. The Ct value was derived 
from a log-linear plot of the PCR signal against the cycle number, which depicts the Ct value as 
an exponential instead of a linear term. Hence, the data were converted to a linear form using 
2-ΔΔCt (transformed data). In order to examine the statistical significance of the relevant change, 
independent two tailed T-tests were performed on the transformed data. 
 
2.4 General data presentation and statistical methods 
The data in this thesis is presented as mean values ± standard error of the mean (S.E.M.), 
calculated from the following formula: 
Standard error of the mean = standard deviation of values 
       √number of values 
 
All statistical analyses were performed using IBM SPSS® Statistics software, version 20 for 
windows (IBM United Kingdom Ltd, Hampshire, UK). The data were analysed by either 2-tailed, 
paired T-test, independent samples T-test, one-way analysis of variance (ANOVA) or repeated 
measures ANOVA, where appropriate. All statistical tests were performed with an alpha value 
of <0.05 regarded as significant. Interaction statistics are only reported if they reach significance, 
unless otherwise stated in experimental chapters. Post hoc pairwise comparisons were 
performed using Tukey’s honestly significant difference (HSD) test, unless otherwise stated in 
experimental chapters. Repeated measures data were assessed for equality of variance using 
Mauchly’s test of sphericity, with the Greenhouse-Geisser correction used if the assumption of 
Sphericity was violated and the Greenhouse-Geisser estimate of sphericity (ɛ) < 0.75. If the 
assumption of Sphericity was violated and ɛ > 0.75, the Huynh-Feldt correction was used. 
Similarly, homogeneity of variances for data was assessed using Levene’s test, and the Welch 
test used in the event of data violating this assumption. Specific details of statistical analyses are 
described in the relevant experimental chapter. 
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Chapter 3: Age- and learning-dependent changes in the transcriptional profile of the 
heterozygous HdhQ150 mouse model of Huntington’s disease 
3.1 Introduction 
Implicit learning has previously been defined as “…(learning that) occurs without concurrent 
awareness of what is being learned” (Shanks and Stjohn, 1994). Human neuroimaging studies 
have identified implicit learning as a complex process likely to utilise a number of regions in the 
brain, with evidence of striatal (Rauch et al., 1997; Schendan et al., 2003; Aizenstein et al., 2004; 
Destrebecqz et al., 2005; Reiss et al., 2005; Bennett et al., 2011; Gheysen et al., 2011), cortical 
(Honda et al., 1998; Schendan et al., 2003; Aizenstein et al., 2004; Bennett et al., 2011), 
hippocampal (Schendan et al., 2003; Gheysen et al., 2010) and medial temporal lobe (Schendan 
et al., 2013) involvement in the processing of implicit information. Cases of HD patients with 
deficits in this form of learning have been reported (Heindel et al., 1989; Knopman and Nissen, 
1991; Gabrieli et al., 1997; Kim et al., 2004). Conversely, other studies have not observed such 
impairments (Brown et al., 2001; Schneider et al., 2010). The discrepancy in these findings may 
be the result of differences in methodology, as suggested by Brown and colleagues (2001), while 
the correlation between abnormal striatal activity, identified by fMRI, and implicit learning 
impairments in HD patients discovered by Kim et al. (2004) provides strong evidence that this 
learning deficiency can occur in cases of HD. Deficits in implicit learning have also been identified 
in Parkinson’s disease (Wilkinson et al., 2009; Schendan et al., 2013; Gamble et al., 2014), a 
disorder that, similar to HD, is characterised by striatal dysfunction (Gerfen et al., 1990; Hughes 
et al., 1993), which supports the theory that the striatum plays a key role in implicit learning. 
Motor symptom onset in HD, which is often the criteria used for diagnosis of disease onset 
(Kirkwood et al., 2000; Walker, 2007; Long et al., 2014), is often preceded by subtle cognitive 
disturbances in processes such as implicit learning (Kim et al., 2004; Ghilardi et al., 2008; van 
Asselen et al., 2012), semantic memory and visual discrimination (Lawrence et al., 1998b), 
working memory (van Walsem et al., 2010; Stout et al., 2011) and emotion recognition (Gray et 
al., 1997; Johnson et al., 2007; Stout et al., 2011). Over time, early-stage HD patients show a 
progressive decline in a number of cognitive capabilities including those related to working 
memory (Tabrizi et al., 2011; Harrington et al., 2012), emotion recognition (Stout et al., 2012; 
Tabrizi et al., 2013) and executive functioning (Stout et al., 2012; Hart et al., 2013; Tabrizi et al., 
2013). Implicit learning capabilities have been shown to decline in healthy ageing, with changes 
in frontostriatal activity believed to contribute to this deterioration (Aizenstein et al., 2006; 
Bennett et al., 2011; Schendan et al., 2013). Thus, it is feasible that the frontostriatal 
degeneration that progresses over time in the premanifest phase of HD (Tabrizi et al., 2009; 
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Tabrizi et al., 2011; Tabrizi et al., 2013) may contribute to the implicit learning deficits that can 
arise in the disease, as suggested in an earlier imaging study of the condition (Kim et al., 2004). 
Transcriptional dysregulation is hypothesised to be an integral mechanism in the 
pathophysiology of HD (Cha, 2000; Sugars and Rubinsztein, 2003; Thomas, 2006; Buckley et al., 
2010; Bowles et al., 2012; Seredenina and Luthi-Carter, 2012), with evidence of gene expression 
level alterations arising in a range of neural structures (Hodges et al., 2006; Johnson et al., 2008; 
Neueder and Bates, 2014; Capurro et al., 2015), including the striatum (Augood et al., 1996; 
Norris et al., 1996; Desplats et al., 2006; Hodges et al., 2006; Kuhn et al., 2007). Similar changes 
in the transcriptome have been reported in a number of mouse models of HD (Luthi-Carter et 
al., 2000; Luthi-Carter et al., 2002; Kuhn et al., 2007; Johnson et al., 2010; Giles et al., 2012; 
Neueder and Bates, 2014; Bayram-Weston et al., 2015). Importantly, aberrant gene expression 
level profiles have been identified in individual cells, and in the absence of neurodegeneration 
and neurotransmission abnormalities (Hodges et al., 2006; Runne et al., 2008; Capurro et al., 
2015), suggesting that the abnormal transcriptional patterns identified in HD are attributable to 
the intrinsic effects of mHtt and not purely the result of the neuronal death characteristic of the 
disease.  
The SILT is a “9-hole” operant box based task developed to allow investigation into implicit 
learning, where a predictable light sequence is embedded amongst other unpredictable light 
sequences. Implicit learning is demonstrated in the task by mice responding with greater 
accuracy and/or speed to the predictable sequence than to unpredictable sequences. Quinolinic 
acid lesions to the striatum have previously been found to disrupt general SILT performance 
(Trueman et al., 2005), as well as acquisition and retention of the task (Brooks et al., 2007), while 
deficits in overall task performance have been identified in the HdhQ92 and YAC128 mouse 
models of HD at 4M and 6M, respectively (Trueman et al., 2007; Brooks et al., 2012d). 
The HdhQ150 knock-in mouse model of HD has previously been found to present with early 
cognitive deficits in spatial learning and extra-dimensional set shifting that manifest prior to 
motor dysfunction (Brooks et al., 2006; Brooks et al., 2012b), as well as a transcriptional profile 
that undergoes longitudinal alterations similar to those found in human HD (Giles et al., 2012) 
and YAC128 mouse brain (Bayram-Weston et al., 2015). The current study aimed to utilise the 
SILT as a means to examine implicit learning in the HdhQ150 model of HD, and also to investigate 
changes in the transcriptome as a result of disease genotype, ageing and cognitive training. 
Ageing was examined from 3M to 6M, as this has been identified as the optimum timeframe to 
investigate ageing before senescence begins (Flurkey et al., 2007) and because it could be 
argued to act as a premanifest stage of HD in the HdhQ150 line, with previous reports of 
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cognitive dysfunction in the absence of motor abnormalities within this timeframe (Brooks et 
al., 2006; Brooks et al., 2012b). Gene expression level analyses using microarray investigation 
were performed across this timeframe in an attempt to identify early ageing-dependent 
transcriptional alterations comparable to those seen later in the lifetime of this model (Giles et 
al., 2012). Animals were trained to one of two stages of learning – to acquisition of a simple 
conditioning task or acquisition of the SILT – to elucidate whether HdhQ150/+ mice present with 
an abnormal capacity for acquisition of conditioning or implicit learning, and also to probe 
whether any gene expression level differences arise between these forms of learning using a 
microarray. 
 
3.2 Methods 
3.2.1 Declarative statement 
Experimental design and all behavioural work, including tissue collection, in the current chapter 
was carried out by another party prior to me commencing my PhD program. Analysis of 
behavioural data and all molecular techniques and analyses, unless otherwise specified, were 
performed by me. 
 
3.2.2 Animals 
44 naïve female mice were used in this experimental chapter, with genotypes: HdhQ150/+ (n=23) 
and Hdh+/+ (n=21). HdhQ150/+ CAG repeat sequences ranged from 129 to 164 CAGs (Mean: 149.50 
± 10.57). General husbandry conditions were as described in Chapter 2.1, except in regards to 
housing, with animals in this experiment being housed in pairs. All animals were between 7 and 
9 weeks of age at the start of testing. 
 
3.2.3 Experimental design 
Each experimental cohort received different behavioural training protocols (Table 3.1). Animals 
in Group A and Group B had no behavioural training and were unhandled (except during routine 
home cage cleaning), being left in their home cages until sacrifice at 3M or 6M, respectively. 
Group C mice were trained to acquisition in the CRF task, before sacrifice at 3M. Group D mice 
received training to acquisition in CRF before being placed in operant boxes with no SILT 
program run and were sacrificed at 6M. Animals in Group E were trained to acquisition in CRF 
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prior to training in the five-choice serial reaction time task (5-CSRTT) and SILT, before being 
sacrificed at 6M. 
 
Table 3.1. Table of behavioural groups, animal numbers and training paradigms. Mean CAG 
repeat length is presented as data ± S.E.M. 
 
3.2.4 Behavioural training protocols 
3.2.4.1 Magazine training 
Mice in Groups C (n=9), D (n=8) and E (n = 8) underwent 1 day of magazine training in order to 
permit the mice to learn the association between magazine light illumination and food reward. 
The magazine light was illuminated and 150 µL of reward was delivered at the onset of the 20 
min session. Upon removal of the head from the magazine, the light would extinguish for 10 s 
before again illuminating and 5 µL of reward delivered. This reward contingency was maintained 
for the remainder of the session. Following magazine training, mice began the next task in the 
series, the CRF task. 
 
3.2.4.2 CRF task 
CRF task training was undertaken by mice in order to teach the animals to associate the presence 
of an operant aperture light with the delivery of a food reward, which is a necessary prerequisite 
for animals to be able to perform the more complex 5-CSRTT and SILT, and was also utilised to 
examine the ability of mice to acquire a simple conditioning task. Mice were required to perform 
a single nose-poke to the light stimulus presented in the centre hole (hole 5) of the operant box 
in order to receive a food reward. Sessions lasted 20 min and 1 session was performed each day. 
When the hole 5 stimulus light was presented, a correct nose-poke caused simultaneous 
extinction of the stimulus light, delivery of food reward and illumination of the magazine light 
Group Hdh+/+ HdhQ150/+ Mean CAG 
repeat length 
2M 3M 6M 
A 5 4 152.26 ± 6.18 Unhandled Take brains - 
B 6 4 149.10 ± 4.43 Unhandled Unhandled Take brains 
C 4 5 155.56 ± 2.99 Train to CRF 
acquisition 
Take brains - 
D 3 5 141.60 ± 5.80 Train to CRF 
acquisition 
Test boxes, 
no program 
Take brains 
E 3 5 145.46 ± 3.22 Train to CRF 
acquisition 
Full SILT 
training 
Take brains 
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(Fig. 3.1). Once the mouse collected the reward and removed its head from the magazine, the 
magazine light was extinguished. Following a 2 s inter-trial-interval (ITI), the next trial began 
through the illumination of the hole 5 light. In the event of a correct response not being made 
within 10 s of the hole 5 stimulus light presentation, the light stimulus was extinguished and the 
house lights illuminated for 5 s before a new trial began after a 2 s ITI. 
Animals performed 5 days of CRF training. Following CRF acquisition, mice in Group E (n = 8) 
began 5-CSRTT training whilst animals in Group C (n = 9) were sacrificed and their brains taken 
for gene expression level analysis, and animals in Group D (n = 8) were placed in the operant 
boxes with no further program run until sacrifice at 6M. 
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Figure 3.1. A pictorial representation of the CRF task. A light stimulus is presented in hole 5 of 
the operant box (A). Upon nose-poking the light stimulus, the light stimulus in hole 5 is 
extinguished whilst the magazine light stimulus is simultaneously illuminated (B). Once the 
animal has collected the food reward (C), and removed its head from the magazine, the 
magazine light is extinguished (D). There is a 2 s inter-trial-interval (ITI) before a new trial is 
commenced through the illumination of the hole 5 stimulus light (A). 
 
 
 
 
A 
 
 
 
 
B 
 
 
 
 
 
C 
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3.2.4.3 5-CSRTT 
5-CSRTT training is required in order to teach mice that a np into the illuminated operant 
aperture light (of which five apertures are available: holes 1, 3, 5, 7, and 9) will result in delivery 
of a food reward, which expands upon the CRF task because any of the five available stimulus 
lights may be illuminated in the 5-CSRTT, as opposed to the one stimulus light that is illuminated 
in the CRF (hole 5). The 5-CSRTT is a necessary prerequisite for animals to be able to perform 
the more complex SILT, which is detailed in Chapter 3.2.4.4, and also allows examination into 
the attentional capacities of animals. This behavioural task requires mice to make a single np 
into a pseudo randomly chosen illuminated hole in order to gain a reward. Stimulus hole 
illumination occurs pseudo randomly to ensure that each hole is illuminated an equivalent 
number of times during a session, therefore ensuring that a bias towards stimulus holes does 
not form. Sessions lasted 20 min and one session was performed each day. When a stimulus 
light was presented, a correct nose-poke caused simultaneous extinction of the stimulus light, 
delivery of food reward and illumination of the magazine light (Fig. 3.2). Once the mouse 
collected the reward and removed its head from the magazine, the magazine light was 
extinguished. Following a 2 s ITI, the next trial began through illumination of a pseudo randomly 
chosen hole light. The light stimulus was presented continuously until the mouse responded, 
and in the result of an incorrect response, the light stimulus was extinguished and the house 
light illuminated for 5 s before a new trial began. In each trial, any one of the five accessible 
holes may be illuminated. Performance on the task was measured by performance accuracy to 
stimulus lights, with accuracy defined as the percentage of initiated trials in which the animal 
makes a correct response to the presented stimulus. Mice performed 5-CSRTT training until both 
genotypes reached a mean accuracy level of 80% (11 sessions), before commencing SILT 
training. 
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Figure 3.2. A pictorial representation of a trial in the 5-CSRTT. A trial begins when a pseudo 
randomly chosen stimulus light is illuminated (A). Nose-poking the correct light stimulus causes 
simultaneous extinction of the hole light stimulus, illumination of the reward magazine and 
reward delivery (B). Once the animal has collected the food reward (C), and removed its head 
from the magazine, the magazine light is extinguished. A 2 s ITI occurs before a new trial is 
commenced through the illumination of a pseudo randomly chosen stimulus light (A). 
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3.2.4.4 SILT 
SILT sessions lasted 20 min and 1 session was performed each day. The SILT requires mice to 
correctly respond to 2 consecutive stimuli in order to gain a food reward. The first response, S1, 
is as described for the 5-CSRTT (Fig.3.2A; Fig. 3.3A). Following a correct S1 response, the S1 light 
would extinguish and a S2 would illuminate in a pseudo randomly chosen alternate hole (Fig. 
3.3B). For the first phase of SILT training, S2 was presented continuously until the mouse 
responded, with a correct S2 response resulting in simultaneous extinguishing of the S2, 
illumination of the magazine reward light and delivery of food reward (Fig. 3.3C). During the 
second SILT testing phase, the S2 stimulus was presented for 2 s before being extinguished. 
Upon collection of food reward and subsequent removal of the head from the reward magazine, 
the reward magazine light is extinguished and a timer is started. After a 2 s ITI a new trial would 
begin by illumination of a pseudo randomly chosen S1 (Fig. 3.3A). To allow investigation into 
implicit learning, a single predictable 2-light sequence was embedded within the random 
presentations of 2 light sequences. This predictable sequence occurred when the S1 was hole 3, 
and the S2 presentation always followed in hole 7 (Fig. 3.4). Nose-poking an incorrect hole 
during S1 or S2 presentation would result in trial termination and a 5 s time-out interval (TOI) 
where the house lights would be illuminated prior to the onset of a new trial. 
Performance on the task was measured by performance accuracy and reaction times to stimulus 
lights. Performance accuracy was calculated by the number of correct responses as a percentage 
of the total number of trials initiated. For S1 responses, accuracy and reaction times were 
analysed by hole (hole 1, 3, 5, 7, 9) whilst S2 responses were evaluated by the distance between 
the S1 and S2, referred to as the step-size (number of steps). Performance on the predictable 2-
step hole 3-7 presentations were compared against that recorded on the opposite unpredictable 
hole 7-3 combination. Mice performed the SILT until performance was judged to have reached 
asymptote, which occurred following 3 days of continuous S2 training and 18 days of 2 s S2 
training. 
Seven error terms were examined during SILT performance, with each capable of identifying 
different behavioural traits. Incorrect choices to S1 or S2 consisted of a np to an unlit stimulus 
hole, or of a magazine entry, during S1 or S2 presentation, and are used to examine the accuracy 
and attention levels of mice. Incorrect S1 and S2 choice rates were calculated as percentages of 
the number of total responses made to S1 and S2 presentation, respectively. The rate of 
perseverative np to S1 was used to examine perseverative behaviour in animals and was 
calculated as a percentage of the total number of responses made during S1 presentation, as 
was the rate of magazine entries during S1 presentation. The rate of responses during ITI or TOI 
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was investigated in order to assess impulsivity in the mice, and was calculated as an error rate 
per ITI or incorrect response to S2, respectively. Not responding to the S2 stimulus within 10 s 
would result in a TOI, which was used as a measure of the psychomotor processing speed or 
attentional capacity of animals, and was calculated as a percentage of the total number of S1 
responses made. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. A pictorial representation of a trial in the SILT. A trial begins through illumination of 
a pseudo randomly chosen S1 (A). Correctly responding to S1 results in simultaneous extinction 
of the S1 light and illumination of a pseudo randomly chosen S2 (B). Successfully nose-poking 
the S2 stimulus causes illumination of the reward magazine light and food reward delivery (C). 
Once the animal has collected the food reward (D), and removed its head from the magazine, 
the magazine light is extinguished. There is a 2 s ITI before a new trial is commenced through 
the illumination of a randomly chosen S1 stimulus light (A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
C 
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Predictable sequence:    Unpredictable sequence: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. A pictorial representation of the predictable and unpredictable sequences within 
the SILT. The predictable sequence of stimuli begins with S1 illumination of hole 3 and is 
followed by S2 illumination of hole 7. In unpredictable sequences, presentation of the S1 light 
occurs pseudo randomly in one of holes 1, 5, 7 or 9 and followed by pseudo randomly chosen 
S2 presentation in any of the remaining available holes. In this unpredictable sequence example, 
S1 is presented in hole 9 and the subsequent S2 may occur in any of holes 1, 3, 5 or 7. 
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3.2.5 Molecular methodology 
3.2.5.1 RNA extraction 
RNA was prepared from right hemisphere striatum dissected from animals at 3M or 6M as 
described in Chapter 2.3.1, with RINs of RNA samples ranging from 8.1 to 9.6 (8.66 ± 0.07).  
 
3.2.5.2 Microarray and microarray analyses 
Microarray was performed by Dr. Joanne Morgan of Cardiff University’s CBS (Cardiff, UK) using 
GeneChip® Mouse Gene 2.0 ST Array chips 
(http://www.affymetrix.com/catalog/131476/AFFY/Mouse+Gene+ST+Arrays#1_1; product 
code: 902119; Affymetrix, California, USA), and microarray gene expression level data was 
analysed using Partek® Genomics SuiteTM Version 6.6 (Partek Incorporated, Missouri, USA). 
A three-way ANOVA was performed on the microarray gene expression level data with age, 
genotype and learning (unhandled, acquisition of CRF or full-SILT) as variables, and also using 
the same variables as interaction terms in a three-way interaction. Statistical significance was 
taken using a false discovery rate (FDR)-corrected p-value of less than 0.05 (FDR p < 0.05).  
 
3.2.5.3 Quantification of gene expression levels by RT-qPCR 
Microarray gene expression level data was validated by TaqMan®-mediated (Life Technologies 
Corporation, Carlsbad, California, USA) RT-qPCR, as described in Chapter 2.3.2. The number of 
samples used for each group in the RT-qPCR is given in Table 3.2, and each reaction was 
performed in triplicate. 
Group Number of samples 
Hdh+/+ 3M U 5 
Hdh+/+ 6M U 6 
HdhQ150/+ 3M U 4 
HdhQ150/+ 6M U 4 
Hdh+/+ 3M A 4 
HdhQ150/+ 3M A 5 
Hdh+/+ 6M A 3 
HdhQ150/+ 6M A 5 
Hdh+/+ 6M S 3 
HdhQ150/+ 6M S 5 
Table 3.2. The number of samples in each group used for RT-qPCR. 
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Genes to be investigated were chosen based on the findings of the microarray (see Chapter 
3.3.2.3.1) and are listed in Table 3.3. 
 
Gene name Gene symbol ID 
Beta-actin Actb Mm00607939_s1 
calbindin 2 Calb2 Mm00801461_m1 
glucagon-like peptide 1 receptor Glp1r Mm00445292_m1 
G protein-coupled receptor 165 Gpr165 Mm01233063_m1 
potassium voltage-gated channel, subfamily H, 
member 3 
Kcnh3 Mm01310207_m1 
potassium inwardly-rectifying channel, 
subfamily J, member 4 
Kcnj4 Mm02027786_s1 
ribonuclease P RNA component H1 Rpph1 Mm04336066_s1 
solute carrier family 17, member 6 Slc17a6 Mm00499876_m1 
small nucleolar RNA, H/ACA box 74A Snora74a Mm04241346_s1 
ubiquitin C Ubc Mm02525934_g1 
uracil phosphoribosyltransferase Uprt Mm01234398_m1 
zic family member 1 Zic1 Mm00656094_m1 
Table 3.3. Identification codes for Taqman® oligonucleotide probes used in the study. 
 
3.2.6 Statistical analyses 
Statistical analyses were performed using IBM SPSS® Statistics 20 software (IBM United Kingdom 
Ltd, Hampshire, UK). Behavioural data for the 6M HdhQ150/+ and Hdh+/+ mice are presented, with 
the 5-CSRTT and SILT data collapsed across the final 5 days of testing for statistical analyses. All 
parameters that involved repeated measures were analysed using multifactorial ANOVA, with 
Tukey’s HSD test used for post-hoc analysis if data met the assumption of homogeneity of 
variances and Games Howell post-hoc test used if the data did not meet this assumption. 
Sphericity of data was assessed using Mauchly’s test of Sphericity, with the Greenhouse-Geisser 
correction used if the assumption of Sphericity was violated and the Greenhouse-Geisser 
estimate of sphericity (ɛ) < 0.75. If the assumption of Sphericity was violated and ɛ > 0.75, the 
Huynh-Feldt correction was used. Similarly, homogeneity of variances for data was assessed 
using Levene’s test, and the Welch test used in the event of data violating this assumption. For 
RT-qPCR data, specific two group comparisons were analysed by independent samples t-tests 
with Holm-Bonferroni sequential correction used for multiple hypothesis testing correction. A 
one-way ANOVA was performed on 3 group comparisons and a post-hoc Tukey’s HSD test 
performed on comparisons in which a main effect was found to be significant. 
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3.3 Results  
3.3.1 Behavioural analyses 
3.3.1.1 CRF task performance 
Over the five days of CRF training, both genotypes showed a trend towards an increase in the 
number of responses made (Fig. 3.5), suggesting that animals had learned to successfully 
perform the task. A repeated measures ANOVA reported no significant difference in the number 
of responses made between HdhQ150/+ mice and their wild-type counterparts (main effect of 
genotype: F1,6 = 3.280, p = 0.120). There was no difference in the number of responses made 
across the 5 days of testing (main effect of day: F4, 24 = 1.267, p = 0.310), and no significant 
interaction between genotype and day of testing (day*genotype: F4, 24 = 0.217, p = 0.816).  
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 3.5. The mean number of responses made by Hdh+/+ and HdhQ150/+ animals over the 5 
days of training in the CRF task. There was no effect of genotype on the mean number of trials 
initiated by Hdh+/+ and HdhQ150/+ mice over the five days of CRF training. Values are means ± 
S.E.M; Hdh+/+: n = 3; HdhQ150/+: n = 5. 
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3.3.1.2 5-CSRTT performance 
A significant difference in mean accuracy to S1 was identified between genotypes (main effect 
of genotype: F1,6 = 7.932, p = 0.030), with HdhQ150/+ animals presenting with lower levels of 
accuracy than their wild-type counterparts at 6M (Fig. 7A). A strong effect of session was found 
on mean accuracy (main effect of session: F4, 24 = 205.588, p < 0.001), and there was a significant 
interaction between session and genotype (genotype*session: F4, 24 = 3.156, p = 0.032). Post-hoc 
tests found that mean accuracy was significantly higher in the final fourth and fifth days of 5-
CSRT training compared to the first (p < 0.001), second (p < 0.001) and third (p < 0.001) days of 
testing (Fig. 3.6A). A difference in mean accuracy between the final fourth and fifth sessions was 
also reported (p < 0.001). Unlike mean accuracy, there was no significant difference in the 
number of trials performed between genotypes in the 5-CSRTT (main effect of genotype: F1, 6 = 
0.142, p = 0.719). There was, however, an increase in the number of trials performed across the 
final 5 days of testing (main effect of session: F4, 24 = 8.300, p < 0.001), and this effect was found 
to be independent of genotype (genotype*session: F4, 24 = 0.331, p = 0.855). Post-hoc analyses 
only found a significant increase in the number of trials performed between the first and fifth 
days of testing (Fig. 7B; p = 0.041). 
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Figure 3.6. Mean accuracy and number of trials performed over the final five days of 5-CSRTT 
testing for Hdh+/+ and HdhQ150/+ mice. Genotype had a significant effect on accuracy (A) but not 
the number of trials performed (B) in the 5-CSRTT. Day of training was found to significantly 
affect the accuracy (A) and number of trials performed (B). Values shown are means ± S.E.M.; 
Hdh+/+: n = 3; HdhQ150/+: n = 5. 
* Denotes a significant difference from day 4 # Denotes a significant difference from day 5 
† Denotes a significant difference between genotypes 
* p < 0.05 *** p < 0.001 
 
*** *** *** 
### ### ### 
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### 
††† 
 
† 
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3.3.1.3 SILT performance 
Overall task accuracy during successive days of testing shows progressive improvement for both 
genotypes in accuracy to S1 and S2 (Fig. 3.7A and B), suggesting that both groups of mice were 
able to successfully learn the SILT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Overall task accuracy on consecutive days of training and testing on the SILT for 
Hdh+/+ and HdhQ150/+ groups. Task accuracy is defined as the percentage of initiated trials in 
which the animal makes a correct response to S1 (A) or S2 (B). Values are means ± S.E.M.; Hdh+/+: 
n = 3; HdhQ150/+: n = 5. 
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Examination of the accuracy and reaction times to S1 over the last 5 days of the task showed 
that there was no difference in performance between genotypes (main effect of genotype: F1,6 
= 1.428, p = 0.277). After subdividing the response to S1 to account for the location of the 
stimulus, there was significant variation in accuracy to each hole (Fig. 3.8A; main effect of hole 
location: F4, 24 = 3.952, p = 0.013), independent of genotype (genotype*hole location: F4, 24 = 
0.573, p = 0.685). Tukey’s HSD post-hoc test correcting for multiple testing, however, reported 
no significant difference in accuracy levels between any of the hole locations (p = n.s. for all 
comparisons). Reaction times to S1 did not significantly differ between HdhQ150/+ and Hdh+/+ 
animals (Fig. 3.8D; main effect of genotype: F1,6 = 0.891, p = 0.382), were not affected by hole 
location (Fig. 3.8D; main effect of hole location: F1.557, 9.341 = 1.429, p = 0.280), and there was no 
interaction between genotype and hole location (genotype*hole location: F1.557, 9.341 = 0.588, p = 
0.534).  
The response to S2 revealed no differences in accuracy between HdhQ150/+ mice and their Hdh+/+ 
littermates (main effect of genotype: F1,6 = 0.005, p = 0.946). Levels of accuracy to S2 showed 
significant variation depending on the number of steps between S1 and S2 (Fig. 3.8B; main effect 
of step number: F1.316, 7.899 = 16.040, p = 0.003), and this effect was independent of genotype 
(genotype*step number: F1.316, 7.899 = 0.432, p = 0.584). Post-hoc analyses reported a significant 
decrease in accuracy levels for S2 where S1 and S2 were 3 or 4 steps apart in comparison to 
where S1 and S2 were only 1 step (p = 0.038 and p = 0.036, respectively). Similar to S2 accuracy, 
reaction times to S2 did not significantly differ between HdhQ150/+ and Hdh+/+ mice (Fig. 3.8E; 
main effect of genotype: F1,6 = 0.002, p = 0.966) and the number of steps between S1 and S2 
stimuli strongly influenced reaction time to S2 (Fig. 3.8E; main effect of step number: F1.190, 7.139 
= 28.558, p = 0.001). Reaction times to S2 were significantly faster when S1 and S2 were 1 step 
apart than when there was a distance of 2, 3 or 4 steps between the stimuli (Fig. 3.8E; p = 0.003, 
p = 0.003 and p < 0.001, respectively). There was no significant interaction between genotype 
and the number of steps between S1 and S2 causing an effect on reaction times to S2 
(genotype*step number: F1.190, 7.139 = 0.823, p = 0.416).  
There was no significant difference in predictive accuracy to S2 between HdhQ150/+ and Hdh+/+ 
mice (Fig. 3.8C; main effect of genotype: F1,6 = 0.250, p = 0.635). Both genotypes showed 
improved response accuracy on predictable trials compared to unpredictable trials (Fig. 3.8C; 
main effect of predictability: F2, 12 = 3.980, p = 0.047). There was no interaction between trial 
predictability and genotype (genotype*predictability: F2, 12 = 0.095, p = 0.910). As with predicted 
accuracy to S2, there was no significant difference in reaction times to S2, based on 
predictability, between genotypes (Fig. 3.8F; main effect of genotype: F1,6 = 0.194, p = 0.675). 
Neither genotype showed a significant difference in reaction time to predictable versus 
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unpredictable trials (Fig. 3.8F; main effect of predictability: F1.142, 6.852 = 0.037, p = 0.882), and 
there was no interaction between genotype and stimulus predictability 
(genotype*predictability: F1.142, 6.852 = 0.234, p = 0.675).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Data for the SILT collapsed over the last 5 days of testing for Hdh+/+ and HdhQ150/+ 
mice. Panels (A-F) show accuracy and reaction times to S1 by holes (A and D), and accuracy and 
reaction times to S2 by steps (B and E) and predictability (C and F). Accuracy and reaction times 
to S1 (A and D, respectively) showed no significant difference between genotypes, independent 
of hole location. Similarly, no significant difference in accuracy or reaction times to S2 was found 
between genotypes, based on number of steps between S1 and S2 (B and E) or predictability of 
S2 (C and F). Values are means ± S.E.M.; Hdh+/+: n = 3; HdhQ150/+: n = 5. 
~ Denotes a significant difference from the 1 step distance between S1 and S2 
* p < 0.05 ** p < 0.01 *** p < 0.001 
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Seven error terms and the total number of S1 and S2 trials were analysed and summarised in 
Table 3.4. An independent t-test reported no difference in the number of S1 or S2 trials initiated 
by Hdh+/+ and HdhQ150/+ animals (t(6) = 0.436, p = 0.678 and t(6) = -0.437, p = 0.677, respectively), 
and none of the seven error terms analysed showed a significant difference between genotypes 
(Table 3.4). 
 
Mean number of trials 
initiated 
Hdh+/+ HdhQ150/+ t(6) =  p-value 
S1 trialsa 179.33 ± 15.88 163.80 ± 25.28 0.436 0.678 
S2 trialsa 108.80 ± 6.36 123.48 ± 24.92 -0.437 0.677 
Error rates of specific error 
types 
    
Incorrect choice in S1b 15.66 ± 6.03 14.18 ± 5.29 0.179 0.864 
Incorrect choice in S2c 11.11 ± 4.41 13.53 ± 5.11 -0.322 0.759 
Magazine poke in S1b 23.12 ± 3.78 15.17 ± 3.82 1.373 0.219 
Perseverative np to S1b 11.76 ± 5.10 12.67 ± 4.01 -0.140 0.894 
Np in ITId  0.63 ± 0.13 1.29 ± 0.43 -1.133 0.300 
Np per TOIe 2.12 ± 0.97 1.01 ± 0.20 1.474 0.191 
TO during S2b 6.29 ± 1.13 8.96 ± 2.78 -0.705 0.507 
Table 3.4. Error analyses of the SILT performance of HdhQ150/+ mice. t value statistics are 
presented with degrees of freedom (df) of 6 unless otherwise stated. Values presented are 
means ± S.E.M.; Hdh+/+: n = 3; HdhQ150/+: n = 5. Abbreviations: ITI, inter-trial interval; TOI, time 
out interval; TO, time out. 
a Mean total counts. 
b Error rates as a percentage of the total number of S1 trials initiated. 
c Error rates as a percentage of the total number of S2 trials initiated. 
d Error rates per ITI. 
e Error rates per incorrect S2 trial. 
 
3.3.1.4 Behavioural results summary 
To summarise, no behavioural differences were evident between HdhQ150/+ and Hdh+/+ mice at 
6M in CRF or SILT performance. However, in the 5-CSRTT, HdhQ150/+ animals exhibited 
significantly lower levels of accuracy compared to their wild-type counterparts in the final two 
days of testing. 
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3.3.2 Gene expression level analyses  
3.3.2.1 Microarray chips 
This experiment used Affymetrix GeneChip® Mouse Gene 2.0 ST Array chips (see Chapter 
3.2.5.2), which contain oligonucleotide probes that interrogate multiple loci on every exon of 
every transcript, thus allowing evaluation of whole-transcriptome gene expression levels at the 
gene and exon levels. Each array chip contains >698,000 probes, allowing investigation into 
expression levels of >33,000 genes, as well as >2,000 long intergenic non-coding RNAs. 
 
3.3.2.2 Quality control metrics 
Principal components analysis (PCA) is a mathematical technique that is useful in data reduction 
and allows visual estimation and clustering of data (Quackenbush, 2001), and was performed as 
an early exploratory analysis of global gene expression level patterns across all samples. The PCA 
mapping indicates that the main sources of variation in gene expression levels in this experiment 
are age and behavioural training, with genotype having a lesser contribution (Fig. 3.9). 
Examination of the PCA mapping in Figure 3.9 indicates that gene expression level patterns of 
untrained animals at 6M form a separate cluster from those of animals that are trained to 
acquisition or untrained at 3M, and also separate from those of animals that have performed 
any form of training at 6M.  
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Figure 3.9. Age and training account for a greater amount of gene expression level changes 
than genotype. Age is the main principal component, accounting for 12.7% of gene expression 
level variance. The second principal component is behavioural training (untrained, acquisition 
or full-SILT), which accounts for 9.01% of the variance in gene expression levels, while genotype 
is the third principal component and accounts for only 6.03% of the variance in gene expression 
levels. There is a clear separation of gene expression profiles between untrained animals at 6M 
and all other groups. n = 3-6/group. 
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3.3.2.3 Differential gene expression levels 
A three-way ANOVA was performed on the microarray gene expression level data with age, 
genotype and learning (unhandled, acquisition or full-SILT) as variables, and also using the same 
variables as interaction terms in a three-way interaction. Statistical significance was taken using 
FDR p < 0.05, with FDR estimation generated by Benjamini-Hochberg procedure, and no 
minimum magnitude of fold-change was defined when generating lists of genes showing 
significantly altered expression levels. Thus, gene lists were created using the parameters 
described in Table 3.5, with the number of genes present in each list also recorded in Table 3.5.  
Briefly, the largest number of significant gene expression level changes were identified as a 
result of ageing in untrained wild-type animals (Hdh+/+ 3M U vs Hdh+/+ 6M U: n = 2,940), while 
untrained HdhQ150/+ mice presented with a smaller number of significant age-dependent gene 
expression level changes (HdhQ150/+ 3M U vs HdhQ150/+ 6M U: n = 122). In each genotype, learning-
dependent gene expression level changes were identified between untrained animals and those 
that had undergone training to acquisition in the CRF or performed full-SILT training, and the 
number of gene expression level changes resulting from the behavioural paradigms were higher 
in Hdh+/+ animals than in their HdhQ150/+ counterparts (Table 3.5). However, animals trained to 
acquisition of the CRF and animals that had underwent complete training and performance in 
the SILT displayed 0 significant gene expression level changes in both genotypes (Hdh+/+ 6M A vs 
Hdh+/+ 6M S: n = 0; HdhQ150/+ 6M A vs HdhQ150/+ 6M S: n = 0). 0 genes presented with significantly 
altered expression levels as a result of genotype in any of the genotype-dependent comparisons 
examined (Table 3.5).  
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Group comparison Number of genes differentially expressed 
Hdh+/+ 3M U vs HdhQ150/+ 3M U 0 
Hdh+/+ 3M U vs Hdh+/+ 6M U 2, 940 
Hdh+/+ 3M U vs Hdh+/+ 3M A 0 
HdhQ150/+ 3M U vs HdhQ150/+ 6M U 122 
HdhQ150/+ 3M U vs HdhQ150/+ 3M A 0 
Hdh+/+ 6M U vs HdhQ150/+ 6M U 0 
Hdh+/+ 6M U vs Hdh+/+ 6M A 596 
Hdh+/+ 6M U vs Hdh+/+ 6M S 189 
Hdh+/+ 6M A vs Hdh+/+ 6M S 0 
HdhQ150/+ 6M U vs HdhQ150/+ 6M A 375 
HdhQ150/+ 6M U vs HdhQ150/+ 6M S 145 
HdhQ150/+ 6M A vs HdhQ150/+ 6M S 0 
Hdh+/+ 3M A vs Hdh+/+ 6M A 0 
HdhQ150/+ 3M A vs HdhQ150/+ 6M A 0 
Hdh+/+ 3M A vs HdhQ150/+ 3M A  0 
Hdh+/+ 6M A vs HdhQ150/+ 6M A 0 
Hdh+/+ 6M S vs HdhQ150/+ 6M S 0 
Hdh+/+ vs. HdhQ150/+ 0 
Age 450 
Learning 873 
Genotype 0 
3M vs 6M 0 
U vs A 96 
U vs S 0 
A vs S 0 
Age*Learning*Genotype Interaction 378 
Table 3.5. Microarray gene expression level group comparisons and gene list sizes. No fold 
change limit was applied and genes were counted as significantly differentially expressed if FDR-
corrected p < 0.05. n = 3-6/group. Abbreviations: 3M, 3 months of age; 6M, 6 months of age; U, 
unhandled; A, trained to acquisition on the CRF; S, performed full SILT training. 
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Hierarchical clustering of genes based on gene expression level values derived from the lists of 
genes showing significantly altered expression levels between groups allows visualisation of the 
grouping of differentially expressed genes. Clustering based on the gene list derived from the 
comparison between untrained Hdh+/+ animals at 3M and 6M showed strong evidence that 
untrained 6M old animals, of both genotypes, have a distinct gene expression level profile 
compared to animals that underwent training at 3M or 6M, but also to untrained animals at 3M 
(Fig. 3.10), supporting the findings from the PCA analysis (Fig. 3.9). 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.10. Heat map representing hierarchical clustering of genes based on gene expression 
level values derived from the Hdh+/+ 3M U vs. Hdh+/+ 6M U comparison gene list. Data was 
transformed whereby the mean expression value for each gene was 0, with a standard deviation 
of 1. Blue indicates a reduction in gene expression levels and red indicates an increase in gene 
expression levels, whilst grey is indicative of no change in gene expression levels. n = 3-6/group. 
Abbreviations: 6M, 6 months of age; U, unhandled. 
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3.3.2.4 Validation of microarray gene expression level results using RT-qPCR 
Calbindin 2 (Calb2), glucagon-like peptide 1 receptor (Glp1r), G protein-coupled receptor 165 
(Gpr165), potassium voltage-gated channel, subfamily H, member 3 (Kcnh3), potassium 
inwardly-rectifying channel, subfamily J, member 4 (Kcnj4), ribonuclease P RNA component H1 
(Rpph1), solute carrier family 17 member 6 (Slc17a6), small nucleolar RNA, H/ACA box 74A 
(Snora74a), uracil phosphoribosyltransferase (Uprt), and zic family member 1 (Zic1) were genes 
identified as showing altered expression levels in microarray group comparisons (Table 3.6) and 
were chosen for RT-qPCR analysis based on the mean level of gene expression, fold-change in 
expression (log2) and coefficient of variation reported for the gene in any group comparison in 
the microarray (Table 3.6). Actb and Ubc were used as endogenous controls because they 
showed no significant differences in expression in comparisons between groups (data not 
shown) and have been reported to show stable levels of expression within the striatum of a 
mouse model of HD (Benn et al., 2008a).  
 
Gene Group Comparison FDR p-
value 
Mean 
Gene 
Expression 
Fold-
Change 
CV  
(%) 
Calb2 Hdh+/+ 3M U vs Hdh+/+ 6M U 2.97 x 10-03 8.31 -2.68 18.55 
Glp1r Hdh+/+ 3M U vs Hdh+/+ 6M U 8.40 x 10-04 8.28 -2.88 19.15 
Gpr165 Hdh+/+ 3M U vs Hdh+/+ 6M U 1.55 x 10-03 8.47 -1.76 11.20 
Kcnh3 Hdh+/+ 3M U vs Hdh+/+ 6M U 2.65 x 10-04 9.08 +1.35 6.89 
Kcnj4 Hdh+/+ 3M U vs Hdh+/+ 6M U 1.57 x 10-03 8.62 +1.25 7.61 
 
 
Rpph1 
HdhQ150/+ 3M U vs HdhQ150/+ 6M U 
HdhQ150/+ 6M U vs HdhQ150/+ 6M A 
HdhQ150/+ 6M U vs HdhQ150/+ 6M S 
Hdh+/+ 3M U vs Hdh+/+ 6M U 
Hdh+/+ 6M U vs Hdh+/+ 6M A 
Hdh+/+ 6M U vs Hdh+/+ 6M S 
1.25 x 10-05 
3.56 x 10-05 
8.50 x 10-05 
2.60 x 10-04 
5.62 x 10-05 
2.54 x 10-04 
 
 
11.39 
+0.75 
-0.66 
-0.60 
-0.51 
-0.67 
-0.55 
 
 
2.72 
Slc17a6 Hdh+/+ 3M U vs Hdh+/+ 6M U 3.51 x 10-03 8.02 -2.47  17.91 
 
Snora74a 
Hdh+/+ 3M U vs Hdh+/+ 6M U 
Hdh+/+ 6M U vs Hdh+/+ 6M A 
Hdh+/+ 6M U vs Hdh+/+ 6M S 
5.88 x 10-05 
4.21 x 10-04 
1.06 x 10-05 
 
7.48 
+0.85 
-0.81 
-1.02 
 
6.03 
 
 
Uprt 
HdhQ150/+ 3M U vs HdhQ150/+ 6M U 
HdhQ150/+ 6M U vs HdhQ150/+ 6M A 
HdhQ150/+ 6M U vs HdhQ150/+ 6M S 
Hdh+/+ 3M U vs Hdh+/+ 6M U 
Hdh+/+ 6M U vs Hdh+/+ 6M S 
2.45 x 10-08 
2.22 x 10-08 
5.85 x 10-08 
1.73 x 10-10 
5.14 x 10-08 
 
 
9.13 
-0.78 
+0.75 
+0.69 
-0.83 
+0.69 
 
 
3.70 
Zic1 Hdh+/+ 3M U vs Hdh+/+ 6M U 1.21 x 10-03 9.18 -1.96 11.80 
Table 3.6. Microarray data for genes chosen for validation by RT-qPCR. Genes found to be 
exhibiting the largest mean gene expression level values and fold-changes (log2) between 
groups in the microarray data were chosen for validation by RT-qPCR. n = 3-6/group. 
Abbreviations: CV, coefficient of variation. 
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3.3.2.4.1 Genotype-dependent gene expression level changes 
In accordance with the microarray findings, none of the genes investigated showed any 
differences in expression levels between genotypes in any comparison where genotype is the 
only variable between groups (Table 3.7). 
 
 
 
 
Table 3.7. The statistical values for RT-qPCR gene expression level comparisons between 
genotypes using independent samples t-tests, with Holm-Bonferroni sequential correction 
for multiple hypothesis test correction. In the event of data violating the assumption of 
homogeneity of variances, as assessed by Levene’s test for homogeneity of variances, results 
of the Welch test were used and the t-statistic value altered as a result of this. n = 3-6/group.
Group 
comparison 
Calb2 Glp1r Gpr165 Kcnh3 Kcnj4 
Hdh+/+ 3M U vs. 
HdhQ150/+ 3M U 
t(5) =  -0.246 
p = 1.000 
t(5) =  -0.523 
p = 1.000 
t(5) =  -0.181 
p = 1.000 
t(5) = 0.353  
p = 1.000 
t(5) =  0.477 
p = 1.000 
Hdh+/+ 3M A vs. 
HdhQ150/+ 3M A 
t( 7) = -0.887  
p = 1.000 
t( 7) = -1.400 
p = 1.000 
t( 7) = -1.709 
p = 1.000 
t( 7) = 1.092 
p = 1.000 
t( 7) = 1.010 
p = 1.000 
Hdh+/+ 6M U vs. 
HdhQ150/+ 6M U 
t(8) = -0.109 
p = 1.000 
t(8) = 0.173 
p = 1.000 
t(8) = 0.594 
p = 1.000 
t(8) = -0.929 
p = 1.000 
t(8) = -0.832 
p = 1.000 
Hdh+/+ 6M A vs. 
HdhQ150/+ 6M A 
t(6) = 0.941 
p = 1.000 
t(6) = 4.149 
  p = 0.060 
t(6) = 1.273  
p = 1.000 
t(6) = -1.555 
p = 0.856 
t(4.409) =  -1.893 
p = 0.875 
Hdh+/+ 6M S vs. 
HdhQ150/+ 6M S 
t(6) = 0.053 
p = 1.000 
t(6) = -0.338 
p = 1.000 
t(6) = -0.033 
p = 1.000 
t(6) = -0.084 
p = 1.000 
t(6) = 0.323 
p = 1.000 
Group 
comparison 
Rpph1 Slc17a6 Snora74a Uprt Zic 1 
Hdh+/+ 3M U vs. 
HdhQ150/+ 3M U 
t(5) =  0.325 
  p = 1.000 
t(5) =  0.153 
p = 1.000 
t(5) =  -0.572 
p = 1.000 
t(5) =  -1.590 
p = 1.000 
t(5) =  0.235 
  p = 1.000 
Hdh+/+ 3M A vs. 
HdhQ150/+ 3M A 
t( 7) = -1.233 
p = 1.000 
t( 7) = -0.674 
p = 1.000 
t( 7) = -0.088 
p = 1.000 
t( 7) = -1.831 
p = 1.000 
t( 7) = -1.123 
p = 1.000 
Hdh+/+ 6M U vs. 
HdhQ150/+ 6M U 
t(3.466) = 0.238 
p = 1.000 
t(8) = -.0662 
p = 1.000 
t(8) = -0.496 
p = 1.000 
t(8) = 0.366 
p = 1.000 
t(8) = 0.018 
p = 1.000 
Hdh+/+ 6M A vs. 
HdhQ150/+ 6M A 
t(6) = 0.103 
p = 1.000 
t(6) = -0.501 
p = 1.000 
t(6) = 0765 
p = 1.000 
t(6) = 0.856 
p = 1.000 
t(6) = 2.026 
p = 0.801 
Hdh+/+ 6M S vs. 
HdhQ150/+ 6M S 
t(6) = 1.620 
p = 1.000 
t(6) = -0.231 
p = 1.000 
t(6) = 0.909 
p = 1.000 
t(6) = 1.017 
p = 1.000 
t(6) = -0.082 
p = 1.000 
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3.3.2.4.2 Behavioural training-dependent gene expression level changes  
RT-qPCR reported striatal expression of Rpph1 to be different between Hdh+/+ mice that had 
undergone one of the three behavioural training protocols at 6M (Fig. 3.11A; F2, 9 = 9.783, p = 
0.006). Post-hoc analysis reported significantly lower Rpph1 expression levels in the Hdh+/+ 6M 
S group in comparison to Hdh+/+ 6M U mice (Table 3.8b; p = 0.005), as reported in the microarray 
(Table 3.6). Similar to Rpph1 expression, levels of Snora74a expression within the striatum were 
also found to be significantly altered as a result of training in 6M old Hdh+/+ animals (Fig. 3.11B; 
F2, 9 = 12.245, p = 0.003). CRF training resulted in significantly decreased Snora74a expression 
levels compared to untrained counterparts (Table 3.8b; p = 0.004) and the decreased expression 
levels resulting from full-SILT training versus an absence of training also reached significance 
(Table 3.8b; p = 0.016), with both comparisons also reporting significant reductions in expression 
levels in the microarray (Table 3.6). Statistical results for all RT-qPCR investigations examining 
behavioural training-dependent striatal gene expression level alterations can be found in Table 
3.8a. 
 
 
 
 
 
 
 
 
 
Figure 3.11. RQ values of Rpph1 (A) and Snora74a (B) behaviour-dependent striatal expression 
levels following RT-qPCR to confirm microarray data. At 6M, full-SILT trained Hdh+/+ mice show 
significantly reduced expression of Rpph1 compared to untrained animals of the same genotype 
at 6M (A). Similarly, CRF and full-SILT training both lead to decreased expression of Snora74a 
within the striatum of 6M Hdh+/+ animals, compared to their untrained counterparts (B). Data 
presented is mean fold change ± S.E.M.; Hdh+/+ 6M A: n = 3; Hdh+/+ 6M S: n = 3; Hdh+/+ 6M U: n = 
6. 
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Table 3.8a. The statistical values for RT-qPCR gene expression level comparisons between 
groups of animals where behavioural training was the only variable. An independent t-test 
with Holm-Bonferroni sequential correction was used to examine differences between specific 
two-group comparisons, while a one-way ANOVA was performed on 3 group comparisons and 
a post-hoc Tukey’s HSD test performed on comparisons in which a main effect was found to be 
significant. n = 3-6/group. 
 
 
 
 
 
Table 3.8b. The p-values of group comparisons from a post-hoc Tukey test for the genes in 
which a main effect was found to be significant in a one-way ANOVA (Table 3.8a).
Group 
comparison 
Calb2 Glp1r Gpr165 Kcnh3 Kcnj4 
Hdh+/+ 3M U vs. 
Hdh+/+ 3M A 
t(7) = -1.573 
p = 1.000 
t(7) = -0.955 
p = 1.000 
t(7) = -0.278 
p = 1.000 
t(7) = 1.252 
p = 1.000 
t(7) = 1.539 
p = 1.000 
Hdh+/+ 6M U vs. 
Hdh+/+ 6M A vs. 
Hdh+/+ 6M S 
F2, 9 = 0.038 
p = 0.963 
F2, 9 = 0.282 
p =0.761 
F2, 9 = 2.667 
p =0.123 
F2, 9 = 0.063 
p =0.939 
F2, 9 = 0.369 
p =0.702 
HdhQ150/+ 3M U 
vs. HdhQ150/+ 3M 
A 
t(5) = -1.365 
p = 1.000 
t(5) = -1.028 
p = 1.000 
t(5) = -1.592 
p = 1.000 
t(1.201) = 
1.106 
p = 1.000 
t(5) = 2.473 
p = 0.560 
HdhQ150/+ 6M U 
vs. HdhQ150/+ 6M 
A vs. HdhQ150/+ 
6M S 
F2, 11 = 
0.736 
p = 0.501 
F2, 4.942 = 
2.483 
p = 0.179 
F2, 11 = 0.520 
P = 0.608 
F2, 11 = 0.673 
p = 0.530 
F2, 11 = 0.843 
p = 0.456 
Group 
comparison 
Rpph1 Slc17a6 Snora74a Uprt Zic 1 
Hdh+/+ 3M U vs. 
Hdh+/+ 3M A 
t(7) = 0.725 
p = 1.000 
t(7) = -3.479 
  p = 0.100 
t(7) = -0.490 
p = 1.000 
t(7) = -0.214 
p = 1.000 
t(7) = -2.285 
p = 0.504 
Hdh+/+ 6M U vs. 
Hdh+/+ 6M A vs. 
Hdh+/+ 6M S 
F2, 9 = 9.783 
 p = 
0.006** 
F2, 9 = 0.664 
p = 0.538 
F2, 9 = 12.245 
 p = 0.003** 
F2, 9 = 0.083 
p = 0.921 
F2, 9 = 0.637 
p = 0.551 
HdhQ150/+ 3M U 
vs. HdhQ150/+ 
3M A 
t(5) = -0.630 
p = 1.000 
t(5) = -2.109 
p = 0.801 
t(5) = -0.004 
p = 1.000 
t(5) = 0.099 
p = 1.000 
t(5) = -1.120 
p = 1.000 
HdhQ150/+ 6M U 
vs. HdhQ150/+ 
6M A vs. 
HdhQ150/+ 6M S 
F2, 11 = 
0.704 
p = 0.515 
F2, 11 = 0.284 
p = 0.758 
F2, 11 = 1.581 
p = 0.249 
F2, 11 = 0.532 
p = 0.602 
F2, 11 = 0.737 
p = 0.501 
Group comparison Rpph1 Snora74a 
Hdh+/+ 6M U vs. 
Hdh+/+ 6M A 
p = 0.094    p = 0.004** 
Hdh+/+ 6M U vs. 
Hdh+/+ 6M S 
  p = 0.005**  p = 0.016* 
Hdh+/+ 6M A vs. 
Hdh+/+ 6M S 
p = 0.270 p = 0.724 
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3.3.2.4.3 Gene expression level changes as a result of ageing 
The microarray reported a large number of genes whose altered expression levels were changed 
between 3M and 6M (Table 3.5), with the majority of genes to be investigated by RT-qPCR 
showing altered expression between the Hdh+/+ 3M U and Hdh+/+ 6M U groups (Table 3.6). RT-
qPCR did not find significant differences in striatal expression levels of any of the genes 
investigated for the Hdh+/+ 3M U and Hdh+/+ 6M U group comparison found to show variation in 
the microarray (Table 3.9). However, significant differences in striatal gene expression levels 
that can be attributed to ageing were found between Hdh+/+ 3M A and Hdh+/+ 6M A animals for 
Glp1r (Fig. 3.12A; t(5) = -5.963, p = 0.020) and Zic 1 (Fig. 3.12B; t(5) = -5.156, p = 0.036). These 
comparisons were not found to be significant in the microarray investigation. All other possible 
ageing-dependent striatal expression changes in the genes investigated by RT-qPCR were found 
to be non-significant (Table 3.9).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. RQ values of Glp1r (A) and Zic 1 (B) ageing-dependent striatal expression levels, 
in CRF trained Hdh+/+ animals, following RT-qPCR to confirm microarray data. Both genes show 
significant reductions in striatal expression levels between Hdh+/+ animals from 3M to 6M, 
neither of which were reported in the microarray (Table 3.6). Data presented is mean fold 
change ± S.E.M.; Hdh+/+ 3M A: n = 4; Hdh+/+ 6M A: n = 3. 
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Table 3.9. The statistical values for age-dependent gene expression level comparisons 
examined using RT-qPCR and independent samples t-tests. Independent samples t-tests with 
Holm-Bonferroni sequential correction for multiple hypothesis testing corrections were 
performed to examine differences in gene expression levels between groups. n  = 3-6/group.
Group comparison Calb2 Glp1r Gpr165 Kcnh3 Kcnj4 
Hdh+/+ 3M U vs. 
Hdh+/+ 6M U 
t(9) = -3.500 
  p = 0.063 
t(9) = -3.504 
  p = 0.063 
t(9) = -3.311 
  p = 0.063 
t(9) = 3.732 
  p = 0.050 
t(9) = 2.972 
 p = 0.064 
Hdh+/+ 3M A vs. 
Hdh+/+ 6M A 
t(5) = -1.533 
p = 1.000 
t(5) = -5.963 
  p = 0.020* 
t(5) = -1.969 
p = 1.000 
t(5) = 1.567 
p = 1.000 
t(5) = 1.364 
p = 1.000 
HdhQ150/+ 3M U vs. 
HdhQ150/+ 6M U 
t(4) = -2.046 
p = 0.990 
t(4) = -1.688 
p = 1.000 
t(4) = -1.016 
p = 1.000 
t(4) = 0.679 
p = 1.000 
t(4) = 0.601 
p = 1.000 
HdhQ150/+ 3M A vs. 
HdhQ150/+ 6M A 
t(8) = 0.236 
p = 1.000 
t(8) = 0.387 
p = 1.000 
t(8) = 0.935 
p = 1.000 
t(8) = -1.020 
p = 1.000 
t(8) = -1.204 
p = 1.000 
Group comparison Rpph1 Slc17a6 Snora74a Uprt Zic 1 
Hdh+/+ 3M U vs. 
Hdh+/+ 6M U 
t(9) = 2.438 
 p = 0.114 
t(9) = -3.479 
  p = 0.063 
t(9) = 1.270 
p = 0.472 
t(9) = -0.447 
p = 0.665 
t(9) = -3.135 
 p = 0.063 
Hdh+/+ 3M A vs. 
Hdh+/+ 6M A 
t(5) = -0.650 
p = 1.000 
t(5) = 0.695 
p = 1.000 
t(5) = -1.116 
p = 1.000 
t(5) = -0.476 
p = 1.000 
t(5) = -5.156 
  p = 0.036* 
HdhQ150/+ 3M U vs. 
HdhQ150/+ 6M U 
t(4) = 0.638 
p = 1.000 
t(4) = -2.612 
p = 0.590 
t(3.824) = 1.792 
p = 1.000 
t(4) = 1.885 
p = 1.000 
t(4) = -1.357 
p = 1.000 
HdhQ150/+ 3M A vs. 
HdhQ150/+ 6M A 
t(8) = 0.476 
p = 1.000 
t(8) = 0.275 
p = 1.000 
t(8) = -0.679 
p = 1.000 
t(8) = 2.400 
 p = 0.430 
t(8) = 0.627 
p = 1.000 
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3.3.2.4.3 Microarray validation by RT-qPCR summary 
To summarise the findings of the RT-qPCR based validation of the microarray gene expression 
level data, two genes showed significant differences in levels of expression in group comparisons 
in the RT-qPCR analyses that were also identified in the microarray investigation. Both Rpph1 
and Snora74a showed significantly altered levels of mRNA transcripts in Hdh+/+ mice at 6M that 
had undergone different levels of behavioural training in the RT-qPCR (Table 3.8a; Fig. 3.11) and 
microarray investigations (Table 3.6). RT-qPCR also revealed gene expression level changes that 
are attributable to ageing that were not identified in the microarray, where CRF trained Hdh+/+ 
animals at 6M present with significantly decreased levels of striatal Glp1r and Zic1 in comparison 
to their CRF trained counterparts at 3M (Table 3.9; Fig. 3.12). RT-qPCR did not find significant 
differences in striatal gene expression levels for the remaining group comparisons presenting 
with such changes in the microarray. However, the fold-changes identified in the RT-qPCR 
analyses did show the same trend of expression (positive or negative fold-changes) for 19 of the 
21 comparisons showing such changes in the microarray (Table 3.10). 
 
Table 3.10. A summary table for the validation of the microarray gene expression level results 
by RT-qPCR. The fold-changes in expression levels for the gene in each comparison for both the 
microarray and RT-qPCR results are presented. The gene expression level alteration trend 
between the microarray and RT-qPCR findings are said to be validated if the fold-changes of both 
investigations are in the same direction (positive or negative fold-change). n = 3-6/group. 
Gene Group Comparison Microarray 
Fold-Change 
RT-qPCR 
Fold-Change 
Trend 
Validation? 
Calb2 Hdh+/+ 3M U vs Hdh+/+ 6M U -2.68 -10.04 Yes 
Glp1r Hdh+/+ 3M U vs Hdh+/+ 6M U -2.88 -17.04 Yes 
Gpr165 Hdh+/+ 3M U vs Hdh+/+ 6M U -1.76 -4.24 Yes 
Kcnh3 Hdh+/+ 3M U vs Hdh+/+ 6M U +1.35 +3.19 Yes 
Kcnj4 Hdh+/+ 3M U vs Hdh+/+ 6M U +1.25 +2.84 Yes 
 
 
Rpph1 
HdhQ150/+ 3M U vs HdhQ150/+ 6M U 
HdhQ150/+ 6M U vs HdhQ150/+ 6M A 
HdhQ150/+ 6M U vs HdhQ150/+ 6M S 
Hdh+/+ 3M U vs Hdh+/+ 6M U 
Hdh+/+ 6M U vs Hdh+/+ 6M A 
Hdh+/+ 6M U vs Hdh+/+ 6M S 
+0.75 
-0.66 
-0.60 
-0.51 
-0.67 
-0.55 
+1.24 
-1.29 
-1.18 
+1.25 
-1.25 
-1.50 
Yes 
Yes 
Yes 
No 
Yes 
Yes 
Slc17a6 Hdh+/+ 3M U vs Hdh+/+ 6M U -2.47 -9.51 Yes 
 
Snora74a 
Hdh+/+ 3M U vs Hdh+/+ 6M U 
Hdh+/+ 6M U vs Hdh+/+ 6M A 
Hdh+/+ 6M U vs Hdh+/+ 6M S 
+0.85 
-0.81 
-1.02 
+1.38 
-2.84 
-2.30 
Yes 
Yes 
Yes 
 
 
Uprt 
HdhQ150/+ 3M U vs HdhQ150/+ 6M U 
HdhQ150/+ 6M U vs HdhQ150/+ 6M A 
HdhQ150/+ 6M U vs HdhQ150/+ 6M S 
Hdh+/+ 3M U vs Hdh+/+ 6M U 
Hdh+/+ 6M U vs Hdh+/+ 6M S 
-0.78 
+0.75 
+0.69 
-0.83 
+0.69 
-1.06 
+1.03 
+1.16 
-1.06 
-1.02 
Yes 
Yes 
Yes 
Yes 
No 
Zic1 Hdh+/+ 3M U vs Hdh+/+ 6M U -1.96 -5.05 Yes 
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3.3.2.5 Pathway analysis of microarray gene expression level data 
Initial pathway analyses were performed on gene lists generated in the microarray (Table 3.5), 
the results of which are presented in Tables 3.11 and 3.12. The microarray reported 0 genes 
showing differences in expression levels in any comparison where genotype was the only 
discriminating factor (Table 3.5), thus genotype-dependent pathway analyses were not 
performed.
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Table 3.11. Comparison of the top 10 significant GO biological categories identified by DAVID pathway analysis for the gene lists listed in Table 3.5. Data are FDR 
p-values from a DAVID analysis (Huang et al., 2009a, b); n = 3-6/group. Abbreviations: NS = Not significant; OTT = Outside top 10 significant GO biological pathways. 
Comparison 1 2 3 4 5 6 
GO Category Hdh+/+ 3M U vs 
Hdh+/+ 6M U 
Hdh+/+ 6M U vs 
Hdh+/+ 6M A 
Hdh+/+ 6M U vs 
Hdh+/+ 6M S 
HdhQ150/+ 3M U vs 
HdhQ150/+ 6M U 
HdhQ150/+ 6M U vs 
HdhQ150/+ 6M A 
HdhQ150/+ 6M U vs 
HdhQ150/+ 6M S 
Protein localisation (GO:0008104) 1.61 x 10-12 5.22 x 10-03 NS 1.61 x 10-12 2.23 x 10-07 NS 
Protein transport (GO:0015031) 7.04 x 10-12 1.09 x 10-02 NS 7.04 x 10-12 3.28 x 10-07 NS 
Establishment of protein localisation 
(GO:0045184) 
1.33 x 10-11 1.69 x 10-03 NS 1.33 x 10-11 4.00 x 10-07 NS 
Cellular protein localisation (GO:0034613) 5.46 x 10-08 NS NS 5.46 x 10-08 9.56 x 10-03 NS 
Ribonucleotide binding (GO:0032553) 7.53 x 10-05 NS NS OTT NS NS 
Intracellular transport (GO:0046907) 4.69 x 10-07 NS NS 1.31 x 10-07 1.63 x 10-03 NS 
Cellular macromolecule localisation 
(GO:0070727) 
7.60 x 10-08 NS NS 7.60 x 10-08 4.76 x 10-02 NS 
Nucleotide binding (GO:0000166) OTT NS NS OTT NS NS 
Intracellular protein transport (GO:0006886) 1.84 x 10-07 NS NS 1.87 x 10-07 NS NS 
Purine nucleotide binding (GO:0017076) 1.51 x 10-06 NS NS OTT NS NS 
Vesicle-mediated transport (GO:0016192) OTT NS NS 3.66 x 10-04 9.26 x 10-05 NS 
GTP binding (GO:0005525) OTT NS 1.63 x 10-04 OTT 1.03 x 10-04 NS 
Golgi apparatus (GO:0005794) OTT NS NS OTT 3.99 x 10-04 NS 
Small GTPase mediated signal transduction 
(GO:0007264) 
1.83 x 10-07 NS NS 1.83 x 10-07 NS NS 
Guanyl ribonucleotide binding (GO:0032561) OTT NS 2.18 x 10-04 2.03 x 10-03 1.52 x 10-04 NS 
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Table 3.12. Comparison of the top 10 significant GO biological categories identified by DAVID pathway analysis for overlaps between groups of interest from 
gene lists listed in Table 3.5. Data are FDR p-values from DAVID analysis (Huang et al., 2009a, b); n = 3-6/group. Abbreviations: NS = Not significant.
Comparison 1 2 3 4 5 
GO Category Hdh+/+ 3M U vs Hdh+/+ 
6M U & HdhQ150/+ 3M 
U vs HdhQ150/+ 6M U 
Overlap 
Hdh+/+ 6M U vs Hdh+/+ 
6M A & HdhQ150/+ 6M 
U vs HdhQ150/+ 6M A 
Overlap 
Hdh+/+ 6M U vs Hdh+/+ 
6M S & HdhQ150/+ 6M U 
vs HdhQ150/+ 6M S 
Overlap 
Hdh+/+ 6M U vs 
Hdh+/+ 6M A & Hdh+/+ 
6M U vs Hdh+/+ 6M S 
Overlap 
HdhQ150/+ 6M U vs 
HdhQ150/+ 6M A & 
HdhQ150/+ 6M U vs 
HdhQ150/+ 6M S Overlap 
Protein localisation (GO:0008104) 2.62 x 10-06 1.01 x 10-05 NS NS NS 
Protein transport (GO:0015031) 1.80 x 10-04 1.15 x 10-05 NS NS NS 
Establishment of protein localisation 
(GO:0045184) 
1.98 x 10-04 2.17 x 10-05 NS NS NS 
Cellular protein localisation (GO:0034613) NS NS NS NS NS 
Ribonucleotide binding (GO:0032553) NS NS NS NS NS 
Intracellular transport (GO:0046907) 7.76 x 10-03 7.52 x 10-03 NS NS NS 
Cellular macromolecule localisation 
(GO:0070727) 
NS NS NS NS NS 
Nucleotide binding (GO:0000166) NS NS NS NS NS 
Intracellular protein transport (GO:0006886) NS NS NS NS NS 
Purine nucleotide binding (GO:0017076) NS NS NS NS NS 
Vesicle-mediated transport (GO:0016192) 2.07 x 10-03 5.65 x 10-04 NS NS NS 
GTP binding (GO:0005525) 4.10 x 10-03 NS NS NS NS 
Golgi apparatus (GO:0005794) 7.42 x 10-03 4.26 x 10-02 NS NS NS 
Small GTPase mediated signal transduction 
(GO:0007264) 
4.81 x 10-02 NS NS NS NS 
Guanyl ribonucleotide binding (GO:0032561) 5.03 x 10-03 NS NS NS NS 
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3.3.2.5.1 Behavioural training-dependent pathway analyses 
Both genotypes showed alterations in three similar pathways as a result of CRF training, 
identified by examination of pathway group comparisons 3.11.2 and 3.11.5 (Table 3.11), which 
suggests that striatal protein transport and localisation, and the establishment of protein 
localisation, undergo change as a result of simple conditioning learning. HdhQ150/+ animals, 
however, also show significant gene expression level changes in pathways associated with other 
aspects of protein production and transport, such as in the Golgi apparatus and vesicle-mediated 
transport, as well as in signalling pathways that include guanosine-5'-triphosphate (GTP) 
binding. 170 genes show significant alterations resulting from simple conditioning learning in 
the striatum of both genotypes (Fig. 3.13), and are associated with cellular localisation and 
trafficking, including vesicle-mediated transport and Golgi apparatus activity (Table 3.12.2). 
 
  
 
 
 
 
 
Figure 3.13. The overlap between striatal genes differentially expressed as a result of simple 
conditioning learning between Hdh+/+ and HdhQ150/+ mice. 170 genes were found to overlap 
between genotypes as a result of CRF training. n = 3-6/group. 
 
Performing a complex serial visual discrimination task produced changes in few biological 
pathways in each genotype (Table 3.11.3 & 3.11.6), although it is worth noting that, unlike CRF-
only trained animals, HdhQ150/+ mice show significant alterations in a fewer number of GO 
categories than their Hdh+/+ counterparts, with implicit learning altering zero GO processes in 
HdhQ150/+ mice (Table 3.11.6). Hdh+/+ animals were found to exhibit significant differences in 
expression of genes associated with a smaller number of biological categories after implicit 
learning compared to CRF training, though both forms of learning seem to only alter gene 
expression level changes in specific biological processes (GTP binding, and protein localisation 
Hdh+/+ 6M U vs Hdh+/+ 6M A (n = 596) HdhQ150/+ 6M U vs HdhQ150/+ 6M A (n = 375) 
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and transport, respectively). Only 49 genes were significantly altered following implicit learning 
in both genotypes (Fig. 3.14), and were not found to be associated with any GO biological 
processes showing significant alteration (Table 3.12.3). 
 
 
 
 
 
 
 
 
Figure 3.14. The overlap between striatal genes differentially expressed as a result of implicit 
learning between Hdh+/+ and HdhQ150/+ mice. 49 genes were found to overlap between 
genotypes as a result of implicit learning. n = 3-6/group. 
 
As a result of CRF training and implicit learning, a large proportion of genes exhibit abundant 
expression changes in the striatum of both genotypes (Hdh+/+ n = 122, HdhQ150/+ = 110; Fig. 3.15 
& Fig. 3.16). DAVID analyses reported that genes showing an overlap of altered expression 
between conditioning and implicit learning in Hdh+/+ animals were not significantly associated 
with any GO biological pathways (Table 3.12.4), however they were associated with the non-GO 
process “acetylation” (FDR p = 3.36 x 10-02). Similarly, the 110 genes that underwent expression 
changes as a result of both conditioning and implicit learning in HdhQ150/+ animals were not 
significantly associated with any GO biological categories (Table 3.12.5). 
 
 
 
 
 
Hdh+/+ 6M U vs Hdh+/+ 6M S (n = 189) HdhQ150/+ 6M U vs HdhQ150/+ 6M S (n = 145) 
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Figure 3.15. The overlap between striatal genes differentially expressed as a result of 
conditioning and implicit learning in Hdh+/+ mice. 122 genes were found to overlap between 
learning paradigms in Hdh+/+ animals. n = 3-6/group. 
 
 
 
 
 
 
 
 
Figure 3.16. The overlap between striatal genes differentially expressed as a result of CRF 
training and implicit learning in HdhQ150/+ mice. 110 genes were found to overlap between 
learning paradigms in HdhQ150/+ animals. n = 3-6/group. 
 
Of the genes that underwent significant expression changes in response to, or as a result of, 
both conditioning and implicit learning, 40 of these genes exhibited altered expression in both 
genotypes (Fig. 3.17). 82 of the genes found to be associated with both types of learning 
presented with transcriptional changes only in Hdh+/+ animals, whilst 70 only underwent 
significant changes in expression in HdhQ150/+ animals (Fig. 3.17). The genes altered following 
Hdh+/+ 6M U vs Hdh+/+ 6M S (n = 189) Hdh+/+ 6M U vs Hdh+/+ 6M A (n = 596) 
HdhQ150/+ 6M U vs HdhQ150/+ 6M S (n = 145) HdhQ150/+ 6M U vs HdhQ150/+ 6M A (n = 375) 
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acquisition of a simple conditioning task and acquisition of a complex serial visual discrimination 
task in both genotypes were most associated with GTP signal transduction and protein transport 
(data not shown), although DAVID analyses reported no significant association with any GO 
process. The 82 striatal mRNAs that underwent expression changes only in Hdh+/+ mice after 
acquisition of a simple conditioning task and acquisition of a complex serial visual discrimination 
task were linked with structural roles, such as microtubule and tubulin binding, and protein 
transportation (data not shown), as defined by their GO clustering classification. However, this 
did not reach statistical significance. Transcriptional changes only reported in HdhQ150/+ animals 
were also associated with protein transportation and structural roles, and oxidoreductase 
activity was another pathway associated with the genes (data not shown), though again there 
were no significant associations with any of the GO pathways. 
 
 
 
 
 
 
 
 
Figure 3.17. The overlap between striatal genes differentially expressed as a result of 
conditioning and implicit learning in both Hdh+/+ and HdhQ150/+ mice. 40 genes were found to 
overlap between learning paradigms in both genotypes of animals. n = 3-6/group. 
 
3.3.2.5.2 Pathway analyses of ageing group comparisons 
Pathway analysis of differential gene expression level signatures between 3M and 6M show 
similar functions in the absence of training in the Hdh+/+ and HdhQ150/+ striata (Table 3.11.1 & 
3.11.4), suggesting protein localisation and transport, and GTP activity are altered in ageing. 109 
genes were found to overlap between genotypes as a result of ageing in the absence of 
behavioural training (Fig. 3.18), and were associated with protein localisation and transport, and 
GTP activity (Table 3.12.1), as would be anticipated. Pathway analyses were not performed on 
HdhQ150/+ 6M U vs HdhQ150/+ 6M A & HdhQ150/+ 
6M U vs HdhQ150/+ 6M S (n = 110) 
Hdh+/+ 6M U vs Hdh+/+ 6M A & Hdh+/+ 
6M U vs Hdh+/+ 6M S (n = 122) 
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the other age-dependent comparisons (Hdh+/+ 3M A vs Hdh+/+ 6M A and HdhQ150/+ 3M A vs 
HdhQ150/+ 6M A) because there were 0 genes identified in the microarray as showing significantly 
altered expression levels in either comparison (Table 3.5).  
 
 
 
 
 
 
 
 
Figure 3.18. The overlap between striatal genes differentially expressed as a result of ageing 
between Hdh+/+ and HdhQ150/+ mice. 109 genes were found to overlap between genotypes as a 
result of ageing in the absence of behavioural training. n = 3-6/group. 
 
3.4 Discussion 
The current chapter aimed to evaluate the potential effects of the HD genotype, ageing, and 
different forms of learning on the striatal transcriptome of mice. No differences in behaviours 
tested were evident between HdhQ150/+ and Hdh+/+ animals at 2M-6M in CRF or SILT performance, 
but HdhQ150/+ mice did present with impaired performance in the 5-CSRTT. Both genotypes were 
found to able to perform the SILT, with neither genotype presenting with an implicit learning 
deficit at 6M. The striatal gene expression level profiles of HdhQ150/+ and Hdh+/+ mice did not 
differ at any time point or learning phase examined, using a microarray investigation, which 
suggests that a transcriptional phenotype is not present in the heterozygous HdhQ150 mouse 
model of HD at 3M or 6M. The GO biological pathways of protein transport and localisation, and 
GTP signalling were associated with striatal mRNAs showing significant transcriptional 
alterations as a result of ageing between 3M and 6M. Performance of CRF training produced 
alterations in common biological pathways in both genotypes, and a greater number of striatal 
transcriptional changes were evident following CRF training alone than as a result of CRF, 5-
CSRTT and SILT performance. 
Hdh+/+ 3M U vs Hdh+/+ 6M U (n = 2, 940) 
 
HdhQ150/+ 3M U vs HdhQ150/+ 6M U (n = 122) 
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3.4.1 Effects of Huntington’s disease genotype on behavioural performance 
No significant difference was reported between the performances of HdhQ150/+ and Hdh+/+ 
animals in the CRF, suggesting that HdhQ150/+ mice do not present with an impairment in the 
acquisition of a simple conditioning task at 2M. A significant difference was reported between 
accuracy levels of HdhQ150/+ and Hdh+/+ animals in the 5-CSRTT, a task utilised to assess visual 
attention (Muir et al., 1993), with HdhQ150/+ mice exhibiting lower levels of accuracy than their 
wild-type counterparts. The interaction of genotype and session also reported levels of 
significance in the 5-CSRTT, however the latency of responses to stimuli were comparable 
between genotypes. These findings suggest that HdhQ150/+ mice at 3M show impaired visual 
attentional functioning and delayed acquisition of the 5-CSRTT, phenotypes that have not 
previously been identified in this mouse model. 
Using a probe of implicit learning (Trueman et al., 2005), the current study tested the ability of 
HdhQ150/+ mice to learn a complex serial visual discrimination task. There was no difference in 
accuracy to S1 between HD and control animals, and stimulus location did not affect accuracy 
to S1 for either genotype. Reaction times to S1 were also comparable between genotypes, with 
no significant difference between performance levels, independent of hole location. Mean 
accuracy and reaction times of HdhQ150/+ and Hdh+/+ animals to S2 were similar, with no 
significant variation between genotypes while the number of steps between S1 and S2 was 
found to significantly affect accuracy and reaction times to S2 for both genotypes, as anticipated. 
Both genotypes of mice seem to exhibit the cognitive capacity for implicit learning, as 
demonstrated by a higher performance accuracy on predictable than unpredictable S2 trials. 
However, predictive accuracy to S2 did not differ significantly between genotypes, suggestive of 
a lack of deficit in implicit learning in the HdhQ150/+ animals. HdhQ150/+ mice were also found to 
perform a comparable number of S1 and S2 trials across the final 5 days of testing as their wild-
type counterparts, which is indicative of healthy motivational drive and activity levels at 3M-4M, 
and is corroborated by previous evidence where heterozygous HdhQ150 animals did not present 
with an activity deficit until 40 weeks of age (Lin et al., 2001). The proportion of all types of errors 
made in the SILT was equivalent between genotypes and suggests that, at the age examined, 
HdhQ150/+ animals do not present with a phenotype of abnormal impulsivity, attention, 
perseveration or motor learning that have been identified in previous SILT-based studies 
examining striatal lesions (Trueman et al., 2005; Brooks et al., 2007) and the HdhQ92 and 
YAC128 mouse lines of HD (Trueman et al., 2007; Brooks et al., 2012d). 
These results indicate that 6M old HdhQ150/+ mice do not present with deficits in implicit learning, 
similar to previous reports in striatal lesion (Trueman et al., 2005) and HdhQ92/Q92 mice (Trueman 
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et al., 2007). The lack of deficit in implicit learning may be due to the relatively low level of 
neuropathology present in our model at this age, with neuronal intranuclear inclusion formation 
and striatal cell loss only present from 5M and 6M, respectively (Bayram-Weston et al., 2012). 
Therefore, it is possible that any striatal dysfunction present in the animals at this time-point 
may not be severe enough to cause cognitive impairment in the SILT, and so examining the 
model at a later stage in the lifespan may reveal a behavioural phenotype. However, deficits in 
reversal and spatial learning (Brooks et al., 2012a) have previously been reported at similar ages 
(6M and 4M, respectively) in homozygous HdhQ150 mice. Thus, it is possible that the HdhQ150/+ 
animals did not present with learning deficits because of a gene-dosage effect where animals 
homozygous for the mutant allele show greater impairment than mice heterozygote for the 
mutant allele, as suggested previously (Lin et al., 2001). Previous SILT-based lesion studies have 
suggested that striatal dysfunction does not affect the implicit learning capabilities of rats (Jay 
and Dunnett, 2007) or mice (Trueman et al., 2005; Brooks et al., 2007). Thus, it is reasonable to 
suggest that differences in implicit learning did not arise between genotypes because the neural 
structure likely to have undergone the greatest degree of degeneration in the HD mouse model, 
the striatum, may not play a key role in implicit learning in the rodent brain, which is supported 
by similar findings in the HdhQ92 line (Trueman et al., 2007). Another possibility for the lack of 
a significant difference in performance between the two genotypes is simply that the number 
of animals used in the study is likely to be too low to accurately represent either population 
(animals that performed full-SILT training: Hdh+/+: n = 3; HdhQ150/+: n = 5). 
 
3.4.2 The effects of Huntington’s disease genotype on gene expression levels 
The lack of significant mRNA transcript level differences between genotypes suggests that a 
transcriptional phenotype does not arise in heterozygote HdhQ150 animals at 3M-6M. This may 
be the result of a gene-dosage effect, as HdhQ150/Q150 mice have previously been found to show 
abnormal gene expression profiles at 6M compared to wild-type animals (Giles et al., 2012), or 
may again be due to the low number of mice used in the study.  
 
3.4.3 Effects of ageing on striatal gene expression levels 
The current findings suggest that ageing results in altered expression of genes associated with 
protein processing and synaptic signalling, shown by G protein-associated biological processes, 
in the mouse striatum, similar to those noted previously in the mouse hypothalamus and cortex 
(Jiang et al., 2001). Ageing in laboratory mice has previously been strongly linked with 
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transcriptional alterations associated with immune responses (Swindell, 2009), which was not 
evident in our data. There are a number of factors that may contribute to the inconsistency 
between our data and that of Swindell (2009), such as the difference in background mouse 
strains used in either study. Animals on a C57BL6/J background were utilised in our study whilst 
multiple strains were assessed by Swindell. The age ranges examined also differed between the 
two studies, which is likely to contribute to the differing findings, and Swindell’s report of altered 
immune response as a result of ageing was taken from analyses of multiple mouse tissues 
whereas the current study only assessed striatal transcription.  
This study found that untrained 6M old HdhQ150/+ mice exhibited fewer transcriptional changes 
as a result of ageing compared to wild-type animals. This trend is in contrast to that seen in a 
previous study by Giles and colleagues (2012), where homozygote HdhQ150 animals presented 
with a greater number of ageing-dependent striatal transcriptional changes than their wild-type 
equivalents. The genetic discrepancies between our findings and the aforementioned previous 
findings could be an issue of gene dosage, with the current study examining heterozygous 
animals while homozygous animals were used by Giles and colleagues (2012), or power because 
of the low number of animals used in our study. Nevertheless, the trend of a substantially 
abnormal number of ageing-related mRNA expression changes observed in HdhQ150/+ mice may 
be an early indication of a genetic phenotype that arises in knock-in animals prior to a 
behavioural phenotype. 
 
3.4.4 Effects of age and training on gene expression levels 
The investigation into the striatal mechanisms underlying potential cognitive deficits in the 
HdhQ150/+ mouse model of HD uncovered a substantial difference in gene expression levels 
depending on whether the mice had received any task-based training. Examination of the PCA 
and microarray list of gene expression level changes in group comparisons suggests that the 
performance of learning tasks between 2M-4M appears to maintain the striatal transcription 
profile close to that of the 3M mice rather than that seen in their untrained 6M contemporaries. 
Our data are consistent with the notion that behavioural training acts to prevent or ameliorate 
ageing-associated gene expression level changes. Similar assertions have previously been made, 
whereby an exercise protocol seemed to reverse ageing-related memory decline and decreases 
in hippocampal histone H4 acetylation levels (Lovatel et al., 2013). However, there are 
limitations in the present study that may confound this conclusion: the untrained groups did not 
perform any learning tasks, but they also remained unhandled and were not placed in the test 
environment of the operant boxes. Thus, it is possible that the effects of training observed could 
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be a result of handling, which is likely to have multiple effects on the handled mice such as 
increasing fear and anxiety, both of which are known to affect neural gene expression levels 
(Malkani and Rosen, 2000; Hovatta et al., 2005; Coryell et al., 2007; Pantazopoulos et al., 2011; 
Spencer et al., 2013). The lack of exposure to the test environment of the operant box, in 
untrained animals, may also confound the effects of training, as extended exposure to novel 
environments has been found to alter gene expression levels within the striatum (Struthers et 
al., 2005). 
 
3.4.5 The effects of conditioning and implicit learning on striatal gene expression levels 
The current study found a number of genes showing altered expression following CRF training 
or implicit learning. Simple conditioning produced changes in expression of a relatively large 
number of genes in Hdh+/+ and HdhQ150/+ animals, which were associated with protein transport 
in wild-type mice and mostly protein transport and GTP signalling in knock-in animals. Implicit 
learning following CRF and 5-CSRTT induced less transcriptional changes than CRF alone, 
suggesting that neural remodelling occurs early in behaviour acquisition and smaller 
modifications to expression need to be induced later. The mRNAs showing significant alterations 
following implicit learning were associated with protein transport and localisation in wild-type 
mice, while those showing variation in HdhQ150 animals were not significantly associated with 
any GO pathways. Pathway analyses did not identify significant associations with any GO 
biological processes in genes presenting with significant activity level changes as a result of both 
forms of learning. 
A lower number of gene expression level changes were identified in animals that had undergone 
implicit learning following CRF and 5-CSRTT acquisition than those that had performed CRF alone 
at 2M before being sacrificed at 6M. It has been reported that extended exposure to novel 
environments can alter gene expression levels within the striatum (Struthers et al., 2005). This 
effect cannot be the cause of the lower number of genes showing altered transcription levels in 
SILT trained animals, however, because the 6M old acquisition trained animals, whilst only being 
trained at 2M, were placed in the operant boxes in the absence of SILT training until sacrifice at 
6M. Thus, the 6M old CRF trained animals had the same level of operant box exposure as the 
SILT trained mice. This suggests that learning at 2M is capable of altering gene expression levels 
in a stable manner up to 6M. 
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3.4.6 Conclusions 
This chapter aimed to assess the behavioural performance of HdhQ150/+ mice in a test of implicit 
learning (Trueman et al., 2005), and to assess the transcriptional responses that genotype, 
ageing and performing different levels of operant-based instrumental learning produce in this 
mouse model of HD. Behaviour was assessed using CRF, 5-CSRTT and the SILT, similar to that 
used previously (Trueman et al., 2005; Brooks et al., 2007; Trueman et al., 2007; Trueman et al., 
2012b), but an implicit learning behavioural phenotype was not discovered in HdhQ150/+ mice at 
3M-4M, seemingly dismissing the hypothesis that HdhQ150/+ mice at 3M-4M may display an 
implicit learning deficit. Conversely, a deficit in the 5-CSRTT was reported in HdhQ150/+ mice at 
3M, which has not previously been reported, and suggests that these animals present with an 
impairment in visual attention and delayed acquisition of the 5-CSRTT at 3M. These conclusions 
require replication, due to the low number of animals that performed the tasks in the current 
study, and re-examination of the model using a greater number of behavioural subjects would 
be recommended. A microarray reported no gene expression level differences between 
HdhQ150/+ mice and their wild-type controls.  
Inspection of the microarray PCA and gene lists suggested that the performance of cognitive 
tasks between 3M-6M may act to maintain the striatal transcriptional profile of 6M old animals 
closer to that of 3M old animals, with 6M old untrained animals displaying a transcriptional 
profile dissimilar to both 3M old animals and 6M old mice that had undergone CRF or SILT 
training. This interpretation of the data may be confounded by a number of limitations however, 
as the sample size of each group was low and unevenly distributed, and also because untrained 
animals had not received any substantial handling and were not introduced to the test 
environment that the trained animals had experienced, both of which have been previously 
found to influence neural gene expression levels (Malkani and Rosen, 2000; Hovatta et al., 2005; 
Struthers et al., 2005; Coryell et al., 2007; Pantazopoulos et al., 2011; Spencer et al., 2013). The 
microarray reported that ageing produced significant changes in striatal expression levels of 
mRNAs related to protein processing and synaptic transport, as has previously been identified 
in the mouse hypothalamus and cortex (Jiang et al., 2001). 
Microarray analyses identified a number of gene expression level changes arising from 
performance of a simple conditioning task and a more complex serial visual discrimination task 
examining implicit learning, when compared to untrained animals. When individually assessing 
each genotype on each task, performance of both tasks resulted in alterations in biological 
pathways associated with protein transport and localisation, and GTP binding, although there 
were no significant associations with any biological processes when genetic analyses of the two 
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tasks were compared. As such, these biological processes may act as a generic network related 
to learning, in the striatum. The lack of distinction found between the striatal transcriptional 
components of simple conditioning and the more complex implicit learning task may be the 
result of a similar genetic profile being required for acquisition of both tasks.  
In summary, at 2M-3M there were no differences in the performance of CRF between 
genotypes, and while a subtle difference arose between HdhQ150/+ and Hdh+/+ mice in the 5-CSRTT 
this behavioural phenotype did not present itself in the SILT. No broad spectrum striatal gene 
expression level changes were observed in Q150 mice compared to wild-type animals at any 
time point or learning phase. This work identified potential generic striatal learning associated 
biological pathways in wild-type animals, highlighting the role of protein transport and 
localisation, and GTP binding in the striatum for learning. 
 
3.4.7 Summary of key results from Chapter 3 
 Identification of novel visual attention impairment and delayed acquisition of the 5-
CSRTT in female HdhQ150/+ mice at 3M. 
 No implicit learning deficits were identified using the SILT in female HdhQ150/+ mice at 
3M-4M. 
 Microarray investigation reported no genotype-dependent striatal gene expression 
level differences between HdhQ150/+ and wild-type littermate controls. 
 Ageing from 3M-6M resulted in similar transcriptional profiles in the striata of HdhQ150/+ 
and wild-type littermate controls. 
 A microarray reported no genetic differences between the striata of CRF and SILT 
trained animals. 
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Chapter 4: Investigating the transcriptional correlates of spatial discrimination and 
reversal learning in C57BL/6 mice 
The investigation into age- and learning-dependent changes in the transcriptional profile of 
HdhQ150/+ mice in chapter 3 identified a trend in striatal transcription profiles between untrained 
animals and those that had undergone differing levels of behavioural training. In order to 
investigate transcriptional aspects of cognitive performance across learning stages in further 
detail, the current study examined SD and RL at distinct time points in wild-type C57BL/6 mice. 
Specifically, striatal gene expression levels were investigated following the first session of SD 
and RL training as a means of identifying neural gene expression level changes associated with 
early acquisition of SD and RL. Striatal gene expression levels were also examined following the 
final session upon which animals reached criteria in each task, in order to identify neural gene 
expression level changes associated with maintenance of SD and RL tasks. 
 
4.1 Introduction 
Problem solving can be broken down into its cognitive processes and these include planning, 
judgement, management, anticipation, decision-making and reasoning. Successful performance 
of these cognitive procedures is also dependent upon proficient observance of the external 
environment, storage and retrieval of relevant information from long-term memory, inhibition 
of inappropriate information, and manipulation and integration of the appropriate information. 
The application and management of all these mental functions is referred to as executive 
function, with executive function previously defined as “…a product of the co-ordinated 
operation of various [cognitive] processes to accomplish a particular goal in a flexible manner” 
(Funahashi, 2001). As suggested by this definition, an integral feature of executive function is 
the cognitive flexibility required to adapt to changing circumstances when making a decision and 
also reverse decisions based on differential conditions, and RL can be defined as a subset of 
cognitive flexibility. 
The neural structures and pathways underpinning RL have been investigated using a number of 
approaches, with strong evidence for involvement of both the striatum and frontal cortex in this 
form of memory. For example, lesion studies in non-human primates identified that the 
prefrontal cortex is necessary for cognitive flexibility (Roberts et al., 1990; Roberts et al., 1992) 
and this finding has since been replicated in rodent lesion studies (Kim and Ragozzino, 2005; 
Brigman and Rothblat, 2008). Similar studies have also identified the striatum as being integral 
for behavioural flexibility (Featherstone and McDonald, 2005; Clarke et al., 2008; Castane et al., 
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2010), while complementary roles of the prefrontal cortex and striatum in cognitive flexibility 
have also been proposed as a result of lesion studies (Ragozzino, 2007; McDonald et al., 2008b). 
This theory of frontostriatal circuitry governing behavioural flexibility is further strengthened by 
functional magnetic resonance imaging evidence of altered frontal cortical and striatal activity 
during reversal of a previously learnt rule in healthy human patients (Cools et al., 2002; 
Kringelbach and Rolls, 2003; Hampton and O'Doherty, 2007; Ghahremani et al., 2010). 
Furthermore, individuals with lesions to the frontal cortex or striatum show impairments in a 
variety of RL tasks (Hornak et al., 2004; Bellebaum et al., 2008), which also indicates that this 
form of learning may be dependent on the frontostriatal circuitry. 
As the striatum and cortex are the neural structures that undergo the largest degree of 
degeneration in HD (Vonsattel et al., 1985; Gusella and MacDonald, 2009; Tabrizi et al., 2011; 
Tabrizi et al., 2013), it is unsurprising that impairments in cognitive flexibility have been 
reported. Such impairments in cognitive flexibility have been reported in HD sufferers, with 
evidence of deficits in the performance of simple RL (Lange et al., 1995; Lawrence et al., 1999), 
task switching (Aron et al., 2003), attentional set shifting (Lawrence et al., 1996; Lawrence et al., 
1998b), and the Stroop test (Tabrizi et al., 2013). Cognitive flexibility has also been examined in 
mouse models of HD. One study examined the performance of homozygous HdhQ150 animals 
in a complex extra-dimensional set shifting task that requires mice learn to dig for a reward 
based upon digging medium or odour, and where a number of rule reversals occur (Brooks et 
al., 2006). In comparison to their wild-type counterparts, HdhQ150/Q150 mice exhibited deficits in 
extra-dimensional set shifting as well as recall impairments for compound reversal and intra-
dimensional set shifting in this task. A similar extra-dimensional set shifting impairment, albeit 
using a different behavioural task, has also been reported in the YAC128 (Brooks et al., 2012f) 
and R6/1 (Harrison et al., 2013) mouse models of HD. Further evidence of cognitive inflexibility 
in the HdhQ150 mouse model of HD is provided by the identification of a reversal learning deficit 
in the Morris water maze task from 6M in homozygous mutants (Brooks et al., 2012b). More 
recently, cognitive inflexibility has been reported in both BACHD and zQ175 mice using a 
touchscreen based operant task (Farrar et al., 2014). 
The neuroanatomical basis of cognitive flexibility has been extensively investigated, and the 
genetic mechanisms underlying RL have seen similar levels of examination in recent years. This 
has led to the identification of a number of genes that are believed to play a role in RL (Table 
4.1). One such gene is Dopamine receptor D2 (Drd2), which encodes dopamine D2 receptors 
(DRD2s). Drd2 has been found to mediate RL in a number of studies, with evidence that 
transgenic mice lacking functional DRD2s are incapable of learning a new rule in an odour 
learning task (Kruzich et al., 2006) and are impaired in the reversal element of an attention set 
102 
 
shifting task (Desteno and Schmauss, 2009). Chronic pharmacological antagonism of DRD2s in 
otherwise healthy C57BL/6 mice also caused an impairment in RL of the attention set shifting 
task. Conversely, Drd2 expression in the PFC has been found to inversely correlate with RL 
capabilities of mice, where heightened levels of Drd2 were associated with poor RL performance 
(Laughlin et al., 2011). While there are contradictory findings in the studies mentioned, each 
study does highlight the importance of Drd2 in RL in mice. Evidence for the role of DRD2s in 
human cognitive flexibility is also available, where impaired RL and abnormal striatal activity, as 
assessed using fMRI, was reported in individuals carrying a polymorphism in DRD2 that causes 
reduced expression of striatal DRD2s (Jocham et al., 2009).  
 
Gene name Gene 
symbol 
Finding Species Study 
Adenosine 
A2A receptor 
Adora2A 
Selective inactivation of A2ARs in striatal 
neurons enhances RL. 
Mouse 
(Wei et al., 
2011) 
Activity-
regulated 
cytoskeleton-
associated 
protein 
Arc 
1) Striatal Arc mRNA expression 
correlates with RL performance. 
2) Methamphetamine attenuates Arc 
expression in dorsal striatum and 
abolishes the correlation between Arc 
mRNA levels and RL performance. 
3) Acute disruption of Arc disrupts 
retention of RL. 
Rat 
(Daberkow 
et al., 2007) 
(Daberkow 
et al., 2008) 
 
 
(Pastuzyn et 
al., 2012) 
Brain-derived 
neurotrophic 
factor 
Bdnf 
1) Hippocampal Bdnf expression is 
induced during contextual learning. 
2) Spatial learning produces an increase 
in hippocampal Bdnf levels, and BDNF 
mRNA and protein level reduction results 
in impaired spatial memory retention. 
3) Disruption of BDNF exon IV-dependent 
transcription and reduced activity-
induced BDNF expression levels cause an 
impairment in learning in the first day of 
RL training in the MWM. 
Rat 
 
Rat 
 
 
 
Mouse 
(Hall et al., 
2000) 
(Mizuno et 
al., 2000) 
 
 
(Sakata et 
al., 2013) 
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cAMP 
response 
element-
binding 
protein 1 
Creb1 
1) CREB activation is increased in the 
hippocampus during spatial learning. 
2) Striatum-dependent response learning 
causes elevated levels of CREB activation 
in the striatum. 
3) Hippocampal CREB1 is decreased in 
aged rats with spatial memory 
impairments. 
4) Spatial memory deficits are associated 
with decreased levels of CREB activation 
in the hippocampus of aged rats. 
Rat 
(Mizuno et 
al., 2002) 
(Colombo et 
al., 2003) 
 
(Brightwell 
et al., 2004) 
 
(Porte et al., 
2008) 
Dopamine D2 
receptor 
Drd2 
1) Drd2 deletion impairs ability to learn 
new rule in odour learning task. 
2) Chronic DRD2 antagonism using 
haloperidol impairs RL of a set-shifting 
task. 
3) Presence of DRD2 polymorphism 
associated with impaired RL ability and 
abnormal striatal activity. 
4) Drd2 expression in the PFC is inversely 
correlated with RL ability. 
Mouse 
 
Mouse 
 
 
Human 
 
 
Mouse 
 
(Kruzich et 
al., 2006) 
(Desteno and 
Schmauss, 
2009) 
(Jocham et 
al., 2009) 
 
(Laughlin et 
al., 2011) 
Homer 
scaffolding 
protein 1 
Homer1 
1) Homer1 knock-out produces deficits in 
spatial learning and memory. 
2) Hippocampal Homer1 deletion 
produces a diverging phenotype on 
motivational behaviour in operant 
conditioning. 
3) Striatal Homer1a transcription is 
elevated following instrumental learning. 
Mouse 
(Jaubert et 
al., 2007) 
(Wagner et 
al., 2014) 
 
 
(Hernandez 
et al., 2006) 
Table 4.1. A summary of research relating to instrumental learning, spatial learning and RL for 
the genes examined by RT-qPCR in the current study. 
 
A trend in striatal transcription profiles between untrained animals and those that had 
undergone differing levels of behavioural training in the SILT was identified in Chapter 3. Based 
upon this trend and the strong evidence of a cognitive flexibility deficit in HD, a genetic basis of 
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RL and a number of candidate genes underpinning RL, the current study aimed to examine the 
transcriptional profile of healthy C57BL/6 mice at different stages of SD and RL. This was 
designed as a preliminary study to an investigation of the biological mechanisms governing SD 
and RL in the HdhQ150/+ mouse model of HD. A microarray investigation was utilised in order to 
examine the entire transcriptional profile of the striatum of each behavioural group, while RT-
qPCR was used to validate microarray data and examine the expression levels of specific mRNAs 
associated with SD and RL (Table 4.1). Because transcription was being investigated in the 
current experiment, a novel SD and RL operant task similar to that used by Farrar and colleagues 
(2014) was utilised that requires less motor activity and olfactory input than the behavioural 
tasks used in previous investigations of cognitive flexibility in HD animals (Brooks et al., 2006; 
Brooks et al., 2012f; Harrison et al., 2013), as locomotor activity and olfactory input are both 
known to influence gene expression levels (Berchtold et al., 2002; Cotman and Berchtold, 2002; 
Farmer et al., 2004; Irwin and Byers, 2012). 
 
4.2 Methods 
4.2.1 Subjects 
Forty-eight naïve male C57BL/6J mice (Harlan, UK) were housed 4 animals per cage and animal 
husbandry was as described in Chapter 2.1.2. All animals were between 22 and 24 weeks-of-age 
at the start of testing, and were water restricted throughout testing, as described in Chapter 
2.1.2.  
 
4.2.2 Experimental design 
Animals were randomly allocated into one of the following six behavioural training groups (Fig. 
4.1): chronic magazine training; continuous reinforcement (CRF) until criteria (CRF 
maintenance); 1 day of SD training (SD acquisition); SD to criteria (SD maintenance); one day of 
RL (RL acquisition); and RL to criteria (RL maintenance). Each training group consisted of eight 
mice. All animals (n = 48) underwent an initial session of magazine training, as described in 
Chapter 4.2.3.1. Eight animals continued magazine training and never received any other form 
of behavioural training (chronic magazine training group) while the remaining mice (n = 40) 
underwent CRF training to criteria, as described in Chapter 4.2.3.2, following the initial magazine 
training session. Upon reaching criteria in the CRF task, eight animals were sacrificed (CRF 
maintenance) while the remaining mice (n = 32) began SD training, as described in Chapter 
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4.2.3.3, with eight animals performing a single session of SD training before sacrifice (SD 
acquisition) and the remaining mice (n = 24) performing the SD task to criteria. Once criterion 
was reached in the SD task, eight animals were sacrificed (SD maintenance) while the remaining 
mice (n = 16) performed the RL task, as described in Chapter 4.2.3.4. Eight of the remaining mice 
performed a single RL training session before sacrifice (RL acquisition) and the final eight animals 
performed the task to criteria before sacrifice (RL maintenance). Animals were sacrificed 
individually when reaching criteria in a task, with each individual mouse sacrificed when they 
reached criteria and not sacrificed as a group once the group as a unit reached criteria. 
There was an instance where behavioural groups were paired to one another. Animals in the 
chronic magazine training group were paired to those in the CRF maintenance group whereby 
upon reaching criteria in CRF training, the said mouse from the CRF maintenance group, as well 
as a mouse from the magazine training group, would be sacrificed and tissue extracted for gene 
expression level analyses.  
 
 
 
 
 
 
 
 
Figure 4.1. Behavioural training in the experimental design. Mice in each group underwent 
different levels of behavioural training.  
 
4.2.3 Behavioural training protocols 
4.2.3.1 Magazine training 
Animals underwent 1 day of magazine training in order to permit the mice to learn the 
association between magazine light illumination and food reward. The magazine light was 
illuminated and 150 µL of reward was delivered at the onset of the 20 min session. Upon removal 
 Magazine Training (n=48) 
 CRF acquisition (n=40) 
 Chronic magazine training 
(n=8)  
 SD acquisition (n=32) 
 SD maintenance (n=24) 
 RL acquisition (n=16) 
 RL maintenance (n=8) 
Time 
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of the head from the magazine, the light would extinguish for 10 s before again illuminating and 
5 µL of reward delivered. This reward contingency was maintained for the remainder of the 
session. 
 
4.2.3.2 CRF task 
Mice performed CRF training as described in Chapter 3.2.4.2. Criterion in the task was set at ≥50 
np in three consecutive sessions for the current study. Animals performed the task until criteria 
was met, at which point mice were either sacrificed and tissue taken for dissection or training 
begun in the SD task. 
 
4.2.3.3 SD task 
In the SD task, mice had to correctly respond to two consecutive chained stimuli to receive a 
reward. Sessions lasted 20 min and one session was performed each day. As with the CRF task, 
the hole 5 stimulus light in the operant box was illuminated and the mouse must nose-poke (np) 
this stimulus light. When this stimulus light was present, a correct np caused simultaneous 
extinction of the hole 5 stimulus light and illumination of hole 3 and hole 7 stimulus lights (Fig. 
4.2). In the result of a hole 5 np not being made within 10 s of hole 5 stimulus light presentation, 
the light stimulus was extinguished and the house lights illuminated for 5 s before a new trial 
began following a 2 s ITI. Upon presentation of hole 3 and hole 7 light stimuli, mice were required 
to np the light stimulus of either hole 3 or hole 7. The light to be chosen was counterbalanced 
between animals, whereby half of the mice of each genotype were trained to np the stimulus 
light of hole 3 whilst the opposing half were trained to np the stimulus light of hole 7. When hole 
3 and hole 7 stimulus lights were present, a correct np resulted in simultaneous hole 3 and hole 
7 light stimuli extinction, magazine light illumination and food reward delivery. Once the mouse 
collected the reward and removed its head from the magazine, the magazine light was 
extinguished. Following a 2 s ITI, the next trial began through the illumination of the centre hole 
light. In the result of an incorrect response to hole 3 and hole 7 stimulus lights, an incorrect 
response was recorded, the light stimuli extinguished and the house lights illuminated for 5 s 
before a new trial began after a 2 s ITI. 
Training performance on this task was calculated as percent accuracy (((correct 
choices)/(correct choices + incorrect choices)) x 100). Criterion was judged to be met when a 
minimum of 85% accuracy was reached in three consecutive sessions. Animals performed the 
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task until criteria was met, at which point mice were either sacrificed and tissue taken for 
dissection or they moved on to training in the RL task. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. A pictorial representation of the SD task. A light stimulus is presented in hole 5 of 
the operant box (A). Upon nose-poking the light stimulus, the light stimulus in hole 5 is 
extinguished and holes 3 and 7 light stimuli are illuminated (B). The mouse then has to choose 
which hole to np. Nose-poking the correct hole leads to extinction of holes 3 and 7 stimulus light 
and illumination of the magazine light stimulus (C). Once the animal has collected the food 
reward (D), and removed its head from the magazine, the magazine light is extinguished. There 
is a 2 s inter-trial-interval (ITI) before a new trial is commenced through illumination of the hole 
5 stimulus light (A). 
 
 
 
 
A 
 
 
 
 
B 
 
 
C 
 
 
 
 
 
D 
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4.2.3.4 RL task 
In the RL task, mice (n = 16) had to correctly respond to two consecutive stimuli to receive a 
reward. Sessions lasted 20 min and one session was performed each day. The RL task was 
identical to the SD task described in Chapter 4.3.2.3 except that mice had to respond to the 
opposing stimulus light (of either hole 3 or hole 7) than that responded to in the previous SD 
phase. For example, if an animal had previously learnt to np the stimulus light of hole 7 when 
presented with holes 3 and 7 stimuli lights, the mouse would now have to np the hole 3 stimulus 
light in order to gain a reward.  
Training performance on this task was calculated as percent accuracy (((correct choices/(correct 
choices + incorrect choices)) x 100). Criterion was judged to be met when a minimum of 85% 
accuracy was reached in three consecutive sessions. RL performance was also analysed by 
subdividing performance into two distinct stages based upon the percent of correct choices 
made in each session, specifically according to whether performance was <50% correct or ≥50% 
correct, as implemented by previous studies examining mouse RL (Davies et al., 2005; Brigman 
et al., 2008; Brigman et al., 2010; Graybeal et al., 2011). Sessions where accuracy is <50% reflects 
performance when perseveration to the previously learnt rule is high, while sessions where trials 
committed on ≥50% correct reflect performance where perseveration is relatively low and the 
ability to form new reinforce-stimulus associations (Davies et al., 2005; Brigman et al., 2008). 
Eight mice performed one session of RL training before sacrifice and tissue extraction, forming 
the RL acquisition group. The remaining eight mice performed the task until criteria was met, at 
which point mice were either sacrificed and tissue taken (RL maintenance group). One mouse 
was unable to reach criterion in the RL task and was therefore removed from all analyses. Thus 
the RL criteria group consisted of seven animals instead of eight. 
 
4.2.4 Molecular methodology 
4.2.4.1 RNA extraction 
RNA was prepared from whole striatum dissected from animals following the first session of a 
task or upon reaching criteria in a task, as described in Chapter 2.3.1. RINs of RNA samples 
ranged from 7.7 to 9.5 (8.52 ± 0.08). 
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4.2.4.2 Microarray and microarray analyses 
Microarray was performed by Megan Musson of Cardiff University’s Central Biotechnology 
Services (Cardiff, UK) using MouseRef-8 v2.0 Expression Beadchips (product code: BD-202-0202; 
Illumina Inc., California, USA), and microarray gene expression data was analysed using Partek® 
Genomics SuiteTM Version 6.6 (Partek Incorporated, Missouri, USA).  
 
4.2.4.3 Quantification of gene expression levels by RT-qPCR 
Microarray gene expression level data was validated by TaqMan®-mediated (Life Technologies 
Corporation, Carlsbad, California, USA) RT-qPCR, as described in Chapter 2.3.2, and each 
reaction was performed in triplicate. The genes to be investigated were chosen based upon the 
findings of previous studies examining RL in mice, as discussed in Chapter 4.1, and are listed in 
Table 4.2. 
 
Gene name Gene symbol ID 
beta actin Actb Mm00607939_s1 
adenosine A2a receptor Adora2A Mm00802075_m1 
activity regulated cytoskeletal-associated protein Arc Mm01204954_g1 
brain derived neurotrophic factor Bdnf Mm04230607_s1 
cAMP responsive element binding protein 1 Creb1 Mm00501607_m1 
dopamine receptor D2 Drd2 Mm00438545_m1 
homer homolog 1 Homer1 Mm00516275_m1 
ubiquitin C Ubc Mm02525934_g1 
Table 4.2. Identification codes for Taqman® oligonucleotide probes used in the current study. 
 
4.2.5 Statistical analyses 
Statistical analyses were performed using IBM SPSS® Statistics software (Version 20; IBM United 
Kingdom Ltd, Hampshire, UK). Behavioural and RT-qPCR data were analysed by two-way ANOVA, 
with learning stage (acquisition or maintenance) and task (SD or RL) as independent variables. 
Specific two-group comparisons were analysed by independent samples t-tests, with Holm-
Bonferroni sequential correction used for multiple hypothesis testing correction. Sphericity of 
data was assessed using Mauchly’s test of Sphericity, with the Greenhouse-Geisser correction 
used if the assumption of Sphericity was violated and the Greenhouse-Geisser estimate of 
sphericity (ɛ) < 0.75. If the assumption of Sphericity was violated and ɛ > 0.75, the Huynh-Feldt 
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correction was used. Similarly, homogeneity of variances for data was assessed using Levene’s 
test, and the Welch test used in the event of data violating this assumption.  
 
4.3 Results 
4.3.1 Microarray quality control metrics 
PCA was performed as an early exploratory analysis of global striatal gene expression level 
patterns across all samples (Fig. 4.3), and the close grouping of subjects from all behavioural 
groups suggests that there is little variation in gene expression level patterns between 
behavioural groups. This indicates that neither behavioural task or learning stage significantly 
contribute to the striatal gene expression level patterns identified in the experiment, which is 
supported by the results of the gene expression level analyses reported in Table 4.3. The small 
percentage of contribution to the gene expression level profiles by the principal components, at 
only 12.7% and 8.22%, is also indicative of an absence of a causal effect of behavioural learning 
stage or task performance on striatal gene expression levels. Other principal components, such 
as RNA extraction batch, microarray processing batch, and housing cage group, were found to 
have no significant effect on gene expression level profiles in the PCA (data not shown). 
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Figure 4.3. The PCA of the striatal transcriptional profiles of each behavioural group reveals 
no clear grouping of transcriptional profiles. Learning stage is the main principle component, 
which accounts for 12.7% of the variance in gene expression levels while task performance is 
the second principle component and accounts for 8.22% of the variance. The PCA reveals no 
clear separation of any group from another, suggesting the gene expression level profiles of each 
group show high levels of similarity. n = 4/group. 
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4.3.2 Microarray gene expression levels 
A two-way ANOVA was performed on the microarray gene expression level data with learning 
stage and task performed as variables, and also using the same variables as interaction terms in 
a two-way interaction. Statistical significance was taken using FDR p < 0.05, with FDR estimation 
generated by Benjamini-Hochberg procedure, and no minimum magnitude of fold-change was 
defined when generating lists of genes showing significantly altered expression levels. This 
approach did not yield statistically significant changes in expression for any gene in any 
comparison examined (Table 4.3). Hence, pathway analyses from the microarray findings found 
later in the current chapter utilise microarray gene expression level results from lists of genes 
presenting with differential levels of expression generated using a nominal (FDR-uncorrected) 
p-value (Table 4.3). 
 
 
 
 
 
 
Independent variable/group 
comparison 
Number of genes differentially expressed 
FDR<0.05 Nominal p-value 
Learning stage 0 1,192 
Task 0 950 
Learning stage*task 0 1,140 
Magazine vs CRF maintenance 0 338 
SD acquisition vs SD maintenance 0 300 
RL acquisition vs RL maintenance 0 674 
SD acquisition vs RL acquisition 0 437 
SD maintenance vs RL maintenance 0 434 
SD maintenance vs RL acquisition 0 317 
Table 4.3. The number of genes showing altered expression levels within the striatum as a 
result of the independent variables and in different group comparisons at two different 
significance stringencies in the microarray investigation. n = 4/group. 
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4.3.3 CRF task 
4.3.3.1 Behaviour 
Results of the CRF task revealed that all groups performed the task equivalently, in terms of the 
number of sessions required to reach criteria (Fig. 4.4A; main effect of group: F3, 27 = 2.269, p = 
0.103) and the average number of responses made in the final three days of testing (Fig. 4.4B; 
main effect of group: F3, 27 = 1.414, p = 0.260). 
 
 
 
 
 
 
 
 
 
Figure 4.4. Performance of animals in the CRF task. In the CRF task, all groups took a comparable 
number of sessions to reach criteria (A) and performed a similar mean number of responses 
during the final three sessions (B). Values shown are mean ± S.E.M.; n = 7-8/group. 
 
4.3.3.2 Validation of microarray gene expression level results and investigation of candidate 
gene expression levels by RT-qPCR 
Creb1 was identified in the nominal p-value microarray list as being one of the genes 
downregulated in the striatum of animals that reached criteria in CRF, in comparison to their 
chronic magazine trained counterparts (p = 0.043). RT-qPCR was performed to validate this 
finding, as well as to investigate the expression levels of other genes of interest, and reported 
no difference in Creb1 transcription between the two groups (Table 4.4; t(6) = 1.737, p = 0.665). 
The remaining genes investigated by RT-qPCR also presented with comparable levels of 
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expression between groups (Table 4.4), despite a trend of increased gene expression levels for 
all genes investigated in CRF maintenance animals being identified (Fig. 4.5).  
 
Table 4.4. The statistical values for RT-qPCR striatal expression level comparisons between 
magazine trained and CRF maintenance groups. A t-statistic of 6 was used, unless otherwise 
stated. n = 4/group. 
 
4.3.3.3 Pathway analyses of microarray data 
Microarray investigation reported 0 genes displaying significantly altered expression levels 
between the striata of chronic magazine training and CRF maintenance animals, the group 
comparison used to investigate CRF-dependent transcription alterations, at the FDR p<0.05 
significance level (Table 4.3). Utilising the nominal p-value of 0.05 identified 338 genes 
presenting with significant changes in expression between chronic magazine training and CRF 
maintenance striata (Table 4.3). Pathway analyses revealed that these genes were associated 
with biological processes that include cell signalling, shown by associations with the GO 
pathways ion channel activity (GO:0005216; p = 3.39 x 10-02), substrate channel activity 
(GO:0022838; p = 1.88 x 10-02) and plasma membrane function (GO:0005886; p = 1.26 x 10-02), 
and odorant binding (GO:0005549; p = 3.30 x 10-02). 
 
 
 
 
 
Gene investigated t(6) = p-value 
Adora2A 0.804 1.000 
Arc 0.207 1.000 
Bdnf t(3.905) = 0.875 1.000 
Creb1 1.737 0.665 
Drd2 1.516 0.720 
Homer1 3.758 0.054 
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Figure 4.5. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) striatal expression levels between magazine trained and CRF maintenance groups 
following RT-qPCR to confirm microarray data. A trend of increased expression levels in the CRF 
maintenance group is seen in each gene examined, however all gene expression level 
differences between groups were found to be non-significant. Values shown are mean ± S.E.M.; 
n = 4/group. 
n.s. = non-significant 
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4.3.4 SD and RL general performance 
4.3.4.1 Behaviour 
A two-way ANOVA examining the effect of learning stage (acquisition or maintenance) and task 
(SD or RL) on a number of behavioural measures was performed.  Learning stage significantly 
affected mean accuracy to S2 (main effect of learning stage: F1, 26 = 129.546, p < 0.001), as did 
the task being performed (main effect of task: F1, 26 = 10.095, p = 0.004). A significant interaction 
between the effects of learning stage and task was also reported for mean accuracy to S2 
(learning stage*task: F1, 26 = 9.185, p = 0.005).  
Analysis of the simple main effects found mean accuracy during RL acquisition to be considerably 
lower than during SD acquisition (Fig. 4.6; p < 0.001), while there was no difference in accuracy 
levels between maintenance of SD and RL (Fig. 4.6; p = 0.918). Independent samples t-tests were 
used to examine any potential differences in mean accuracy between acquisition and 
maintenance of either the SD or RL task, and identified a significant increase in accuracy from 
SD acquisition to SD maintenance (Fig. 4.6; t(7.118) = -4.559, p = 0.002) and from RL acquisition 
to RL maintenance (Fig. 4.6; t(6.887) = -37.329, p < 0.001). 
 
 
 
 
 
 
 
 
Figure 4.6. The mean percentage accuracy of animals during acquisition and maintenance of 
the SD and RL tasks. Mean accuracy levels during acquisition of RL were significantly lower than 
those during acquisition of SD, while significant increases in accuracy from SD acquisition to SD 
maintenance and RL acquisition to RL maintenance were also reported. Values shown are mean 
± S.E.M.; n = 7-8/group. 
* Denotes a significant difference from the SD Acquisition group 
† Denotes a significant difference from the RL Acquisition group 
** p < 0.01 *** p < 0.001 
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4.3.4.2 Validation of microarray gene expression level results and investigation of candidate 
gene expression levels by RT-qPCR  
A two-way ANOVA was performed on the microarray data to examine striatal expression in the 
mouse genome and, at FDR p<0.05, revealed no significant changes in transcription of any gene 
as a result of learning stage or task, or of an interaction between learning stage and task (Table 
4.3). Investigating striatal gene expression levels of specific group comparisons of interest (SD 
acquisition vs SD maintenance, RL acquisition vs RL maintenance, SD acquisition vs RL 
acquisition, SD maintenance vs RL maintenance, SD maintenance vs RL acquisition) in the 
microarray data also failed to identify any significant alterations, in any of the group 
comparisons, using FDR p<0.05 (Table 4.3). Decreasing the stringency of significance, through 
the use of a nominal p-value, lead to the discovery of a number of genes showing evidence of 
altered transcription in the striatum in all the aforementioned group comparisons (Table 4.3). 
A two-way ANOVA examining striatal expression of all genes of interest, using RT-qPCR, revealed 
no significant effect of either learning stage or task on transcription levels (Table 4.5). Similarly, 
no interaction between learning stage and task was reported for any of the genes investigated 
(Table 4.5). 
 
Gene of 
interest 
Learning stage Task Learning stage*Task 
F1, 11 =  p-value F1, 11 =  p-value F1, 11 =  p-value 
Adora2A 0.001 0.982 2.399 0.150 0.139 0.716 
Arc 0.955 0.350 1.531 0.242 1.569 0.236 
Bdnf 0.133 0.722 1.302 0.278 0.990 0.341 
Creb1 0.438 0.522 0.865 0.372 1.213 0.294 
Drd2 0.354 0.564 0.261 0.619 0.311 0.588 
Homer1 0.167 0.690 0.817 0.385 0.295 0.598 
Table 4.5. The statistical values of the two-way ANOVA examining the effect of learning stage 
and task on striatal gene expression levels of all genes of interest in SD acquisition and 
maintenance, and RL acquisition and maintenance groups. n = 4/group. 
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4.3.5 SD task 
4.3.5.1 Behaviour 
As expected, all groups that reached criteria in the SD task required a comparable number of SD 
sessions to reach criteria (Fig. 4.7; main effect of group: F2, 20 = 0.574, p = 0.572) and also 
performed a comparable rate of below-chance perseverative errors (Fig. 4.7; main effect of 
group: F2, 20 = 0.386, p = 0.684) and above-chance acquisition errors (Fig. 4.7; main effect of 
group: F2, 20 = 0.824, p = 0.497). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Behaviour in the SD task. All experimental groups that performed the SD task to 
criteria displayed comparable performance levels in the task, as shown by the number of 
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sessions required to reach criteria (A), and the rates of perseverative (B) and acquisition (C) 
errors. The data presented are mean values ± S.E.M.; n = 7-8/group. 
 
4.3.5.2 Validation of microarray gene expression level results and investigation of candidate 
gene expression levels by RT-qPCR 
The striatal transcriptome of CRF maintenance and SD acquisition animals were compared as a 
means of investigating gene expression level changes that arise as a result of early SD learning. 
The six genes of interest examined by RT-qPCR showed no significant differences in striatal 
expression levels between the CRF maintenance and SD acquisition groups (Table 4.6), despite 
a trend of SD acquisition animals exhibiting decreased striatal expression levels for each gene 
(Fig. 4.8). 
 
Gene of interest t(6) =  p-value 
Adora2A -1.361 0.756 
Arc -1.481 0.756 
Bdnf -0.410 1.000 
Creb1 -2.268 0.384 
Drd2 -0.522 1.000 
Homer1 -2.189 0.384 
Table 4.6. Statistical values from the independent-samples t-test examining potential 
differences in striatal gene expression levels between CRF maintenance and SD acquisition 
groups. n = 4/group. 
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Figure 4.8. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) striatal expression levels between CRF maintenance and SD acquisition groups 
following RT-qPCR to confirm microarray data. A trend of decreased expression levels in the SD 
acquisition group is seen in each gene examined, however all gene expression level differences 
between groups were found to be non-significant. Values shown are mean ± S.E.M.; n = 4/group. 
n.s. = non-significant 
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In order to examine the genetic differences between early and late SD learning, the 
transcriptional profiles of SD acquisition and SD maintenance animals were compared. The 
results of the RT-qPCR failed to demonstrate differences in transcription levels of any of the 
genes under investigation (Table 4.7), however, a general trend of increased striatal expression 
levels for all genes examined, with the exception of Adora2A, was exhibited in SD maintenance 
animals (Fig. 4.9). 
 
Gene of interest t(6) =  p-value 
Adora2A -0.223 1.000 
Arc 2.153 0.450 
Bdnf 0.391 1.000 
Creb1 1.366 1.000 
Drd2 0.023 1.000 
Homer1 0.676 1.000 
Table 4.7. Statistical values from the independent-samples t-test examining potential 
differences in striatal gene expression levels between SD acquisition and SD maintenance 
groups. n = 4/group. 
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Figure 4.9. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) striatal expression levels between SD acquisition and SD maintenance groups 
following RT-qPCR to confirm microarray data. A trend of increased expression levels in the SD 
maintenance group is seen in each gene examined, with the exception of Adora2A (A), however 
all gene expression level differences between groups were found to be non-significant. Values 
shown are mean ± S.E.M.; n = 4/group. 
n.s. = non-significant 
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4.3.5.3 Pathway analyses of microarray data 
The nominal p-value microarray list identified 404 striatal mRNAs as having altered expression 
levels between CRF maintenance and SD acquisition mice (Table 4.3). DAVID analyses found that 
these genes showed enrichment with biological processes that include small GTPase mediated 
signal transduction (GO:0007264; p = 3.44 x 10-02), microtubule cytoskeleton (GO:0015630; p = 
3.58 x 10-02) and microtubule organizing center (GO:0005815; p = 3.55 x 10-02). 
In order to examine the genetic differences between early and late SD learning, the 
transcriptional profiles of SD acquisition and SD maintenance animals were compared. 300 
genes showed altered expression in the striatum between animals that had undergone an initial 
acquisition session of SD training and those that had learnt the task to criteria, when using a 
nominal p-value (Table 4.3). Pathway analyses identified a number of genes being significantly 
associated with transport processes, such as anion and solute antiporter activity (GO:0015301; 
p = 2.25 x 10-02 and GO:0015300; p = 2.50 x 10-02, respectively), but also noted significant 
associations with transcriptional regulation, notably transcription repressor activity 
(GO:0016564; p = 3.61 x 10-02) and negative regulation of transcription from RNA polymerase II 
promoter (GO:0000122; p = 4.71 x 10-02). A number of genes presenting with altered expression 
were also associated with transcriptional regulation through epigenetic mechanisms, shown by 
an association with the GO pathway of histone-lysine N-methyltransferase activity 
(GO:0018024), although this association did not reach levels of significance (p = 0.055). 
 
4.3.6 RL task 
4.3.6.1 Behaviour 
It was only possible to compare performance in the first session of RL between groups, as only 
the RL maintenance group advanced past this stage of the task. Mean accuracy was found to be 
comparable between groups in the initial RL session (Fig. 4.10A; main effect of group: t(11) = 
1.276, p = 0.228), as was the rates of perseverative (Fig. 4.10B; main effect of group: t(11) = -
1.276, p = 0.228) and acquisition (Fig. 4.10C; main effect of group: t(11) = -1.276, p = 0.228) errors. 
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Figure 4.10. Behaviour in the initial session of the RL task. RL acquisition and maintenance 
animals displayed comparable performance levels in the initial session of the RL task, as shown 
by the mean accuracy (A), and the rates of perseverative (B) and acquisition (C) errors. The data 
presented are mean values ± S.E.M.; RL Acquisition: n = 8; RL Maintenance: n = 7. 
 
Examining the number of sessions required to reach criteria in the SD and RL task by RL 
maintenance animals, using a paired samples t-test, revealed no significant difference between 
the number of sessions needed to attain criteria in the two tasks (Fig. 4.11; t(6) = -0.521, p = 
0.621). 
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Figure 4.11. A comparison of the number of sessions required to reach criteria in the SD and 
RL tasks by RL maintenance animals. RL maintenance animals required a comparable number 
of sessions to achieve criteria in each task. The data presented are mean values ± S.E.M.; n = 7. 
 
4.3.6.2 Validation of microarray gene expression level results and investigation of candidate 
gene expression levels by RT-qPCR 
Expression levels of genes of interest were examined in RL acquisition and RL maintenance 
groups’ striata using RT-qPCR and failed to identify significant variation in expression levels of 
any gene between groups (Table 4.8). Two of the fours genes of interest displayed a trend 
towards increased expression levels in RL maintenance animals (Fig. 4.12A & Fig. 4.12E) while 
the remaining genes investigated displayed trends of decreased expression levels in RL 
maintenance mice (Fig. 4.12). 
Gene of interest t(5) =  p-value 
Adora2A 0.350 1.000 
Arc -0.153 1.000 
Bdnf -1.301 1.000 
Creb1 -0.283 1.000 
Drd2 1.090 1.000 
Homer1 -0.96 1.000 
Table 4.8. The statistical values from the independent-samples t-test, with Holm-Bonferroni 
multiple hypothesis test corrections, examining striatal gene expression levels in RL 
acquisition and RL maintenance mice. n = 4/group. 
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Figure 4.12. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) striatal expression levels between RL acquisition and RL maintenance groups 
following RT-qPCR to confirm microarray data. A trend of increased expression levels in the RL 
maintenance group is seen for Adora2A (A) and Drd2 (E), while all remaining genes investigated 
show a trend towards decreased expression levels in these animals. However, all gene 
expression level differences between groups were found to be non-significant. Values shown 
are mean ± S.E.M.; n = 4/group. 
n.s. = non-significant 
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The striatal expression levels of the genes of interest were examined in SD maintenance and RL 
acquisition animals in order to investigate the neural correlates of early RL acquisition, as well 
as to validate the microarray findings. Supporting the microarray findings, when taking 
significance at FDR p<0.05, examination of the RT-qPCR data for the six genes of interest 
revealed no alteration in striatal transcription between SD maintenance and RL acquisition 
groups for any gene investigated (Table 4.9). However, a trend towards an increase in gene 
expression levels in the striata of RL acquisition animals was identified for all genes investigated 
(Fig. 4.13), with the exception of Drd2 (Fig. 4.13E). 
 
Gene of interest t(5) =  p-value 
Adora2A 0.909 1.000 
Arc 0.208 1.000 
Bdnf 1.571 1.000 
Creb1 0.218 1.000 
Drd2 -0.067 1.000 
Homer1 0.344 1.000 
Table 4.9. Statistical values from the independent-samples t-test examining potential 
differences in striatal gene expression levels between SD maintenance and RL acquisition 
groups. n = 4/group. 
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Figure 4.13. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) striatal expression levels between SD maintenance and RL acquisition groups 
following RT-qPCR to confirm microarray data. A trend of increased expression levels in the RL 
acquisition group is seen for all genes investigated, with the exception of Drd2 (E). However, all 
gene expression level differences between groups were found to be non-significant. Values 
shown are mean ± S.E.M.; n = 4/group. 
n.s. = non-significant 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
R
Q
Adora2A
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
R
Q
Arc
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
R
Q
Bdnf
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
R
Q
Creb1
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
R
Q
Drd2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
R
Q
Homer1
n.s. 
n.s. 
n.s. 
n.s. 
n.s. n.s. 
A B 
C D 
E F 
RL Acquisition 
SD Maintenance 
129 
 
4.3.5.3 Pathway analyses of microarray data 
The microarray investigation identified 674 mRNAs presenting with significant fluctuations in 
striatal expression levels between RL acquisition and RL maintenance animals (Table 4.3), which 
can be argued to correlate with the late acquisition of RL. DAVID pathway analysis reported 
alterations in genes significantly associated with a number of cellular signalling processes, such 
as plasma membrane (GO:0005886; p = 4.97 x 10-03), peptidyl-serine phosphorylation 
(GO:0018105; p = 5.53 x 10-03), calcium ion binding (GO:0005509; p = 1.08 x 10-02) and protein 
domain specific binding (GO:0019904; p = 1.33 x 10-02). 
To investigate gene expression level differences that arise from early acquisition of RL, the 
striatal transcriptomes of SD maintenance and RL acquisition groups were also analysed. SD 
maintenance and RL acquisition striatal gene expression level profiles were found to exhibit 
variation in 317 transcripts in the microarray investigation, when using a nominal p-value for 
significance (Table 4.3). These mRNAs significantly associate with a multitude of biological 
processes, and the most highly significant were related to activation of immune response 
(GO:0002253; p = 4.32 x 10-04), regulation of fibroblast growth factor signalling pathway 
(GO:0040036; p = 5.95 x 10-04), extracellular space (GO:0005615; p = 2.44 x 10-03) and regulation 
of protein amino acid phosphorylation (GO:0001932; p = 3.18 x 10-03). 
 
4.4 Discussion 
Chapter 3 identified a trend in gene expression level profiles between groups that were 
untrained and those that had undergone different levels of behavioural training. Specifically, a 
greater number of transcriptional changes arose between untrained animals and those that had 
undergone initial CRF training in comparison to the number arising between untrained mice and 
those that had performed CRF, 5-CSRTT and SILT. The current study looked to identify striatal 
expression changes at distinct phases of SD and RL in healthy C57BL/6 animals, as a precursor 
to examining transcription levels during SD and RL in the HdhQ150 mouse model of HD in a later 
study. Behavioural results were as anticipated, with mice capable of reaching criteria in both the 
SD and RL task, and significant effects of learning stage and task on performance accuracy, as 
well as a significant interaction between learning stage and task. Surprisingly, microarray 
exploration of striatal transcription reported an absence of significant expression changes 
between any of the learning stage comparisons, when stringent multiple test corrections were 
utilised. RT-qPCR analyses of striatal learning-associated genes acted to verify the microarray 
findings by also discovering no differences in expression between any of the learning stages. 
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These findings suggest that striatal gene expression level changes that arise at the different 
stages of SD and RL in wild-type animals may not be of a high enough magnitude to be detected 
by a microarray investigation. There is also the possibility that the dorsal and ventral striatum 
may function differentially in RL, resulting in the absence of signal found in the current study. 
 
4.4.1 CRF task 
All groups that undertook CRF training performed the task equivalently, as shown by a 
comparable mean number of responses being made per session and an analogous mean number 
of sessions required to attain criteria in the task. This was anticipated, as all groups consisted of 
animals of the same genotype and sex, at the same age. The results of the microarray, however, 
were unexpected, with 0 genes presenting significant changes in striatal expression between 
CRF and chronic magazine trained mice when significance was taken at FDR p<0.05. One reason 
for this absence of transcriptional diversity is the possibility that the striatal gene expression 
level profiles of each group are comparable because the natural magnitude of gene expression 
level changes that occur following acquisition of CRF in wild-type animals are not high enough 
to be detected by microarray. When investigating the role of transcription in learning, it is 
common practice to use a ‘bottom-up’ approach to alter the genetic profile of animals prior to, 
or during, behavioural testing using transgenic (Silva et al., 1992b; Bourtchuladze et al., 1994; 
Sakimura et al., 1995; Abel et al., 1997; McClung and Nestler, 2003; Gerstein et al., 2012) or 
pharmacological methods (Egerton et al., 2005; Bredy and Barad, 2008; Romieu et al., 2008; 
Stefanko et al., 2009; Haettig et al., 2011; Dagnas et al., 2013). This approach often yields 
changes in transcription or behaviour, which can be linked to the gene(s) or pathway(s) under 
investigation. The current study used a ‘top-down’ approach where behaviour was examined 
before examination of potential genetic differences. It is possible that using an approach of this 
nature in wild-type animals does not lead to transcriptional changes large enough for detection 
by microarray, as suggested by the lack of microarray findings when using stringent multiple test 
corrections. Another potential reason for the lack of significant microarray findings is that 
examining gene expression level alterations in chronically trained animals may be too late in the 
learning process to identify such changes, as the variations in transcription may arise after the 
first few sessions of acquisition when plasticity is induced. 
Pathway analyses of the genes reporting significant differences in expression in the microarray 
when a nominal p-value was utilised identified that these genes were highly associated with a 
number of cell signalling functions and odorant binding. This might imply that these biological 
processes are necessary for acquisition of the CRF task, and are similar to the findings of Chapter 
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3 where cell signalling via GTP mechanisms were altered following CRF acquisition. Creb1, a gene 
associated with learning (Brightwell et al., 2004; Tyan et al., 2008), was identified in the nominal 
p-value microarray list as having greater expression levels in the striatum of CRF trained animals 
than their magazine trained counterparts. This would suggest that striatal Creb1 levels play a 
role in the acquisition of conditioning learning. However, this conclusion is contradicted by the 
evidence from the RT-qPCR data, which found no significant difference in Creb1 transcription 
between chronic magazine and CRF trained animals.  
 
4.4.2 SD task 
The behavioural data from the SD task, in terms of accuracy, was as expected. Learning stage 
and task were both found to significantly affect performance levels, and an interaction between 
the two independent variables was also reported. The SD acquisition animals produced a mean 
accuracy of ≈50%, which would be the performance level anticipated in the first session of a 
two-choice paradigm by chance. Heightened accuracy was seen in the SD maintenance group, 
which was expected because animals were actively learning the task between the initial session 
and final three sessions. Such an increase in accuracy was also anticipated, and necessary, 
because SD maintenance animals were required to reach ≥85% accuracy across the final three 
sessions in order to reach criteria in the task. Accuracy levels dropped to the lowest point during 
RL acquisition, which was also anticipated based on the findings of previous RL studies (Havekes 
et al., 2006; Izquierdo et al., 2006; Trinh et al., 2012; Brigman et al., 2013), as animals were 
learning a new rule at this stage and would be expected to show high levels of perseveration to 
the originally learnt rule in this initial session. A final increase in performance levels occurred 
between RL acquisition and maintenance, which would be predicted because animals become 
adept at learning the new rule between the first and final three RL sessions, similar to the 
increase in accuracy seen between SD acquisition and SD maintenance. The number of sessions 
required to reach criteria in the SD task was examined in the three behavioural groups that 
reached criteria in this task as a means of ensuring that any gene expression level differences 
that may arise between groups did not simply occur because of different performance 
capabilities, or levels of intelligence, in the SD task. As anticipated, the three groups all required 
a similar number of sessions to reach criteria, and also performed a comparable ratio of 
perseverative and acquisition errors, which shows that mice in each group were equally capable 
of performing the SD task.  
The microarray exploration of striatal transcription reported no significant changes in expression 
of any genes as a result of learning stage or task performed, and also reported no variation in 
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expression resulting from the interaction of learning stage and task. Direct group comparisons 
of interest, examining expression at different phases of SD learning, such as CRF maintenance 
vs SD acquisition, and SD acquisition vs SD maintenance, also failed to identify any mRNAs 
presenting with altered expression levels when using an FDR<0.05. The genetic components of 
early SD learning, examined by the CRF maintenance vs SD acquisition group comparison and 
using the nominal p-value gene list, were associated with biological pathways including those 
concerning cell structure and organisation, and also cell signalling through GTPase signal 
transduction. This indicates that early acquisition of a spatial learning task produces alterations 
in a number of aspects of cellular regulation, and supports previous findings of spatial learning-
dependent alterations to cellular structure and signalling (Cavallaro et al., 2002; Burger et al., 
2008; Klur et al., 2009; Paban et al., 2010). However, the genetic correlates of SD learning have 
also previously been examined by microarray investigation, with 19 genes displaying significant 
changes in expression in the rat hippocampus following SD learning in the hole-board maze task 
(Robles et al., 2003). The mRNAs identified by Robles et al. (2013) were associated with 
processes that include axonal growth and guidance, signal transduction, neurotransmitter and 
neuropeptide receptors and nuclear proteins; none of which were associated with SD learning 
in the present study. The discrepancies in biological processes associated with SD in the two 
studies are likely to be the result of a number of differences in experimental design, such as the 
contrasting species of animals, brain regions and behavioural tasks examined in either study. 
The time at which gene expression levels were examined following training also differed 
between the two studies, with the current study investigating transcription 20 min after the 
initial or final SD session while Robles and colleagues (2013) waited until 3 h after the third SD 
acquisition session, which is likely to contribute to the differing findings. It is important to note, 
however, that the pathway analyses discussed in the current study have been produced from 
gene lists created in the absence of stringent multiple test corrections and caution must 
therefore be taken when drawing conclusions from the work. None of the six genes investigated 
by RT-qPCR showed any changes in striatal expression as a result of performing a single session 
of SD training after reaching criteria in CRF. This suggests that striatal expression of these genes 
may not play an active role in the early acquisition of SD learning. It is possible that expression 
of these genes elsewhere in the brain may be necessary for early acquisition of the SD task. It is 
most likely that hippocampal transcription of these genes may alter following SD learning, based 
upon the wealth of evidence implicating the hippocampus as the neural region underpinning 
spatial learning (Silva et al., 1992b; Silva et al., 1992a; Bliss and Collingridge, 1993; McHugh et 
al., 1996; Tsien et al., 1996; Burgess et al., 2002) and evidence of altered hippocampal expression 
of multiple genes affecting, or resulting from, spatial learning (Aiba et al., 1994a; Guzowski et 
al., 2000; Mizuno et al., 2000; Guzowski et al., 2001; Vazdarjanova et al., 2002; Wood et al., 
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2005). Hippocampal expression of one of the genes examined by RT-qPCR, Arc, has previously 
been found to correlate with learning of the hippocampal-dependent spatial Morris water maze 
task following just one session of training (Guzowski et al., 2001). Based on this evidence, it is 
possible that the SD acquisition animals of the current study may exhibit increased levels of 
hippocampal Arc transcription in comparison to CRF maintenance animals. The hippocampus 
was extracted from animals in the current study, so it is possible that future analysis of this tissue 
may reveal such changes in gene expression levels. 
The genetic profile associated with late SD learning was investigated by comparing the striatal 
expression of SD acquisition and SD maintenance mice. When using a nominal p-value, this 
revealed significant changes in genes associated with cellular transport, specifically of anion and 
solute antiporter activity, as well as transcriptional regulation. It is well established that 
transcriptional regulation is associated with learning and memory (Izquierdo and Medina, 1997; 
Impey et al., 1998; Hall et al., 2000; Jones et al., 2001; Saura et al., 2004), which acts to 
strengthen the findings of the current study that the GO biological process of transcriptional 
regulation would be altered during acquisition of a spatial learning task. Some of the genes 
presenting with altered expression levels in the nominal p-value microarray list were also 
associated with transcriptional regulation through epigenetic mechanisms; however, this 
association did not reach significance. In support of this finding, and although the association 
did not reach levels of significance in the present study, epigenetic regulation of transcription 
has previously been found to play a role in learning and memory in a number of studies (Korzus 
et al., 2004; Guan et al., 2009; Stefanko et al., 2009; Barrett et al., 2011; McQuown et al., 2011), 
and it is possible that the association in question may have reached significance with a larger 
number of samples in each microarray comparison (n = 4 in the current study). As with early SD 
learning, there were no significant differences in expression levels identified for the six genes of 
interest examined by RT-qPCR between the SD acquisition and SD maintenance animals. This 
suggests that striatal transcription of the genes under investigation do not play a role in the late 
acquisition of a spatial learning task. It is possible that expression of these genes may influence, 
or be influenced by, spatial learning but that their striatal expression is not key to this form of 
learning, as previously suggested. Expression of the immediate early gene Arc within the 
hippocampus is known to be necessary for the consolidation of long term memory in the spatial 
Morris water maze task (Guzowski et al., 2000) and also correlates with learning of the task 
(Guzowski et al., 2001). Similarly, hippocampal expression of another immediate early gene, 
Bdnf, is also associated with hippocampus-dependent learning (Hall et al., 2000; Mizuno et al., 
2000). These studies indicate that examination of transcription within the hippocampal tissue of 
SD acquisition and maintenance animals in the current study may yield significant differences in 
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expression in Arc and Bdnf. Interestingly, similar upregulation of expression of both genes have 
been reported in the cortex of animals following hippocampus-dependent spatial learning (Park 
et al., 2011), which suggests that similar changes may be identified in the PFC tissue extracted 
from SD maintenance animals of the current investigation, in comparison to SD acquisition 
counterparts. Thus examining transcription in the other extracted neural regions, particularly 
the hippocampus, in the future may prove worthwhile. Alternatively, the lack of evidence for 
altered expression of either Arc or Bdnf within the striatum following late SD learning in the 
current study, in combination with evidence of hippocampal and cortical changes in 
transcription of both genes following spatial learning (Guzowski et al., 2000; Hall et al., 2000; 
Mizuno et al., 2000; Guzowski et al., 2001; Park et al., 2011), argues that striatal signalling of 
these genes does not form part of a neural network required for spatial learning. A number of 
studies have linked activation of the transcription factor CREB, through phosphorylation 
(Gonzalez and Montminy, 1989), in the hippocampus with a role in spatial learning and memory 
(Mizuno et al., 2002; Brightwell et al., 2004; Porte et al., 2008; Sekeres et al., 2010; Aguiar et al., 
2011; Chen et al., 2014) while long-term memory of a response strategy has previously been 
found to require CREB function in the dorsolateral striatum, independent of such activity in the 
dorsolateral hippocampus (Brightwell et al., 2008). From these studies, it was hypothesised that 
performance of the SD task to criterion would result in heightened levels of CREB expression in 
both the hippocampus and striatum. However, the data from the present study indicates that 
striatal Creb1 transcription does not alter across any time point of SD learning, potentially 
suggestive of an absence of a role of striatal CREB signalling in SD learning and seemingly 
contradicting this hypothesis. The aforementioned studies that examine CREB signalling did so 
using Western blotting to analyse protein levels of phosphorylated CREB, the activated form of 
the transcription factor, while the current study, on the other hand, analysed Creb1 transcription 
using RT-qPCR. The disparity in methodology between the current study and the published 
studies is likely to be a factor that contributes to the rejection of the CREB hypothesis outlined. 
By examining transcriptional levels of Creb1, the current study investigated the level of Creb1 
mRNA present but did not evaluate the levels of the activated protein, with the activated form 
of CREB being the integral factor in spatial learning and memory in the previously discussed 
papers. Hence, future work using Western blots to examine protein levels of CREB in the 
striatum and hippocampal tissue of animals in the current study would act to better test the 
previously outlined CREB signalling hypothesis. 
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4.4.3 RL task 
As previously discussed, there was a clear and anticipated effect of RL on accuracy levels, with 
high accuracy levels achieved across the final three days of SD training dropping to highly 
perseverative low accuracy performance on the first day of RL training. This demonstrates that 
mice still had a preference for the formerly rewarded hole in the initial RL session, similar to 
findings of other studies examining RL (Havekes et al., 2006; Izquierdo et al., 2006; Trinh et al., 
2012; Brigman et al., 2013). A subsequent rise in accuracy levels then occurred between the 
initial RL session and the final three sessions of RL training, as would be expected. Examining the 
number of sessions to reach criteria in the SD and RL tasks in the RL maintenance group revealed 
that mice required a similar number of sessions in order to fully acquire each task. This was 
somewhat unexpected, as previous studies investigating RL have reported a larger number of 
sessions being required to acquire the RL task than the original task (Izquierdo et al., 2006; 
Brigman et al., 2013). This should not lessen the validity of the task, as other studies have also 
reported wild-type animals requiring a comparable number of sessions to reach criteria in a RL 
task as the original task (Kruzich et al., 2006) or comparable levels of accuracy being attained by 
wild-type animals in the RL task as seen in the original task after a similar number of sessions 
(Havekes et al., 2006). 
Unexpectedly, when using an FDR p-value<0.05 the microarray investigation failed to find any 
genes that presented with altered expression levels between RL acquisition and RL maintenance 
animals, or between SD maintenance and RL acquisition mice. This seems to suggest that either 
no transcriptional changes occur between any of the distinct learning phases examined in the 
current study, which seems unlikely because of the strong association of gene expression levels 
and RL identified by numerous studies (Davies et al., 2005; Izquierdo et al., 2006; Mitchell et al., 
2007; Brigman et al., 2008; McDowell et al., 2010), or that the transcriptional changes that do 
occur were not identified as a result of the experimental design. As previously discussed, the use 
of a ‘top-down’ rather than a ‘bottom-up’ approach might contribute to the lack of significant 
changes identified in the microarray in the current study, as could the relatively small sample 
sizes in the microarray (n/group = 4). Another factor that may be instrumental in the lack of 
significant microarray findings is the method of striatal dissection. In the present study the 
striatum was dissected from each hemisphere as a whole entity, meaning that it was not 
microdissected into distinct regions. It is possible that microdissecting the striatum into dorsal 
and ventral regions may have yielded substantial gene expression level differences between 
such regions in the microarray. This might have been produced significant findings because it is 
known that distinct regions of the striatum play dissociable roles in learning (Reading et al., 
1991; Featherstone and McDonald, 2004; Reiss et al., 2005; Atallah et al., 2007; Darvas and 
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Palmiter, 2010, 2011; Darvas et al., 2014; Burton et al., 2015) and previous studies have 
identified significant differences in RL behaviour and gene expression levels when subdividing 
the striatum into similar distinct regions (Hernandez et al., 2006; Daberkow et al., 2007; 
Graybeal et al., 2011). Thus it is plausible that by extracting the striatum as a whole, any gene 
expression level differences that may arise between distinct regions of the striatum could be 
getting lost and made unidentifiable to the microarray and RT-qPCR investigations. Therefore, 
microdissecting the striatum into subregions may be a worthwhile endeavour in future genetic 
studies. Similarly, it is possible that the lack of tissue specificity, in terms of neuron population 
rather than region specificity, may be responsible for the lack of gene expression level 
differences between groups. A previous investigation into the molecular mechanisms of RL using 
in situ hybridisation has identified performance-related striatal neuron-specific alterations in Arc 
transcription levels (Daberkow et al., 2007). Specifically, Arc expression was found to be 
heightened in the preproenkephalin-negative striatonigral cells of the dorsomedial striatum of 
rats that required fewer trials to attain criteria in a RL task. Thus, the results of Daberkow and 
colleagues (2007) suggest that examining gene expression levels in specific striatal neuron 
populations, as opposed to the entire neuron population of the striatum examined in the 
present study, may have yielded significant results. A recent paper utilised 
immunohistochemistry to map regional expression of the immediate early gene c-Fos within the 
brain across a number of stages of visual discrimination and RL (Brigman et al., 2013). This also 
indicates that examining specific neuron populations or regional patterns of transcription in the 
current study may have yielded significant findings. The study by Brigman and colleagues (2013) 
examined behaviour and gene expression levels across the early and late phases of visual 
discrimination and RL, similar to the current study, but also inspected gene expression levels 
during a ‘mid’ phase of RL where session performance of animals was around chance levels 
(50%). Evidence of altered c-Fos expression levels in the dorsolateral striatum were reported 
between the early, mid and late phases of RL. It is possible that significant gene expression level 
differences were not reported in the present study because the changes in transcription 
required for RL occur outside of the learning stages examined, and that the inclusion of a mid-
stage RL group, as used by Brigman and colleagues (2013), may have identified such differences. 
The microarray identified 317 genes showing altered patterns of expression between the striata 
of SD maintenance and RL acquisition mice, when using a nominal p-value, and this group 
comparison acts as an indication of striatal gene expression level changes during early 
acquisition of RL. The mRNAs presenting with varied transcription during this learning phase 
were most highly associated with immune response, fibroblast growth factor signalling, 
extracellular space and protein modification, which suggests that these biological processes play 
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a role in early acquisition of RL. To my knowledge, the current study is the first microarray 
investigation into the distinct phases of RL in healthy wild-type animals, making a comparison of 
the present pathway analysis findings with previous work impossible. RT-qPCR exploration for 
the six genes under investigation revealed no significant differences in levels of striatal 
transcripts between the SD maintenance and RL acquisition animals, suggesting that changes in 
striatal expression of the genes evaluated are not required for early acquisition of a RL task. Drd2 
has been strongly linked with RL, with previous evidence indicating that transgenic mice lacking 
DRD2s are incapable of learning a new rule in an odour discrimination task (Kruzich et al., 2006) 
and that DRD2 antagonism through haloperidol treatment impairs RL of an attentional set-
shifting task in wild-type animals (Desteno and Schmauss, 2009). Based on these findings, one 
could expect to see an increase in striatal Drd2 expression following acquisition of a RL task. It is 
likely that such an increase in transcription was not apparent during early acquisition of RL 
because the RL acquisition group of animals showed high perseverance towards the original rule 
during the first RL session, therefore performing poorly in the RL task. Thus, with their low 
proficiency in the RL task, an increase in striatal Drd2 expression would not be expected, which 
was the case. Conversely, an investigation into the genetic basis of RL across 51 distinct strains 
of mice reported an inverse correlation between ventral mesencephalic and PFC Drd2 
expression and RL performance capabilities, where high expression of Drd2 was correlated with 
poor behavioural performance (Laughlin et al., 2011). This finding suggests that differences in 
PFC Drd2 expression levels should arise during early acquisition of the RL task, although this 
investigation has not been performed in the current study. With PFC Drd2 transcription levels 
being found to inversely correlate with RL performance (Laughlin et al., 2011), the highly 
perseverative RL acquisition group would be expected to display heightened Drd2 expression 
within the PFC, as they are not proficient in the RL task. Because of this, it may be of interest for 
future work to examine Drd2 transcription within the PFC tissue extracted in the present study. 
It is important to note that Laughlin and colleagues (2011) did not identify a correlation between 
striatal Drd2 levels and RL performance. Another gene that has been linked to RL is Bdnf, with a 
recent paper identifying an early RL acquisition impairment in a spatial memory task in mice 
with activity-dependent BDNF expression reduction (Sakata et al., 2013). Animals with 
hippocampal reduction of activity-driven BDNF expression performed significantly poorer than 
wild-type counterparts on the first RL session of the Morris water maze, a behavioural task 
assessing hippocampus-dependent spatial memory (Morris, 1981; D'Hooge and De Deyn, 2001). 
From this finding, one could hypothesise that mice with poor performance in the initial session 
of a spatially-driven RL task, such as the RL acquisition group in the current study, may present 
with decreased levels of Bdnf expression in the hippocampus compared to animals that had high 
accuracy in the previously learnt rule. The present study has not examined hippocampal 
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transcription of Bdnf; however, it may be of interest to do so in the future based on the 
hypothesis discussed. 
Pathway analyses reported that the mRNAs showing altered expression within the striatum as a 
result of late acquisition of the RL task, when using a nominal p-value, were most highly linked 
with a number of cellular signalling roles. The GO biological processes associated with late RL 
acquisition included plasma membrane, peptidyl-serine phosphorylation, calcium ion binding 
and protein domain specific binding. This indicates that acquisition of a RL task is dependent 
upon striatal cellular signalling, and again it is difficult to assess this finding in relation to 
published literature because the present study is the first microarray investigation into the 
genetic foundations of RL in healthy wild-type mice, to my knowledge. The six genes investigated 
by RT-qPCR showed comparable striatal expression levels between RL acquisition and RL 
maintenance mice, suggesting that these striatal mRNAs do not play a role in the late acquisition 
of RL. Based on the finding that transgenic inactivation of A2ARs in the striatum enhanced RL in 
mice (Wei et al., 2011), it was hypothesised that successful acquisition of RL in the present study 
would produce a decrease in striatal and PFC Adora2A expression. This hypothesis was rejected 
by both the microarray and RT-qPCR findings for striatal expression levels, with RL acquisition 
and maintenance animals showing comparable Adora2A transcription intensities, and there are 
a number of reasons why this may be the case. As discussed previously, it is possible that the 
‘top-down’ approach used to examine RL-dependent gene expression level differences in the 
current study is not capable of generating changes in transcription in wild-type animals that are 
large enough for detection by microarray or RT-qPCR. It is possible that changes in Adora2A 
expression may be detected in other regions of the brain, potentially in the PFC as knock-out of 
A2ARs in the entire forebrain also resulted in enhanced RL capabilities (Wei et al., 2011). This 
seems unlikely, however, as inactivation of A2ARs restricted to striatal neurons only was 
sufficient for the enhanced RL phenotype, suggesting that the striatal A2ARs are the cause of the 
RL behavioural modification and thus making it more likely that striatal expression of Adora2A 
would have altered. It is possible that the hypothesised changes in RL maintenance animals’ 
striatal Adora2A expression may have occurred in RL sessions between the early and late phases 
of RL acquisition but prior to sacrifice. Therefore, a subsequent increase in striatal A2AR protein 
levels may have arisen and comparison of these protein levels in the striatal tissue of RL 
acquisition and maintenance animals may be of future interest. Proficiency in the performance 
of a RL task has been found to correlate with striatal expression of the immediate early gene Arc 
(Daberkow et al., 2007) and disruption of this expression is capable of disrupting RL memory 
retention in rats (Pastuzyn et al., 2012). These studies suggest that Arc signalling is critical for RL 
and lead to the generation of the hypothesis that fully acquiring the RL task in the present study 
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would produce heightened Arc transcription within the striatum. However, Arc transcription 
within the striatum was statistically analogous between RL acquisition and RL maintenance 
mice, indicating that expression of this immediate early gene in the striatum does not correlate 
with RL task performance and contradicts the aforementioned findings. One potential reason 
for the contradictions between our findings and those previously reported is the difference in 
neural region specificity examined in the studies. The present study examined the striatum in its 
entirety while the work of Daberkow and colleagues (2007) and Pastuzyn and associates (2012) 
examined specific regions of the striatum, most notably the dorsomedial striatum. It is 
conceivable that examining transcription of the striatum in the dorsomedial and dorsolateral 
regions, or potentially dorsal and ventral regions because of the small size of the mouse brain, 
may have yielded significant differences in Arc expression. These hypothetical variations in 
expression may have arisen between subregions within the same group, dorsal versus ventral 
transcription profiles for example, or may have been generated between groups, with the 
dorsomedial striatum potentially showing altered expression between the RL acquisition and RL 
maintenance groups, for example, as suggested by Daberkow and colleagues (2007). The 
present study also examined all neuron types within the striatum, which may have led to 
confounding, as the original correlation between Arc and RL task ability was discovered not only 
overall in the dorsomedial striatum but also in specific preproenkephalin–negative cells within 
the striatum (Daberkow et al., 2007). Another variable that could contribute to the lack of 
correlation between the Arc expression findings of the current study and previous reports are 
the species of animal examined, with mice and rats investigated, respectively. Performance in a 
RL task has previously been inversely correlated with expression of Drd2 in the PFC (Laughlin et 
al., 2011), which raises the possibility that the RL maintenance animals in the current study may 
exhibit decreased Drd2 transcription in the PFC when compared with RL acquisition mice. This 
comparison has not yet been performed, but might be a worthwhile investigation in the future. 
 
4.4.4 Conclusions 
Healthy 22-24 weeks of age C57BL/6 mice were capable of performing the CRF, SD and RL tasks 
as anticipated, with animals able to attain criteria in all tasks and the expected differences in 
accuracy levels seen between behavioural groups. Unexpectedly, the microarray investigation 
revealed that 0 genes showed altered striatal transcriptional profiles across any of the 
behavioural group comparisons. This absence of significant gene expression level variation may 
be the result of striatal gene expression level changes that arise at the different stages of SD and 
RL in wild-type animals may not be of a high enough magnitude to be detected by a microarray 
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investigation. Conversely, a combination of the method of microdissection of the striatum, the 
choice of neural region examined and the behavioural stage at which transcription was 
evaluated could potentially contribute to the lack of significant transcriptional difference found. 
RT-qPCR analyses of learning and memory associated genes verified the microarray findings by 
reporting no significant differences in striatal expression levels between behavioural groups. 
 
4.4.5 Summary of key results from Chapter 4 
 C57BL/6 mice demonstrated the expected behavioural performance in CRF, SD and RL 
tasks. 
 Microarray investigation reported 0 genes exhibiting significant changes in striatal 
expression between any of the behavioural groups. 
 RT-qPCR analyses did not report significant variation in striatal expression of Adora2A, 
Arc, Bdnf, Creb1, Drd2 or Homer1 between any of the behavioural groups examined. 
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Chapter 5: Investigating the transcriptional correlates of spatial discrimination in the 
HdhQ150/+ mouse model of HD. 
Chapter 4 investigated the transcriptional basis of cognitive flexibility by examining changes in 
striatal gene expression levels across multiple stages of SD and RL in wild-type C57BL/6 animals. 
A microarray and RT-qPCR investigation were unable to identify striatal gene expression level 
changes significantly associated with performance of SD or RL tasks in the C57BL/6 mice. A lack 
of striatal dissection specificity was identified as a possible cause of the absence of significant 
gene expression level variation in the study. The present study aimed to further probe the 
transcriptional correlates of SD learning by investigating SD performance capabilities and striatal 
expression levels, of the genes investigated by RT-qPCR in chapter 4, in the HdhQ150/+ mouse 
model of HD, with increased striatal dissection specificity. 
 
5.1 Introduction 
The HD phenotype displays a variety of cognitive disturbances that include impairments in 
executive function (Lange et al., 1995; Lawrence et al., 1996; Lawrence et al., 1999; Aron et al., 
2003; Tabrizi et al., 2013), implicit learning (Heindel et al., 1989; Knopman and Nissen, 1991; 
Gabrieli et al., 1997; Kim et al., 2004), working memory (Tabrizi et al., 2011; Harrington et al., 
2012) and emotion recognition (Stout et al., 2012; Tabrizi et al., 2013). Another cognitive process 
that shows disruption in HD is that of spatial learning and memory, where patients have 
presented with spatial location learning impairments (Brandt et al., 2005; Pirogovsky et al., 
2015) and deficits in spatial memory (Lange et al., 1995; Lawrence et al., 2000; Davis et al., 2003) 
and perception (Soliveri et al., 2002). Similar deficits in spatial learning and memory have also 
been reported in mouse models of HD, with evidence of such impairments identified in HdhQ92 
(Brooks et al., 2012a), HdhQ111 (Giralt et al., 2012), R6/1 (Pang et al., 2006; Smith et al., 2006; 
Giralt et al., 2011b; Brooks et al., 2012e), R6/2 (Lione et al., 1999; Murphy et al., 2000) and 
YAC128 animals (Brooks et al., 2012c). Similarly, homozygous HdhQ150 mice have previously 
displayed spatial learning impairments, as shown by having progressively slower improvement 
in response latencies as trial numbers increased in the Morris water maze, from 16 weeks of age 
compared to wild-type animals (Brooks et al., 2012b). 
There is evidence linking gene expression level changes with spatial learning and memory 
capabilities, and the genes investigated by RT-qPCR in Chapter 4 of this thesis (Adora2a, Arc, 
Bdnf, Creb1, Drd2 and Homer1) have been associated with such cognitive processes, with this 
evidence highlighted in Chapter 4.1 and 4.4.2. Chapter 4 examined the neural basis of SD and 
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cognitive flexibility in C57BL/6 mice using a microarray and RT-qPCR investigation and, 
surprisingly, there was no evidence of striatal transcriptional correlates of SD or RL at any of the 
learning stages examined (see Chapter 4.3). Despite this lack of learning-dependent changes in 
expression of the genes investigated, these genes are of interest in the current study because 
they have all previously been implicated in HD pathogenesis. For example, Adora2A is implicated 
in HD because the A2ARs produced by this gene are localised within the brain to striatopallidal 
MSNs that degenerate in HD (Schiffmann et al., 1991a; Schiffmann et al., 1991b) and are lost 
throughout the course of the disease because of this striatal neurodegeneration (Martinezmir 
et al., 1991; Glass et al., 2000). Similar decreases in striatal A2AR levels have also been reported 
in the R6/1 mouse model of HD (Villar-Menendez et al., 2013). An association of Adora2A 
expression with the HD phenotype has been established within the human condition and animal 
models of the disease, whereby reduced levels of striatal ADORA2A mRNA transcripts were 
reported in post-mortem tissue extracted from HD patients and similar differences in Adora2A 
expression levels identified in R6/1, R6/2, HdhQ92/Q92 and HdhQ150/Q150 mice (Hodges et al., 2006; 
Kuhn et al., 2007). As previously mentioned, all the genes investigated in Chapter 4 and under 
investigation in the current study have previously been implicated in HD pathogenesis, the key 
findings of which have been summarised in Table 5.1. 
 
Gene name Gene 
symbol 
Finding Species Study 
Adenosine 
A2A 
receptor 
Adora2A 
1) A2ARs are expressed in 
striatopallidal MSNs in the 
striatum. 
2) Within the brain, ADORA2A 
mRNA is exclusively located in 
MSNs of the striatum. 
3) Early HD neuropathology causes 
massive loss of A2AR levels due to 
striatopallidal MSN degeneration. 
4) Striatal A2AR density is 
transiently increased in R6/2 mice 
at postnatal days 7-21 while 
Adora2A mRNA levels are 
decreased from postnatal day 21. 
5) Adora2A expression levels are 
decreased in the striata of HD 
patients and R6/1, R6/2, HdhQ92/Q92 
and HdhQ150/Q150 mice. 
7) A2AR knockout worsens motor 
behaviour and survival in N171-
82Q mice. 
8) A2AR levels are decreased in 
R6/2 mice from 12 weeks of age. 
Rat 
 
 
Human 
 
 
Human 
 
 
Mouse 
 
 
 
 
Human 
& 
Mouse 
 
Mouse 
 
 
Mouse 
 
(Schiffmann et 
al., 1991a) 
 
(Schiffmann et 
al., 1991b) 
 
(Glass et al., 
2000) 
 
(Tarditi et al., 
2006) 
 
 
 
(Hodges et al., 
2006; Kuhn et 
al., 2007) 
 
(Mievis et al., 
2011) 
(Villar-
Menendez et 
al., 2013) 
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9) Hyperactivation of A2ARs and 
DRD1s contributes to deficits in 
novel object recognition, 
spontaneous alternation, and 
passive avoidance task 
performance in R6/1 mice. 
10) Inactivation of A2ARs prevents 
working memory deficits in R6/2 
mice. 
 
Mouse 
 
 
 
 
 
Mouse 
 
(Tyebji et al., 
2015) 
 
 
 
 
(Li et al., 2015) 
 
Activity-
regulated 
cytoskeleton
-associated 
protein 
Arc 
1) Following Morris water maze 
training, HdhQ111/+ mice present 
with decreased expression levels of 
Arc mRNA in the hippocampus 
compared to wild-type animals. 
2) Arc localises with nuclear 
aggregates in R6/2 mouse brain. 
Mouse 
 
 
 
 
Mouse 
 
(Giralt et al., 
2012) 
 
 
 
(Maheshwari 
et al., 2012) 
 
Brain-
derived 
neurotrophic 
factor 
 
Bdnf 
1) HTT-mediated BDNF 
transcription is lost in HD. 
2) HTT-mediated upregulation of 
BDNF transcription through 
inhibition of the silencing activity 
of the neuron restrictive silencer 
element is lost in HD. 
3) HD causes loss of HTT-mediated 
BDNF transport along 
microtubules. 
4) Decreased BDNF levels reported 
in R6/2 mice, and BDNF rescue 
ameliorates disease phenotype. 
5) Decreased BDNF levels reported 
in R6/1 mice, and BDNF delivery 
ameliorates disease phenotype. 
6) BDNF levels are reduced in the 
serum of HD patients. 
7) Decreased BDNF levels reported 
in HdhQ92 and HdhQ111 mice, and 
BDNF delivery ameliorates disease 
phenotype. 
8) BDNF levels are reduced in the 
cortex of HD patients. 
9) BDNF delivery ameliorates LTP 
and long-term memory deficits in 
HdhQ140 mice. 
10) Decreased BDNF levels 
reported in YAC128 mice, and 
BDNF overexpression ameliorates 
disease phenotype. 
11) Peripheral BDNF mRNA & 
plasma protein levels are not 
reliable HD biomarkers. 
12) Decreased BDNF levels 
reported in zQ175 mice.  
Human 
 
Human 
& 
Mouse 
 
 
Human 
& 
Mouse 
Mouse 
 
 
Mouse 
 
 
Human 
 
Mouse 
 
 
 
Human 
 
Mouse 
 
 
Mouse 
 
 
 
Human 
 
 
 
Mouse 
(Zuccato et al., 
2001) 
(Zuccato et al., 
2003) 
 
 
 
(Gauthier et 
al., 2004) 
 
(Zuccato et al., 
2005; Giralt et 
al., 2011a) 
(Pang et al., 
2006; Gharami 
et al., 2008) 
(Ciammola et 
al., 2007) 
(Lynch et al., 
2007) 
 
 
(Zuccato et al., 
2008) 
(Simmons et 
al., 2009) 
 
(Xie et al., 
2010) 
 
 
(Zuccato et al., 
2011) 
 
(Ma et al., 
2015) 
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cAMP 
response 
element-
binding 
protein 1 
Creb1 
1) Striatal cells derived from 
HdhQ111/Q111 mice exhibit abnormal 
Creb1 activity. 
2) CREB1 is significantly 
upregulated in white adipose tissue 
of HD patients. 
Mouse 
 
 
Mouse 
 
 
(Benn et al., 
2008b) 
 
(McCourt et 
al., 2015) 
 
Dopamine 
D2 receptor 
 
Drd2 
1) Decreased DRD2 binding in the 
striatum of asymptomatic and 
symptomatic HD patients. 
2) Decreased DRD2 binding in the 
striatum of asymptomatic HD 
patients. 
3) Correlation between loss of 
striatal DRD2 density and duration 
of illness in HD patients. 
4) D1DR, D2DR and dopamine 
transporter density are predictive 
of cognitive deficits in HD. 
5) Striatal DRD2 mRNA 
progressively decreases with 
increasing HD pathology. 
6) Striatal DRD2 binding levels 
correlate with cognitive ability in 
HD patients. 
7) Asymptomatic and symptomatic 
HD patients present with a 
progressive loss of DRD2 binding 
levels. 
8) Early HD neuropathology causes 
massive loss of DRD2 levels due to 
striatopallidal MSN degeneration. 
9) Progressive loss of DRD2s in the 
striatum, and temporal and frontal 
cortex in HD patients. 
10) Reduced striatal Drd2 
expression levels in R6/1, R6/2, 
HdhQ92/Q92, HdhQ150/Q150 mice and 
HD patients. 
11) Decreased DRD2 levels in 
striatal primary neuron model of 
HD. 
12) Reduced striatal Drd2 
expression levels in YAC128 but not 
BACHD mice.  
Human 
 
 
Human 
 
 
Human 
 
 
Human 
 
 
Human 
 
 
Human 
 
 
Human 
 
 
 
Human 
 
 
Human 
 
 
Human 
& 
Mouse 
 
Human 
 
 
Mouse 
(Antonini et 
al., 1996) 
 
(Weeks et al., 
1996) 
 
(Ginovart et 
al., 1997) 
 
(Backman et 
al., 1997) 
 
(Augood et al., 
1997) 
 
(Lawrence et 
al., 1998a) 
 
(Andrews et 
al., 1999) 
 
 
(Glass et al., 
2000) 
 
(Pavese et al., 
2003) 
 
(Kuhn et al., 
2007) 
 
 
(Runne et al., 
2008) 
 
(Pouladi et al., 
2012) 
Homer 
scaffolding 
protein 1 
Homer1 
12) Reduced striatal expression 
levels of Homer1 in R6/1, R6/2, 
HdhQ92/Q92, HdhQ150/Q150 mice and 
HD patients. 
Human 
& 
Mouse 
 
(Kuhn et al., 
2007) 
Table 5.1. A summary of research relating to the HD phenotype for the genes examined by RT-
qPCR in the current study. 
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The current study originally planned to examine cognitive flexibility in the HdhQ150/+ mouse 
model of HD but, due to the need for larger animal numbers in each group, the RL element of 
the study was removed in order to enable simplification of the study, allowing the study to 
address the learning where gene expression level changes were most likely to be evident. The 
current study was simplified in order to contain a larger number of animals of each genotype in 
two behavioural groups; untrained animals and animals trained to criteria in the SD task 
described in Chapter 4.2.3.3. Thus, the present study aimed to investigate the SD capacities of 
the heterozygous HdhQ150 mouse model of HD, if any differences in striatal expression levels 
arise between HdhQ150/+ and Hdh+/+ animals for any of the genes discussed here, and whether 
potential gene expression level differences correlate with SD task performance. Based upon the 
previous investigations into HD pathogenesis and the genes under investigation in the current 
study (summarised in Table 5.1), it is anticipated that striatal expression levels of all genes 
investigated will be reduced in HdhQ150/+ mice. The lack of evidence for SD performance 
associated changes in mRNA levels for the genes under investigation in C57BL/6 mice, identified 
in Chapter 4, suggests that SD task performance may not correlate with expression levels of 
these genes in the current study. The lack of specificity of striatal dissections was raised as a 
potential reason for the lack of gene expression level changes identified in Chapter 4, therefore 
the present study aimed to address this hypothesis by microdissecting the striatum into dorsal 
and ventral striatal regions for RT-qPCR analyses. Increasing sample numbers and dissection 
specificity, compared to those performed in Chapter 4, may therefore lead to SD task 
performance correlating with gene expression levels. It is important to note that the 
investigation performed in Chapter 4 only examined gene expression levels in wild-type C57BL/6 
mice, while the current study is examining transcription levels in both wild-type and HdhQ150/+ 
animals. Thus, it is possible that the HD genotype examined in the present study may present 
with SD task performance that correlates with striatal expression levels of the genes under 
investigation. 
 
5.2 Methods 
5.2.1 Subjects 
Fifty-eight naïve male mice (genotypes: HdhQ150/+ (n = 28) and Hdh+/+ littermates (n = 30) on a 
C57BL/6J background) were housed 1-5 animals per cage and animal husbandry was as 
described in Chapter 2.1.2. HdhQ150/+ CAG repeat sequences ranged from 117 to 140 CAGs 
(Mean: 130.83 ± 6.20). All animals were between 44 and 52 weeks-of-age at the start of testing, 
and were water restricted throughout testing, as described in Chapter 2.1.2.  
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5.2.2 Experimental design 
Animals of both genotypes were randomly allocated into 1 of 2 behavioural training groups: 
untrained or SD. An equal number of animals of either genotype were placed in the two 
behavioural groups (HdhQ150/+: untrained (n = 14) and SD (n = 14); Hdh+/+: untrained (n = 15) and 
SD (n = 15)). The motor ability of all animals (n = 58) was examined by rotarod (see Chapter 
5.2.3.1) 1 week prior to operant testing. Animals that were to undergo SD training (n = 29) 
performed an initial session of magazine training, as described in Chapter 4.2.3.1. Following this 
initial magazine training, mice were trained to criteria in the CRF task as described in Chapter 
5.2.3.4. Upon reaching criteria in the CRF task, animals performed the SD task until reaching 
criteria, as described in Chapter 5.2.3.5, before sacrifice and tissue extraction.  
Individual untrained animals were paired to a SD trained counterpart of the same genotype 
throughout operant testing, whereby an untrained mouse would receive an equivalent number 
of food rewards in a session as its SD trained counterpart received. This occurred as described 
in Chapter 5.2.3.2, and untrained mice were sacrificed after performing the same number of 
operant sessions as their SD trained counterpart. 
 
5.2.3 Behavioural training protocols 
5.2.3.1 Rotarod 
For the duration of testing mice had ad libitum access to food and water, except during the 300 
s rotarod sessions where there was no access to food or water. Mice performed an initial 
habituation session consisting of cycles of 30 s of maintained rotation speed followed by 15 s of 
linear acceleration across 300 s. This habituation session was followed by sessions in which rod 
speed rotation accelerated linearly from 5 to 50 rpm across 300 s. Sessions were performed 
once a day until the motor ability of both genotypes plateaued across two consecutive sessions 
(five sessions). Motor ability was examined across the final two sessions. Latency to first fall was 
recorded in each session and was the measure of motor ability. After each fall, mice were placed 
back onto the rotarod until the end of the session.  
 
5.2.3.2 Untrained food reward delivery program 
Untrained animals (HdhQ150/+: n=14; Hdh+/+: n=15) received no behavioural training, per se, but 
were paired to a same-genotype littermate in the SD group, whereby untrained animals received 
147 
 
an equivalent number of rewards in each session as their SD trained counterpart received in the 
previous session. Animals underwent an initial magazine training session, where 150 µL of 
reward was delivered at the onset of the 20 min session and upon removal of the head from the 
magazine, a 10 s delay would occur before another 5 µL of reward delivered. This reward 
contingency was maintained for the remainder of the session.  
Reward delivery in subsequent operant sessions was determined by the performance of their 
SD counterpart. Reward delivery occurred in the absence of magazine light illumination in all 
sessions, to ensure that no association was made between the magazine light and food reward. 
 
5.2.3.3 Magazine training 
SD animals (HdhQ150/+: n=14; Hdh+/+: n=15) underwent 1 session of magazine training in order to 
permit the mice to learn the association between magazine light illumination and food reward. 
The magazine light was illuminated and 150 µL of reward was delivered at the onset of the 20 
min session. Upon removal of the head from the magazine, the light would extinguish for 10 s 
before again illuminating and 5 µL of reward delivered. This reward contingency was maintained 
for the remainder of the session.  
 
5.2.3.4 CRF task 
Mice performed CRF training as described in Chapter 3.2.4.2. Criterion in the task was set at ≥50 
np in three consecutive sessions for the current study. Animals performed the task until criteria 
was met, at which point mice began the next phase of behavioural training; the SD task. 
 
5.2.3.5 SD task 
Mice performed SD training as described in Chapter 4.2.3.3. Training performance on this task 
was calculated as percent accuracy (((correct choices)/(correct choices + incorrect choices)) x 
100). Criterion was judged to be met when a minimum of 85% accuracy was reached in three 
consecutive sessions. Seven error terms were examined during SD performance, with each 
capable of identifying different behavioural traits, as described in Chapter 3.2.4.4. Animals 
performed the task until criteria was met, at which point mice were sacrificed and tissue taken 
for dissection.  
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5.2.4 Molecular methodology 
5.2.4.1 RNA extraction 
RNA was prepared from dorsal and ventral striata following the protocol outlined in Chapter 
2.3.1. Quantity and quality of RNA was assessed on a NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific Inc., Massachusetts, USA).  
 
5.2.4.2 Quantification of gene expression levels by RT-qPCR 
Striatal RNA was converted to cDNA using a High Capacity RNA to cDNA™ kit (Life Technologies 
Corporation, California, USA) as outlined in Chapter 2.3.2.1 before Taqman® mediated qPCR was 
performed using the protocol described in Chapter 2.3.2.2. The genes to be investigated were 
those examined in Chapter 4, and are listed in Table 5.2. 
Gene name Gene symbol ID 
beta actin Actb Mm00607939_s1 
adenosine A2A receptor Adora2A Mm00802075_m1 
activity-regulated cytoskeletal-associated 
protein 
Arc Mm01204954_g1 
brain derived neurotrophic factor Bdnf Mm04230607_s1 
cAMP responsive element binding protein 1 Creb1 Mm00501607_m1 
dopamine receptor D2 Drd2 Mm00438545_m1 
homer scaffolding protein 1 Homer1 Mm00516275_m1 
ubiquitin C Ubc Mm02525934_g1 
Table 5.2. Identification codes for Taqman® oligonucleotide probes used in the current study. 
 
5.2.5 Statistical analyses 
Statistical analyses were performed using IBM SPSS® Statistics software (Version 20; IBM United 
Kingdom Ltd, Hampshire, UK). Behavioural was analysed by independent samples t-tests, with 
Holm-Bonferroni sequential correction used for multiple hypothesis testing correction. RT-qPCR 
data was analysed by a three-way ANOVA, with genotype (Hdh+/+ or HdhQ150/+), training 
(untrained or SD) and striatal region (dorsal or ventral) as independent variables. Specific two-
group comparisons were analysed by independent samples t-tests, with Holm-Bonferroni 
sequential correction used for multiple hypothesis testing correction. The assumption of 
149 
 
Sphericity of data was assessed using Mauchly’s test of Sphericity, with the Greenhouse-Geisser 
correction used if the assumption of Sphericity was violated and the Greenhouse-Geisser 
estimate of sphericity (ɛ) < 0.75. If the assumption of Sphericity was violated and ɛ > 0.75, the 
Huynh-Feldt correction was used. Similarly, homogeneity of variances for data was assessed 
using Levene’s test, and the Welch test used in the event of data violating this assumption. 
 
5.3 Results 
5.3.1 Behavioural results 
5.3.1.1 Rotarod 
To assess the motor capabilities of HdhQ150/+ animals, mice underwent rotarod training prior to 
operant behavioural training. An independent samples t-test reported no significant difference 
in the mean fall latency between Hdh+/+ and HdhQ150/+ animals (Fig. 5.1; t(56) = 0.069, p = 0.945). 
 
 
 
 
 
 
 
 
Figure 5.1. Motor ability of Hdh+/+ and HdhQ150/+ animals, as assessed on the rotarod. Hdh+/+ (n 
= 30) and HdhQ150/+ (n = 28) mice showed comparable motor ability on the rotarod prior to 
operant training. Values shown are mean ± S.E.M. 
 
5.3.1.2 CRF task 
Examining the mean number of sessions to criteria in the CRF task revealed that HdhQ150/+ mice 
required a greater number of sessions to reach the designated criteria than Hdh+/+ mice (Fig. 
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5.2A; t(27) = -3.301, p = 0.003). In the final 3 days of CRF training, HdhQ150/+ mice performed 
significantly fewer np per session than their wild-type counterparts (Fig. 5.2B; t(27) = 2.807, p = 
0.009). Conversely, examination of the total number of trials performed across all sessions until 
criteria was reached revealed no difference in performance between genotypes (Fig. 5.2C; t(27) 
= -1.026, p = 0.314). Averaging the total number of np made across all sessions until criteria was 
met identified that HdhQ150/+ mice made, on average, significantly fewer CRF responses in each 
session throughout the entirety of FR1 training (Fig. 5.2D; t(27) = 3.025, p = 0.005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. Behavioural performance in the CRF task. HdhQ150/+ (n = 14) animals took a greater 
number of sessions to reach criteria (A) in the CRF task, and also made fewer responses in the 
final 3 sessions before criteria was met than their wild-type (n = 15) counterparts (B). No 
difference was reported in the total number of trials performed throughout CRF training (C), 
while HdhQ150/+ mice made a significantly lower mean number of np across all CRF sessions (D). 
Values are means ± S.E.M. 
** p < 0.01             
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5.3.1.3 SD task 
HdhQ150/+ mice required a significantly greater number of sessions to reach criteria in the SD task 
in comparison to their wild-type counterparts (Fig. 5.3A; t(15.235) = -2.936, p = 0.010). 
Conversely, mean accuracy over the final 3 test sessions was comparable between genotypes 
(Fig. 5.3B; t(27) = -0.902, p = 0.375). Likewise, mean accuracy when examined across all sessions 
until criteria was met was analogous between HdhQ150/+ and Hdh+/+ animals (Fig. 5.3C; t(27) = 
1.471, p = 0.153).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. SD performance in HdhQ150/+ and Hdh+/+ mice. HdhQ150/+ mice (n = 14) required a 
greater number of sessions to reach criteria in the SD task than Hdh+/+ mice (n = 15) (A). However, 
the mean accuracy of HdhQ150/+ and Hdh+/+ mice were equivalent when examined in the final 3 
SD sessions (B) and across all SD sessions (C). Values shown are mean ± S.E.M. 
* p < 0.05 
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Genotypes showed a difference in the mean number of centre hole S1 np made over the final 3 
SD sessions (t(27) = 2.363, p = 0.026), with HdhQ150/+ mice initiating fewer S2 trials than Hdh+/+ 
mice (Fig. 5.4A). On the other hand, investigating the total number of S2 trials initiated across 
all SD sessions revealed no difference in the total number of S1 np made between genotypes 
(Fig. 5.4B; t(27) = -1.020, p = 0.317). When the total number of correct S1 np were averaged 
across the number of sessions required to reach criteria, to give the mean number of S2 trials 
initiated across all SD sessions, Hdh+/+ mice were found to initiate a greater amount of S2 trials 
than HdhQ150/+ animals (Fig. 4C; t(19.587) = 2.822, p = 0.011). The equivalent number of total S2 
trial initiation across all SD sessions between genotypes (Fig. 5.4B) is therefore a result of the 
HdhQ150/+ animals performing fewer S2 trial initiations per session across a greater number of 
sessions, in order to reach criteria in the task, cancelling out the higher number of S2 trials 
initiated by Hdh+/+ animals in fewer sessions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. S2 trial initiation in the SD task. HdhQ150/+ animals (n = 14) initiated significantly fewer 
S2 trials over the final 3 sessions of SD training than their wild-type (n = 15) counterparts (A). 
0
10
20
30
40
50
60
N
u
m
b
e
r 
o
f 
tr
ia
ls
 (
n
)
S2 trials initiated over final 3 sessions
* 
A. 
0
100
200
300
400
500
N
u
m
b
e
r 
o
f 
tr
ia
ls
 (
n
)
Total number of S2 trials initiatedB. 
0
10
20
30
40
50
N
u
m
b
e
r 
o
f 
tr
ia
ls
 (
n
)
S2 trials initiated across all sessions
* 
C. 
153 
 
This impairment was not observed in the total number of S2 trials initiated across all SD sessions 
(B). However, when the mean number of S2 trials initiated per SD session, for all sessions, was 
examined the deficit in trial initiation was again apparent (C). Values shown are means ± S.E.M. 
* p < 0.05 
 
An independent samples t-test revealed HdhQ150/+ subjects showed significantly delayed 
latencies in responding to the correct S2 stimulus (Table 5.3; t(19.907) = -2.992, p = 0.007) and 
S1 stimulus (Table 5.3; t(27) = -2.932, p = 0.007). However, genotypes presented with equivalent 
response latencies when collecting food reward (Table 5.3; t(27) = -1.895, p = 0.069).  
 
Response latency Hdh+/+ HdhQ150/+ 
Correct response 
reaction time (s) 
  1.93 ± 0.32 ** 3.97 ± 0.60 
Correct S1 response 
time (s) 
  3.41 ± 0.16 ** 4.20 ± 0.22 
Reward collection 
latency (s) 
1.26 ± 0.09 1.48 ± 0.08 
 
Table 5.3. Response latencies of HdhQ150/+ and Hdh+/+ animals during the final 3 sessions of SD 
training. Delayed latencies in correct responses to both S1 and S2 stimuli were reported in 
HdhQ150/+ animals (n = 14) compared to wild-type animals (n = 15), however there were no 
significant differences between genotypes in response times when collecting food reward. 
Values shown are means ± S.E.M. 
** p < 0.01 
 
Seven error terms were investigated and are summarised in Table 5.4. An independent t-test 
identified wild-type animals as performing a significantly greater percentage and proportion of 
incorrect and perseverant responses during S1 presentation, respectively (Table 5.4; t(27) = 
2.277, p = 0.031 and t(27) = 2.101, p = 0.045, respectively), than HdhQ150/+ animals. However, 
during S1 presentation there was no evidence of altered error rates between genotypes in the 
number of incorrect magazine entries made (Table 5.4; t(23.396) = 1.679, p = 0.106). During S2 
presentation HdhQ150/+ and Hdh+/+ mice were found to have made an equivalent percentage of 
incorrect choices (Table 5.4; t(27) = 0.917, p = 0.367), and rate of incorrect magazine entries 
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(Table 5.4; t(27) = -1.162, p = 0.255) and perseverant responses (Table 5.4; t(27) = -1.196, p = 
0.242). Both genotypes also made a comparable percentage of responses during TOIs (Table 5.4; 
t(17.630) = -0.712, p = 0.486). 
 
 
 
 
 
 
Table 5.4. Error terms of HdhQ150/+ and Hdh+/+ animals during the final 3 sessions of SD training. 
Hdh+/+ mice (n = 15) were found to produce a higher number of incorrect and perseverant 
responses to S1 presentation than their HdhQ150/+ (n = 14) counterparts. No other error term 
showed significant differences between genotypes. Values shown are means ± S.E.M. 
* p < 0.05 
a Error rates as a percentage of the total number of S1 trials initiated. 
b Error rates as a percentage of the total number of S2 trials initiated. 
c Error rates per S1 trial initiated. 
d Error rates per S2 trial initiated. 
e Error rates per incorrect S2 trial. 
 
5.3.2 Molecular results 
5.3.2.1 Investigation of candidate gene expression levels by RT-qPCR 
A three-way ANOVA was performed on data gathered from the RT-qPCR investigating dorsal and 
ventral striatal gene expression levels between untrained or SD trained heterozygous HdhQ150 
animals and their wild-type littermates, and is summarised in Table 5.5. HdhQ150/+ mice 
presented with lower striatal expression levels for Adora2A (main effect of genotype: F1, 32 = 
11.559, p = 0.002), Arc (main effect of genotype: F1, 32 = 12.576, p = 0.001), Drd2 (main effect of 
genotype: F1, 32 = 8.525, p = 0.006) and Homer1 (main effect of genotype: F1, 32 = 12.981, p = 
0.001) compared to their wild-type counterparts while no difference in striatal expression levels 
was identified between genotypes for Bdnf (main effect of genotype: F1, 32 = 0.835, p = 0.368) or 
Creb1 (main effect of genotype: F1, 32 = 0.805, p = 0.376). Investigating specific two group 
Error rates of specific error 
types 
Hdh+/+ HdhQ150/+ 
Incorrect choice in S1a   36.18 ± 1.70 * 30.02 ± 2.13 
Incorrect choice in S2b 7.55 ± 0.59 6.50 ± 1.01 
Magazine poke in S1c 0.14 ± 0.02 0.11 ± 0.01 
Magazine poke in S2d 0.13 ± 0.02 0.19 ± 0.04 
Perseverant nose poke to S1c    0.17 ± 0.02 * 0.11 ± 0.02 
Perseverant nose poke to S2d 0.05 ± 0.01 0.07 ± 0.01 
Hole poke in TOIe 15.53 ± 1.80 18.79 ± 4.21 
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comparisons by independent samples t-tests revealed significantly decreased expression levels 
of Homer1 in the ventral striatum of untrained HdhQ150/+ mice compared to the mRNA transcripts 
in the ventral striatum of their untrained wild-type counterparts (Fig. 5.5; t(8) = -4.462, p = 
0.012). All other two group comparisons investigating genotype-dependent changes in gene 
expression levels failed to report significant differences between genotypes in any gene under 
investigation (Appendix 1.1-1.5). 
Gene of 
interest 
Genotype Training Striatal region 
F1, 32 =  p-value F1, 32 =  p-value F1, 32 =  p-value 
Adora2A 11.559 0.002** 0.303 0.586 3.445 0.073 
Arc 12.576 0.001** 0.051 0.822 6.553 0.015* 
Bdnf 0.835 0.368 0.458 0.503 4.403 0.044* 
Creb1 0.805 0.376 0.263 0.612 2.737 0.108 
Drd2 8.525 0.006** 0.839 0.367 6.358 0.017* 
Homer1 12.981 0.001** 0.822 0.371 0.033 0.857 
Table 5.5. Statistical values of the three-way ANOVA examining potential differences in striatal 
gene expression levels as a result of genotype, training and striatal region from which RNA 
was dissected. 
 
 
 
 
 
 
 
 
Figure 5.5. RQ values of Homer1 genotype-dependent expression levels in the ventral striatum 
of untrained mice. Untrained HdhQ150/+ animals present with significantly decreased levels of 
Homer1 transcription levels in the ventral striatum compared to untrained wild-type 
counterparts. Data shown is mean fold change ± S.E.M.; n = 5/group. 
* p < 0.05 
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The level of training (untrained or trained to criteria in SD) undertaken by animals did not 
present with significant influence on striatal expression levels of any gene investigated in the 
three-way ANOVA (Table 5.5). Similarly, independent samples t-tests examining training-
dependent alterations in striatal transcription levels in specific two group comparisons revealed 
no significant changes in expression levels of any gene in any comparison made (Appendix 1.6-
1.10). 
Expression levels of Arc and Drd2 were elevated in the dorsal striatum in comparison to the 
ventral striatum (main effect of striatal region: F1, 32 = 6.553, p = 0.015; and main effect of striatal 
region: F1, 32 = 6.358, p = 0.017, respectively) whereas the opposite was true for Bdnf (main effect 
of striatal region: F1, 32 = 4.403, p = 0.044). The remaining genes investigated showed no 
differences in expression levels based on the striatal region investigated (Table 5.5). Examining 
two group comparisons where the striatal region investigated was the only variable between 
groups, by independent samples t-tests, revealed no significant differences in expression levels 
of any gene studied (Appendix 1.11-1.15). 
A significant interaction between the effects of genotype and training was identified for Homer1 
striatal expression levels (genotype*training: F1, 32 = 8.098, p = 0.008), while no other interaction 
was found to be significant in any of the genes investigated (Appendix 1.16). 
 
5.4 Discussion 
Chapter 4 of this thesis did not identify any learning-dependent gene expression level changes 
in the striatum of C57BL/6 mice at several distinct stages of SD and RL. As a result of this, the 
design of the present study was simplified in order to examine the genotype- and learning-
dependent gene expression level correlates of SD, without the RL component of Chapter 4, in 
HdhQ150/+ mice alongside the SD behavioural abilities of this mouse model. Rotarod assessment 
of heterozygous HdhQ150 animals and their wild-type counterparts revealed heathy motor 
capabilities in this mouse model of HD at 44-52 weeks of age. In the CRF task, HdhQ150/+ animals 
presented with impaired acquisition and made significantly fewer correct responses per session 
compared to wild-type animals. HdhQ150/+ animals also required a greater number of sessions to 
reach criteria in the SD task than Hdh+/+ animals, suggestive of a SD acquisition impairment, but 
displayed equivalent levels of SD accuracy. RT-qPCR analyses revealed decreased expression 
levels of Adora2A, Arc, Drd2 and Homer1 in the striatum of HdhQ150/+ mice when compared to 
wild-type animals, which is consistent with previous investigations into gene expression level 
changes in HD (Table 5.1). SD task performance was found to have no effect on the expression 
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levels of any of the genes under investigation in the current study, in either genotype, supporting 
the findings of Chapter 4. mRNA levels of Arc and Drd2 were found to be increased in the dorsal 
striatum in comparison to the ventral striatum, while expression levels of Bdnf were decreased 
in the dorsal striatum. However, dorsal and ventral striatal expression levels did not differ in any 
of the specific two-group comparisons made in the current study, which rejects the hypothesis 
proposed in Chapter 4.4; that the lack of gene expression level changes between behavioural 
groups was the result of a lack of specificity of striatal tissue dissection. 
 
5.4.1 Effects of Huntington’s disease genotype on behavioural performance 
The rotarod assessment of the motor ability of animals reported no significant differences in the 
mean fall latency between genotypes. This indicates that HdhQ150/+ mice present with normal 
motor capabilities at 44-52 weeks of age, which is supported by previous evidence of equivalent 
motor performance in HdhQ150/+ and wild-type animals up to 100 weeks of age (Heng et al., 
2007). This evidence suggests that any behavioural abnormalities that may arise in the HdhQ150/+ 
mice in the current study are not the result of impaired motor capabilities, as these animals 
presented with healthy motor capabilities prior to operant testing and a previous study has 
reported continuation of these normal motor abilities past the time point in the mouse lifetime 
at which operant testing was performed in the current study (Heng et al., 2007). 
In the CRF task, HdhQ150/+ animals required a significantly greater number of sessions to reach 
criteria than their wild-type counterparts, and also made significantly fewer correct responses 
per session during the final 3 sessions until criteria was reached and across all CRF sessions than 
Hdh+/+ mice. These findings suggest that heterozygous HdhQ150 mice present with delayed 
acquisition and impaired performance of a continuously reinforced response from 44-52 weeks 
of age, and is the first report of such a deficit in the HdhQ150/+ mouse model of HD, to my current 
knowledge. This delayed acquisition and impaired performance in the CRF task may be indicative 
of an impairment in cognitive abilities or potentially a motivational deficit. CRF task performance 
impairments were not identified in HdhQ150/+ animals at 26 weeks of age (see Chapter 3), which 
indicates that onset of this deficit occurs between 26 and 44-52 weeks of age. In order to 
ascertain whether these CRF task performance impairments are attributable to a motivational 
deficit, which can be compared to the apathy that occurs in HD (Soliveri et al., 2002; Roos, 2010; 
Tabrizi et al., 2013), it may be worthwhile for future studies to examine performance in the 
progressive ratio task. The progressive ratio task is an operant behavioural test that is frequently 
used to examine motivational states of animals by measuring the breakpoint at which animals 
stop responding in order to receive a reward (Hodos, 1961; Richardson and Roberts, 1996). Thus, 
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the progressive ratio task may be able to provide further insight into the potential motivational 
deficit identified in the HdhQ150/+ mouse model of HD, which is suggested by the impaired CRF 
task performance. Another possible cause of the delayed acquisition and impaired performance 
of the CRF task by HdhQ150/+ animals could be that this genotype display reduced levels of 
palatability to the food reward, thus decreasing their motivation to obtain the reward. In order 
to assess this theory, it may be valuable for future studies to examine lick clustering of HdhQ150/+ 
and Hdh+/+ animals when in the presence of the food reward used in the current study (Yazoo® 
strawberry flavoured milkshake). Changes in the size of lick clusters, based on prescribed intra-
lick intervals, have been shown to be sensitive to the consumption of more or less palatable 
solutions (Hsiao and Fan, 1993), suggesting that lick cluster size is the main determinant of 
palatability and can therefore provide an index related to hedonic components of behaviour 
(Davis and Smith, 1992). Thus, performing lick cluster analyses on HdhQ150/+ mice may reveal 
whether their abnormal CRF task acquisition and performance in the current study is the result 
of a decreased hedonic response to the food reward, which could result in the motivational 
deficit theorised earlier.  
Using the mean number of sessions to criteria in the SD task as a measure of task performance 
identified a deficit in SD capabilities in HdhQ150/+ animals in comparison to their wild-type 
counterparts, as shown by HdhQ150/+ mice requiring a significantly greater number of sessions to 
reach criteria in the task. When examining accuracy levels between genotypes, there were no 
significant differences in mean accuracy across the final three SD test sessions or across all SD 
sessions until criteria was met between HdhQ150/+ and Hdh+/+ animals. Thus, these data suggest 
that HdhQ150/+ mice at 46-60 weeks of age exhibit delayed acquisition of a SD task, yet they can 
achieve SD task performance at the level seen in wild-type animals. Homozygous HdhQ150 
animals have previously been shown to present with spatial learning impairments identified 
using the Morris water maze, with deficits arising from 16 weeks of age (Brooks et al., 2012b). 
The finding of impaired spatial learning acquisition in HdhQ150/Q150 animals by Brooks and 
colleagues (2012b), shown by the knock-in mice presenting with progressively slower 
improvement in response latencies as Morris water maze trial numbers increase when 
compared to wild-type littermates, is comparable to the deficit in SD acquisition seen in the 
current study. The delayed acquisition of the SD task seen in HdhQ150/+ mice in the current study 
can also be argued to be comparable to the impaired initial spatial location learning previously 
identified in HD patients (Brandt et al., 2005; Pirogovsky et al., 2015). Conversely, the ability of 
HdhQ150/+ animals to perform the SD task, once acquired, at a level comparable to their wild-type 
littermates is not representative of the impaired spatial memory capabilities that have been 
seen in certain HD patient reports (Lange et al., 1995; Lawrence et al., 2000; Davis et al., 2003). 
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It is possible that the striatal neurodegeneration that occurs in the HdhQ150/+ mouse model of HD 
may not be substantial enough at the time point examined to adversely affect long term spatial 
memory but is capable of disrupting acquisition of such memory. This interpretation of the data 
is supported by neuroanatomical evidence of the presence of reactive gliosis, and ubiquitin- and 
Htt-positive nuclear inclusions throughout the striatum of HdhQ150/+ mice from 40 weeks of age, 
in the absence of striatal volume and neuronal cell loss, which occurs from approximately 100 
weeks of age (Lin et al., 2001; Tallaksen-Greene et al., 2005; Heng et al., 2007).  
Analysis of response latencies during the final 3 sessions of the SD task revealed further evidence 
of potentially decreased cognitive capabilities for SD in heterozygous HdhQ150 animals. 
HdhQ150/+ mice took significantly longer to correctly respond to both S1 and S2, while retrieving 
food rewards at comparable response latencies as Hdh+/+ animals. The response latencies data 
strengthens the suggestion that the behavioural abnormalities observed in the HdhQ150/+ mice 
are a result of compromised cognitive processing, and not a result of potential motor ability 
deterioration as time progressed. This is suggested because one would expect the food reward 
latencies to also be delayed, comparably to the correct S1 and S2 delayed latencies, if impaired 
motor ability were the cause of the behavioural abnormalities. Therefore, because this is not 
the case, it is likely that the delayed S1 and S2 response latencies are an indication of slowed 
cognitive processing, or increased indecision, in HdhQ150/+ animals. 
Examining the number of trials performed by animals in the SD task allows a comparison to be 
made between the levels of motivation exhibited by genotypes. Hdh+/+ animals initiated a 
significantly greater mean number of S2 trials in the SD task, both over the final 3 SD sessions 
and across all SD sessions, than HdhQ150/+ animals. These data, taken with the CRF data described 
earlier, suggest that HdhQ150/+ mice may present with a motivational deficit at 46-60 weeks of 
age when compared to Hdh+/+ mice of an equivalent age. This is the first report of a potential 
motivation abnormality in this mouse model of HD, to our current knowledge. As discussed 
earlier, however, detailed investigation into the hedonic responses and motivational drive of the 
HdhQ150/+ animals, potentially through use of lick cluster analyses and the progressive ratio task, 
respectively, would be required to confidently conclude whether a motivational abnormality is 
present in this mouse model of HD. 
Hdh+/+ mice were found to produce a higher number of perseverant and incorrect (np in hole 3 
or hole 7) responses to S1 presentation than their HdhQ150/+ counterparts. These errors are often 
seen as a result of subjects being overzealous in their pursuit of a food reward, causing mice to 
either inadvertently np the S1 an excessive number of times as a means to ensure S2 occurrence, 
in the case of heightened perseverance, or to not np deeply enough into the S1 hole before 
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rushing to np S2, in the case of heightened incorrect S1 responses. Performing fewer of these 
perseverative and incorrect S1 responses suggests that HdhQ150/+ animals may have impaired 
cognition in comparison to their wild-type counterparts. The finding of decreased perseverance 
in the HdhQ150/+ mice is somewhat surprising, as HD patients have shown impaired performance 
of RL tasks as a result of heightened perseverance to the previously learnt rule (Massman et al., 
1990; Lange et al., 1995; Lawrence et al., 1996; Lawrence et al., 1999). However, levels of 
perseveration to S1 in the SILT were comparable in wild-type and HdhQ150/+ mice in Chapter 3 of 
this thesis (see Chapter 3.3.1 and Table 3.4). The discrepancies between the perseveration levels 
of HdhQ150/+ animals in the current study and Chapter 3 may be the result of the different 
methodologies, or behavioural tasks, used in the two studies. It is also possible that the 
differences in ages of the mice may be the cause of the different findings of the two studies, 
with mice being 6M in Chapter 3 and 10M-14M of age in the current study. This suggests that 
decreased perseveration is a behavioural phenotype in HdhQ150/+ animals at 10M-14M, and that 
this phenotype arises sometime after 6M. 
 
5.4.2 The effects of Huntington’s disease genotype on striatal gene expression levels 
A three-way ANOVA reported decreased levels of Adora2A, Arc, Drd2 and Homer1 mRNA 
transcripts in the striatum of HdhQ150/+ mice, while Bdnf and Creb1 presented with equivalent 
levels of striatal expression as those seen in wild-type animals. Adora2A transcribes a G-protein-
coupled receptor with preferential neural expression within the striatum, with particular 
localisation on the striatopallidal MSNs vulnerable to degeneration in HD (Schiffmann et al., 
1991a; Schiffmann et al., 1991b). Levels of A2ARs decrease during HD (Martinezmir et al., 1991; 
Glass et al., 2000), although it is not known whether the decrease in A2AR levels causes 
neurodegeneration in HD or is a side effect of such degeneration. Associations between Adora2A 
and the HD phenotype have also been identified in the R6 mouse models of HD, where protein 
levels of A2ARs are decreased in R6/1 animals from 12 weeks of age (Villar-Menendez et al., 2013) 
and R6/2 mice present with decreased Adora2A mRNA levels from postnatal day 21 (Tarditi et 
al., 2006). One study has reported decreases in striatal Adora2A expression in the R6/1, R6/2, 
HdhQ92/Q92 and HdhQ150/Q150 mouse models of HD, alongside similar reductions in ADORA2A in HD 
patients’ striata (Kuhn et al., 2007). Similarly, the current study reports that HdhQ150/+ mice 
display significantly reduced levels of Adora2A expression within the striatum from 46-60 weeks 
of age. Expression of Adora2A has previously been associated with cognition (Wei et al., 2011), 
and the reduction in striatal Adora2A mRNA levels identified in the current study coincided with 
impaired performance in the SD task. This suggests that the decreased expression levels of 
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Adora2A may contribute to the cognitive impairment identified in HdhQ150/+ mice, however, 
specific comparisons examining Adora2A expression in the striatum of SD trained HdhQ150/+ and 
Hdh+/+ animals reported no significant differences between genotypes. Recent studies present 
evidence that A2AR inactivation may actually be beneficial in cognition in HD; knockout of A2ARs 
has been found to prevent working memory deficits in R6/2 animals (Li et al., 2015) while 
antagonism of A2ARs, in combination with DRD1 antagonism, improves cognitive ability in R6/1 
mice (Tyebji et al., 2015). This indicates that despite displaying decreased Adora2A expression 
(Kuhn et al., 2007), A2AR hyperactivity may lead to cognitive dysfunction in HD mice. 
Nevertheless, the present study supports evidence from both human and rodent studies of HD 
that reduced expression levels of Adora2A is associated with HD pathogenesis. 
Another candidate gene in the current study that has previously been associated with the HD 
phenotype is Arc. Hippocampal Arc mRNA levels have been found to be significantly lower in 
HdhQ111/+ mice than in wild-type animals following Morris water maze training (Giralt et al., 
2012), suggesting that abnormal Arc expression plays a role in cognitive dysfunction in HD. This 
was not found to be the case in the current study, as Arc expression levels did not differ between 
HdhQ150/+ and Hdh+/+ animals that had undergone SD training. Instead, Arc mRNA transcripts 
were found to be significantly reduced in HdhQ150/+ animals using a three-way ANOVA, suggesting 
that the HD phenotype produces a reduction in Arc gene expression levels from 46-60 weeks of 
age in the HdhQ150/+ mouse model of HD. To our current knowledge, this is the first evidence of 
Arc being associated with the phenotype of the HdhQ150 mouse model of HD. 
Levels of Drd2 mRNA were identified as being significantly reduced in the striatum of HdhQ150/+ 
mice when compared with Hdh+/+ animals. DRD2s have been strongly implicated in the 
pathogenesis of HD, with numerous reports of progressive loss of striatal DRD2s and DRD2 
binding in asymptomatic carriers (Antonini et al., 1996; Weeks et al., 1996; Andrews et al., 1999) 
and symptomatic patients (Ginovart et al., 1997; Glass et al., 2000; Pavese et al., 2003). Striatal 
dopaminergic neurotransmission markers, including DRD2 binding markers, have also been 
found to be predictive of cognitive deficits in HD patients (Backman et al., 1997; Lawrence et al., 
1998a). Progressive decreases in striatal DRD2 mRNA expression have been reported in post-
mortem HD brains with increasing pathology (Augood et al., 1997), while primary neuron models 
of the disease have also exhibited such decreases (Runne et al., 2008). Abnormal dopaminergic 
gene expression levels have also been shown to translate from human cases of HD to mouse 
models of the disease, with evidence of reduced Drd2 expression levels in the striatum of R6/1, 
R6/2, HdhQ92/Q92 and HdhQ150/Q150 animals (Kuhn et al., 2007). Similar decreases in striatal Drd2 
levels have also been identified in YAC128 mice, but were not apparent in BACHD animals 
(Pouladi et al., 2012). The present study supports the evidence that a reduction in dopaminergic 
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neurotransmission expression levels occurs in HD pathology, by providing evidence of decreased 
Drd2 expression levels in the HdhQ150/+ mouse model of HD from 44-60 weeks of age. 
Homer1 is a gene that produces proteins associated with a number of roles, such as regulating 
dendritic and axonal targeting of a metabotropic glutamate receptor (Ango et al., 2000) and 
addiction to cocaine (Ghasemzadeh et al., 2003; Szumlinski et al., 2004; Ary et al., 2013), and 
has also been implicated in spatial learning and memory (Jaubert et al., 2007; Gerstein et al., 
2012; Gerstein et al., 2013). The present study reports decreased expression levels of Homer1 
in the striatum of the HdhQ150/+ mouse model of HD from 46-60 weeks of age, which suggests 
that abnormal Homer1 signalling may contribute to HD phenotype. This theory is supported by 
previous findings of a reduction in Homer1 mRNA transcripts in the R6/1, R6/2, HdhQ92/Q92 and 
HdhQ150/Q150 mouse models of HD, as well as a decrease in HOMER1 expression levels in post-
mortem striatal tissue of HD patients (Hodges et al., 2006; Kuhn et al., 2007). To further elucidate 
the role of Homer1 signalling in HD, it may be of interest for future studies to examine gene 
expression or protein levels of the three specific Homer1 isoforms (Homer1a, Homer1b and 
Homer1c) individually, as opposed to solely examining the gene expression levels of Homer1 
that occurred in the current study. 
Neither Bdnf nor Creb1 displayed differing levels of gene expression between HdhQ150/+ and 
Hdh+/+ animals. This finding in BDNF signalling is somewhat surprising because Bdnf has been 
strongly associated with the HD phenotype. For example, wild-type HTT is known to up-regulate 
BDNF transcription by inhibiting the silencing activity of the neuron restrictive silencer element 
(Zuccato et al., 2003) and this up-regulatory mechanism is lost in the presence of mHTT, causing 
decreased production of cortical BDNF (Zuccato et al., 2001). Wild-type HTT has also been found 
to enhance transport of BDNF along microtubules and that this transport activity is lost in HD, 
resulting in loss of neurotrophic support and neuronal toxicity (Gauthier et al., 2004). 
Furthermore, reductions in BDNF mRNA and protein levels have been identified in the serum 
and cortex of human HD patients (Ciammola et al., 2007; Zuccato et al., 2008), which also 
strengthens the evidence that abnormal BDNF signalling is apparent in HD. A number of mouse 
models of HD also present with decreased BDNF levels, with overexpression or upregulation of 
BDNF found to ameliorate the disease phenotype in HdhQ92 and HdhQ111 (Lynch et al., 2007), 
HdhQ140 (Simmons et al., 2009), R6/1 (Pang et al., 2006; Gharami et al., 2008), R6/2 (Zuccato 
et al., 2005; Giralt et al., 2011a) and YAC128 mice (Xie et al., 2010). Based on the body of 
evidence presented here, one would have anticipated that Bdnf mRNA levels would have been 
decreased in the striatum of HdhQ150/+ animals but this was not found to be the case. A number 
of the studies mentioned here also report decreased cortical levels of Bdnf mRNA or protein 
(Zuccato et al., 2005; Gharami et al., 2008), thus examining Bdnf transcription or protein levels 
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in the PFC tissue taken from subjects in the present study may reveal similar decreases in BDNF 
signalling in HdhQ150/+ animals. It is also entirely possible that abnormalities in BDNF signalling 
may appear later in the HdhQ150/+ mouse lifespan than examined in the current study, therefore 
examining mRNA and protein levels of BDNF in older animals may be of interest. 
As briefly highlighted, Creb1 expression levels did not show significant variation between 
HdhQ150/+ mice and their wild-type counterparts. CREB1 is a transcription factor that activates 
transcription through recruitment of CREB binding protein  (Guan et al., 2002), a protein that 
augments the activity of phosphorylated CREB as a means of activating transcription of cAMP-
responsive genes (Chrivia et al., 1993; Kwok et al., 1994). There has only been one report of 
abnormal Creb1 expression or activity in HD, to our current knowledge, which found abnormal 
Creb1 activity in striatal cells derived from HdhQ111/Q111 mice (Benn et al., 2008b). Thus, the 
current finding of equivalent Creb1 expression levels in HdhQ150/+ and Hdh+/+ animals is not 
unexpected. 
To summarise, the present study identified reductions in the striatal expression levels of 
Adora2a, Arc, Drd2 and Homer1 in the HdhQ150/+ mouse model of HD, which supports a large 
body of evidence linking these genes to HD pathogenesis (see Table 5.1). BDNF has also been 
strongly implicated in HD pathology by previous reports (Table 5.1), yet there were no significant 
differences in striatal BDNF mRNA levels between HdhQ150/+ and Hdh+/+ animals in the present 
study. A similar equivalence in striatal expression levels between genotypes was identified for 
Creb1. 
 
5.4.3 Effects of SD training on gene expression levels 
As discussed throughout Chapter 4.4, the genes under investigation in the current study have 
strong associations with cognition, where decreased expression levels of Arc (Daberkow et al., 
2007; Kelly et al., 2008; Pastuzyn et al., 2012), Bdnf (Mizuno et al., 2000; Sakata et al., 2013), 
Creb1 (Brightwell et al., 2004; Porte et al., 2008), Drd2 (Kruzich et al., 2006; Desteno and 
Schmauss, 2009; Jocham et al., 2009) and Homer1 (Jaubert et al., 2007; Gerstein et al., 2012; 
Gerstein et al., 2013) have all previously been associated with impaired cognitive capabilities. 
Conversely, inactivation of Adora2A has previously been found to enhance the working memory 
and RL abilities of wild-type mice (Wei et al., 2011) as well as a number of cognitive abilities in 
the R6/1 and R6/2 mouse models of HD (Li et al., 2015; Tyebji et al., 2015). Based upon these 
previous reports, it was originally hypothesised in Chapter 4 that mice performing different 
levels of the SD and RL tasks would present with elevated levels of Arc, Bdnf, Creb1, Drd2 and 
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Homer1 expression levels while showing decreased levels of Adora2A mRNA transcripts. This 
hypothesis was rejected in Chapter 4.4, however, with no evidence of changes in striatal 
expression levels of any of the genes under investigation at any stage of SD or RL training (see 
Chapter 4.3 and 4.4). The results of the current study support the findings of Chapter 4, with a 
three-way ANOVA reporting equivalent expression levels for all genes under investigation 
between untrained and SD trained animals. The present study strengthens the conclusions from 
Chapter 4 that striatal expression levels of Adora2A, Arc, Bdnf, Creb1, Drd2 and Homer1 do not 
alter as a result of SD performance. It is possible that changes in expression levels of the genes 
examined may occur in the hippocampus, instead of the striatum, after SD task performance, as 
spatial learning is known to be hippocampus-dependent (Silva et al., 1992b; Silva et al., 1992a; 
Bliss and Collingridge, 1993; McHugh et al., 1996; Tsien et al., 1996; Burgess et al., 2002). This 
theory is also supported by evidence of altered hippocampal expression of a number of genes 
affecting, or resulting from, spatial learning (Aiba et al., 1994a; Guzowski et al., 2000; Mizuno et 
al., 2000; Guzowski et al., 2001; Vazdarjanova et al., 2002; Wood et al., 2005). Thus, investigating 
hippocampal gene expression levels of animals in the present study may reveal SD dependent 
changes in mRNA transcript levels. 
Based upon the findings of Chapter 4, where expression levels of the genes under investigation 
did not differ depending on the level of cognitive training performed, it was hypothesised that 
if any cognitive impairments were to be identified in HdhQ150/+ animals in the current study, the 
levels of mRNA transcripts for the genes under investigation would not differ between SD 
trained animals of either genotype. Cognitive impairments were identified in HdhQ150/+ animals, 
and specific two group comparisons examining striatal expression levels between SD trained 
HdhQ150/+ and Hdh+/+ animals proved this hypothesis correct, with all genes showing equivalent 
levels of expression between SD trained mice of either genotype. However, a three-way ANOVA 
did report a significant interaction between the effects of genotype and training for Homer1 
striatal expression levels. 
 
5.4.4 Gene expression levels in the dorsal and ventral striatum 
Microdissecting the striatum into its dorsal and ventral regions, and performing subsequent RT-
qPCR analyses on these specific regions, identified region specific differences in expression levels 
of Arc, Bdnf, and Drd2. Specifically, the dorsal striatum presented with increased levels of Arc 
and Drd2 expression alongside decreased Bdnf expression levels, in comparison to ventral 
striatum tissue. In order to address the altered mRNA levels of Drd2 identified between the 
ventral and dorsal striatum, it is necessary to examine striatal neuronal populations and 
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organisation. MSNs use GABA as a neurotransmitter (Kita and Kitai, 1988) and comprise 
approximately 90-95% of striatal neurons (Gerfen, 1992a, b). Two key subpopulations of MSNs 
have been defined based upon their projection targets; whether they project to the globus 
pallidus or the substantia nigra. It is known that the majority of striatopallidal neurons, the MSNs 
that project from the striatum to the globus pallidus (Kawaguchi et al., 1990), express enkephalin 
and DRD2 (Gerfen and Young, 1988; Gerfen et al., 1990; Lemoine et al., 1990; Lemoine and 
Bloch, 1995) while the majority of striatonigral neurons, the MSNs that project from the striatum 
to the substantia nigra (Kawaguchi et al., 1990) express substance P, dynorphin and DRD1 
(Gerfen and Young, 1988; Gerfen et al., 1990; Lemoine and Bloch, 1995). It is believed that, 
across the majority of the striatum, there are approximately equal numbers of striatopallidal 
and striatonigral neurons and that the distribution of these neurons are intermixed throughout 
the striatum (Gerfen, 1992a, b). Based upon the general distribution of Drd2 expressing 
striatopallidal MSNs throughout the striatum, it was anticipated that Drd2 expression levels 
would not differ between the ventral and dorsal striatum. This was not the case in the current 
study, as the dorsal striatum presented with increased Drd2 expression levels in comparison to 
the ventral striatum. This finding of striatal region-specific Drd2 expression levels is supported 
by reports of DRD2 membrane expression being higher in the dorsolateral striatum than the 
dorsomedial striatum (Yin et al., 2009) and anatomical segregation of striatonigral and 
striatopallidal MSNs in the caudal region of the dorsal striatum (Gangarossa et al., 2013). While 
the concept of striatal region-specific Drd2 expression level differences of the current study are 
supported by these reports, Gangarossa and colleagues (2013) identified a caudal region of the 
dorsal striatum that lacks DRD2 striatopallidal neurons. This would suggest that Drd2 expression 
levels should be decreased in the dorsal striatum of the current study, but the opposite was 
found to be true. The different methods of investigation used in the two studies may contribute 
to the discrepancies of the current study and that of Gangarossa et al. (2013). The present study 
examined mRNA levels of genes of interest using RT-qPCR while Gangarossa et al. (2013) used 
immunofluorescence to determine protein levels and 3D reconstruction modelling of tissue 
slides to determine neuronal location. Thus, the different methods used to examine different 
molecular elements is likely to contribute to the apparent discrepancies in findings of the two 
studies.  
The differences in Bdnf and Arc transcript levels between the dorsal and ventral regions of the 
striatum reported in the current study were unanticipated. This was unexpected for Bdnf 
expression because although BDNF is neurotrophic for dopaminergic neurons of the substantia 
nigra (Hyman et al., 1991), striatal Bdnf mRNA expression levels have previously been found to 
be very low (Hofer et al., 1990; Xie et al., 2010) because BDNF is generated in the cortex and 
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transported to the striatum through axonal anterograde transport in frontostriatal neurons 
(Altar et al., 1997). Based upon this evidence, one would expect Bdnf mRNA levels to be low 
within the striatum and also of equivalent levels within the dorsal and ventral striatum, as Bdnf 
is highly expressed in the frontal cortex and its protein transported to, and dispersed 
throughout, the striatum. Similarly, Arc induction is known to occur through N-methyl-D-
aspartate (NMDA)-receptor activation, where Arc is transported to activated synapses and 
locally translated (Lyford et al., 1995; Steward et al., 1998; Bramham et al., 2008). Induction of 
Arc expression occurs within the MSNs of the striatum (Vazdarjanova et al., 2006) and in an 
experience-dependent manner (Guzowski et al., 1999; Vazdarjanova et al., 2002; Daberkow et 
al., 2007). From these studies, one would anticipate that Arc mRNA levels would be equivalent 
in the dorsal and ventral regions of the striatum in the current study because the MSNs capable 
of inducing Arc expression are believed to be evenly distributed throughout the striatum 
(Gerfen, 1992a, b). Based upon the evidence highlighted here, the differences reported in Bdnf 
and Arc expression levels between the dorsal and ventral striatum in the present study may be 
the result of previously unidentified differences in striatal regional expression of these genes. 
Examining transcription levels in the dorsal and ventral striatum separately did not identify 
learning-dependent gene expression level changes in any of the genes investigated in the 
current study, as examined using a three-way ANOVA or independent t-tests on specific two-
group comparisons. This acts to disprove the hypothesis presented in Chapter 4.4, that 
microdissection of the striatum and examination of gene expression levels in the dorsal and 
ventral striatum may yield cognitive based changes in mRNA levels of the genes investigated. 
This further suggests that striatal expression levels of Adora2A, Arc, Bdnf, Creb1, Drd2 and 
Homer1 are not altered as a result of SD performance, and play no role in SD performance 
capabilities. However, it is possible that alterations in transcription levels of these genes may 
arise at the level of individual cells, as examined using fluorescent in-situ hybridisation, following 
SD performance, and this was not investigated in the current study. 
 
5.4.5 Conclusions 
Male HdhQ150/+ mice presented with impaired acquisition and performance of the CRF task 
alongside a deficit in the acquisition of a SD task, in the absence of motor deficits on the Rotarod, 
at 44-60 weeks of age. Cognitive dysfunction in the SD task did not coincide with learning-
dependent changes in the striatal mRNA levels of Adora2A, Arc, Bdnf, Creb1, Drd2 or Homer1, 
as assessed by RT-qPCR. This is in support of the findings of Chapter 4, which reported equivalent 
striatal expression levels across a number of stages of SD and RL in healthy C57BL/6 mice for all 
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of the genes under investigation. In the present study, HdhQ150/+ mice presented with 
significantly decreased striatal expression levels of Adora2A, Arc, Drd2 and Homer1 in 
comparison to wild-type animals. This is in support of previous evidence linking a reduction in 
the expression of these genes with HD pathogenesis (Table 5.1). Conversely, Bdnf and Creb1 
were both found to present with comparable levels of expression in the striatum of HdhQ150/+ 
and Hdh+/+ animals. This equivalence in Bdnf expression levels was unexpected because reduced 
BDNF signalling has previously been implicated as a potential mechanism of HD pathology (Table 
5.1), although evidence that BDNF is transported from the frontal cortex to the striatum (Altar 
et al., 1997) suggests that it may be worthwhile to examine mRNA levels of Bdnf in the PFC tissue 
extracted from subjects in the current study. Differences between dorsal and ventral striatum 
expression levels of Arc, Bdnf and Drd2 were also identified in the current study. 
 
5.4.6 Summary of key results from Chapter 5 
 At 44-60 weeks of age, HdhQ150/+ mice demonstrated impaired acquisition and 
performance of the CRF task, and impaired acquisition of the SD task. 
 RT-qPCR investigation revealed significantly decreased striatal expression levels of 
Adora2A, Arc, Drd2 and Homer1 in HdhQ150/+ mice at 44-60 weeks of age, while Bdnf and 
Creb1 expression levels were equivalent between HdhQ150/+ and Hdh+/+ animals. 
 As found in Chapter 4, RT-qPCR investigation revealed no significant variation in striatal 
expression of Adora2A, Arc, Bdnf, Creb1, Drd2 or Homer1 as a result of SD training. 
 RT-qPCR analyses revealed that the dorsal striatum of animals presented with 
heightened Arc and Drd2 mRNA levels in comparison to the ventral striatum, while Bdnf 
expression levels were decreased in the dorsal striatum. 
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Chapter 6: General discussion 
HD is a neurodegenerative disorder that presents with an array of symptoms that fall into three 
broad categories: motor, cognitive, and psychiatric impairments. The discovery that a single 
genetic mutation is responsible for disease manifestation, and identification of the gene in 
question, HTT, has led to the generation of multiple cellular and rodent models of the condition. 
Transcriptional dysregulation has been identified as a pathogenic mechanism in HD (Boutell et 
al., 1999; Luthi-Carter et al., 2000; Zuccato et al., 2001; Kegel et al., 2002; Sipione et al., 2002; 
Hodges et al., 2006; Kuhn et al., 2007; Zuccato et al., 2007; Johnson et al., 2008; Johnson et al., 
2010), and has been associated with cognitive impairments in both human HD patients (Augood 
et al., 1997; Zuccato et al., 2001; Cui et al., 2006; Hodges et al., 2006; Zuccato et al., 2008; 
Chaturvedi et al., 2012; Jeong et al., 2012) and mouse models of the disease (Morton et al., 
2005; Hodges et al., 2008; Giralt et al., 2009; Giles et al., 2012; Giralt et al., 2012; Li et al., 2015). 
Based on this evidence, the primary aim of this thesis was to investigate the cognitive capabilities 
and striatal transcriptional profile of the heterozygous HdhQ150 mouse model of HD, a model 
that has undergone cellular and behavioural characterisation but has not received extensive 
cognitive evaluation (Table 1.2). A summary and discussion of the findings are presented here, 
followed by potential future directions based upon the current work. 
 
6.1 Summary and discussion of main findings 
6.1.1 Cognitive impairment in HdhQ150/+ mice 
6.1.1.1 Early-onset visuospatial attention deficits in the 5-CSRTT 
Novel impairments in visual attention and delayed acquisition of the 5-CSRTT were identified in 
heterozygous HdhQ150 animals at 13 weeks of age (Chapter 3). Similar visuospatial attention 
deficits have been reported in HD patients (Lawrence et al., 2000; Bachoud-Levi et al., 2001; 
Lemiere et al., 2004; Fielding et al., 2006c; Fielding et al., 2006b; Fielding et al., 2006a) and 
HdhQ92 mice (Trueman et al., 2009; Trueman et al., 2012a), which supports the validity of the 
cognitive impairment identified in the current study and suggests that this phenotype may be 
recapitulated in other knock-in mouse models of the disease. This cognitive impairment arises 
relatively early in the life of HdhQ150/+ animals, which is somewhat surprising because cognitive 
deficits have not previously been identified in the heterozygote genotype and those reported in 
homozygote animals manifested at a later timeframe of 17-26 weeks (Brooks et al., 2012b). A 
number of studies have identified apparent gene dosage effects within behavioural and 
neuropathological phenotypes in the HdhQ150 mouse model, where symptoms typically arise 
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earlier in homozygote animals compared to their heterozygote counterparts (Lin et al., 2001; 
Tallaksen-Greene et al., 2005; Heng et al., 2007). Thus, because of this apparent gene dosage 
effect and the early onset of spatial and RL deficits in homozygote HdhQ150 animals (Brooks et 
al., 2012b), the visuospatial attention deficit identified in HdhQ150/+ mice at 13 weeks of age in 
the current work was not expected this early in the lifespan. However, visuospatial attention in 
the 5-CSRTT has not previously been examined in homozygote HdhQ150 animals, to my current 
knowledge, and it is possible that deficits similar to those seen in the current study may arise 
earlier in HdhQ150/Q150 mice than in HdhQ150/+ counterparts. The visuospatial attention impairment 
identified at 13 weeks of age in the current work is unlikely to be caused by increased 
neuropathology in the HdhQ150/+ mice because visuospatial attention has been identified to be a 
neocortical process (Nobre et al., 1997; Casey et al., 2000; Beauchamp et al., 2001; Umarova et 
al., 2010; Kravitz et al., 2011; Bartolomeo et al., 2012) and HdhQ150/+ animals do not present with 
cortical pathology until 50-52 weeks of age, which is in the form of NII formation (Lin et al., 2001; 
Tallaksen-Greene et al., 2005). Due to the frontostriatal nature of this cognitive process, it is 
possible that the visuospatial attention deficits identified are a result of abnormal gene 
expression level changes in the HdhQ150/+ cortex. However, the experimental design of the 
current work does not allow further investigation of this hypothesis, as brains were removed for 
analyses following CRF or SILT training, but not after 5-CSRTT performance.  
Although the cognitive deficit in question has previously been identified in HD patients 
(Lawrence et al., 2000; Bachoud-Levi et al., 2001; Lemiere et al., 2004; Fielding et al., 2006c; 
Fielding et al., 2006b; Fielding et al., 2006a) and another mouse model of the disease (Trueman 
et al., 2009; Trueman et al., 2012a), it is possible that the impairment observed in the current 
work is not a true reflection of the visuospatial attention ability of the HdhQ150/+ or Hdh+/+ mouse 
populations due to the low number of animals that performed the behavioural tasks in Chapter 
3 (Hdh+/+: n = 3; HdhQ150/+: n = 5). Therefore, re-examination of heterozygous HdhQ150 
performance in the 5-CSRTT using a greater number of behavioural subjects would be 
recommended in order to replicate and validate the findings of the current work. Another 
limitation of the findings from Chapter 3 is that female mice were utilised in behavioural tasks 
but were not examined for stages of oestrous cycle throughout testing, or upon the day of 
sacrifice for molecular analyses. This is important to note because the stage of a female mouse’s 
oestrous cycle is able to significantly affect behaviour (Walf et al., 2009; ter Horst et al., 2013; 
Martini et al., 2014; Dey et al., 2015) and neural gene expression regulation (Puri et al., 2006; 
Sica et al., 2009; Cushman et al., 2014). Thus, it is possible that mice examined in the present 
study may have been at different stages of oestrous during 5-CSRTT performance and at time of 
sacrifice, which could have impacted 5-CSRTT performance and gene expression level profiles. 
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As a result of this potential limitation, male mice were used for subsequent experiments because 
there would be no potential impact of oestrous on behavioural and molecular analyses. 
 
6.1.1.2 Healthy implicit learning capacity in the SILT at 14-17 weeks of age 
A deficit in implicit learning was not identified in HdhQ150/+ animals at 14-17 weeks of age in the 
current study. This aspect of cognition has been shown to activate a variety of cortical and 
subcortical structures within the brain, including the striatum (Rauch et al., 1997; Honda et al., 
1998; Schendan et al., 2003; Aizenstein et al., 2004; Destrebecqz et al., 2005; Reiss et al., 2005; 
Gheysen et al., 2010; Bennett et al., 2011; Gheysen et al., 2011; Schendan et al., 2013), and 
displays evidence of dysfunction in HD (Heindel et al., 1989; Knopman and Nissen, 1991; Gabrieli 
et al., 1997; Kim et al., 2004). As discussed with regards to the visuospatial attention 
investigation using the 5-CSRTT, the lack of an implicit learning deficit reported in HdhQ150/+ mice 
at 14-17 weeks of age could be anticipated because of the potential gene dosage effect on the 
behavioural phenotype in this mouse model. Similarly, a deficit in this task may not have arisen 
because heterozygote HdhQ150 animals do not display overt striatal pathology at this age, with 
neuropathology evident in the form of striatal NII formation from 40-42 weeks of age (Tallaksen-
Greene et al., 2005), heightened striatal GFAP levels at 51-60 weeks of age (Lin et al., 2001; Yu 
et al., 2003), and a decrease in striatal neuron number at 100 weeks of age (Heng et al., 2007). 
Thus, the lack of neuropathology in this model at the age examined may account for the healthy 
implicit learning performance levels observed in the current study.  
Lesion studies have suggested that striatal dysfunction does not affect the implicit learning 
abilities of rats (Jay and Dunnett, 2007) or mice (Trueman et al., 2005; Brooks et al., 2007) in the 
SILT. This could be argued to suggest that differences in implicit learning did not arise between 
genotypes in the current work because the neural structure likely to have undergone the 
greatest degree of degeneration in the HdhQ150/+ mice, the striatum, may not play a key role in 
SILT-based implicit learning in the rodent brain, which is supported by similar findings in the 
HdhQ92 line (Trueman et al., 2007). Alternatively, an implicit learning deficit may not have been 
observed in HdhQ150/+ animals in the current work because the behavioural task used to 
investigate this form of cognition may not be sensitive enough to identify such deficits. Despite 
being developed and utilised to assess neural mechanisms in implicit learning, the SILT has not 
successfully identified implicit learning deficits in mice. Cognitive deficits identified using the 
SILT include impairments in motor learning and visuospatial attention (Trueman et al., 2005; 
Brooks et al., 2007; Trueman et al., 2007, 2008; Brooks et al., 2009; Brooks et al., 2012d), 
however, the ability to utilise the predictable information in the task was retained in all studies, 
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as occurred in the current work. Thus, an apparent lack of sensitivity of the SILT task to detect 
implicit learning deficits may be a possible reason that such impairments were not evident in 
HdhQ150/+ mice in the work described here. 
 
6.1.1.3 Mid-onset CRF task performance deficit 
HdhQ150/+ animals displayed impaired CRF task acquisition and performance at 44-52 weeks of 
age (Chapter 5), which is the first report of such an impairment in the HdhQ150 mouse model 
of HD, to my current knowledge. This deficit was not observed in HdhQ150/+ mice at 13 weeks of 
age in the current work (Chapter 3), which suggests that onset of this deficit in heterozygous 
HdhQ150 animals occurs between 13 and 44-52 weeks of age. The validity of this conclusion is 
questionable, however, because of the different genders of animals used in the two experiments 
assessing CRF performance in HdhQ150/+ animals; Chapter 3 utilised female mice whereas Chapter 
5 used male animals. Thus, it is possible that the differences in HdhQ150/+ CRF task performance 
identified between the time points examined resulted from sex-dependent variations in 
cognitive ability. A number of sex-dependent differences in cognition have been reported 
outside of HD mouse models (Bowman et al., 2009; Duvoisin et al., 2010; Yue et al., 2011; 
Breitberg et al., 2013; Jasarevic et al., 2013; Sanches et al., 2013; Suwalska and Lojko, 2014), 
including variation in age-related cognitive decline (Zanos et al., 2015). Similarly, gender has 
previously been shown to differentially affect behavioural phenotypes in a variety of HD mouse 
models, with sex-dependent differences observed in cognitive ability and depressive symptoms 
in R6/1 mice (Renoir et al., 2011; Mo et al., 2013; Mo et al., 2014), circadian dysfunction in 
BACHD mice (Kuljis et al., 2016), and anxiety in HdhQ140 animals (Dorner et al., 2007). 
Therefore, examination of CRF task performance in both male and female HdhQ150/+ mice at 13 
and 44-52 weeks of age may be necessary to establish whether the deficit observed at 44-52 
weeks of age results from age- or sex-dependent changes in cognitive ability.  
It is also possible that the abnormal CRF task performance observed in HdhQ150/+ animals in the 
current work is not a cognitive deficit but a motivational deficit, which may be the result of 
decreased palatability to the food reward, as discussed in Chapter 5.4.1. In order to elucidate 
which of these behavioural phenotypes accounts for the CRF task performance deficit, 
examination of HdhQ150/+ mice lick cluster response to the Yazoo® strawberry flavoured 
milkshake reward and performance in the progressive ratio task may be required. Unpublished 
data from our laboratory (Brooks et al., unpublished) demonstrates that HdhQ150/+ animals 
display equivalent levels of palatability for sucrose pellets as their wild-type counterparts at 17-
26 weeks of age (Figure 6.1), which suggests that a decreased hedonic response to the food 
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reward is unlikely to be responsible for the CRF task performance impairment observed in the 
current work. However, palatability to the Yazoo® strawberry flavoured milkshake reward used 
in the current study has yet to be performed in HdhQ150/+ animals.  
 
 
 
 
 
 
 
 
Figure 6.1. The mean weight of sucrose pellets consumed (g/kg) by Hdh+/+ and HdhQ150/+ 
animals (Brooks et al., unpublished). Hdh+/+ (n = 13) and HdhQ150/+ (n = 11) mice consumed an 
equivalent weight of sucrose pellets at 17-26 weeks of age (main effect of genotype: t(22) = 
0.633, p = 0.533). Values shown are mean ± S.E.M. 
 
Conditional and optogenetic studies have demonstrated that the direct and indirect pathways 
of the basal ganglia (see Chapter 1.1.2.2) play opposing roles in reward and motivation; 
conditional knockout of striatopallidal neurons of the indirect pathway causes an increase in 
drug reinforcement in the conditioned place preference paradigm (Durieux et al., 2009) while 
activation of these neurons by optogenetic means leads to a decrease in drug reward (Lobo et 
al., 2010), which suggests that the indirect pathway inhibits drug reinforcement, and therefore 
inhibits the rewarding effect of drug-use. Conversely, optogenetic activation of striatonigral 
neurons of the direct pathway results in an increase in drug reinforcement (Lobo et al., 2010) 
while blockade of this pathway causes a decrease in drug reinforcement (Hikida et al., 2010), 
suggesting that activation of the direct pathway facilitates drug reinforcement, and thus reward. 
Based upon this evidence, and evidence that the indirect pathway first undergoes degeneration 
in HD (Reiner et al., 1988), one would anticipate that HdhQ150/+ animals would display a 
phenotype of increased palatability and motivation, which is opposite to the potential 
motivation phenotype observed in the current work. However, recent evidence of separate 
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dorsal and ventral striatonigral DRD1 neuron-dependent circuits for the metabolic and hedonic 
responses to sugar (Tellez et al., 2016) suggests that HdhQ150/+ animals would display healthy 
levels of palatability and motivation to the milkshake food reward, as DRD1 neurons of the direct 
striatonigral pathway are resistant to degeneration until the later stages of HD (Reiner et al., 
1988). It is clear from these studies that the neuroanatomical basis of hedonic response is likely 
to be complex and is not yet fully understood, making it difficult to hypothesise how the striatal 
cell loss observed in mouse models of HD may affect motivation and hedonistic responses in the 
animals. Furthermore, previous reports demonstrate that HdhQ150/+ mice do not present with 
significant striatal neuron number loss until after 70 weeks of age (Heng et al., 2007), which is 
beyond the age that animals were examined in the current study, suggesting that neuron loss is 
unlikely to cause the potential motivational abnormality observed in HdhQ150/+ animals. 
However, the presence of striatal NIIs (Tallaksen-Greene et al., 2005) and heightened levels of 
reactive gliosis (Lin et al., 2001) have been demonstrated in HdhQ150/+ mice at the ages examined 
in the current work, suggesting that pathological damage to specific subpopulations of striatal 
neurons could account for the motivational deficits observed. Thus, examining NII formation, 
reactive gliosis, and gene expression levels in the distinct subpopulations of neurons in the direct 
and indirect pathways of the basal ganglia may be worthwhile in future studies investigating 
motivation in HdhQ150/+ mice, as opposed to investigating transcriptional level changes across all 
cell types in the striatum, which occurred in the current work. 
 
6.1.1.4 Mid-onset SD impairments 
The behavioural work of Chapter 5 revealed impaired acquisition in a test of SD at 46-60 weeks 
of age in heterozygous HdhQ150 animals. This was shown by HdhQ150/+ mice requiring a greater 
number of sessions to reach criteria in the SD task than their wild-type counterparts, while the 
mean accuracy levels of each genotype were equivalent across the final three SD sessions and 
across all SD sessions until criteria was met. Thus, HdhQ150/+ animals were capable of reaching 
comparable levels of accuracy as Hdh+/+ mice but presented with delayed acquisition of the SD 
task. The identification of a delayed SD acquisition phenotype in the current work is supported 
by previous evidence of spatial learning impairments in the HdhQ150 mouse model of HD 
(Brooks et al., 2012b) and HD patients (Brandt et al., 2005; Pirogovsky et al., 2015). It is possible 
that the delayed acquisition phenotype observed is caused by striatal neuropathology in the 
HdhQ150/+ animals, with evidence of striatal NII presence (Tallaksen-Greene et al., 2005) and 
heightened levels of reactive gliosis (Lin et al., 2001) in this mouse model at the ages examined 
in the current work. This hypothesis is supported by the striatum’s role in acquisition of a new 
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rule in a set-shifting task (Provost et al., 2012) and the activation of a cortical-striatal-
hippocampal network during rule-learning (Poldrack et al., 1999; Toni and Passingham, 1999; 
Seger and Cincotta, 2005; Seger and Cincotta, 2006). However, the substantial evidence linking 
hippocampal activity with spatial learning and memory ability (Morris, 1981; Silva et al., 1992b; 
Moser et al., 1995; Tsien et al., 1996; Maguire et al., 1997; Maguire et al., 2000; Burgess et al., 
2002; Ekstrom et al., 2003), and the lack of an interaction between aberrant striatal gene 
expression levels and SD task behaviour in HdhQ150/+ animals in the current study, suggests that 
this SD acquisition deficit may not be striatal, but hippocampal, in nature. Future analyses of 
hippocampal gene expression level profiles in the HdhQ150/+ animals of the current work may be 
of interest in order to elucidate the molecular mechanisms accountable for the SD task 
acquisition deficit observed. 
Despite reaching comparable levels of accuracy with wild-type animals across the final 3 SD 
sessions until criteria was met, the response latencies to both S1 and S2 were lengthened in 
heterozygote HdhQ150 mice during these trials. These response impairments are unlikely to be 
the result of a motor deficit in HdhQ150/+ animals because the response latencies for food reward 
collection were comparable between genotypes, and one would anticipate that HdhQ150/+ mice 
would also display lengthened response latencies for reward collection if their motor capabilities 
were diminished. HdhQ150/+ animals did not present with a motor deficit on the rotarod task prior 
to operant testing, which further opposes the suggestion that a motor abnormality is 
responsible for the lengthened S1 and S2 response latencies observed. It is possible that a motor 
deficit may have arisen in the HdhQ150 animals during operant testing in the current study, as 
motor ability was not re-assessed following operant testing, however, the food reward response 
latency data discussed and previous reports of healthy rotarod performance in HdhQ150/+ mice 
up to 100 weeks of age (Heng et al., 2007) suggest that motor abnormalities were not present 
during operant testing.  
The increased response latencies to S1 and S2 observed in HdhQ150/+ animals, in the likely 
absence of motor deficits, indicates that these mice may present with a phenotype of reduced 
cognitive processing speed. This phenotype can be compared to that seen in HD patients, 
whereby sufferers demonstrate diminished ability in tasks that assess cognitive processing, 
including the Stroop task (Snowden et al., 2001; Snowden et al., 2002; Tabrizi et al., 2012; Tabrizi 
et al., 2013), which may be attributed to the involvement of the striatum in “selection of action” 
in response to an action (Houk and Wise, 1995; Houk et al., 2007) and its degeneration in HD 
(Lange et al., 1976; Vonsattel et al., 1985; Aylward et al., 1997; Vonsattel and DiFiglia, 1998; 
Aylward et al., 2004; Tabrizi et al., 2009; Aylward et al., 2011; Tabrizi et al., 2011; Tabrizi et al., 
2012; Tabrizi et al., 2013). Thus, the aforementioned striatal neuropathology previously 
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observed in HdhQ150/+ mice at the ages examined in the current work may contribute to the 
slowed cognitive processing described here. Although such neuropathological features were not 
examined in HdhQ150/+ animals in the current work because of financial and time restraints, 
hemispheric brain tissue of these animals is available for examination of such neuropathology 
in future studies. The lack of an interaction between aberrant striatal gene expression levels and 
SD task performance in HdhQ150/+ animals indicates that the potential cognitive processing 
phenotype identified in the current study is not due to abnormal striatal transcription levels of 
Adora2A, Arc, Bdnf, Creb1, Drd2, or Homer1. However, it is possible that striatal transcriptional 
dysfunction of genes that were not examined in the current work may contribute to this 
phenotype. 
HdhQ150/+ animals were also found to initiate significantly fewer S2 trials in the SD task, both over 
the final 3 sessions until criteria was met and across all sessions performed, than their wild-type 
counterparts. Taken with the CRF phenotype described earlier, these data suggest that HdhQ150/+ 
mice may present with a motivational deficit at 46-60 weeks of age when compared to Hdh+/+ 
mice of an equivalent age. As discussed earlier, however, detailed investigation into the hedonic 
responses and motivational drive of the HdhQ150/+ animals would be required to confidently 
conclude whether a motivational abnormality is present in this mouse model of HD. 
 
6.1.2 Transcriptional correlates of cognition 
6.1.2.1 The effects of CRF, 5-CSRTT and SILT performance on striatal transcription 
The microarray investigation of Chapter 3 identified a relatively large number of genes that 
displayed significant expression level differences between untrained animals and those that had 
undergone cognitive task performance, and RT-qPCR analyses validated 19 of the 21 significant 
gene expression level change group comparisons investigated. CRF task performance in both 
Hdh+/+ and HdhQ150/+ animals produced changes in transcription levels of genes that were found 
to be associated with protein localisation and transport, with a number of these transcripts 
overlapping between genotypes. Thus, CRF performance seems to result in changes expression 
levels of genes associated with protein transport and localisation, which is unsurprising given 
the evidence that performance of learning and memory tasks causes alteration to dendritic 
spine morphology through the synthesis, transport and localization of synaptic proteins (Martin 
et al., 2000; Miller et al., 2002; Sutton and Schuman, 2006; Sekino et al., 2007; Tanaka et al., 
2008). Genes displaying altered levels of transcription in HdhQ150/+ animals following CRF task 
performance were also associated with other aspects of protein production and transport, such 
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as in the Golgi apparatus and vesicle-mediated transport, and signaling pathways that include 
GTP binding. This seems to suggest that CRF task performance, or simple conditioning, in 
HdhQ150/+ mice results in alterations to transcription levels of genes involved in a wider range of 
biological processes than occurs in wild-type animals, however, there were no significant 
differences in gene expression levels between genotypes reported in the microarray. Similar 
gene expression level changes were identified following implicit learning albeit with fewer 
transcripts showing altered levels of transcription, and with HdhQ150/+ animals displaying 
differences in expression levels of genes associated with fewer biological pathways than their 
wild-type counterparts. This seems to suggest that implicit learning results in alterations to 
transcription levels of genes involved in a narrower range of biological processes in HdhQ150/+ 
mice than occurs in Hdh+/+ animals. However, as was found in gene expression level differences 
following CRF task performance, no significant differences in gene expression levels were 
reported between genotypes. Performing cognitive training seemed to affect ageing-dependent 
changes in gene expression levels, with the PCA and microarray list of gene expression level 
changes in group comparisons suggesting that the performance of behavioural tasks between 
2M-4M appears to maintain the striatal transcription profile close to that of 3M mice rather than 
that seen in their untrained 6M contemporaries. This supports the theory that behavioural 
training acts to prevent or ameliorate gene expression level changes associated with ageing, and 
similar results have reported that an exercise protocol seems to reverse ageing-related memory 
decline and decreases in hippocampal histone H4 acetylation levels in rats (Lovatel et al., 2013). 
There are methodological considerations that limit the efficacy of the gene expression level 
results reported in Chapter 3. One such limitation is that the untrained animals in the 
experiment were unhandled, other than for routine husbandry and weighing, and that these 
mice did not receive exposure to the behavioural training environment. This may confound the 
transcription level findings because we cannot confidently state that the gene expression level 
differences that arise between trained and untrained animals are the result of the cognitive 
tasks performed by the trained mice, as untrained mice did not receive the same exposure to 
handling or the operant boxes as their behaviourally trained counterparts. This could potentially 
mean that the effects of cognitive task performance observed may be a result of handling, which 
is likely to have multiple effects on the handled mice that may include increased fear and 
anxiety, both of which are known to affect neural gene expression levels (Malkani and Rosen, 
2000; Hovatta et al., 2005; Coryell et al., 2007; Pantazopoulos et al., 2011; Spencer et al., 2013). 
Exposure to the operant boxes may also have caused the gene expression level changes 
observed in trained animals, as striatal transcription is susceptible to alteration by extended 
exposure to novel environments (Struthers et al., 2005). The lack of vaginal smear testing to 
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ascertain the stage of oestrous cycle in the female mice used in the gene expression level 
investigation in Chapter 3, as previously discussed in Chapter 6.1.1.1, also confounds the results 
of the microarray and RT-qPCR investigations. Because the stage of oestrous of each mouse was 
not known at the time of sacrifice for molecular analyses, it is not possible to ascertain whether 
the gene expression level differences reported between groups were the result of the cognitive 
training undertaken or variations in oestrous cycle. To eradicate such methodological confounds 
from later experiments, male mice were utilised and behavioural control groups were given 
equivalent exposure to the testing environments of the operant boxes as animals that received 
cognitive training. 
 
6.1.2.2 The striatal transcriptional correlates of SD and RL 
The microarray investigation in Chapter 4 did not identify any significant gene expression level 
changes in wild-type C57BL6/J animals as a result of any forms of behavioural training, and the 
RT-qPCR investigation confirmed this finding by reporting zero training-dependent changes in 
expression levels of genes previously associated with SD and/or RL (Table 4.1). Similarly, the RT-
qPCR investigation in Chapter 5 reported no significant differences in expression levels of these 
same genes as a result of SD learning in Hdh+/+ or HdhQ150/+ animals. Despite clear increases in 
accuracy being observed in behavioural training, an indication that the animals were able to 
learn, these unaltered transcriptional profiles were identified.  
It was postulated that the lack of gene expression level differences identified in the microarray 
and RT-qPCR investigations in Chapter 4 may have been the result of an absence of striatal 
dissection specificity, where the striatum was extracted and examined as a whole. This was 
hypothesised because of evidence that distinct regions of the striatum play dissociable roles in 
learning (Reading et al., 1991; Featherstone and McDonald, 2004; Reiss et al., 2005; Atallah et 
al., 2007; Darvas and Palmiter, 2010, 2011; Darvas et al., 2014; Burton et al., 2015) and that 
previous studies have identified significant differences in RL behaviour and gene expression 
levels when subdividing the striatum into similar distinct regions (Hernandez et al., 2006; 
Daberkow et al., 2007; Graybeal et al., 2011). However, striata were microdissected into dorsal 
and ventral striatal regions for RT-qPCR analyses in Chapter 5, which did not lead to the 
identification of gene expression level changes associated with cognition. This therefore seems 
to reject the hypothesis that the lack of striatal dissection specificity in Chapter 4 was 
accountable for the absence of significant learning-dependent gene expression level changes. 
Although a role of the striatum has been identified in a potential cortical-striatal-hippocampal 
network for spatial learning (Floresco et al., 1997; Mair et al., 2002; Pooters et al., 2016) and in 
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a frontostriatal network for RL (Cools et al., 2002; Featherstone and McDonald, 2005; Ragozzino, 
2007; Bellebaum et al., 2008; Clarke et al., 2008; Ghahremani et al., 2010; Ruge and 
Wolfensteller, 2016), the evidence presented in the current work suggests that striatal 
transcription may not be integral to, or altered by, performance of such learning paradigms in 
mice. 
One potential reason for the absence of transcriptional diversity reported as a result of SD and 
RL is the possibility that the striatal gene expression level profiles of each group were 
comparable because the natural magnitude of gene expression level changes that occur 
following performance of these tasks in wild-type animals are not high enough to be detected 
by microarray. When investigating the role of transcription in learning, it is common practice to 
use a ‘bottom-up’ approach to alter the genetic profile of animals prior to, or during, behavioural 
testing using transgenic (Silva et al., 1992b; Bourtchuladze et al., 1994; Sakimura et al., 1995; 
Abel et al., 1997; McClung and Nestler, 2003; Gerstein et al., 2012) or pharmacological methods 
(Egerton et al., 2005; Bredy and Barad, 2008; Romieu et al., 2008; Stefanko et al., 2009; Haettig 
et al., 2011; Dagnas et al., 2013). This approach often yields changes in transcription or 
behaviour, which can be linked to the gene(s) or pathway(s) under investigation. The current 
study used a ‘top-down’ approach where behaviour was examined before examination of 
potential genetic differences. It is possible that using an approach of this nature in wild-type, 
and therefore genetically and pharmacologically unaltered, animals does not lead to 
transcriptional changes large enough for detection by microarray or RT-qPCR, as suggested by 
the lack of significant gene expression level differences using either technique. These findings 
also seem to indicate that striatal transcriptional regulation of the genes investigated do not 
play a role in SD or RL, although this conclusion is contradicted by evidence provided by multiple 
studies, the majority of which utilise the ‘bottom-up’ approach discussed (Table 4.1). 
The behavioural training stage at which animals were sacrificed in Chapter 4 may be partly 
responsible for the lack of learning-dependent gene expression level changes observed. Mice 
were either sacrificed following 1 session of SD or RL training, or upon reaching criterion in these 
tasks, where criterion consisted of reaching ≥85% accuracy over three consecutive behavioural 
sessions. It is possible that gene expression level differences did not arise between animals 
culled at these distinct stages because of the potential temporal requirement needed for 
learning-dependent transcription to occur. It is possible, for example, that molecular differences 
were not identified between striata of animals that reached criteria in the SD and RL tasks 
because the gene expression level changes responsible for each form of learning (if they produce 
separate molecular substrates in the striatum) were arising in sessions at which the animals 
were improving in cognitive ability rather than when they had reached the cognitive peak of 
179 
 
≥85% accuracy over three consecutive sessions (Figure 6.2). Thus, examining a mid-point in 
cognitive ability, where accuracy levels are intermediate (at 60-80% accuracy in the SD task, for 
example), may have yielded significant gene expression level differences between groups 
(Figure 6.2). This theory is supported by evidence that the dorsolateral and posterior 
dorsomedial striatum of rats show differing levels of gene expression following performance of 
an intermediate number of instrumental learning sessions (6 sessions) when compared to 
performance of a minimal (3) or extended (10) number of sessions (Anna Powell thesis, Cardiff 
University, 2013). Differences in gene expression levels have also been identified between a 
‘mid-RL accuracy’ group of mice and animals that had undergone 1 session of RL or had reached 
criteria in the task (Brigman et al., 2013), which also suggests that incorporation of an 
intermediate cognitive ability group in the current work may have yielded significant gene 
expression level differences. Incorporating this intermediate cognitive ability behavioural group 
based on mean accuracy, however, may have presented difficulty in establishing the criterion 
for intermediate accuracy. 
It is also possible that performance of only 1 session of SD or RL training is insufficient to produce 
significant learning-dependent gene expression level changes because animals should be 
performing at chance level, or lower than chance level due to perseverative responding of the 
previously learnt rule, at these time points. This would mean that animals may not necessarily 
be learning the task requirements at this stage of training, which could explain the lack of 
significant learning-dependent transcription level differences that arise between animals that 
reached criteria in SD task and those that performed 1 session of RL. However, this theory seems 
to be contradicted by differences in gene expression levels being identified between animals 
that have undergone only 1 initial learning session and those that have received a greater 
number of learning sessions or 1 initial learning session of a new rule (Brigman et al., 2013). 
Conversely, early learning gene expression level changes have been evaluated following the 
performance of 3 initial behavioural training sessions in other published literature (Havekes et 
al., 2006; Hernandez et al., 2006), which may reflect anticipation of the methodological 
consideration raised here. 
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Figure 6.2. A graph of hypothetical mean accuracy data illustrating where potential gene 
expression level differences may have arisen during SD and RL. As learning may have already 
occurred by the time animals had reached 85% accuracy for 3 consecutive sessions, as suggested 
by the molecular findings of Chapters 4 and 5, it is hypothesised that examining gene expression 
levels in a group of animals at sessions in which they display an intermediate level of cognitive 
ability in either task would be more likely to show learning-dependent gene expression level 
differences. 
 
Use of a novel behavioural task examining SD and RL may have contributed to the absence of 
SD- and RL-dependent gene expression level changes in the current work. Gene expression level 
changes dependent on these forms of learning have been investigated in rodents using 
behavioural tasks that include the Morris water maze (McDowell et al., 2010; Wei et al., 2011; 
Trinh et al., 2012; Fentress et al., 2013; Sakata et al., 2013), Y-maze (Havekes et al., 2006; Trinh 
et al., 2012), T-maze (Daberkow et al., 2007; Pastuzyn et al., 2012), attention-set-shifting 
(Egerton et al., 2005; Desteno and Schmauss, 2009), and, more recently, in touchscreen operant 
boxes (Izquierdo et al., 2006; Brigman et al., 2008; Brigman et al., 2009; Brigman et al., 2010; 
Graybeal et al., 2011; Brigman et al., 2013; Kolisnyk et al., 2013). It is possible that the likelihood 
of identifying SD- or RL-dependent gene expression level differences may have been higher had 
a well-characterised behavioural task, such as the aforementioned tasks, been used in the 
current work. However, with the exception of the touchscreen operant boxes, these behavioural 
Similar gene expression 
Altered gene 
expression? 
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tasks have greater dependence on non-cognitive functions, such as motor ability or olfaction, 
than the tasks described in the current work, and were not utilised because these faculties have 
been associated with gene expression level changes themselves, which may have obscured 
potential mRNA level changes that resulted from altered cognition. 
Other potential limitations of the current molecular work include those that have previously 
been discussed, which includes the fact that only striatal tissue was examined in molecular 
investigations. However, tissue was also extracted from a number of other brain regions, such 
as the hippocampus, PFC and cerebellum, meaning that molecular investigations into learning-
dependent gene expression level changes in these neural structures is possible in the future. 
Similarly, only mRNA levels were examined in the current work, while the protein levels or 
localisation of the products of these transcripts were not investigated by Western blot or 
immunohistochemistry, for example. Investigating the protein levels of the genes examined in 
the current work may have contributed to the elucidation of the molecular basis of cognition 
studied here, as mRNA levels of a gene do not necessarily correspond with its level of protein 
product. However, striatal tissue, as well as tissue from the aforementioned neural regions, was 
extracted and remains available for such protein analyses in the future, but financial and time 
constraints meant that these investigations were not possible in this thesis. 
 
6.1.3 The striatal transcriptional profile in HdhQ150/+ mice 
The microarray and RT-qPCR investigations of Chapter 3 reported no significant differences 
between expression levels of the transcriptional profiles of HdhQ150/+ and Hdh+/+ animals at 13 or 
26 weeks of age. Significant striatal gene expression level differences that recapitulate aspects 
of those seen in human HD patients have previously been reported between homozygous 
HdhQ150 mice and wild-type counterparts at 26-96 weeks of age (Hodges et al., 2006; Kuhn et 
al., 2007; Giles et al., 2012; Bayram-Weston et al., 2015), which indicates that a transcriptional 
phenotype does arise in the HdhQ150 mouse model of HD. The evidence presented in Chapter 
5 of the current work, of decreased expression levels of Adora2A, Arc, Drd2 and Homer1 in the 
striatum of HdhQ150/+ mice at 44-60 weeks of age, also provides evidence for an abnormal 
transcriptional phenotype, and strengthens the evidence for abnormal signaling or expression 
of these genes in the HD phenotype (Table 5.1). This is the first report of a transcriptional 
phenotype in heterozygous HdhQ150 animals, to my current knowledge, and suggests that 
manifestation of this phenotype may be age- or sex-dependent in HdhQ150/+ mice, as such 
abnormalities were not identified in younger female mice at 13 or 26 weeks of age in the current 
work. It is important to note that RT-qPCR analyses were not performed on the same genes in 
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Chapter 3 as those in Chapter 5, meaning that differences in striatal expression levels of 
Adora2A, Arc, Drd2 and Homer1 may have arisen in the female HdhQ150/+ mice at 13 or 26 weeks 
of age. However, the microarray investigation performed in Chapter 3 contradicts this 
suggestion, as expression levels of these genes were found to be equivalent between HdhQ150/+ 
and Hdh+/+ animals (data not shown). 
As previously discussed, the molecular findings of Chapter 3 may be limited because the stage 
of oestrous cycle at which each HdhQ150/+ mouse was present at the time of sacrifice was 
unknown, however this methodological consideration was corrected for Chapter 5 by using male 
mice. The relatively small sample sizes used in the molecular analyses (n/group = 3-6) may also 
be a limitation of the current work, as the analyses may be underpowered and thus may not be 
fully representative of the HdhQ150/+ mouse population; financial restraints did not allow 
increased sample sizes for subsequent studies. HdhQ150/+ mice in Chapter 5 displayed evidence 
of a genomic drift in CAG repeat size, whereby the mean CAG repeat observed was 
approximately 130 CAGs. This may also limit the conclusions made because the mutant mice 
had CAG repeat lengths shorter than those of the original HdhQ150 line, and thus may not be 
fully representative of the HdhQ150/+ mouse population, however, previous studies have also 
utilised mice displaying similar genetic drift in CAG lengths (Bayram-Weston et al., 2012d; Giles 
et al., 2012). 
 
6.2 Future directions 
Directions for future work could include molecular investigations, of both mRNA and protein 
levels, of relevant tissue extracted from animals in the current work, which in the cases of 
Chapters 4 and 5 would most likely involve examining PFC and hippocampal tissue, because of 
the aforementioned associations of the PFC with RL and the hippocampus with spatial learning 
and memory. Examining CRF task performance at 13 and 44-52 weeks of age in both male and 
female HdhQ150/+ mice may also be of interest, in order to elucidate whether the acquisition and 
performance impairments identified at 44-52 weeks of age in this genotype were age- or sex-
dependent. Behavioural assessment of the hedonistic responses and motivation levels of 
HdhQ150/+ mice may also be of interest in future studies, as an attempt to reveal whether 
alterations to either of these psychological domains is responsible for the CRF task acquisition 
and performance deficits observed in these animals, or for their decreased SD task response 
latencies. Due to the low numbers of animals used in the SILT investigation, an attempt to 
replicate the visuospatial attention deficit observed in the 5-CSRTT at 13 weeks of age in 
HdhQ150/+ mice may also be worthwhile, through behavioural evaluation of a larger sample of 
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animals in this task. Investigating the molecular correlates of visual discrimination and RL in 
HdhQ150/+ mice using touchscreen-based operant boxes may also be of value, as these boxes have 
been implemented in a large number of studies examining these forms of learning (Izquierdo et 
al., 2006; Brigman et al., 2008; Brigman et al., 2009; Brigman et al., 2010; Graybeal et al., 2011; 
Brigman et al., 2013; Kolisnyk et al., 2013), and because investigation into RL in these animals 
was removed from the current work due to the lack of transcriptional correlates for this form of 
learning being identified in wild-type animals. These operant boxes were unavailable for use 
throughout the current work, however, if visual discrimination deficits, similar to the SD 
impairments observed, were to be identified in HdhQ150/+ animals, the conclusions of the current 
work would be strengthened further. Use of these touchscreen operant boxes have identified 
psychomotor slowing, and visual discrimination and RL deficits in the BACHD and zQ175 mouse 
models of HD (Farrar et al., 2014). It would be of interest to see if the use of these boxes 
produces similar impairments in HdhQ150/+ animals, with the results of the current behavioural 
work suggesting that a visual discrimination task acquisition deficit may arise.  
 
6.3 Concluding remarks 
In conclusion, the data presented in this thesis indicate that HdhQ150/+ animals display a series of 
novel cognitive impairments that recapitulate aspects of the cognitive phenotype observed in 
HD. These consist of deficits in the acquisition and performance of the CRF task, impaired 
visuospatial attention in the 5-CSRTT, and delayed acquisition and cognitive processing of SD 
learning, however, implicit learning capabilities in the SILT were found to be unaltered between 
HdhQ150/+ and Hdh+/+ animals. Investigation into the transcriptional correlates of cognition was 
ultimately unsuccessful, with microarray and RT-qPCR analyses being unable to identify 
significant learning-dependent gene expression level changes in the striata of either HdhQ150/+ or 
wild-type animals following tests of conditioning, implicit learning, SD, or RL. Differences in 
striatal expression levels of Adora2A, Arc, Drd2 and Homer1 were reported between HdhQ150/+ 
and Hdh+/+ animals at 44-60 weeks of age, which supports previous evidence of abnormal 
expression or signaling of these genes in the HD phenotype. Overall, this body of work 
contributes novel evidence that heterozygote animals of the HdhQ150 mouse model of HD 
present with molecular and cognitive phenotypes comparable to those seen in the human form 
of the disease. 
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Appendix 
 
Group comparison Gene of interest Statistics 
Hdh+/+ untrained dorsal striatum vs 
HdhQ150/+ untrained dorsal striatum 
Adora2A t(8) = -3.274, p = 0.066 
Arc t(8) = -2.263, p = 0.159 
Bdnf t(8) = -0.268, p = 1.000 
Creb1 t(8) = -0.438, p = 1.000 
Drd2 t(8) = -2.803, p = 0.115 
Homer1 t(4.174) = -3.007, p = 0.152 
Hdh+/+ untrained ventral striatum vs 
HdhQ150/+ untrained ventral striatum 
Adora2A t(8) = -1.617, p = 0.580 
Arc t(8) = -2.431, p = 0.205 
Bdnf t(8) = -0.875, p = 0.814 
Creb1 t(8) = -0.553, p = 0.814 
Drd2 t(8) = -1.259, p = 0.732 
Homer1 t(8) = -4.462, p = 0.012 
Hdh+/+ SD trained dorsal striatum vs 
HdhQ150/+ SD trained dorsal striatum 
Adora2A t(4.720) = -0.855, p = 1.000 
Arc t(8) = -2.094, p = 0.420 
Bdnf t(8) = -0.107, p = 1.000 
Creb1 t(8) = 0.866, p = 1.000 
Drd2 t(5.081) = -0.261, p = 1.000 
Homer1 t(8) = -0.075, p = 1.000 
Hdh+/+ SD trained ventral striatum vs 
HdhQ150/+ SD trained ventral striatum 
Adora2A t(8) = -1.938, p = 0.445 
Arc t(8) = -0.877, p = 1.000 
Bdnf t(8) = -0.842, p = 1.000 
Creb1 t(8) = 2.190, p = 0.360 
Drd2 t(8) = -1.175, p = 1.000 
Homer1 t(8) = -0.648, p = 1.000 
Appendix 1.1. RT-qPCR results for genotype-dependent gene expression level changes. 
Specific two-group comparisons were analysed by independent samples t-tests, with Holm-
Bonferroni sequential correction used for multiple hypothesis testing correction. Homogeneity 
of variances for data was assessed using Levene’s test, and the Welch test used in the event of 
data violating this assumption. The test where a significant effect of genotype was identified is 
highlighted in bold. 
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Appendix 1.2. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) dorsal striatal expression levels between untrained Hdh+/+ and HdhQ150/+ animals 
following RT-qPCR. A trend of decreased expression levels in the dorsal striatum of untrained 
HdhQ150/+ mice is seen for all genes investigated. However, all gene expression level differences 
between groups were found to be non-significant (Appendix 1.1). Values shown are mean ± 
S.E.M.; n = 5/group. 
n.s. = non-significant 
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Appendix 1.3. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) ventral striatal expression levels between untrained Hdh+/+ and HdhQ150/+ animals 
following RT-qPCR. A trend of decreased expression levels in the ventral striatum of untrained 
HdhQ150/+ mice is seen for all genes investigated, however, significant gene expression level 
differences between groups were only reported for Homer1 (F; Appendix 1.1). Values shown are 
mean ± S.E.M.; n = 5/group. 
* p < 0.05                n.s. = non-significant 
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Appendix 1.4. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) dorsal striatal expression levels between SD trained Hdh+/+ and HdhQ150/+ animals 
following RT-qPCR. A trend of decreased expression levels in the dorsal striatum of SD trained 
HdhQ150/+ mice is seen for all genes investigated, with the exception of Creb1 (D). However, all 
gene expression level differences between groups were found to be non-significant (Appendix 
1.1). Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Appendix 1.5. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) ventral striatal expression levels between SD trained Hdh+/+ and HdhQ150/+ animals 
following RT-qPCR. A trend of decreased expression levels in the ventral striatum of SD trained 
HdhQ150/+ mice is seen for all genes investigated, with the exception of Creb1 (D). However, all 
gene expression level differences between groups were found to be non-significant (Appendix 
1.1). Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Group comparison Gene of 
interest 
Statistics 
Hdh+/+ untrained dorsal striatum vs 
Hdh+/+ SD trained dorsal striatum 
Adora2A t(8) = -0.842, p = 1.000 
Arc t(8) = -1.535, p = 0.815 
Bdnf t(8) = -0.116, p = 1.000 
Creb1 t(8) = 0.120, p = 1.000 
Drd2 t(8) = -1.889, p = 0.576 
Homer1 t(8) = -1.117, p = 1.000 
Hdh+/+ untrained ventral striatum vs 
Hdh+/+ SD trained ventral striatum 
Adora2A t(8) = -0.393, p = 1.000 
Arc t(8) = -0.268 p = 1.000 
Bdnf t(8) = 0.763, p = 1.000 
Creb1 t(8) = -1.589, p = 0.755 
Drd2 t(8) = -0.429, p = 1.000 
Homer1 t(8) = -2.805, p = 0.138 
HdhQ150/+ untrained dorsal striatum vs 
HdhQ150/+ SD trained dorsal striatum 
Adora2A t(8) = 0.549, p = 1.000 
Arc t(8) = -0.028, p = 1.000 
Bdnf t(8) = 0.074 p = 1.000 
Creb1 t(8) = 1.209, p = 1.000 
Drd2 t(8) = 1.411, p = 0.980 
Homer1 t(8) = 2.694, p = 0.162 
HdhQ150/+ untrained ventral striatum vs 
HdhQ150/+ SD trained ventral striatum 
Adora2A t(8) = -0.019, p = 1.000 
Arc t(8) = 0.615, p = 1.000 
Bdnf t(6.443) = 0.948, p = 1.000 
Creb1 t(8) = 0.875, p = 1.000 
Drd2 t(8) = 0.406, p = 1.000 
Homer1 t(8) = 0.713, p = 1.000 
Appendix 1.6. RT-qPCR results for behavioural training-dependent gene expression level 
changes. Specific two-group comparisons were analysed by independent samples t-tests, with 
Holm-Bonferroni sequential correction used for multiple hypothesis testing correction. 
Homogeneity of variances for data was assessed using Levene’s test, and the Welch test used in 
the event of data violating this assumption. 
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Appendix 1.7. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) dorsal striatal expression levels between untrained and SD trained Hdh+/+ animals 
following RT-qPCR. A trend of decreased expression levels in the dorsal striatum of SD trained 
Hdh+/+ mice is seen for all genes investigated, with the exception of Creb1 (D). However, all gene 
expression level differences between groups were found to be non-significant (Appendix 1.6). 
Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Appendix 1.8. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) ventral striatal expression levels between untrained and SD trained Hdh+/+ animals 
following RT-qPCR. A trend of decreased expression levels in the ventral striatum of SD trained 
Hdh+/+ mice is seen for all genes investigated, with the exception of Bdnf (C). However, all gene 
expression level differences between groups were found to be non-significant (Appendix 1.6). 
Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Appendix 1.9. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) dorsal striatal expression levels between untrained and SD trained HdhQ150/+ 
animals following RT-qPCR. A trend of increased expression levels in the dorsal striatum of SD 
trained HdhQ150/+ mice is seen for all genes investigated, with the exception of Arc (B). However, 
all gene expression level differences between groups were found to be non-significant 
(Appendix 1.6). Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Appendix 1.10. RQ value comparison of Adora2A (A), Arc (B), Bdnf (C), Creb1 (D), Drd2 (E), and 
Homer1 (F) ventral striatal expression levels between untrained and SD trained HdhQ150/+ 
animals following RT-qPCR. A trend of increased expression levels in the ventral striatum of SD 
trained HdhQ150/+ mice is seen for all genes investigated, with the exception of Adora2A (A). 
However, all gene expression level differences between groups were found to be non-significant 
(Appendix 1.6). Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Group comparison Gene of 
interest 
Statistics 
Hdh+/+ untrained dorsal striatum vs 
Hdh+/+ untrained ventral striatum 
Adora2A t(8) = 1.062, p = 0.957 
Arc t(8) = 3.032, p = 0.096 
Bdnf t(8) = -0.795, p = 0.957 
Creb1 t(8) = -1.811, p = 0.432 
Drd2 t(8) = 1.972, p = 0.420 
Homer1 t(8) = -0.647, p = 0.957 
Hdh+/+ SD trained dorsal striatum vs 
Hdh+/+ SD trained ventral striatum 
Adora2A t(8) = 0.329, p = 1.000 
Arc t(8) = 1.140, p = 1.000 
Bdnf t(8) = -2.112, p = 0.408 
Creb1 t(8) = 0.062, p = 1.000 
Drd2 t(8) = 0.511, p = 1.000 
Homer1 t(8) = -0.114, p = 1.000 
HdhQ150/+ untrained dorsal striatum vs 
HdhQ150/+ untrained ventral striatum 
Adora2A t(8) = 0.892, p = 1.000 
Arc t(8) = 1.246, p = 1.000 
Bdnf t(8) = -0.381, p = 1.000 
Creb1 t(8) = -1.069, p = 1.000 
Drd2 t(8) = 0.830, p = 1.000 
Homer1 t(8) = 0.011, p = 1.000 
HdhQ150/+ SD trained dorsal striatum vs 
HdhQ150/+ SD trained ventral striatum 
Adora2A t(8) = 2.315, p = 0.245 
Arc t(8) = 0.659, p = 1.000 
Bdnf t(8) = -1.323, p = 0.888 
Creb1 t(8) = -0.576, p = 1.000 
Drd2 t(8) = 2.799, p = 0.138 
Homer1 t(8) = 0.488, p = 1.000 
Appendix 1.11. RT-qPCR results for striatal region-dependent gene expression level changes. 
Specific two-group comparisons were analysed by independent samples t-tests, with Holm-
Bonferroni sequential correction used for multiple hypothesis testing correction. Homogeneity 
of variances for data was assessed using Levene’s test, and the Welch test used in the event of 
data violating this assumption. 
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Appendix 1.12. RQ value comparison of dorsal and ventral striatal Adora2A (A), Arc (B), Bdnf 
(C), Creb1 (D), Drd2 (E), and Homer1 (F) expression levels in untrained Hdh+/+ animals following 
RT-qPCR. A trend in expression levels is not apparent between the dorsal and ventral striatum 
of untrained Hdh+/+ mice. All gene expression level differences between groups were found to 
be non-significant (Appendix 1.11). Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Appendix 1.13. RQ value comparison of dorsal and ventral striatal Adora2A (A), Arc (B), Bdnf 
(C), Creb1 (D), Drd2 (E), and Homer1 (F) expression levels in SD trained Hdh+/+ animals 
following RT-qPCR. A trend in expression levels is not apparent between the dorsal and ventral 
striatum of SD trained Hdh+/+ mice. All gene expression level differences between groups were 
found to be non-significant (Appendix 1.11). Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Appendix 1.14. RQ value comparison of dorsal and ventral striatal Adora2A (A), Arc (B), Bdnf 
(C), Creb1 (D), Drd2 (E), and Homer1 (F) expression levels in untrained HdhQ150/+ animals 
following RT-qPCR. A trend in expression levels is not apparent between the dorsal and ventral 
striatum of untrained HdhQ150/+ mice. All gene expression level differences between groups were 
found to be non-significant (Appendix 1.11). Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Appendix 1.14. RQ value comparison of dorsal and ventral striatal Adora2A (A), Arc (B), Bdnf 
(C), Creb1 (D), Drd2 (E), and Homer1 (F) expression levels in SD trained HdhQ150/+ animals 
following RT-qPCR. A trend of decreased expression levels in the ventral striatum of SD trained 
HdhQ150/+ mice is identified in the genes investigated, with the exceptions of Bdnf (C) and Creb1 
(D). However, all gene expression level differences between groups were found to be non-
significant (Appendix 1.11). Values shown are mean ± S.E.M.; n = 5/group. 
n.s. = non-significant 
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Interaction Gene of 
interest 
Statistics 
Genotype*Training 
Adora2A F1, 32 = 0.590, p = 0.448 
Arc F1, 32 = 0.947, p = 0.338 
Bdnf F1, 32 = 0.089, p = 0.767 
Creb1 F1, 32 = 3.531, p = 0.069 
Drd2 F1, 32 = 3.788, p = 0.060 
Homer1 F1, 32 = 8.098, p = 0.008 
Genotype*Striatal Region 
Adora2A F1, 32 = 0.293, p = 0.592 
Arc F1, 32 = 0.078, p = 0.782 
Bdnf F1, 32 = 0.220, p = 0.643 
Creb1 F1, 32 = 0.045, p = 0.833 
Drd2 F1, 32 = 0.257, p = 0.616 
Homer1 F1, 32 = .0389, p = 0.537 
Training*Striatal Region 
Adora2A F1, 32 = 0.014, p = 0.905 
Arc F1, 32 = 0.578, p = 0.453 
Bdnf F1, 32 = 0.553, p = 0.462 
Creb1 F1, 32 = 1.090, p = 0.304 
Drd2 F1, 32 = 0.987, p = 0.328 
Homer1 F1, 32 = 0.221, p = 0.642 
Genotype*Training*Striatal Region 
Adora2A F1, 32 = 0.149, p = 0.702 
Arc F1, 32 = 0.002, p = 0.963 
Bdnf F1, 32 = 0.006, p = 0.940 
Creb1 F1, 32 = 0.253, p = 0.618 
Drd2 F1, 32 = 1.199, p = 0.282 
Homer1 F1, 32 = 0.002, p = 0.966 
Appendix 1.16. RT-qPCR results for striatal gene expression level change independent variable 
interactions. RT-qPCR data was analysed by a three-way ANOVA, with genotype (Hdh+/+ or 
HdhQ150/+), training (untrained or SD) and striatal region (dorsal or ventral) as independent 
variables. The test in which a significant interaction was identified is highlighted in bold. 
 
 
 
 
 
